Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026

I, Sarah Syme, as delegate of the Secretary of the Department of Health, Disability and Ageing, make the following instrument.

Dated 28 September 2026

Sarah Syme
Assistant Secretary
Regulatory Engagement Branch
Health Products Regulation Group
Department of Health, Disability and Ageing

Authorised Version F2026L01327 registered 30/09/2026

Contents

Reader's guide i

Introduction i

Classification iii

Principles of scheduling iv

Reading the schedules v

Availability of poisons vii

Appendices viii

Appendix A (General exemptions) viii

Appendix B (Substances considered not to require control by scheduling) ix

Appendix C (blank) ix

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8) ix

Appendix E (First aid instructions for poisons) ix

Appendix F (Warning statements and general safety directions for poisons) x

Appendix G (Dilute preparations) x

Appendix H (Schedule 3 medicines permitted to be advertised) x

Appendix I (blank) x

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7) x

Appendix K (Human medicines required to be labelled with a sedation warning) x

Appendix L (Requirements for dispensing labels for medicines) x

Appendix M (blank) x

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons xi

Part 1—Preliminary and interpretation 1

1 Name 1

2 Commencement 1

3 Authority 1

4 Repeal and transitional provisions 1

5 Reader's guide and Index 2

6 Definitions 2

7 References to substances 10

8 References to concentration, strength or quantity of substances 11

9 References to boiling or distillation temperatures 11

10 References to standards 11

Part 2—Controls on substances 12

Division 1—Preliminary 12

11 Application of Part 2 12

12 Preparations containing poisons included in different schedules 12

Division 2—Labels 13

Subdivision A—General 13

13 General requirements 13

Authorised Version F2026L01327 registered 30/09/2026

14 Immediate wrapper 13
Subdivision B—Primary packs and immediate containers 13
15 Primary packs and immediate containers 13
16 Signal words 14
17 Cautionary statement—possession without authority illegal 14
18 Cautionary statement—keep out of reach of children 15
19 Cautionary statement—fire and explosion hazard 15
20 Cautionary statement—burns skin and throat 15
21 Cautionary statements for aqueous solution of paraquat 16
22 Cautionary statement—read safety directions 16
23 Cautionary statement—flammable 17
24 Cautionary statement—for animal treatment only 17
25 Cautionary statement—do not swallow 17
26 Approved name and quantity, proportion or strength 17
27 Statement—an anticholinesterase compound 18
28 Directions for use 18
29 Safety directions 19
30 Warning statements 19
31 First aid 20
32 Name and address of manufacturer or distributor 20
33 Warning statements and sedation warnings for certain medicines for human use 21
Subdivision C—Statements of quantity, proportion or strength 21
34 Statements of quantity, proportion or strength 21
Subdivision D—Exemptions from labelling requirements 22
35 Selected containers and measure packs 22
36 Ampoules, pre-filled syringes and injection vials 23
37 Transport containers and wrappings 23
38 Dispensary, industrial, laboratory and manufacturing poisons 23
39 Exemptions from label requirements in certain circumstances 24
40 Dispensed medicines 24
41 Gas cylinders 24
42 Paints 24
43 Camphor and naphthalene 25
Subdivision E—Prohibitions 25
44 Prohibitions 25
Division 3—Containers 27
45 General requirements 27
46 Containers for poisons other than poisons included in Schedule 5 27
47 Containers for poisons included in Schedule 5 27
48 Approved containers 28
49 Child-resistant closures 28
50 Poisons included in Schedule 8 30
51 Exemptions 30
52 Camphor and naphthalene 31
53 Prohibitions—use of containers for poisons 31
Division 4—Storage 32
54 General storage requirements 32
Division 5—Disposal 33
55 General disposal requirements 33

Authorised Version F2026L01327 registered 30/09/2026

Division 6—Record keeping **34**
56 General record-keeping requirements 34
Division 7—Advertising **35**
57 General advertising requirements....35
Division 8—Supply, prescribing, possession or use **36**
58 Poisons included in Schedule 2 36
59 Poisons included in Schedule 3 36
60 Poisons included in Schedule 4 37
61 Poisons included in Schedules 5 and 6....37
62 Poisons included in Schedule 7 37
63 Poisons included in Schedule 10 38
64 Poisons included in Schedule 4 or 8 and Appendix D 38
65 Hawking 39
Division 9—Paints and tinters **40**
66 General requirements 40
67 Definition of *first group paint* 40
68 Definition of *second group paint* 41
Schedule 1—Blank **42**
Schedule 2—Pharmacy medicines **43**
Schedule 3—Pharmacist only medicines **61**
Schedule 4—Prescription only medicines and prescription animal remedies **71**
Schedule 5—Caution **179**
Schedule 6—Poisons **213**
Schedule 7—Dangerous poisons **267**
Schedule 8—Controlled drugs **280**
Schedule 9—Prohibited substances **285**
Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use **293**
Appendix A—General exemptions **299**
1 Exempt preparations and products 299
Appendix B—Substances considered not to require control by scheduling **302**
1 Reasons for including substances in the table in clause 3 302
2 Areas of use in relation to substances included in the table in clause 3 302
3 Substances exempt in certain uses....304

Authorised Version F2026L01327 registered 30/09/2026

Appendix C—Blank 312

Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8 313

1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner 313
2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist....313
3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act....314
4 Poisons available only from or on the order of a specialist physician 314
5 Poisons for which possession without authority is illegal....314
6 Poisons available for human use only from or on the prescription or order of a specialist physician....316
7 Poisons available for human use only from or on the prescription or order of a dermatologist....316
8 Poisons which must be stored in a locked container to prevent unauthorised access 316
9 Poisons available only when prescribed or authorised in certain circumstances 316

Appendix E—First aid instructions for poisons 318

1 Standard statements for first aid instructions 318
2 Poisons information centre contact information in statements 319
3 First aid instructions for poisons 319

Appendix F—Warning statements and general safety directions for poisons 331

1 Warning statements 331
2 Safety directions—general 336
3 Poisons information centre contact information in statements 337
4 Poisons that must be labelled with warning statements and safety directions 337

Appendix G—Dilute preparations 352

1 Substances exempt at or below certain concentrations 352

Appendix H—Schedule 3 medicines permitted to be advertised 354

1 Schedule 3 medicines permitted to be advertised 354

Appendix I—Blank 356

Appendix J—Conditions for availability and use of certain poisons included in Schedule 7 357

1 Conditions for supply of certain poisons included in Schedule 7 357

Appendix K—Human medicines required to be labelled with a sedation warning 360

1 Human medicines required to be labelled with a sedation warning....360

Appendix L—Requirements for dispensing labels for medicines 365

1 General 365
2 Additional warning statements for certain human medicines 365

Authorised Version F2026L01327 registered 30/09/2026

Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist **368**

Index **369**

Authorised Version F2026L01327 registered 30/09/2026

Authorised Version F2026L01327 registered 30/09/2026

Reader's guide

Introduction

This instrument is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the ***Act***), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the *Scheduling Policy Framework* (the ***SPF***) of the Australian Health Ministers' Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration's website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including "medicine" and "poison" (noting that the definition of poison includes medicine).

This instrument serves 2 key purposes.

Firstly, this instrument contains the decisions of the Secretary of the Department of Health, Disability and Ageing or the Secretary's delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, this instrument includes provisions for labelling, containers, storage, disposal, record-keeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products.

The requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.

This instrument is presented with a view to promoting uniform:

- scheduling of poisons throughout Australia; and
- signal headings on labels for poisons throughout Australia; and
- labelling and packaging requirements for poisons throughout Australia; and
- additional controls on the availability and use of poisons in Australia.

The various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following:

- the Act;
- the *Agricultural and Veterinary Chemicals Code Act 1994*;
- the *Agricultural and Veterinary Chemicals Code Regulations 1995*;

Authorised Version F2026L01327 registered 30/09/2026

- the *Therapeutic Goods (Standard for Labelling of Prescription Medicines) (TGO 115) Order 2026*;
- the *Therapeutic Goods (Standard for Labelling of Non-Prescription Medicines) (TGO 116) Order 2026*;
- the *Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017*;
- the *Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017* (TGO 95);
- the *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*;
- the *Therapeutic Goods (Medicines Advisory Statements) Specification 2021* – Schedule 1 Required Advisory Statements for Medicine Labels No. 6 (RASML).

Authorised Version F2026L01327 registered 30/09/2026

Classification

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

Schedule	Title	Description
Schedule 1	Blank	This Schedule is intentionally blank.
Schedule 2	Pharmacy medicines	Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.
Schedule 3	Pharmacist only medicines	Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.
Schedule 4	Prescription only medicines and prescription animal remedies	Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.
Schedule 5	Caution	Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.
Schedule 6	Poisons	Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.
Schedule 7	Dangerous poisons	Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.
Schedule 8	Controlled drugs	Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.
Schedule 9	Prohibited substances	Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Schedule 10 (previously Appendix C)	Substances of such danger to health as to warrant prohibition of supply and use	Substances which are prohibited for the purpose or purposes listed for each poison.

Authorised Version F2026L01327 registered 30/09/2026

Principles of scheduling

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.

Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.

Substances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Authorised Version F2026L01327 registered 30/09/2026

Reading the schedules

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word "**except**" in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption ("reverse scheduling"), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its "approved name" it may be shown under a group term such as:

Authorised Version F2026L01327 registered 30/09/2026

Group	Example
the parent acid of salts	"oxalic acid" to find sodium oxalate
the radical of a salt	"chromates" to find potassium chromate
the element	"arsenic" to find arsenic trioxide
a chemical group with similar toxicological or pharmacological activity	"hydrocarbons, liquid" to find kerosene
a pharmacological group	"anabolic steroidal agents" to find "androsterone"

Authorised Version F2026L01327 registered 30/09/2026

Availability of poisons

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not:

- indicate that the poison is available; or
- indicate that it is has been approved or is efficacious for any use that may be specified in a Schedule; or
- negate any obligation for registration of therapeutic goods, or agricultural or veterinary chemical product containing that poison.

Authorised Version F2026L01327 registered 30/09/2026

Appendices

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

Appendix	Title	Purpose/controls imposed
Appendix A	General exemptions	List of preparations and products exempted from this instrument.
Appendix B	Substances considered not to require control by scheduling	List of poisons exempted from scheduling.
Appendix C	Appendix is intentionally left blank	See Schedule 10.
Appendix D	Additional controls on possession or supply of poisons included in Schedule 4 or 8	List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.
Appendix E	First aid instructions for poisons	First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use).
Appendix F	Warning statements and general safety directions for poisons	Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use).
Appendix G	Dilute preparations	Concentration cut-offs for specified poisons, below which the requirements of this instrument do not apply
Appendix H	Schedule 3 medicines permitted to be advertised	List of medicines included in Schedule 3 that are permitted to be advertised to the public.
Appendix I	Appendix is intentionally left blank	
Appendix J	Conditions for availability and use of Schedule 7 poisons	List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use.
Appendix K	Human medicines required to be labelled with a sedation warning	List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential.
Appendix L	Requirements for dispensing labels for medicines	Requirements applying to labels attached to medicines at the time of dispensing.
Appendix M	Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist Appendix is intentionally left blank and is reserved for future use.	

Appendix A (General exemptions)

Appendix A lists preparations and products that are exempted from this instrument.

Authorised Version F2026L01327 registered 30/09/2026

Appendix B (Substances considered not to require control by scheduling)

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Inclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling).

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

- the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
- the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
- the public access was limited such that scheduling was inappropriate or unnecessary.

The list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns "Reason for Entry" and "Area of Use".

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

Appendix C (blank)

Appendix C is intentionally blank.

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)

Appendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.

Appendix E (First aid instructions for poisons)

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non-toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

The First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or

Authorised Version F2026L01327 registered 30/09/2026

requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as "If in eyes rinse well with water" may be appropriate.

Appendix F (Warning statements and general safety directions for poisons)

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

Appendix G (Dilute preparations)

Appendix G lists concentration cut-offs for specified substances, below which the requirements of this instrument do not apply.

Appendix H (Schedule 3 medicines permitted to be advertised)

Appendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public.

Appendix I (blank)

Appendix I is intentionally blank.

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7)

All poisons included in Appendix J are not to be available except to authorised or licensed persons.

The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation.

Appendix K (Human medicines required to be labelled with a sedation warning)

Medicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential.

Appendix L (Requirements for dispensing labels for medicines)

Appendix L sets out the requirements for labels attached to medicines at the time of dispensing.

Appendix M (blank)

Appendix M is intentionally blank and is reserved for future use.

Authorised Version F2026L01327 registered 30/09/2026

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

Authorised Version F2026L01327 registered 30/09/2026

Authorised Version F2026L01327 registered 30/09/2026

Part 1—Preliminary and interpretation

1 Name

(1) This instrument is the *Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026*.

(2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 51.

Note: This instrument is the ***current Poisons Standard*** for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act).

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information

Column 1	Column 2	Column 3
Provisions	**Commencement**	**Date/Details**
1. The whole of this instrument	1 October 2026.	1 October 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989*.

4 Repeal and transitional provisions

Repeal

(1) The *Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026* is repealed.

Saving—things done under the repealed instrument

(2) If:

(a) a thing was done for a particular purpose under the *Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026* as in force immediately before that instrument was repealed; and

Authorised Version F2026L01327 registered 30/09/2026

(b) the thing could be done for that purpose under this instrument;

the thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument.

(3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued.

5 Reader's guide and Index

(1) The Reader's guide is not part of this instrument.

(2) The Index is not part of this instrument.

6 Definitions

Note 1: The following expressions used in this instrument are defined in the Act:
(a) current Poisons Standard;
(b) poison;
(c) Register;
(d) Secretary;
(e) supply;
(f) therapeutic goods.

Note 2: The definition of ***poison*** in the Act is as follows:

> ***poison*** means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard.

In this instrument:

Act means the *Therapeutic Goods Act 1989*.

agricultural chemical means:

(a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:
(i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or
(ii) destroying a plant; or
(iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or
(iv) modifying an effect of another agricultural chemical; or
(v) attracting a pest for the purpose of destroying it; or

(b) an active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an agricultural chemical product;

but does not include a veterinary chemical.

agricultural chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

Authorised Version F2026L01327 registered 30/09/2026

animal means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

animal feed premix means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal's food.

appropriate authority: each of the following is an ***appropriate authority***:

(a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory;

(b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate;

(c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate.

approved name means:

(a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the *Therapeutic Goods Regulations 1990*; or

(b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*; or

(c) for any other poison—the name for the poison mentioned in the first-occurring of the following paragraphs that applies to the poison:

(i) the name used for the poison in this instrument;

(ii) the name recommended by Standards Australia as the common name for the poison;

(iii) the English name given to the poison by the International Organization for Standardization;

(iv) the name given to the poison by the British Standards Institution;

(v) the English name given to the poison by the European Committee for Standardization (CEN);

(vi) the international non-proprietary name recommended for the poison by the World Health Organization;

(vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the *International Cosmetic Ingredient Dictionary & Handbook* published by the Personal Care Products Council of America;

(viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

Australian Dangerous Goods Code means the *Australian Code for the Transport of Dangerous Goods by Road & Rail*, published by the National Transport Commission, as existing from time to time.

Authorised Version F2026L01327 registered 30/09/2026

Note: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission's website (www.ntc.gov.au).

authorised prescriber means any of the following:

(a) a dental practitioner;

(b) a medical practitioner;

(c) a veterinarian;

(d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect.

blood means whole blood extracted from human donors.

blood components means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

child-resistant closure means:

(a) a closure that complies with the requirements for a child-resistant closure in Australian Standard AS 1928-2007, *Child-resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD)*; or

(b) a closure that complies with the requirements for child-resistant closures specified in *Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017* (TGO 95); or

(c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*; or

(d) in the case of a can fitted with a press-on lid, a lid of the design known as "double tight" or "triple tight".

Note: See also the definition of ***non-access packaging***.

child-resistant packaging means packaging that:

(a) complies with the requirements of Australian Standard AS 1928-2007, *Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD)*; or

(b) is reclosable and complies with the requirements of at least one of the following:

(i) the International Organization for Standardization Standard ISO 8317:2015, *Child-resistant packaging—Requirements and testing procedures for reclosable packages*;

(ii) the British Standards Institution Standard BS EN ISO 8317:2015, *Child-resistant packaging—Requirements and testing procedures for reclosable packages*;

(iii) the Canadian Standards Association Standard CSA Z76.1:21, *Reclosable Child-Resistant Packages*;

(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, *Poison prevention packaging standards* and Section 1700.20, *Testing procedure for special packaging*, as in force from time to time; or

Authorised Version F2026L01327 registered 30/09/2026

(c) a closure that complies with the requirements for child-resistant packaging specified in *Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017* (TGO 95); or

(d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*; or

(e) is in the form of blister or strip packaging:

(i) in which a unit of use is individually protected until the time of release; and

(ii) that complies with section 3 (Requirements for non-reclosable packages) of Australian Standard AS1928-2007, *Child-resistant packages*.

Note: See also the definition of ***non-access packaging***.

compounded in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

cosmetic means a substance or preparation intended for placement in contact with any external part of the human body, including:

(a) the mucous membranes of the oral cavity; and

(b) the teeth;

with a view to:

(c) altering the odours of the body; or

(d) changing its appearance; or

(e) cleansing it; or

(f) maintaining it in good condition; or

(g) perfuming it; or

(h) protecting it.

debitterised neem seed oil means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

dental practitioner means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist).

dermal use means application to the skin primarily for localised effect.

designated solvent means the following:

(a) acetone;

(b) dimethylformamide;

(c) *N*-(*N*-dodecyl)-2-pyrrolidone;

(d) hydrocarbons, liquid;

(e) methanol when included in Schedule 5;

(f) methyl ethyl ketone;

(g) methyl isoamyl ketone;

(h) methyl isobutyl ketone;

(i) *N*-methyl-2-pyrrolidone;

Authorised Version F2026L01327 registered 30/09/2026

(j) *N*-(*N*-octyl)-2-pyrrolidone;
(k) phenyl methyl ketone;
(l) styrene;
(m) tetrachloroethylene;
(n) 1,1,1-trichloroethane.

dispensing label, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing.

Note: See section 40 and Appendix L.

distributor means a person who imports or supplies a poison.

divided preparation means a preparation manufactured and packed as discrete pre-measured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

dosage unit means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

drug means a poison intended for human or animal therapeutic use.

essential oils means:
(a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or
(b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or
(c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components.

external in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

first group paint: see section 67.

free formaldehyde includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.

graphic material means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

hand sanitiser preparation means an antimicrobial skin care product that:
(a) consists of, contains or generates one or more antimicrobial active substances; and
(b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason):
(i) for use on hands when soap and water are not available; and

Authorised Version F2026L01327 registered 30/09/2026

(ii) applied to the hands without rinsing off; and
(iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin.

hawking means to supply (including peddle or distribute or cause to be distributed) in a public place.

height in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

hemp seed oil means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

immediate container includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

immediate wrapper means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

internal use means administration:
(a) orally, except for topical effect in the mouth; or
(b) for absorption and the production of a systemic effect:
(i) by way of a body orifice other than the mouth; or
(ii) parenterally, other than by application to unbroken skin.

label:
(a) means a written statement on a container of a poison; and
(b) in relation to therapeutic goods, includes a display of printed information about the product:
(i) on, or attached to, the goods; or
(ii) on, or attached to, a container or primary pack in which the goods are supplied; or
(iii) supplied with such a container or pack.

main label, for a container of poison, means:
(a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and
(b) if there are 2 or more labels:
(i) the label or the part of the label where the product name is more or most conspicuously shown; or
(ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed.

manufacturer of a poison means a person who manufactures, produces, or packs a poison.

marker dyes or pigments means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from

Authorised Version F2026L01327 registered 30/09/2026

untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot- or boom-spraying.

measure pack means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

medical practitioner means a person who is registered, in a State or internal Territory, as a medical practitioner.

medicine means any poison for therapeutic use.

midwife means a person who is registered, in a State or internal Territory, as a midwife.

non-access packaging, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 4710-2001, *Packages for chemicals not intended for access or contact with their contents by humans*.

Note: See also the definitions of ***child-resistant closure*** and ***child-resistant packaging***.

non-volatile content in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005, *Paints and related materials – Methods of test – Non-volatile content by mass*.

nurse means a person who is registered, in a State or internal Territory, as a nurse.

oromucosal use means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

paint includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

pesticide means any substance or mixture of substances used or intended to be used:

(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

pharmacist means a person who is registered, in a State or internal Territory, as a pharmacist.

primary pack, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply.

Authorised Version F2026L01327 registered 30/09/2026

product sample means a packed poison supplied directly to a consumer:

(a) free of charge or for a nominal charge; and

(b) as a mechanism to promote the supply of the product; and

(c) in the form of:

(i) a small pack produced specifically for the purposes of promotion; or

(ii) a normal commercial pack that in other circumstances could be purchased by the consumer.

public place means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public.

Note: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house.

required advisory statements for medicine labels means the *Therapeutic Goods (Medicines Advisory Statements) Specification 2021*.

restricted flow insert means a restriction:

(a) that is fitted or moulded in the neck of a container; and

(b) that cannot readily be removed from the container by manual force; and

(c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres.

second group paint: see section 68.

selected container means:

(a) an injection vial having a nominal capacity of 10 ml or less; or

(b) a single use syringe; or

(c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less.

solid includes powder.

substance has the same meaning as in Part 6-3 of the Act.

Note 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals.

Note 2: See also section 7.

therapeutic use means use in or in connection with:

(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or

(b) influencing, inhibiting or modifying a physiological process in human beings or animals; or

(c) testing the susceptibility of human beings or animals to a disease or ailment; or

(d) influencing, controlling or preventing conception in human beings or animals; or

(e) testing for pregnancy in human beings or animals; or

(f) the replacement or modification of parts of the anatomy in human beings or animals.

Authorised Version F2026L01327 registered 30/09/2026

tinter means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

topical use means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

toy means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.

transdermal use means application to the skin primarily for systemic effect.

veterinarian means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon.

veterinary chemical means:

(a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:
  (i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or
  (ii) curing or alleviating an injury suffered by the animal; or
  (iii) modifying the physiology of the animal:
    (A) so as to alter its natural development, productivity, quality or reproductive capacity; or
    (B) so as to make it more manageable; or
  (iv) modifying the effect of another veterinary chemical; or
(b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or
(c) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be a veterinary chemical product;

but does not include an agricultural chemical.

veterinary chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

7 References to substances

In this instrument, unless the contrary intention appears, a reference to a substance includes the following:

(a) that substance prepared from natural sources or artificially;
(b) if the substance is a plant (other than a plant included in Schedule 8 or 9)—that plant or any part of that plant when packed or prepared for therapeutic use;
(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative;
(d) every alkaloid of the substance and every salt of such an alkaloid;
(e) every stereoisomer of the substance and every salt of such a stereoisomer;

Authorised Version F2026L01327 registered 30/09/2026

(f) every recombinant form of the substance;

(g) a preparation or admixture containing any proportion of the substance.

Note: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11).

8 References to concentration, strength or quantity of substances

In this instrument, for a reference to a concentration, strength or quantity of a substance:

(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and

(b) the expression "1%" means:

(i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or

(ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and

(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

9 References to boiling or distillation temperatures

In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury).

10 References to standards

A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time.

Authorised Version F2026L01327 registered 30/09/2026

Part 2—Controls on substances

Division 1—Preliminary

11 Application of Part 2

This Part applies to a substance or preparation included in a schedule to this instrument, other than the following:

(a) a preparation or product included in the table in clause 1 of Appendix A;

(b) a substance included in the table in clause 3 of Appendix B when used in an area, sub-area or sub-sub-area of use specified in the table in relation to that substance;

(c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance;

(d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8;

(e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022*, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time.

Note: For paragraph (e), the *Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022* is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au.

12 Preparations containing poisons included in different schedules

(1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation.

(2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation.

(3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5.

Note: Schedule 1 is not currently in use.

Authorised Version F2026L01327 registered 30/09/2026

Division 2—Labels

Subdivision A—General

13 General requirements

(1) A poison must not be supplied unless it is labelled in accordance with this Division.

(2) Any word, expression or statement required by this instrument to be written on a label or container must be written:
  (a) on the outside face of the label or container; and
  (b) in English; and
  (c) in durable characters; and
  (d) in a colour or colours to provide a distinct contrast to the background colour; and
  (e) in letters at least 1.5 mm in height.

(3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if:
  (a) an appropriate authority approves the use of smaller letters; and
  (b) the letters are at least 1 mm in height.

(4) The label must be printed on, or securely attached to:
  (a) the outside of the immediate container; and
  (b) if the immediate container is enclosed in a primary pack—the outside of that primary pack.

14 Immediate wrapper

If a poison is enclosed in an immediate wrapper:
  (a) the poison must be contained in a primary pack labelled in accordance with section 15; and
  (b) the immediate wrapper must be conspicuously labelled with:
    (i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and
    (ii) the approved name of the poison; and
    (iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34.

Subdivision B—Primary packs and immediate containers

15 Primary packs and immediate containers

This Subdivision sets out how the primary pack and immediate container of a poison must be labelled.

Authorised Version F2026L01327 registered 30/09/2026

16 Signal words

(1) The signal word or words for the poison, as shown in the following table, must be written:

(a) on the first line or lines of the main label; and

(b) in bold-face sans serif capital letters of uniform thickness; and

(c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and

(d) with nothing else other than the following written on the same line or lines:

(i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code or a statement of the principal hazard of the poison;

(ii) if the poison is not included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code.

Signal word or words for poisons

Item	For a poison included in the following schedule …	that is to be used for the following purpose …	the signal word or words are …
1	Schedule 2	for any purpose	PHARMACY MEDICINE
2	Schedule 3	for any purpose	PHARMACIST ONLY MEDICINE
3	Schedule 4	for human use	PRESCRIPTION ONLY MEDICINE
4	Schedule 4	for animal use	PRESCRIPTION ANIMAL REMEDY
5	Schedule 5	for any purpose	CAUTION
6	Schedule 6	for any purpose	POISON
7	Schedule 7	for any purpose	DANGEROUS POISON
8	Schedule 8	for any purpose	CONTROLLED DRUG

(2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name for the poison; or

(c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

(3) For the purposes of paragraph (1)(c), the letters need not be larger than:

(a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or

(b) 15 mm on labels for packages having a nominal capacity of more than 2 L.

17 Cautionary statement—possession without authority illegal

If the poison is included in Schedule 8, the cautionary statement:

POSSESSION WITHOUT AUTHORITY ILLEGAL

must be written:

Authorised Version F2026L01327 registered 30/09/2026

(a) on a separate line or lines immediately below the signal words required by section 16; and
(b) in bold-face sans serif capital letters of uniform thickness; and
(c) in letters at least four-tenths the height of the letters used for the signal words; and
(d) with no other statement written on the same line or lines.

18 Cautionary statement—keep out of reach of children

The cautionary statement:

KEEP OUT OF REACH OF CHILDREN

must be written:

(a) on a separate line or lines:
  (i) immediately below the signal word or words required by section 16; or
  (ii) if the cautionary statement "POSSESSION WITHOUT AUTHORITY ILLEGAL" is required by section 17—immediately below that statement; and
(b) in bold-face sans serif capital letters of uniform thickness; and
(c) in letters at least four-tenths the height of the letters used for the signal word or words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

19 Cautionary statement—fire and explosion hazard

(1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement:

FIRE AND EXPLOSION HAZARD

must be written:

(a) on a separate line or lines immediately below the cautionary statement "KEEP OUT OF REACH OF CHILDREN" as required by section 18; and
(b) in bold-face sans serif capital letters of uniform thickness; and
(c) in letters at least four-tenths the height of the letters used for the signal word or words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

(2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code.

20 Cautionary statement—burns skin and throat

If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement:

BURNS SKIN AND THROAT

Authorised Version F2026L01327 registered 30/09/2026

must be written:

(a) on a separate line or lines immediately below the cautionary statement "KEEP OUT OF REACH OF CHILDREN" as required by section 18; and

(b) in bold-face sans serif capital letters of uniform thickness; and

(c) in letters at least four-tenths the height of the letters used for the signal word; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label.

21 Cautionary statements for aqueous solution of paraquat

If the poison is an aqueous solution of paraquat, the cautionary statements:

CAN KILL IF SWALLOWED

DO NOT PUT IN DRINK BOTTLES

KEEP LOCKED UP

must be written:

(a) on separate lines immediately below the cautionary statement "KEEP OUT OF REACH OF CHILDREN" as required by section 18; and

(b) in bold-face sans serif capital letters of uniform thickness; and

(c) in letters at least four-tenths the height of the letters used for the signal words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label.

22 Cautionary statement—read safety directions

(1) If safety directions are required on the label by section 29, the following cautionary statement:

READ SAFETY DIRECTIONS BEFORE OPENING OR USING

or the following cautionary statement:

READ SAFETY DIRECTIONS

must be written:

(a) on a separate line or lines:

(i) immediately below the cautionary statement "KEEP OUT OF REACH OF CHILDREN" as required by section 18; or

(ii) if one or more other cautionary statements is required to be on the line immediately below "KEEP OUT OF REACH OF CHILDREN", immediately below that statement or those statements; and

(b) in bold-face sans serif capital letters of uniform thickness; and

(c) in letters at least four-tenths the height of the letters used for the signal word or words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

(2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels.

Authorised Version F2026L01327 registered 30/09/2026

23 Cautionary statement—flammable

If the poison meets the criteria for a "flammable liquid" in the Australian Dangerous Goods Code, the cautionary statement:

FLAMMABLE

must be written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code.

24 Cautionary statement—for animal treatment only

If the poison is only for the treatment of animals, the cautionary statement:

FOR ANIMAL TREATMENT ONLY

must be written on the main label in bold-face sans serif capital letters of uniform thickness.

25 Cautionary statement—do not swallow

If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement:

DO NOT SWALLOW

must be written in sans serif capital letters on the main label or as part of the directions for use.

26 Approved name and quantity, proportion or strength

(1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be:

(a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) if the poison is not for human therapeutic use—written in bold-face sans serif capital letters on the main label, unless:

(i) a list of approved names is required; and

(ii) it is impractical to include the list on the main label; and

(iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority.

(2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name.

Appropriate names for poisons

Item	Column 1 Poison	Column 2 Appropriate name
1	Alkaline salts	Alkaline salts

Authorised Version F2026L01327 registered 30/09/2026

Appropriate names for poisons		
Item	**Column 1** **Poison**	**Column 2** **Appropriate name**
2	Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules)	Aliphatic amines or aromatic amines
3	Epoxy resins, liquid	Liquid epoxy resins
4	Hydrocarbons, liquid	Liquid hydrocarbons
5	Quaternary ammonium compounds	Quaternary ammonium compound(s)

(3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows:

(a) where the designated solvent is a liquid hydrocarbon—as "liquid hydrocarbons";

(b) where the designated solvent is a ketone—as "ketones";

(c) in any other case—as "solvents" or "other solvents".

27 Statement—an anticholinesterase compound

(1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression:

AN ANTICHOLINESTERASE COMPOUND

must be written immediately below the approved name or the list of declared contents on the label.

(2) This section does not apply to:

(a) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or

(b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

(c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use.

28 Directions for use

If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless:

(a) it is a medicine for human use that is labelled in accordance with:

(i) the *Therapeutic Goods (Standard for Labelling of Prescription Medicines) (TGO 115) Order 2026*; or

(ii) the *Therapeutic Goods (Standard for Labelling of Non-Prescription Medicines) (TGO 116) Order 2026*; or

(b) it is in an agricultural or veterinary chemical product labelled in compliance with the *Agricultural and Veterinary Chemicals Code Act 1994*; or

(c) it is included in Schedule 4 or 8; or

(d) all of the following apply:

Authorised Version F2026L01327 registered 30/09/2026

(i) it is impractical to include such directions on the label;
(ii) the primary pack and the immediate container are labelled with the statement "DIRECTIONS FOR USE: See package insert";
(iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label;
(iv) the insert is enclosed in the primary pack.

29 Safety directions

(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words:

SAFETY DIRECTIONS

written in bold-face capital letters.

(2) This section does not apply to the following:
(a) a poison that:
(i) is a medicine for human use; and
(ii) is labelled in accordance with the required advisory statements for medicine labels;
(b) a poison that:
(i) is an agricultural chemical or a veterinary chemical; and
(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

30 Warning statements

(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together:
(a) if safety directions are included on the label—immediately after the words "SAFETY DIRECTIONS"; or
(b) if there are no safety directions—immediately preceding the directions for use.

(2) This section does not apply to the following:
(a) a poison that:
(i) is a medicine for human use; and
(ii) is labelled in accordance with the required advisory statements for medicine labels;
(b) a poison that:
(i) is an agricultural chemical or a veterinary chemical; and
(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

Authorised Version F2026L01327 registered 30/09/2026

31 First aid

(1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E:

(a) grouped together and prefaced by the following words:

FIRST AID

written in bold-face capital letters; or

(b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions:

(i) written on each immediate container as specified in paragraph (a); and

(ii) replaced on the primary pack with the statement:

FIRST AID: See inner packs.

(2) This section does not apply to the following:

(a) a poison that:

(i) is for human internal use; and

(ii) is included in Schedule 3, 4 or 8;

(b) a poison that:

(i) is a medicine for human use; and

(ii) is labelled in accordance with the required advisory statements for medicine labels;

(c) a poison that:

(i) is an agricultural chemical or a veterinary chemical; and

(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

32 Name and address of manufacturer or distributor

(1) The poison must be labelled with the name and address of its manufacturer or distributor. The address:

(a) must be a physical address in Australia; and

(b) must not be a post office, cable, telegraphic or code address.

(2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be:

(a) the registered name of the corporation or firm, or its branch or division; and

(b) the city or town in which a registered office of the company or firm is situated.

Authorised Version F2026L01327 registered 30/09/2026

33 Warning statements and sedation warnings for certain medicines for human use

Warning statements for certain medicines

(1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause.

Sedation warning for certain medicines

(2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F.

Subdivision C—Statements of quantity, proportion or strength

34 Statements of quantity, proportion or strength

(1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act;

(b) if the poison is for a purpose or purposes other than human therapeutic use—as follows:

(i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation;

(ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation;

(iii) if the poison is a liquid in a solid or semi-solid preparation—as the mass or volume of the poison per stated mass of the preparation;

(iv) if the poison is a solid or semi-solid in a liquid preparation—as the mass of the poison per stated volume of the preparation;

(v) if the poison is a solid or semi-solid in a solid or semi-solid preparation—as the mass of the poison per stated mass of the preparation;

(vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation;

(vii) if the poison is a gas in a solid or semi-solid preparation—as the mass of the poison per stated mass of the preparation;

(viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation;

(c) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;

(d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

Authorised Version F2026L01327 registered 30/09/2026

(i) "contains not more than 10 per cent of (*insert name of the metal*)";
(ii) "contains not more than 30 per cent of (*insert name of the metal*)";
(iii) "contains more than 30 per cent of (*insert name of the metal*)";

(e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product;

(f) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

(g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

(2) In paragraph (1)(g):

derivative includes alkaloid.

Note: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and sub-subparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B).

Subdivision D—Exemptions from labelling requirements

35 Selected containers and measure packs

The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which subsections 36(1) or (2) applies) if:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the immediate container is:
(i) packed in a primary pack labelled in accordance with Subdivision B; and
(ii) labelled with:
(A) the signal word or words for the poison as shown in the table in subsection 16(1); and
(B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and
(C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
(D) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

Authorised Version F2026L01327 registered 30/09/2026

36 Ampoules, pre-filled syringes and injection vials

(1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the selected container or ampoule is:

(i) packed in a primary pack labelled in accordance with Subdivision B; and

(ii) labelled with:

(A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and

(B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(C) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

(2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the poison is not therapeutic goods and all of the following apply:

(i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B;

(ii) the strip is labelled in accordance with this section;

(iii) the ampoule is labelled with:

(A) the approved name of the poison or the trade name of the poison; and

(B) the quantity, proportion or strength of the poison in accordance with section 34.

37 Transport containers and wrappings

The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

38 Dispensary, industrial, laboratory and manufacturing poisons

The labelling requirements of this instrument do not apply to a poison that:

(a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

Authorised Version F2026L01327 registered 30/09/2026

(b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time.

39 Exemptions from label requirements in certain circumstances

(1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison.

(2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force:

(a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID-19:

(i) for the period specified in the exemption; or

(ii) if no period is specified—until revoked by the appropriate authority; or

(b) in any other case:

(i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or

(ii) if no period is specified—12 months from the date of commencement of the exemption.

(3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii).

40 Dispensed medicines

Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that:

(a) is:

(i) supplied by an authorised prescriber; or

(ii) supplied on and in accordance with a prescription written by an authorised prescriber; or

(iii) prepared and supplied by a pharmacist for an individual patient; and

(b) is labelled in accordance with the requirements of clause 1 of Appendix L.

41 Gas cylinders

The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas.

42 Paints

The requirements of Subdivision B do not apply to:

(a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or

(b) a first group paint or second group paint that is labelled with:

Authorised Version F2026L01327 registered 30/09/2026

(i) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

(ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

(iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

(iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or

(c) a tinter which contains only poisons included in Schedule 5; or

(d) a tinter that contains a poison mentioned in a table in section 67 or 68, if:

(i) the tinter is labelled with the name and proportion of the poison; and

(ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.

43 Camphor and naphthalene

The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

(a) complies with section 52; and

(b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B.

Subdivision E—Prohibitions

44 Prohibitions

(1) A label used in connection with a poison must not include:

(a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or

(b) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by a government or government authority unless required by legislation; or

(c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

(d) any trade name or description that:

(i) represents any single constituent of a compound preparation; or

(ii) misrepresents the composition or any property or quality of the poison; or

(iii) gives any false or misleading indication of origin or place of manufacture of the poison.

Authorised Version F2026L01327 registered 30/09/2026

(2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack.

Authorised Version F2026L01327 registered 30/09/2026

Division 3—Containers

45 General requirements

A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met.

46 Containers for poisons other than poisons included in Schedule 5

(1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 2216-1997, *Packaging for poisonous substances*.

(2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, *Packaging for poisonous substances*, if:
  (a) other safety factors are not diminished; and
  (b) the container has a restricted flow insert and a child-resistant closure.

(3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L:
  (a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997, *Packaging for poisonous substances*; and
  (b) the word "POISON" must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirty-second part of the length, height or width of the container, whichever is the greatest.

47 Containers for poisons included in Schedule 5

(1) The container in which a poison included in Schedule 5 is supplied must:
  (a) comply with the container requirements of subsection 46(1) or (3); or
  (b) comply with subsection (2).

(2) A container complies with this subsection if:
  (a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and
  (b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997, *Packaging for poisonous substances*, excluding paragraph 1.4.3; and
  (c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being re-closed to prevent spillage of its contents; and
  (d) the expression "POISON", "NOT TO BE TAKEN" or "NOT TO BE USED AS A FOOD CONTAINER" is:
    (i) embossed or indelibly written on the container; or

Authorised Version F2026L01327 registered 30/09/2026

(ii) printed on a label that complies with subsection (3) that is attached to the container.

(3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

(4) Despite subsection (1), the following poisons included in Schedule 5:

(a) methylated spirit(s);

(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

(c) petrol;

(d) toluene;

(e) xylene;

must not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1).

48 Approved containers

Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS2216-1997 (*Packaging for poisonous substances*) or the requirements of paragraph 46(3)(b) or 47(2)(d) if:

(a) other safety factors are not diminished; and

(b) the container is for a specific purpose; and

(c) an appropriate authority has approved the use of the container for that purpose.

49 Child-resistant closures

(1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a child-resistant closure that:

(a) is appropriate for the container and the poison; and

(b) will retain its child-resistant properties for the expected life of the poison.

Poisons that must be closed with a child-resistant closure

Item	Column 1 Poison	Column 2 Nominal capacity of container
1	Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets	All sizes
2	Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels	5 L/kg or less
3	Alkaline salts included in Schedule 5, when packed and labelled as a food additive	2.5 L or less
4	Anise oil when included in Schedule 5	200 mL or less
5	Basil oil when included in Schedule 5	200 mL or less

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be closed with a child-resistant closure

Item	Column 1 Poison	Column 2 Nominal capacity of container
6	Bay oil when included in Schedule 6	200 mL or less
7	Cajuput oil when included in Schedule 6	200 mL or less
8	Cassia oil when included in Schedule 5	200 mL or less
9	Cineole when included in Schedule 6	2 L or less
10	Cinnamon bark oil when included in Schedule 5	200 mL or less
11	Cinnamon leaf oil when included in Schedule 6	200 mL or less
12	Clove oil when included in Schedule 6	200 mL or less
13	CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) when included in Schedule 6, when presented in a wipe	All sizes
14	Essential oils when included in Schedule 6 because of their natural camphor component	200 mL or less
15	Ethylene glycol when included in Schedule 6	5 L or less
16	Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol	5 L or less
17	Eucalyptus oil when included in Schedule 6	2 L or less
18	Eugenol when included in Schedule 6	200 mL or less
19	Fennel oil when included in Schedule 5	200 mL or less
20	Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid	5 L or less
21	Hydrochloric acid when included in Schedule 6	5 L or less
22	Leptospermum scoparium oil (manuka oil) when included in Schedule 6	200 mL or less
23	Marjoram oil when included in Schedule 5	200 mL or less
24	Melaleuca oil (tea-tree oil) when included in Schedule 6	200 mL or less
25	Methylated spirit excluding preparations or admixtures	5 L or less
26	Methyl salicylate and preparations containing more than 50% of methyl salicylate	200 mL or less
27	Nicotine in liquid preparations when included in Schedule 3 or 4.	All sizes
28	Nutmeg oil when included in Schedule 5	200 mL or less
29	Oil of turpentine	5 L or less
30	Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals	All sizes
31	Pennyroyal oil when included in Schedule 6	200 mL or less
32	Potassium hydroxide as such	2.5 L or less

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be closed with a child-resistant closure		
Item	**Column 1** **Poison**	**Column 2** **Nominal capacity of container**
33	Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 **except** when in pressurised spray packs	5 L or less
34	**D**-Pulegone when included in Schedule 6	200 mL or less
35	Sage oil (Dalmatian) when included in Schedule 6	200 mL or less
36	Sodium hydroxide as such	2.5 L or less
37	Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 **except** when in pressurised spray packs	5 L or less
38	Thujone when included in Schedule 6	200 mL or less
39	Thyme oil when included in Schedule 5	200 mL or less

(2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act.

50 Poisons included in Schedule 8

(1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

(2) This paragraph does not apply to the supply of a poison included in Schedule 8:
- (a) by an authorised prescriber or other authorised supplier; or
- (b) by a pharmacist on the prescription of an authorised prescriber; or
- (c) by a pharmacist employed at a hospital, on the written requisition of:
  - (i) a medical practitioner or dental practitioner; or
  - (ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or
- (d) by a nurse or midwife on the direction in writing of an authorised prescriber.

51 Exemptions

(1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold:
- (a) for human internal or animal internal use; or
- (b) as a solid or semi-solid preparation for human external or animal external use; or
- (c) as a paint, other than a paint for therapeutic or cosmetic use; or
- (d) in containers having a nominal capacity of 15 mL or less; or
- (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or
- (f) solely for dispensary, industrial, laboratory or manufacturing purposes.

Authorised Version F2026L01327 registered 30/09/2026

(2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

(3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 2216-1997, *Packaging for poisonous substances*, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

52 Camphor and naphthalene

(1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

(a) in normal use, prevents removal or ingestion of its contents; and

(b) is incapable of reacting with the poison; and

(c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

(d) has the word "POISON" and the approved name of the poison embossed or indelibly printed on it.

(2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

53 Prohibitions—use of containers for poisons

(1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison.

(2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use.

(3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink.

(4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold.

Authorised Version F2026L01327 registered 30/09/2026

Division 4—Storage

54 General storage requirements

Poisons included in Schedule 2

(1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required.

Poisons included in Schedules 3 and 4

(2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access.

Poisons included in Schedule 6

(3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children.

Poisons included in Schedule 7

(4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following:
   (a) the owner of the retail establishment;
   (b) an employee of the owner;
   (c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner.

Authorised Version F2026L01327 registered 30/09/2026

Division 5—Disposal

55 General disposal requirements

A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety.

Note: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Authorised Version F2026L01327 registered 30/09/2026

Division 6—Record keeping

56 General record-keeping requirements

(1) If a poison included in Schedule 7 is supplied, a record of the following must be kept:

(a) the name and address of the supplier and of the purchaser;

(b) the date of the order and supply;

(c) the approved name or trade name of the poison;

(d) the quantity supplied or sold;

(e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation.

(2) The records mentioned in subsection (1) must be kept for at least 5 years.

Note: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Authorised Version F2026L01327 registered 30/09/2026

Division 7—Advertising

57 General advertising requirements

Poisons included in Schedule 3, 4 and 8

(1) A reference to a poison included in:

(a) Schedule 3, unless included in Appendix H; or

(b) Schedule 4; or

(c) Schedule 8;

must not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

Poisons included in Schedules 9 and 10

(2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement.

Note: Schedule 10 includes poisons previously listed in Appendix C.

Authorised Version F2026L01327 registered 30/09/2026

Division 8—Supply, prescribing, possession or use

58 Poisons included in Schedule 2

(1) A poison included in Schedule 2 must not be supplied by a person other than:
  (a) a person who:
    (i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and
    (ii) is acting in the lawful practice of the person's profession; or
  (b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison.

(2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless:
  (a) the person is carrying on the business of supplying goods by retail sale; and
  (b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and
  (c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed.

(3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to:
  (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or
  (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

59 Poisons included in Schedule 3

(1) A poison included in Schedule 3 must not be supplied by a person other than a person who:
  (a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and
  (b) is acting in the lawful practice of the person's profession.

(2) The following requirements apply if a poison included in Schedule 3 is supplied:
  (a) adequate instructions for use, either written or verbal, must be provided at the time of supply;
  (b) the container of the poison must be labelled with:
    (i) the name of the supplier or the name of the pharmacy (as applicable); and
    (ii) the address from which it was supplied;
  (c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system.

(3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to:
  (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

Authorised Version F2026L01327 registered 30/09/2026

(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

60 Poisons included in Schedule 4

(1) A poison included in Schedule 4 must not be supplied by a person other than:
  (a) a person who:
    (i) is a medical practitioner, dental practitioner or veterinarian; and
    (ii) is acting in the lawful practice of the person's profession; or
  (b) a pharmacist dispensing a legal prescription for the poison; or
  (c) a pharmacist supplying the poison without a prescription as permitted by subsection (2).

(2) A poison included in Schedule 4 may be supplied to a person (the ***patient***) by a pharmacist without a prescription if:
  (a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and
  (b) the patient is under medical treatment with the poison and continuation of medication is essential; and
  (c) the quantity supplied does not exceed 3 days' medication; and
  (d) the pharmacist is satisfied that an emergency exists.

(3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to:
  (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or
  (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

61 Poisons included in Schedules 5 and 6

(1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply.

(2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product).

(3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5.

62 Poisons included in Schedule 7

Possession or use for domestic or domestic garden purposes prohibited

(1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes.

Authorised Version F2026L01327 registered 30/09/2026

Supply for domestic or domestic garden purposes prohibited

(2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes.

Supply of liquid preparations containing paraquat

(3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell.

Supply if authorisation required by appropriate authority

(4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation.

Product samples prohibited

(5) A product sample containing a poison included in Schedule 7 must not be supplied.

Supply of poisons included in Appendix J

(6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause.

63 Poisons included in Schedule 10

A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10.

Note: Schedule 10 includes poisons previously listed in Appendix C.

64 Poisons included in Schedule 4 or 8 and Appendix D

(1) This section applies to a poison included in Schedule 4 or 8.

Supply or prescribing

(2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table.

(3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D.

Possession

(4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs.

Authorised Version F2026L01327 registered 30/09/2026

Storage

(5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access.

65 Hawking

A poison included in Schedule 7 must not be supplied by way of hawking.

Note: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Authorised Version F2026L01327 registered 30/09/2026

Division 9—Paints and tinters

Note: Paints and tinters are poisons that were previously listed in Appendix I.

66 General requirements

(1) A first group paint must not be manufactured, supplied or used for application to:
  (a) a roof or any surface to be used for the collection or storage of potable water; or
  (b) furniture; or
  (c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or
  (d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

(2) An anti-fouling paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the non-volatile content of the paint) must not be manufactured, supplied or used.

(3) A paint (other than an anti-fouling paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the non-volatile content of the paint) must not be manufactured, supplied or used.

(4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, *Safety of toys Part 3: Migration of certain elements (ISO 8124-03:2010, MOD)*, published jointly by, or on behalf of, Standards Australia and Standards New Zealand.

(5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used.

67 Definition of *first group paint*

A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the non-volatile content of the paint) specified in column 2 of the item is a ***first group paint***.

First group paints

Item	Column 1 Substance	Column 2 Proportion
1	ANTIMONY or antimony compounds other than antimony titanate pigments	more than 5%
2	BARIUM salts **except** barium sulfate or barium metaborate	more than 5%
3	CADMIUM or cadmium compounds	more than 0.1%
4	CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc	more than 5%
5	SELENIUM or selenium compounds	more than 0.1%

Authorised Version F2026L01327 registered 30/09/2026

68 Definition of *second group paint*

A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a ***second group paint***.

Second group paints

Item	Column 1 Substance	Column 2 Proportion
1	DICHLOROMETHANE (methylene chloride)	more than 5% by weight
2	ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates	more than 10% by volume
3	HEXYLOXYETHANOL	more than 10% by volume
4	TOLUENE	more than 50% by volume
5	XYLENE	more than 50% by volume

Authorised Version F2026L01327 registered 30/09/2026

Schedule 1—Blank

Note: Schedule 1 is intentionally blank.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 2—Pharmacy medicines

Note: See section 16, subsection 54(1) and section 58.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH_3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing alimemazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

ALOXIPRIN.

AMOROLFINE in preparations for topical use **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except** when:

(a) included in Schedule 4, 5 or 6; or

(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

(i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and

(ii) compliant with the requirements of the required advisory statements for medicine labels; or

(c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

(i) either:

(A) packed in blister or strip packing; or

Authorised Version F2026L01327 registered 30/09/2026

(B) in a container with a child-resistant closure; and

(ii) either:

(A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or

(B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or

(C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the required advisory statements for medicine labels.

ASTODRIMER SODIUM when used in a nasal spray.

ATROPA BELLADONNA (belladonna):

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use in adults and children 6 years of age and over:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations for human therapeutic use.

AZELASTINE:

(a) in preparations for nasal use; or

(b) in topical eye preparations containing 0.05% or less of azelastine.

BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or

Authorised Version F2026L01327 registered 30/09/2026

less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a) containing 10% or less of total local anaesthetic substances, **except** in dermal preparations containing 2% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide **except** in preparations containing 5% or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except**:

(a) in preparations for dermal use; or

(b) in divided topical oral preparations containing 3 mg or less of benzydamine; or

(c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years and over.

BISACODYL in divided preparations for:

(a) oral use **except** in a primary pack containing 20 dosage units or less containing 5 mg or less of bisacodyl per dosage unit; or

(b) rectal use **except**:

(i) in a primary pack containing 12 dosage units or less of suppositories containing 10 mg or less of bisacodyl per dosage unit; or

(ii) in a primary pack containing 25 dosage units or less of enemas containing 10 mg or less of bisacodyl per dosage unit.

BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

Authorised Version F2026L01327 registered 30/09/2026

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5% or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

(a) in a primary pack containing not more than 10 days' supply; and

(b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol **except** in preparations containing 0.5% or less of chlorbutanol.

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5% or less of chloroform.

CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing chlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

CHOLINE SALICYLATE in preparations for oromucosal use.

CICLOPIROX:

(a) in preparations for dermal use containing 2% or less of ciclopirox **except** in preparations for the treatment of tinea pedis; or

(b) in preparations for application to the nails containing 8% or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.

Authorised Version F2026L01327 registered 30/09/2026

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10% or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except for smoking or burning.

DATURA TATULA (stramonium) for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2% or less of Delphinium staphisagria.

DESLORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis when:

(a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and

(b) labelled with a recommended daily dose not exceeding 5 mg of desloratadine.

Authorised Version F2026L01327 registered 30/09/2026

DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing dexchlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

(a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or

(b) in preparations for dermal use containing 4% or less of diclofenac **except** in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or

(c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

Authorised Version F2026L01327 registered 30/09/2026

DUBOISIA LEICHHARDTII for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

ETAFEDRINE.

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 10% or less of ether.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days' supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use **except** in divided preparations:

(a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

(b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

Authorised Version F2026L01327 registered 30/09/2026

(i) in a primary pack containing 10 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

(c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FLUORIDES for human use:

(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:

(i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of required advisory statements for medicine labels; or

(ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/insert name of product] in children 6 years of age or less;

except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(C) Do not swallow; and

(D) Do not use [this product/insert name of product] in children 6 years of age or less;

except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit **except** when:

(i) in a primary pack containing not more than 16 dosage units; and

(ii) labelled only for the treatment of adults and children over 12 years; or

(b) in undivided preparations containing either:

(i) 0.25% or less of flurbiprofen per dose; or

(ii) 10 mg or less of flurbiprofen per dose;

Authorised Version F2026L01327 registered 30/09/2026

except when:

(iii) in a primary pack containing not more than 15 mL; and

(iv) labelled only for the treatment of adults 18 years and over.

FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis of allergic rhinitis or treatment of allergic rhinitis and rhino-conjunctivitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

GELSEMIUM SEMPERVIRENS.

GLUTARAL for human therapeutic use.

GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene **except**:

(a) in preparations for use on infants, as specified in Schedule 4; or

(b) in preparations for cosmetic use, as specified in Schedule 6; or

(c) in other preparations containing 0.75% or less of hexachlorophene.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:

(a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:

Authorised Version F2026L01327 registered 30/09/2026

(i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and

(ii) not labelled for the treatment of children under 12 years of age; or

(c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone **except**:

(a) in hair preparations containing 0.3% or less of hydroquinone; or

(b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYOSCINE:

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

Authorised Version F2026L01327 registered 30/09/2026

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:

(a) in liquid preparations that are sold in the manufacturer's original pack containing 8 g or less of ibuprofen; or

(b) in divided immediate release preparations:

(i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and

(ii) that are labelled not for the treatment of children under 12 years; or

(c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:

(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years or under; and

(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

INDANAZOLINE.

INDOMETACIN in preparations for external use containing 1% or less of indometacin.

IODINE:

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);

except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

Authorised Version F2026L01327 registered 30/09/2026

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use **except**:

(a) when included in Schedule 4; or

(b) when labelled with a recommended daily dose of 24 mg or less of iron:

(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

(ii) in divided preparations:

(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

(B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.

LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

LEVOCABASTINE in topical eye or nasal preparations.

LEVOCETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing not more than 5 days' supply; and

(b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LIDOCAINE in preparations for topical use other than eye drops:

(a) containing 10% or less of total local anaesthetic substances, **except**:

(i) in dermal preparations containing 2% or less of total local anaesthetic substances; or

(ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

Authorised Version F2026L01327 registered 30/09/2026

LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.

LITHIUM in preparations for dermal use containing 1% or less of lithium **except**:

(a) when present as an excipient at 0.25% or less of lithium; or

(b) in preparations containing 0.01% or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less **except** in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis when:

(a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and

(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome **except** when included in Schedule 6.

MERCURY for external use in preparations containing 0.5% or less of mercury.

METHOXAMINE in preparations for external use **except** in preparations containing 1% or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

Authorised Version F2026L01327 registered 30/09/2026

MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer's original pack containing not more than 14 days' supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OLOPATADINE in preparations for nasal use delivering 600 micrograms or less of olopatadine per dose when the maximum recommended daily dose is no greater than 4,800 micrograms for the treatment of allergic rhinitis or rhinoconjunctivitis for up to 6 months in adults and children 12 years of age and over.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

OXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1% or less of such substances.

PAPAVERINE **except** when included in Schedule 4.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

PARACETAMOL for therapeutic use:

(a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or

(b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or

Authorised Version F2026L01327 registered 30/09/2026

(c) in tablets or capsules in blister or strip packaging enclosed in a primary pack containing not more than 50 tablets or capsules; or

(d) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 25 wrapped powders or sachets of granules; or

(e) in other preparations **except**:

(i) when included in Schedule 3 or 4; or

(ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

(A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;

(B) compliant with the requirements of the required advisory statements for medicine labels;

(C) not labelled for the treatment of children 6 years of age or less; and

(D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or

(iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

(A) packed in blister or strip packaging;

(B) in a primary pack containing not more than 16 tablets or capsules;

(C) compliant with the requirements of the required advisory statements for medicine labels;

(D) not labelled for the treatment of children 6 years of age or less; and

(E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

Authorised Version F2026L01327 registered 30/09/2026

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYLEPHRINE **except**:

(a) when included in Schedule 4; or

(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1% or less of phenylephrine.

PHOLCODINE:

(a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10% or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

Authorised Version F2026L01327 registered 30/09/2026

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days' supply **except**:

(a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units; or

(b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 7 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

(a) for topical use containing 3.5% or less of selenium sulfide;

(b) when included in Schedule 4; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

(a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in other preparations containing 1% or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

Authorised Version F2026L01327 registered 30/09/2026

SQUILL **except** in preparations containing 1% or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances **except** in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACHLOROETHYLENE for human therapeutic use.

TETRYZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use **except** in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5% or less of zinc chloride.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 3—Pharmacist only medicines

Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.

ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.

ADRENALINE in:

(a) preparations containing 1% or less of adrenaline; or

(b) intranasal preparations containing 2% or less of adrenaline;

except in preparations that are not for injection containing 0.02% or less of adrenaline.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.

ALIMEMAZINE:

(a) in solid oral preparations **except** when included in Schedule 2; or

(b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;

except in preparations for the treatment of children under 2 years of age.

AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.

AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child-resistant closures.

ASTODRIMER SODIUM **except**:

(a) when included in Schedule 2; or

(b) in a condom lubricant.

AZATADINE in oral preparations.

BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age **except** when included in Schedule 2.

BROMPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:

Authorised Version F2026L01327 registered 30/09/2026

(a) the cannabidiol is either plant derived or, when synthetic, only contains the (-)-CBD enantiomer; and

(b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

(c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and

(d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and

(e) packed in blister or strip packaging or in a container fitted with a child-resistant closure; and

(f) in packs containing not more than 30 days' supply; and

(g) for persons aged 18 years and over.

CELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short-term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTANOL in preparations for human use **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5% or less of chlorbutanol.

CHLORPHENAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days' supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.

CYPROHEPTADINE in oral preparations.

Authorised Version F2026L01327 registered 30/09/2026

CYTISINE in divided oral and oromucosal preparations with a recommended daily dose of 9 mg or less of cytisine as an aid in withdrawal from tobacco smoking in adults.

DEXCHLORPHENAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.

DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

ERYTHRITYL TETRANITRATE for therapeutic use.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

Authorised Version F2026L01327 registered 30/09/2026

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:

(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or

(ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

(a) in preparations for oral use; or

(b) in preparations for rectal use.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or

(c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations, in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories;

except when included in Schedule 2.

HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100

Authorised Version F2026L01327 registered 30/09/2026

mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over.

IBUPROFEN when:

(a) either:

(i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or

(ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and

(b) labelled:

(i) with a recommended daily dose of 1200 mg or less of ibuprofen; and

(ii) not for the treatment of children under 12 years;

except when:

(c) included in Schedule 2; or

(d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

(i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years or under; and

(vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply **except** when included in Schedule 2.

LEVONORGESTREL for emergency post-coital contraception.

Authorised Version F2026L01327 registered 30/09/2026

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations **except** when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

MALATHION in preparations for human external use **except** in preparations containing 2% or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MELATONIN in:

(a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or

(b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METHENAMINE in preparations for therapeutic use.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.

NALOXONE when used for the treatment of opioid overdose.

NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.

NARATRIPTAN when in divided oral preparations containing 2.5 mg or less of naratriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

NICOTINE in therapeutic vaping goods (within the meaning of the *Therapeutic Goods Regulations 1990*) in final dosage form for smoking cessation or the management of nicotine dependence when:

Authorised Version F2026L01327 registered 30/09/2026

(a) for supply to persons aged 18 years and over; and

(b) the pharmacist requests and sights evidence of the patient's identity and age; and

(c) the pharmacist provides professional advice to the patient on alternative cessation supports and therapies, appropriate dose and frequency depending on age, weight and severity of condition, length of treatment, suitable titration, and interactions with other medicines; and

(d) the pharmacist provides contact details about smoking cessation support services to the patient; and

(e) the quantity of the goods does not exceed the quantity that is reasonably required for a patient's therapeutic use for 1 month and that quantity is supplied to the patient only once in a month; and

(f) the concentration of nicotine in the goods does not exceed 20 mg/mL; and

except:

(g) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or

(h) in tobacco prepared and packed for smoking.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply **except** when included in Schedule 2.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply **except** when included in Schedule 2.

Authorised Version F2026L01327 registered 30/09/2026

PARACETAMOL:

(a) when combined with ibuprofen in a primary pack containing 30 dosage units or less **except** when included in Schedule 2; or

(b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or

(c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled "For dispensing only" and "This pack is not to be supplied to a patient"; or

(d) in non-modified release tablets or capsules containing not more than 500 mg paracetamol and in a primary pack containing not more than 100 tablets or capsules **except** when included in or expressly excluded from Schedule 2; or

(e) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled "For dispensing only" and "This pack is not to be supplied to a patient"; or

(f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules **except** when included in or expressly excluded from Schedule 2; or

(g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled "For dispensing only" and "This pack is not to be supplied to a patient"; or

(h) in liquid preparations for oral use **except** when in Schedule 2.

PHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of children under 2 years of age.

Authorised Version F2026L01327 registered 30/09/2026

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply **except** when included in Schedule 2.

RIZATRIPTAN when in divided oral preparations containing 5 mg or less of rizatriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms.

SALBUTAMOL as the only therapeutically active substance:

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40% or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.

SUMATRIPTAN when in divided oral preparations containing 50 mg or less of sumatriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

TERBUTALINE as the only therapeutically active substance:

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.

Authorised Version F2026L01327 registered 30/09/2026

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.

TRIPROLIDINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ULIPRISTAL for emergency post-coital contraception.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less of zolmitriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 4—Prescription only medicines and prescription animal remedies

Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.

Note 2: Substances marked # are listed in Appendix D.

ABACAVIR.

ABALOPARATIDE.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ABEMACICLIB.

ABROCITINIB.

ACALABRUTINIB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

(a) when included in Schedule 2; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

ACITRETIN.

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE **except** when included in Schedule 3.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE in:

(a) topical preparations for the treatment of wounds in humans; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) all other preparations containing adrenaline **except** when included in or expressly excluded from Schedule 3.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AFAMELANOTIDE.

AFATINIB DIMALEATE.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALANYLGLUTAMINE.

ALATROFLOXACIN MESILATE.

ALBENDAZOLE **except**:

(a) when included in Schedule 5 or 6; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

ALECTINIB.

ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ALGLUCOSIDASE.

ALIMEMAZINE **except** when included in Schedule 2 or 3.

ALIROCUMAB.

ALISKIREN.

ALKYL NITRITES **except** when separately specified in these Schedules.

ALLERGENS for therapeutic use.

ALLOPURINOL.

ALLYLESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPELISIB.

ALPHA1-PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALFAXALONE.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

AMCINONIDE.

AMIFAMPRIDINE.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5-AMINOLEVULINIC ACID.

AMINOMETRADINE.

AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMOBARBITAL when packed and labelled for injection.

AMODIAQUINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

AMOROLFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXICILLIN.

AMPHOMYCIN.

AMPHOTERICIN B.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE **except** when included in Schedule 3.

AMYLOCAINE.

ANABOLIC STEROIDAL AGENTS.

ANACAULASE-BCDB.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANDEXANET ALFA.

ANECORTAVE.

ANDROGENIC STEROIDAL AGENTS.

ANDROISOXAZOLE.

ANDROSTANOLONE.

ANDROSTENEDIOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANIMAL BLOOD PRODUCTS for veterinary use including:

(a) whole blood;

(b) blood components, including red cells, white cells, platelets, and plasma (including cryoprecipitate); and

(c) the following plasma-derived therapeutic proteins, and their equivalent recombinant alternatives:

(i) albumin;

(ii) anticoagulation complex;

(iii) C1 esterase inhibitors;

(iv) clotting factors;

(v) fibrinogen;

(vi) protein C;

(vii) prothrombin complex concentrate (PCC);

(viii) thrombin;

(ix) haemoglobin.

ANIRACETAM.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

(a) when separately specified in these Schedules; or

(b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTIHISTAMINES **except**:

(a) when included in Schedule 2 or 3; or

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

AOD-9604 (CAS No. 221231-10-3).

APADAMTASE ALFA.

APALUTAMIDE.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREMILAST.

APREPITANT.

APROTININ.

ARBUTIN (BETA) in oral preparations **except** herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose.

ARECOLINE.

ARIPIPRAZOLE.

ARMODAFINIL.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTESUNATE.

ARTICAINE.

ASCIMINIB.

ASENAPINE.

ASFOTASE ALFA.

ASPARAGINASE.

ASPIRIN when:

(a) combined with caffeine, paracetamol or salicylamide; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) combined with any derivative of the substances mentioned in paragraph (a); or

(c) for injection.

ASTEMIZOLE.

ASUNAPREVIR.

ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATEZOLIZUMAB.

ATINVICITINIB.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESILATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVACINCAPTAD PEGOL.

AVACOPAN.

AVATROMBOPAG.

AVELUMAB.

AVILAMYCIN **except**:

(a) in animal feed premixes containing 15% or less of avilamycin activity; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID for therapeutic use **except** when included in Schedule 2.

AZELASTINE **except** when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALOXAVIR MARBOXIL.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

(a) when included in Schedule 6; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BARICITINIB.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETASONE **except** when included in Schedule 2.

BELANTAMAB MAFODOTIN.

BELATACEPT.

BELIMUMAB.

BELUMOSUDIL.

BELZUTIFAN.

BEMEGRIDE.

BEMPEDOIC ACID.

BENACTYZINE.

BENAZEPRIL.

BENDAMUSTINE.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENRALIZUMAB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZILONIUM.

BENZOCAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 5% or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZATROPINE.

BENZYDAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use; or

(c) in divided topical oral preparations containing 3 mg or less of benzydamine; or

(d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACIN.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

BEXAROTENE.

BEZAFIBRATE.

BEZLOTOXUMAB.

BIBROCATHOL.

BICALUTAMIDE.

BICTEGRAVIR.

BIFONAZOLE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

BILASTINE **except** when included in Schedule 2 or 3.

BIMATOPROST.

BINIMETINIB.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or

(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

BLINATUMOMAB.

BOCEPREVIR.

BOLANDIOL.

BOLASTERONE.

BOLAZINE.

BOLDENONE (dehydrotestosterone).

BOLENOL.

BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or

(b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

BORTEZOMIB.

BOSENTAN.

BOSUTINIB.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BPC-157.

BRENTUXIMAB VEDOTIN.

BRETYLIUM TOSILATE.

BREXPIPRAZOLE.

BRIGATINIB.

BRIMONIDINE **except** when included in Schedule 2.

BRINZOLAMIDE.

BRIVARACETAM.

BROMAZEPAM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

BROMIDES, inorganic, for therapeutic use **except** when separately specified in these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC.

BULEVIRTIDE.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE **except** when included in Schedule 5.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTAMBEN **except** in dermal preparations containing 2% or less of total local anaesthetic substances.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CABERGOLINE.

CABOTEGRAVIR.

CABOZANTINIB.

CADMIUM COMPOUNDS for human therapeutic use.

CAFFEINE for internal therapeutic use **except**:

(a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

(b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine.

CALCIFEDIOL for human internal therapeutic use **except** in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.

CALCIPOTRIOL.

CALCITONIN.

CALCITONIN SALMON.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:

(a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

(b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;

except when:

(c) included in Schedule 3; or

(d) in hemp seed oil at a concentration of 75 mg/kg or less.

CANTHARIDIN.

CAPECITABINE.

CAPIVASERTIB.

CAPMATINIB.

CAPREOMYCIN.

CAPROMORELIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARFILZOMIB.

CARGLUMIC ACID (*N*-carbamoyl-L-glutamic acid).

CARINDACILLIN.

CARIPRAZINE.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASIRIVIMAB.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEDAZURIDINE.

CEFACETRILE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CEFACLOR.

CEFADROXIL.

CEFALEXIN.

CEFALORIDINE.

CEFALOTIN.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIDEROCOL.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB **except** when included in Schedule 3.

CELIPROLOL.

CENEGERMIN.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2% or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2% or less of emetine.

CEPHALONIUM.

CEPHRADINE.

CERITINIB.

CERIVASTATIN.

CERLIPONASE ALFA.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE **except**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

(i) in a primary pack containing not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2% or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL **except** when included in Schedule 3.

CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

CHLOROXYDIENONE.

CHLORPHENAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CHLORTALIDONE.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLIC ACID.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

CICLOSPORIN.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILGAVIMAB.

CILOSTAZOL.

CIMETIDINE **except** when included in Schedule 3.

CIMICOXIB.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINNARIZINE.

CINOXACIN.

CIPAGLUCOSIDASE ALFA.

CIPROFLOXACIN.

CISAPRIDE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CISATRACURIUM BESILATE.

CISPLATIN.

CITALOPRAM.

CJC-1295 (CAS No. 863288-34-0).

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLASCOTERONE.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CLOMIFENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

COBIMETINIB.

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine.

CO-DERGOCRINE.

COLCHICINE.

COLCHICUM AUTUMNALE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

COLESTIPOL.

COLESTYRAMINE for human therapeutic use.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.

COLURACETAM.

CONCIZUMAB.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

(a) when separately specified in these Schedules; or

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5% or less of copper compounds.

CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRISABOROLE.

CRIZOTINIB.

CROFELEMER.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

CYTARABINE.

CYTISINE **except** when included in Schedule 3.

DABRAFENIB MESILATE.

DABIGATRAN.

DACARBAZINE.

DACLATASVIR.

DACLIZUMAB.

DACTINOMYCIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

DANAZOL.

DANICOPAN.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

DARATUMUMAB.

DARBEPOETIN.

DARIFENACIN.

DAROLUTAMIDE.

DARUNAVIR.

DATOPOTAMAB DERUXTECAN.

DATURA spp. **except**:

(a) when included in Schedule 2; or

(b) when separately specified in this Schedule.

DASABUVIR.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DATURA TATULA (stramonium) **except**:

(a) when included in Schedule 2; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) for smoking or burning.

DAUNORUBICIN.

DEANOL for therapeutic use.

DEBRISOQUINE.

DECAMETHONIUM.

DECITABINE.

DEFERASIROX.

DEFERIPRONE.

DEFIBROTIDE.

DEFLAZACORT.

DEGARELIX.

DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE MESILATE.

DELGOCITINIB.

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENGUE VACCINE.

DENOSUMAB.

DEOXYCHOLIC ACID.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DEPEMOKIMAB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DERACOXIB.

DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except:**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:

(i) in a primary pack containing 10 dosage units or less; and

(ii) labelled with a recommended daily dose not exceeding 5 mg of desloratadine.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEUCRAVACITINIB.

DEUTETRABENAZINE.

DEUTIVACAFTOR.

DEXAMETHASONE.

DEXCHLORPHENAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DEXMEDETOMIDINE.

DEXRAZOXANE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

DEXTROPROPOXYPHENE:

(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

(b) liquid preparations containing 2.5% or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use **except** when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or

(ii) containing more than 4% of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFELIKEFALIN.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;

except when included in Schedule 3.

DIHYDROERGOTOXINE.

DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DIIODOHYDROXYQUINOLINE (iodoquinol) **except**:

(a) when included in Schedule 3; or

(b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

DIMETHANDROSTANOLONE.

DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use **except**:

(a) when included in Schedule 6; or

(b) in *in vitro* test kits; or

(c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.

DIMETRIDAZOLE.

DIMIRACETAM.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

DINOPROST.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DIROXIMEL FUMARATE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORAVIRINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOSULEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULAGLUTIDE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

DULOXETINE.

DUPILUMAB.

DURVALUMAB.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDARAVONE.

EDETIC ACID for human therapeutic use **except**:

(a) in preparations containing 0.25% or less of edetic acid; or

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFANESOCTOCOG ALFA.

EFAVIRENZ.

EFGARTIGIMOD ALFA.

EFLORNITHINE.

ELACESTRANT DIHYDROCHLORIDE.

ELAFIBRANOR.

ELBASVIR.

ELETRIPTAN **except** when included in Schedule 3.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ELEXACAFTOR.

ELINZANETANT.

ELOSULFASE ALFA.

ELOTUZUMAB.

ELRANATAMAB.

ELTENAC.

ELTROMBOPAG.

ELUXADOLINE.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2% or less of emetine.

EMPAGLIFLOZIN.

EMTRICITABINE.

ENALAPRIL.

ENASIDENIB.

ENCORAFENIB.

ENESTEBOL.

ENFLICOXIB.

ENFLURANE for therapeutic use.

ENFORTUMAB VEDOTIN.

ENFUVIRTIDE.

ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

ENTRECTINIB.

ENZALUTAMIDE.

EPHEDRA spp. **except** in preparations containing 0.001% or less of ephedrine.

EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

EPITIOSTANOL.

EPLERENONE.

EPLONTERSEN.

EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERENUMAB.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESILATE.

ERLOTINIB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ERTAPENEM.

ERTUGLIFLOZIN.

ERYSIMUM spp.

ERYTHROMYCIN.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESLICARBAZEPINE ACETATE.

ESMOLOL.

ESOMEPRAZOLE **except** when included in Schedule 2.

ESTETROL MONOHYDRATE.

ESTRADIOL **except** when included in Schedule 5.

ESTRIOL.

ESTRAMUSTINE.

ESTROGENS **except** when separately specified in these Schedules.

ESTRONE.

ESTROPIPATE (piperazine estrone sulfate).

ETACRYNIC ACID.

ETANERCEPT.

ETHAMBUTOL.

ETHAMIVAN.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLESTRADIOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

ETHYLDIENOLONE.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine.

ETHYLESTRENOL.

ETIDOCAINE.

ETIDRONIC ACID (includes etidronate disodium):

(a) for internal use; or

(b) in topical preparations **except** in preparations containing 1% or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETOMIDATE.

ETONOGESTREL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ETOPOSIDE.

ETORICOXIB.

ETRANACOGENE DEZAPARVOVEC.

ETRASIMOD.

ETRAVIRINE.

ETRETINATE.

ETYNODIOL.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR **except** when included in Schedule 3.

FAMOTIDINE **except** when included in Schedule 2.

FARICIMAB.

FASORACETAM.

FEBUXOSTAT.

FEDRATINIB.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBENDAZOLE **except** when included in Schedule 5.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FERRIC DERISOMALTOSE.

FEXOFENADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

(c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

(d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FEZOLINETANT.

FIBRINOLYSIN **except** for external use.

FIBROBLAST GROWTH FACTORS.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

FIDAXOMICIN.

FILGOTINIB.

FILGRASTIM.

FINASTERIDE.

FINERENONE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

FLUOXYMESTERONE.

FLUPENTIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURALANER in injectable preparations for use in companion animals.

FLURANDRENOLONE.

FLURAZEPAM.

FLURBIPROFEN **except** when:

(a) included in Schedule 2; or

(b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:

(i) in a primary pack containing not more than 16 dosage units; and

(ii) labelled only for the treatment of adults and children over 12 years; or

(c) in undivided preparations for topical oral use containing either:

(i) 0.25% or less of flurbiprofen per dose; or

(ii) 10 mg or less of flurbiprofen per dose; and

that are:

(iii) in a primary pack containing not more than 15 Ml; and

(iv) labelled only for the treatment of adults 18 years and over.

FLUROXENE for human therapeutic use.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE **except** when separately specified in this Schedule.

FOLLISTATIN.

FOLLITROPIN ALFA.

FOLLITROPIN BETA.

FOLLITROPIN DELTA.

FOMEPIZOLE.

FOMIVIRSEN.

FONDAPARINUX.

FORMEBOLONE.

FORMESTANE.

FORMOTEROL

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilbestrol diphosphate).

FOSFOMYCIN.

FOSINOPRIL.

FOSNETUPITANT.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

FOSPHENYTOIN.

FOSTEMSAVIR.

FOTEMUSTINE.

FRAMYCETIN.

FRUQUINTINIB.

FULVESTRANT.

FURALTADONE.

FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

FUTIBATINIB.

FUZAPLADIB SODIUM.

GABAPENTIN.

GADOQUATRANE.

GALANTAMINE.

GALANTHUS spp.

GALCANEZUMAB.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GARADACIMAB.

GATIFLOXACIN.

GRAZOPREVIR.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GEPOTIDACIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GILTERITINIB.

GITALIN.

GIVOSIRAN.

GLATIRAMER ACETATE.

GLECAPREVIR.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLIPTINS **except** when separately specified in these Schedules.

GLISOXEPIDE.

GLOFITAMAB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

GLUTATHIONE for parenteral use.

GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GRAPIPRANT.

GREPAFLOXACIN.

GRISEOFULVIN.

GROWTH HORMONE RELEASING HORMONES* (GHRHs).

GROWTH HORMONE RELEASING PEPTIDES (GHRPs).

GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6).

GROWTH HORMONE SECRETAGOGUES* (GHSs).

GUAIFENESIN for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in oral liquid preparations containing 2% or less of guaifenesin; or

(c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

GUANFACINE.

GUANIDINE for therapeutic use.

GUSELKUMAB.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (Hemerocallis flava).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHENE:

(a) in preparations for use on infants; or

(b) in other preparations **except**:

(i) when included in Schedule 2 or 6; or

(ii) in preparations containing 0.75% or less of hexachlorophene.

HEXAMETHONIUM.

HEXARELIN.

HEXETIDINE for human internal use.

HEXOBENDINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

HEXOCYCLIUM.

HEXOPRENALINE.

HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).

HISTAMINE for therapeutic use **except** in preparations containing 0.5% or less of histamine.

HMG-CoA REDUCTASE INHIBITORS (including "statins") **except** when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADOTROPHIN **except** in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

(a) for human use **except** when included in Schedule 2 or 3; or

(b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use **except** in preparations containing 10 mg/kg or less of hydrocyanic acid.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

(a) when included in Schedule 2; or

(b) in hair preparations containing 0.3% or less of hydroquinone; or

(c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYDROXYCARBAMIDE.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

HYDROXYPROGESTERONE.

HYDROXYSTENOZOL.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCINE BUTYLBROMIDE **except** when included in Schedule 2 or Schedule 3.

HYOSCYAMUS NIGER **except**:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBRUTINIB.

IBUFENAC.

IBUPROFEN **except** when:

(a) included in Schedule 2 or 3; or

(b) in preparations for dermal use; or

(c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years and under; and

(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

IBUTAMOREN.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDARUCIZUMAB.

IDEBENONE.

IDOXURIDINE **except** in preparations containing 0.5% or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

ILUNOCITINIB.

IMATINIB.

IMDEVIMAB.

IMEPITOIN.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENEM.

IMIPRAMINE.

IMIQUIMOD.

IMLIFIDASE.

IMLUNESTRANT.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INAVOLISIB.

INCLISIRAN.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN.

INEBILIZUMAB.

INFIGRATINIB.

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INGENOL MEBUTATE.

INOTUZUMAB OZOGAMICIN.

INSULIN DEGLUDEC.

INSULIN GLARGINE.

INSULIN-LIKE GROWTH FACTOR I.

INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

IPAMORELIN.

IPILIMUMAB.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IPTACOPAN.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISAVUCONAZOLE.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

(a) for human use; or

(b) for the treatment of mange in dogs.

IVOSIDENIB.

IXABEPILONE.

IXAZOMIB.

IXEKIZUMAB.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5% or less of ketanserin.

KETAZOLAM.

KETOCONAZOLE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN **except**:

(a) in preparations for dermal use; or

(b) when included in Schedule 3.

KETOROLAC (includes ketorolac trometamol).

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANADELUMAB.

LANATOSIDES.

LANDIOLOL.

LANREOTIDE.

LANSOPRAZOLE **except** when included in Schedule 2 or 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LAROTRECTINIB.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

LAZERTINIB.

LEBRIKIZUMAB.

LECANEMAB.

LEDIPASVIR.

LEFETAMINE.

LEFLUNOMIDE.

LEMBOREXANT.

LENACAPAVIR.

LENALIDOMIDE.

LENIOLISIB.

LENOGRASTIM.

LENVATINIB.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LESINURAD.

LETERMOVIR.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

(a) for human therapeutic use; or

(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

LEVOCABASTINE **except** when included in Schedule 2.

LEVOCETIRIZINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LEVODOPA.

LEVOMEPROMAZINE.

LEVOMILNACIPRAN.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOCAINE **except**:

(a) when included in Schedules 2 or 5; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or

(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.

LIDOFLAZINE.

LIFITEGRAST.

LINACLOTIDE.

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIPEGFILGRASTIM.

LIRAGLUTIDE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

(a) when included in Schedule 2; or

(b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or

(c) in preparations containing 0.01% or less of lithium.

LIXISENATIDE.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LONAPEGSOMATROPIN.

LONCASTUXIMAB TESIRINE.

LOPERAMIDE **except**:

(a) when included in Schedule 2; or

(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

LOPRAZOLAM.

LORACARBEF.

LORATADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:

(i) in a primary pack containing 10 dosage units or less; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

LORAZEPAM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

LORLATINIB.

LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL.

LOXAPINE.

LUMACAFTOR.

LUMASIRAN.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE.

LURBINECTEDIN.

LUSPATERCEPT.

LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MACITENTAN for human use.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MARIBAVIR.

MAROPITANT.

MARSTACIMAB.

MAVACAMTEN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MELAGATRAN.

MELANOTAN II.

MELATONIN for human use **except** when included in Schedule 3.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM **except** when included in Schedule 6.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENINGOCOCCAL GROUP B VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTAMINE for human therapeutic use.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME **except** when included in Schedule 2 or 6.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MERCURY for cosmetic or therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

MESABOLONE.

MESALAZINE.

MESNA.

MESTANOLONE (androstalone).

MESTEROLONE.

MESTRANOL.

METANDIENONE.

METARAMINOL.

METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENESTRIL.

METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

METHENOLONE.

METHICILLIN.

METHIMAZOLE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 1% or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYLMERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITAL.

METHYLPHENYLPIRACETAM.

METHYLPREDNISOLONE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

METHYLROSANILINIUM CHLORIDE for human use **except** when used as a dermal marker.

METHYL SALICYLATE in preparations for internal therapeutic use.

METHYLTESTOSTERONE.

METHYLTHIOURACIL.

METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

MIBOLERONE.

MICAFUNGIN.

MICONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.

MIDOSTAURIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MIDODRINE.

MIFEPRISTONE.

MIGALASTAT.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILNACIPRAN.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRABEGRON.

MIRIKIZUMAB.

MIRTAZAPINE.

MIRVETUXIMAB SORAVTANSINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOBOCERTINIB.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MOLIDUSTAT.

MOLINDONE.

MOLNUPIRAVIR.

MOMELOTINIB.

MOMETASONE **except** when included in Schedule 2 or Schedule 3.

MONENSIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use **except** in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use **except**:

(a) in diagnostic test kits; or

(b) when separately specified in these Schedules.

MONOETHANOLAMINE in preparations for injection.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10% or less of moxidectin **except** when included in Schedule 5 or 6.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALMEFENE.

NALORPHINE.

NALOXEGOL.

NALOXONE **except** when in Schedule 3.

NALTREXONE.

NANDROLONE.

NAPROXEN **except** when included in Schedule 2 or 3.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN **except** when included in Schedule 3.

NATALIZUMAB.

NATAMYCIN **except** for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

NEBRACETAM.

NEDOCROMIL.

NEFAZODONE.

NEFIRACETAM.

NEFOPAM.

NELARABINE.

NELFINAVIR (includes nelfinavir mesilate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERATINIB.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NETUPITANT.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE in preparations for human use **except**:

(a) when included in Schedule 3; or

(b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or

(c) in tobacco prepared and packed for smoking.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

NICOTINIC ACID in preparations for:

(a) human therapeutic use **except**:

(i) when separately specified in these Schedules; or

(ii) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(iii) nicotinamide; or

(b) animal therapeutic use when packed and labelled for injection.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NINTEDANIB.

NIRAPARIB.

NIRIDAZOLE.

NIRMATRELVIR.

NIRSEVIMAB.

NISOLDIPINE.

NITISINONE.

NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIVOLUMAB.

NIZATIDINE **except** when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

19-NORANDROSTENEDIOL.

19-NORANDROSTENEDIONE.

NORANDROSTENOLONE.

NORBOLETHONE.

NORCLOSTEBOL.

NORELGESTROMIN.

NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

NORMAL HUMAN IMMUNOGLOBULIN.

NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NUSINERSEN.

NYSTATIN **except** when included in Schedule 2 or 3.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

OBETICHOLIC ACID.

OCLACITINIB.

OCRELIZUMAB.

OCRIPLASMIN.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

ODEVIXIBAT.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLAPARIB.

OLARATUMAB.

OLEANDOMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLIPUDASE ALFA.

OLMESARTAN.

OLODATEROL.

OLOPATADINE **except** when included in Schedule 2.

OLSALAZINE.

OLUTASIDENIB.

OMALIZUMAB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

OMBERACETAM.

OMBITASVIR.

OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE **except** when included in Schedule 2 or 3.

ONASEMNOGENE ABEPARVOVEC.

ONDANSETRON.

OPICAPONE.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORELABRUTINIB.ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 2% or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OSILODROSTAT.

OSIMERTINIB.

OUABAIN.

OVANDROTONE.

OXABOLONE.

OXACILLIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

OXALIPLATIN.

OXANDROLONE.

OXAPROZIN.

OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

OXIRACETAM.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

OXYMESTERONE.

OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

OZANIMOD.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PACLITAXEL.

PALBOCICLIB.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PALOPEGTERIPARATIDE.

PALOVAROTENE.

PAMAQUIN.

PAMIDRONIC ACID (includes pamidronate disodium).

PANCREATIC ENZYMES **except**:

(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

(b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANOBINOSTAT.

PANTOPRAZOLE **except** when included in Schedule 2 or 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

(a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules; or

(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or

(c) in modified release tablets or capsules containing more than 665 mg paracetamol; or

(d) in non-modified release tablets or capsules containing more than 500 mg paracetamol; or

(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules **except** in Schedule 3; or

(g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules **except** when included in Schedule 3; or

(h) for injection; or

(i) for the treatment of animals.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PARITAPREVIR.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PATIROMER SORBITEX CALCIUM.

PATISIRAN.

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGASPARGASE.

PEGCETACOPLAN.

PEGFILGRASTIM.

PEGINTERFERON.

PEGUNIGALSIDASE ALFA.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PEGVALIASE.

PEGVISOMANT.

PEMBROLIZUMAB.

PEMETREXED.

PEMIGATINIB.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** in preparations containing 1% or less of penciclovir for the treatment of *herpes labialis* in packs containing 10 g or less.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isetionate).

PENTHIENATE.

PENTOBARBITAL when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PENTOXIFYLLINE.

PERAMIVIR.

PERAMPANEL.

PERGOLIDE.

PERHEXILINE.

PERICIAZINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5% or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PERTUZUMAB.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITAL.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

PHENTERMINE.

PHENTHIMENTONIUM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

(a) in preparations for injection; or

(b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.

PHENYLPIRACETAM.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract).

PHOLCODINE:

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine;

except when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS **except**:

(a) when separately specified in these Schedules; or

(b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PIBRENTASVIR.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025% or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PINAVERIUM BROMIDE.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Register in preparations:

(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or

(ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or

(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or

(c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PIRETANIDE.

PIRFENIDONE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PIRTOBRUTINIB.

PITAVASTATIN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLITIDEPSIN.

PLERIXAFOR.

PLOZASIRAN.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

POLYACRYLAMIDE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use; or

(c) for veterinary use.

POLYCAPROLACTONE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

POMALIDOMIDE.

PONATINIB.

PONESIMOD.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

(a) when containing less than 550 mg of potassium chloride per dosage unit; or

(b) in preparations for oral rehydration therapy; or

(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

(d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PRADOFLOXACIN.

PRALATREXATE.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMIRACETAM.

PRAMOCAINE.

PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2 (GHRP-2)).

PRALSETINIB.

PRAMPINE.

PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE BENZYLPENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use **except** when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE **except** when included in Schedule 2 or 3.

RABIES VACCINE.

RACETAMS **except** when separately specified in these Schedules.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RAMUCIRUMAB.

RANIBIZUMAB.

RANITIDINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer's original pack containing not more than 14 dosage units; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 7 dosage units.

RANOLAZINE.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REGDANVIMAB.

REGORAFENIB.

RELUGOLIX.

REMDESIVIR.

REMIBRUTINIB.

REMOXIPRIDE.

REPAGLINIDE.

REPOTRECTINIB.

RESERPINE.

RESLIZUMAB.

RETAPAMULIN.

RETEPLASE.

RETIFANLIMAB.

RETIGABINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

RIBAVIRIN.

RIBOCICLIB.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEGEPANT.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

RIOCIGUAT.

RIPRETINIB.

RISANKIZUMAB.

RISDIPLAM.

RISEDRONIC ACID.

RISPERIDONE.

RITLECITINIB.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

RIVASTIGMINE.

RIZATRIPTAN **except** when included in Schedule 3.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

ROLZIRACETAM.

ROMIDEPSIN.

ROMIFIDINE.

ROMIPLOSTIM.

ROMOSOZUMAB.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

ROXIBOLONE.

ROXITHROMYCIN.

ROZANOLIXIZUMAB.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUFINAMIDE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

RUPATADINE.

RUXOLITINIB.

SACITUZUMAB GOVITECAN.

SACUBITRIL.

SAFINAMIDE.

SALBUTAMOL **except** when included in Schedule 3.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SARILUMAB.

SARS-COV-2 (COVID-19) VACCINE.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.

SCOPOLIA CARNIOLICA for therapeutic use.

SEBELIPASE ALFA.

SEBETRALSTAT.

SECUKINUMAB.

SELADELPAR.

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(a) for human oral use with a recommended daily dose of more than 300 micrograms; or

(b) for the treatment of animals **except**:

(i) when included in Schedule 6 or 7; or

(ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or

(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or

(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

(v) in feeds containing 1 g/tonne or less of selenium.

SELETRACETAM.

SELEXIPAG.

SELINEXOR.

SELPERCATINIB.

SELUMETINIB.

SEMAGLUTIDE.

SEPIAPTERIN.

SERELAXIN.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

SILODOSIN.

SILTUXIMAB.

SILVER SULFADIAZINE.

SIMEPREVIR.

SIMVASTATIN.

SIPONIMOD.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CITRATE DIHYDRATE for therapeutic use in dialysis, diafiltration, or total plasma exchange.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM GLYCEROPHOSPHATE HYDRATE.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHENYLBUTYRATE.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for internal use for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SODIUM THIOSULFATE ANHYDROUS for human therapeutic use in preparations for injection.

SODIUM ZIRCONIUM CYCLOSILICATE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

SOFOSBUVIR.

SOLASODINE.

SOLIFENACIN.

SOMAPACITAN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

SOMATROGON.

SOMATROPIN (human growth hormone).

SONIDEGIB.

SONTOQUINE.

SORAFENIB.

SOTALOL.

SOTATERCEPT.

SOTORASIB.

SOTROVIMAB.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPESOLIMAB.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

STANOLONE.

STANOZOLOL.

STAVUDINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

STENABOLIC (SR9009) and other synthetic REV-ERB agonists.

STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBESTROL (diethylstilbestrol).

STIRIPENTOL.

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUCROFERRIC OXYHYDROXIDE.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDE ANTIBIOTICS **except** when separately specified in these Schedules.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN **except** when included in Schedule 3.

SUNIFIRAM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

SUVOREXANT.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFAMIDIS.

TAFASITAMAB.

TAFENOQUINE SUCCINATE.

TAFLUPROST.

TAGRAXOFUSP.

TALAZOPARIB.

TALIGLUCERASE ALFA.

TALIMOGENE LAHERPAREPVEC.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8% or less of oil of tansy.

TAPINAROF.

TASIPIMIDINE SULFATE.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TB-500.

T-CELL RECEPTOR ANTIBODY.

TEBENTAFUSP.

TECLISTAMAB.

TEDUGLUTIDE.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

TELOTRISTAT ETHYL.

TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPLIZUMAB.

TEPOTINIB.

TEPOXALIN.

TEPROTUMUMAB.

TERAZOSIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TERBINAFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

TESTOLACTONE.

TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACOSACTIDE.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

TEZACAFTOR.

TEZEPELUMAB.

THALIDOMIDE.

THENYLDIAMINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOMESTERONE (tiomesterone).

THIOPENTAL.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1% or less of thiourea.

THYMOSIN BETA 4 (THYMOSIN β4).

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TIAMULIN.

TIANEPTINE.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGILANOL TIGLATE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMANOCEPT.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TIOGUANINE.

TIOTROPIUM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TIPEPIDINE.

TIPIRACIL.

TIPRANAVIR.

TIRBANIBULIN.

TIRILAZAD.

TIROFIBAN.

TIRZEPATIDE.

TISLELIZUMAB.

TIXAGEVIMAB.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOFACITINIB.

TOFERSEN.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRABECTEDIN.

TRAMADOL.

TRANDOLAPRIL.

TRAMETINIB DIMETHYL SULFOXIDE.

TRANEXAMIC ACID **except** in preparations containing 3% or less of tranexamic acid for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

TRASTUZUMAB DERUXTECAN.

TRASTUZUMAB EMTANSINE.

TRAVOPROST.

TRAZODONE.

TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

TRESTOLONE.

TRETAMINE.

TRETINOIN **except** for:

(a) hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate; or

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

(b) ethyl lactyl retinoate in preparations for dermal use containing 0.1% or less of ethyl lactyl retinoate.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIENTINE.

TRIFAROTENE.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRIFLURIDINE.

TRIHEXYPHENIDYL.

TRILOSTANE.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROLAMINE when in preparations for tattoo removal.

TROMETAMOL in preparations for injection **except** in preparations containing 3% or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TUCATINIB.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN.

TYPHOID VACCINE.

ULIPRISTAL **except** when included in Schedule 3.

UMECLIDINIUM.

UNIFIRAM.

UNOPROSTONE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

UPADACITINIB.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES for veterinary live virus **except**:

(a) poultry vaccines; or

(b) pigeon pox vaccine; or

(c) scabby mouth vaccine; or

(d) bovine ephemeral fever vaccine; or

(e) bovine herpesvirus-1 vaccine.

VACCINES – PLASMID DNA for animal use **except** when separately specified in these Schedules.

VACCINIA VIRUS VACCINE.

VADADUSTAT.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VANDETANIB.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

VANZACAFTOR.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.

VASOPRESSIN.

VATINOXAN HYDROCHLORIDE.

VECURONIUM.

VEDAPROFEN.

VEDOLIZUMAB.

VELAGLIFLOZIN.

VELAGLUCERASE ALFA.

VELMANASE ALFA.

VELPATASVIR.

VEMURAFENIB.

VENETOCLAX.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERDINEXOR.

VERICIGUAT.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

VILANTEROL.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISMODEGIB.

VISNADINE.

VITAMIN A for human therapeutic or cosmetic use **except**:

(a) in preparations for topical use containing 1% or less of Vitamin A; or

(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

(c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except**:

(a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or

(b) when included in Schedule 3.

VORAPAXAR.

VORASIDENIB.

VORETIGENE NEPARVOVEC.

VORICONAZOLE.

VORINOSTAT.

VORTIOXETINE.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

VOSORITIDE.

VOXILAPREVIR.

VUTRISIRAN.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

ZANUBRUTINIB.

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZILUCOPLAN.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.

ZIPRASIDONE.

ZOLAZEPAM.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

ZOLBETUXIMAB.

ZOLEDRONIC ACID.

ZOLMITRIPTAN **except** when included in Schedule 3.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

Substances marked # are listed in Appendix D

Authorised Version F2026L01327 registered 30/09/2026

Schedule 5—Caution

Note: See paragraph (e) of the definition of ***designated solvent*** in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61.

ABAMECTIN

(a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or

(b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.

ABSCISIC ACID.

ACEQUINOCYL.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH_3COOH) **except**:

(a) when included in Schedule 2 or 6; or

(b) for therapeutic use.

ACETONE **except** in preparations containing 25% or less of designated solvents.

ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.

AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit

(a) for the treatment and prevention of flea infestations and control of ticks in dogs; or

(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5; or

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or

(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

Authorised Version F2026L01327 registered 30/09/2026

(d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:

(i) in food additive preparations for domestic use; or

(ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5;

except when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10% or less of allethrin **except**:

(a) in insecticidal mats; or

(b) in other preparations containing 1% or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 3% or less of alpha-cypermethrin; or

(b) in other preparations containing 1.5% or less of alpha-cypermethrin.

AMETRYN.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.

1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID **except** in plant growth preparations containing 40% or less of 1-aminocyclopropane-1-carboxylic acid.

AMINOCYCLOPYRACHLOR **except** in preparations containing 25% or less of aminocyclopyrachlor.

AMINOPYRALID in preparations containing 22% or less of aminopyralid.

AMISULBROM.

AMITROLE.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia **except**:

(a) in preparations for human internal therapeutic use; or

(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5% or less of free ammonia.

Authorised Version F2026L01327 registered 30/09/2026

AMMONIUM THIOCYANATE **except** in preparations containing 10% or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of anise oil.

ASPIRIN for the treatment of animals, that is in divided preparations, when:

(a) packed in blister or strip packaging; or

(b) in a container with a child-resistant closure.

ATRAZINE.

AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use.

AZELAIC ACID **except** when included in Schedule 2 or 4.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5% or less of methyl chavicol.

Authorised Version F2026L01327 registered 30/09/2026

BEAUVERIA BASSIANA in preparations containing 1 x 10^8 Colony Forming Units (CFu)/mL or less of Beauveria bassiana.

BENALAXYL.

BENDIOCARB in preparations containing 2% or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride **except** in preparations containing 5% or less of benzalkonium chloride.

BENZOFENAP.

BENZOIC ACID (excluding its salts and derivatives) in preparations for agricultural use **except** preparations containing 1% or less of benzoic acid.

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 5% or less of benzoyl peroxide.

BERGAMOT OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.4% or less of bergamot oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or

(b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.

BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.

BIOALLETHRIN in preparations containing 10% or less of bioallethrin **except** in preparations containing 1% or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10% or less of bioresmethrin.

BISPYRIBAC **except** in preparations containing 10% or less of bispyribac.

Authorised Version F2026L01327 registered 30/09/2026

BIXAFEN.

BORIC ACID **except**:

(a) when included in Schedule 4; or

(b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or

(e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.

BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF_3).

BROFLANILIDE in preparations containing 0.3% or less of broflanilide.

BROMUCONAZOLE in preparations containing 20% or less of bromuconazole.

BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray-on administration to the wounds of animals.

BUPROFEZIN **except** in preparations containing 40% or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.

Authorised Version F2026L01327 registered 30/09/2026

BUTRALIN.

BUTROXYDIM.

n-BUTYL ALCOHOL in preparations containing 10% or less of n-butyl alcohol **except**:

(a) in preparations containing 5% or less of n-butyl alcohol; or

(b) in preparations for cosmetic or therapeutic use other than spray form.

CAMELLIA SINENSIS EXTRACT (GREEN TEA EXTRACT) for oral use **except**:

(a) in preparations for human therapeutic use when compliant with the required advisory statements for medicine labels, or

(b) in preparations containing 300 mg or less of epigallocatechin-3-gallate per maximum recommended daily dose.

CAMPHOR as a natural component in essential oils containing 10% or less of camphor **except**:

(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5% or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide **except** in preparations containing 9% or less of carbamide peroxide.

CARBARYL:

(a) in preparations containing 10% or less of carbaryl **except** when included in Schedule 4; or

(b) when impregnated into plastic resin material containing 20% or less of carbaryl.

CASSIA OIL **except**:

(a) in food additives; or

(b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or

(c) in other preparations containing 2% or less of cassia oil.

CHLORFENAC.

CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.

Authorised Version F2026L01327 registered 30/09/2026

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine **except**:

(a) in preparations containing 1% or less of chlorhexidine; or

(b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20% or less of available chlorine, **except**:

(a) when separately specified in these Schedules; or

(b) sodium hypochlorite preparations with a pH of less than 11.5; or

(c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(d) liquid preparations containing less than 2% of available chlorine; or

(e) other preparations containing 4% or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL **except** in preparations containing 3% or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or

(b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or

(c) in other preparations containing 5% or less of chlorpyrifos;

except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a) in food additives; or

(b) in preparations containing 2% or less of cinnamon bark oil.

Authorised Version F2026L01327 registered 30/09/2026

CIS-JASMONE when prepared and packaged as an agricultural chemical **except** when present as a fragrance.

CLETHODIM.

CLIMBAZOLE in preparations containing 40% or less of climbazole **except**:

(a) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

(b) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET.

CLORSULON.

CLOTHIANIDIN in preparations containing 20% or less of clothianidin **except** in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25% or less of clove oil.

COPPER ACETATE in preparations containing 20% or less of copper acetate **except** in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5% or less of copper **except** in preparations containing 1% or less of copper.

COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide **except** in preparations containing 12.5% or less of copper hydroxide.

COPPER OXIDES in preparations containing 25% or less of copper oxides **except**:

(a) in preparations for internal use; or

(b) in marine paints; or

(c) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride **except** in preparations containing 12.5% or less of copper oxychloride.

COPPER SULFATE in preparations containing 15% or less of copper sulfate **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5% or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.

4-CPA.

Authorised Version F2026L01327 registered 30/09/2026

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives **except**:

(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

(i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANTRANILIPROLE.

CYANURIC ACID (excluding its salts and derivatives).

CYAZOFAMID.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10% or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUMETOFEN.

CYFLUTHRIN:

(a) in wettable powders containing 10% or less of cyfluthrin; or

(b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or

(c) in emulsions containing 5% or less of cyfluthrin.

CYHALOFOP-BUTYL.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10% or less of cypermethrin.

Authorised Version F2026L01327 registered 30/09/2026

CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10% or less of cyproconazole.

CYPRODINIL.

CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or

(b) in undivided preparations containing 5% or less of cythioate.

2,4-D in preparations containing 20% or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DECOQUINATE:

DELTAMETHRIN:

(a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or

(b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or

(c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formulation; or

(d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or

(e) in other preparations containing 0.5% or less of deltamethrin;

except:

(f) in factory prepared mosquito nets containing 1% or less deltamethrin; or

(g) in preparations containing 0.1% or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10% or less of *N,N*-diallyldichloroacetamide.

DIAZINON in dust preparations containing 2% or less of diazinon.

Authorised Version F2026L01327 registered 30/09/2026

DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.

DICHLONE.

p-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, **except** in:

(a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(b) liquid preparations containing less than 2% of available chlorine; or

(c) other preparations containing 4% or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or

(b) in other preparations in pressurised spray packs; or

(c) in paints and tinters containing 5% or less of dichloromethane; or

(d) in preparations for human therapeutic use.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or

(b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or

(c) in pressurised spray packs containing 10 g or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine **except** in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) when included in Schedule 10; or

(b) in paints and tinters; or

(c) in other preparations containing 2.5% or less of diethylene glycol.

Authorised Version F2026L01327 registered 30/09/2026

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10% or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

(a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:

WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

(c) in preparations other than for human use containing 20% or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10% or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 40% or less of dimethylacetamide in single dose flow-limited tubes of 5 mL or less for dermal application to companion animals.

DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide **except** in silicone rubber mastic containing 2% or less of dimethylformamide.

1,4-DIMETHYLNAPHTHALENE for use as agricultural chemicals.

3,7-DIMETHYL-2,6-OCTADIENAL and its isomers in cosmetic and household cleaning preparations **except** in preparations containing 5% or less of 3,7-dimethyl-2,6,-octadienal isomers.

DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.

DINICONAZOLE.

DINOTEFURAN **except** in preparations containing 1% or less of dinotefuran.

DI-n-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25% or less of di-n-propyl isocinchomeronate.

DIPHENAMID.

Authorised Version F2026L01327 registered 30/09/2026

DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.

DITHIOPYR.

N-(*N*-DODECYL)-2-PYRROLIDONE in preparations containing 50% or less of *N*-(*N*-dodecyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*-(*N*-dodecyl)-2-pyrrolidone, *N*-methyl-2-pyrrolidone or *N*-(*N*-octyl)-2-pyrrolidone **except** in preparations containing 25% or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.

EMAMECTIN in preparations containing 2% or less of emamectin.

EMODEPSIDE in preparations:

(a) containing 2.5% or less of emodepside for the external treatment of animals; or

(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.

EPYRIFENACIL.

ESBIOTHRIN in preparations containing 10% or less of esbiothrin **except** in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.

ESTRADIOL in implant preparations for growth promotion in animals.

1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N-METHYLMETHANAMINE.

ETHER in preparations containing more than 10% of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN **except** in preparations containing 10% or less of ethoxyquin.

ETHOXYSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) when included in Schedule 10; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in paints or tinters; or

(c) in other preparations containing 2.5% or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25% or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), **except** in preparations containing 40% or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENNEL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5% or less of methyl chavicol.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-*p*-ETHYL.

FENPYRAZAMINE **except** in preparations containing 40% or less of fenpyrazamine.

FENSON.

FENTHION:

(a) in preparations containing 25% or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or

(b) in preparations containing 10% or less of fenthion.

Authorised Version F2026L01327 registered 30/09/2026

FIPRONIL in preparations containing 10% or less of fipronil **except** in preparations containing 0.05% or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-*M*-METHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10% or less of fludioxonil.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or

(b) in oil based preparations containing 1% or less of flumethrin.

FLUMICLORAC PENTYL.

FLUOPYRAM **except** in preparations containing 50% or less of fluopyram.

FLUORIDES in preparations containing 3% or less of fluoride ion **except**:

(a) in preparations for human use; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLURALANER **except** when included in Schedule 4.

FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5% or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.

Authorised Version F2026L01327 registered 30/09/2026

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARAL in preparations containing 5% or less of glutaral **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

(A) IRRITANT; and

(B) Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5% or less of hexaconazole.

HEXAZINONE in preparations containing 25% or less of hexazinone.

HOMOBRASSINOLIDE.

HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

(a) toluene and xylene when included in Schedule 6; or

(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or

(c) food grade and pharmaceutical grade white mineral oils; or

(d) in solid or semi-solid preparations; or

(e) in preparations containing 25% or less of designated solvents; or

(f) in preparations packed in pressurised spray packs; or

(g) in adhesives packed in containers each containing 50 g or less of adhesive; or

(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

(i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) **except**:

Authorised Version F2026L01327 registered 30/09/2026

(a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or

(b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12% or less of hydrogen peroxide **except** in hair dyes containing 6% or less of hydrogen peroxide; or

(b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide **except** in preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H_2SiF_6).

2-HYDROXYETHYL METHACRYLATE **except**:

(a) when included in dental restorative preparations for therapeutic use; or

(b) in nail preparations when labelled “Avoid contact with skin”; or

(c) in other preparations containing 0.1% or less of 2-hydroxyethyl methacrylate when labelled “Avoid contact with skin”.

2-HYDROXYPROPYL METHACRYLATE in nail preparations **except** when labelled “Avoid contact with skin”.

IMAZALIL.

IMAZAMOX **except** in preparations containing 25% or less of imazamox.

IMAZAPIC **except** in preparations containing 25% or less of imazapic.

IMAZAPYR **except** in preparations containing 25% or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25% or less of imazethapyr.

IMIDACLOPRID in preparations containing 20% or less of imidacloprid **except** in preparations containing 5% or less of imidacloprid.

IMIPROTHRIN in preparations containing 50% or less of imiprothrin **except** in preparations containing 10% or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3-iodo-2-propynyl butyl carbamate **except**:

(a) in aqueous preparations not for cosmetic use containing 10% or less 3-iodo-2-propynyl butyl carbamate; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IPCONAZOLE in preparations containing 2% or less of ipconazole.

IRON COMPOUNDS:

(a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):

(i) in preparations for injection containing 20% or less of iron **except** in preparations containing 0.1% or less of iron; or

(ii) in other preparations containing 4% or less of iron **except**:

(A) in liquid or gel preparations containing 0.1% or less of iron; or

(B) in animal feeds or feed premixes; or

(b) for use as agricultural chemicals **except** in preparations containing 4% or less of iron.

ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol **except** in preparations containing 10% or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

(a) in preparations for the prophylaxis of heartworm in cats and dogs; or

(b) in intraruminal implants containing 160 mg or less of ivermectin; or

(c) in preparations containing 3.5% or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or

(d) in other preparations containing 2% or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 1% or less of lambda- cyhalothrin; or

(b) in aqueous preparations containing 10% or less of microencapsulated lambda-cyhalothrin.

LASIODIPLODIA PSEUDOTHEOBROMAE **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

Authorised Version F2026L01327 registered 30/09/2026

LEMON OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.05% or less of lemon oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEMONGRASS OIL in cosmetic and household cleaning preparations **except** in preparations containing 5% or less of 3,7-dimethyl-2,6-octadienal.

LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals **except**:

(a) when included in Schedule 4; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIDOCAINE:

(a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray-on administration to the wounds of animals; or

(b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves.

LIME OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.5% or less of lime oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10% or less of lindane **except** when included in Schedule 2 or 4.

LOTILANER.

LUFENURON **except**:

Authorised Version F2026L01327 registered 30/09/2026

(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MACROPHOMINA PHASEOLINA **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10% or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.

MALATHION in preparations containing 10% or less of malathion **except**:

(a) for human therapeutic use; or

(b) in dust preparations containing 2% or less of malathion.

MANCOZEB.

MANDESTROBIN **except** in preparations containing 25% or less of mandestrobin.

MANDIPROPAMID.

MARJORAM OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of marjoram oil.

MCPA:

(a) in preparations containing 25% or less of MCPA (acid); or

(b) in preparations containing 50% or less of the salts and esters of MCPA.

MEBENDAZOLE for the treatment of animals:

(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

(b) in undivided preparations containing 25% or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

Authorised Version F2026L01327 registered 30/09/2026

MECOPROP in preparations containing 2% or less of mecoprop.

MEFENPYR-DIETHYL.

MEFENTRIFLUCONAZOLE **except** in preparations containing 7.5% or less of mefentrifluconazole.

MEPIQUAT.

MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine **except** in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), **except** in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid)

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35% or less of metalaxyl.

METALDEHYDE in preparations containing 2% or less of metaldehyde.

METARYLPICOXAMID.

METAZACHLOR.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol **except:**

(a) when included in Schedule 10; or

(b) in preparations containing 2% or less of methanol; or

(c) when methanol is present only as a denaturant of ethanol.

METHENAMINE in cosmetic preparations, **except** in preparations containing 0.15% or less of methenamine.

METHIOCARB in pelleted preparations containing 2% or less of methiocarb.

METHIOZOLIN.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a) when included in preparations or admixtures; or

(b) when packed in containers having a capacity of more than 5 L.

Authorised Version F2026L01327 registered 30/09/2026

METHYLATED SPIRIT(S) when packed and labelled as a "biofuel" suitable for use in "spirit burners".

METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25% or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25% or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25% or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

(a) when packed in single use containers having a capacity of 2 mL or less; or

(b) in preparations containing 50% or less of *N*-methyl-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*-methyl-2-pyrrolidone, *N*-(*N*-octyl)-2-pyrrolidone or *N*-(*N*-dodecyl)-2-pyrrolidone **except** in preparations containing 25% or less of designated solvents.

METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate **except**:

(a) in preparations for therapeutic use; or

(b) in preparations containing 5% or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

METIRAM.

METOBROMURON **except** in preparations containing 50% or less of metobromuron.

METOFLUTHRIN:

(a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or

(b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.

METOLACHLOR.

METRAFENONE in preparations containing 50% or less of metrafenone.

MILBEMECTIN in preparations containing 1% or less of milbemectin.

MILBEMYCIN OXIME

Authorised Version F2026L01327 registered 30/09/2026

(a) for the prophylaxis of heartworm in dogs and cats; or

(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 5% or less of monoethanolamine.

MORANTEL in preparations containing 25% or less of morantel **except** in preparations containing 10% or less of morantel.

MOXIDECTIN:

(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or

(b) in preparations for external use for the treatment of cats and dogs, containing 25 mg or less of moxidectin packed in single dose tubes; or

(c) for internal use for the treatment of animals:

(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

(ii) in other preparations containing 2% or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25% or less of NAA.

NALED when impregnated in plastic resin strip material containing 20% or less of naled.

NAPTALAM.

NEOSCYTALIDIUM NOVAEHOLLANDIAE **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.

NICLOSAMIDE in tablet or paste preparations for use in companion animals.

NICOTINIC ACID when packed and labelled for use as an agricultural chemical.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO_3) **except** in preparations containing 0.5% or less of nitric acid.

Authorised Version F2026L01327 registered 30/09/2026

NITROSCANATE for the treatment of animals.

NONANOIC ACID:

(a) when used in a pesticide; or

(b) in other preparations **except** in preparations containing 10% or less of nonanoic acid.

NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 **except**:

(a) when labelled with the statements:

(i) IRRITANT; and

(ii) Avoid contact with eyes; or

(b) in preparations containing 12.5% or less of nonoxinol 9; or

(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10% or less of *N*-octyl bicycloheptene dicarboximide.

N-(*N*-OCTYL)-2-PYRROLIDONE in preparations containing 50% or less of:

(a) *N*-(*N*-octyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*-(*N*-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone; or

(b) *N*-(*N*-dodecyl)-2-pyrrolidone **except** in preparations containing 25% or less of designated solvents.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.

ORANGE OIL (BITTER) **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 1.4% or less of orange oil (bitter); or

(d) in soaps or bath or shower gels that are washed off the skin; or

Authorised Version F2026L01327 registered 30/09/2026

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD **except** in preparations containing 20% or less of penthiopyrad.

PERACETIC ACID in concentrations of 10% or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

(a) in preparations containing 25% or less of permethrin; or

(b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less;

except in preparations containing 2% or less of permethrin.

PETROL **except** preparations containing 25% or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

Authorised Version F2026L01327 registered 30/09/2026

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, **except** in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYL METHYL KETONE **except** in preparations containing 25% or less of designated solvents.

o-PHENYLPHENOL **except** in preparations containing 5% or less of *o*-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10% or less of phosphonic acid (H_3PO_3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H_3PO_4) **except**:

(a) in preparations containing 15% or less of phosphoric acid (H_3PO_4); or

(b) in solid or semi-solid preparations; or

(c) in professional dental kits.

o-PHTHALALDEHYDE in preparations containing 1% or less of *o*-phthalaldehyde.

PICARIDIN **except** in preparations containing 20% or less of picaridin.

PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10% or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5% or less of pirimicarb.

POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts **except** in preparations containing 1% or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLYOXIN D ZINC SALT.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C_{13-15}-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 10% or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:

Authorised Version F2026L01327 registered 30/09/2026

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10% or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite **except**:

(a) in preparations containing 0.5% or less of potassium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b) liquid or semi-solid preparations, the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin **except** in insecticidal mats containing 1% or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20% or less of profoxydim.

PROGESTERONE:

(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

(b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20% or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, **except**:

(a) in preparations containing 30% or less of propionic acid; or

(b) for therapeutic use.

Authorised Version F2026L01327 registered 30/09/2026

PROPOXUR:

(a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or

(b) in dust preparations containing 3% or less of propoxur; or

(c) in granular sugar-based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or

(d) in pressurised spray packs containing 2% or less of propoxur; or

(e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

n-PROPYL ALCOHOL in preparations containing 10% or less of *n*-propyl alcohol **except**:

(a) in preparations containing 5% or less of *n*-propyl alcohol; or

(b) in preparations for cosmetic or therapeutic use other than in spray form.

PROPYZAMIDE.

PROTHIOCONAZOLE-DESCHLORO **except** in preparations containing 0.5% or less of prothioconazole-deschloro.

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE **except** in preparations containing 0.5% or less of prothioconazole-triazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 10% or less of such substances.

PYRIDABEN in preparations containing 25% or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1% or less of pyrithione zinc calculated on the non-volatile content of the paint.

PYRIOFENONE in preparations containing 30% or less of pyriofenone.

Authorised Version F2026L01327 registered 30/09/2026

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds **except**:

(a) when separately specified in these Schedules; or

(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(c) in preparations containing 5% or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1% or less of quinine.

QUINTOZENE.

QUIZALOFOP-*p*-ETHYL in aqueous preparations containing 40% or less of quizalofop-*p*-ethyl.

RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.

RESMETHRIN in preparations containing 10% or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20% or less of robenidine.

ROSIN when packaged for use as a soldering flux or in flux-cored solder.

SAFLUFENACIL in water dispersible granules or a water-based suspension concentrate.

SALICYLANILIDE.

SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.

SEDAXANE.

SELAMECTIN **except** in preparations containing 12% or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3% or less of fluoride ion **except**:

(a) barium silicofluoride when separately specified in this Schedule; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin **except** in preparations containing 1% or less of sinbioallethrin.

SODIUM BROMIDE **except** when included in Schedule 4.

Authorised Version F2026L01327 registered 30/09/2026

SODIUM CHLORATE **except** in preparations containing 10% or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60% or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30% or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10% or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10% or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1% or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10% or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1% or less of sodium nitrite **except**:

(a) in preparations containing 0.5% or less of sodium nitrite; or

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35% or less of sodium percarbonate **except** in preparations containing 15% or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10% or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1% or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPIDOXAMAT.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25% or less of spinosad.

Authorised Version F2026L01327 registered 30/09/2026

SPIROMESIFEN for agricultural use.

STAR ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H_3NO_3S).

SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.

SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10% or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2% or less of tefluthrin.

TEMEPHOS:

Authorised Version F2026L01327 registered 30/09/2026

(a) in liquid preparations containing 10% or less of temephos; or

(b) in powders containing 2% or less of temephos; or

(c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of animals; or

(c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2% or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20% or less of tetraconazole.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

TETRANILIPROLE **except** in preparations containing 20% or less tetraniliprole.

THIABENDAZOLE:

(a) for the treatment of animals; or

(b) when packed and labelled for use as a fungicide **except** in preparations containing 50% or less of thiabendazole.

THIAMETHOXAM in preparations containing 60% or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.

THIOPHANATE-METHYL in preparations containing 25% or less of thiophanate-methyl.

THYME OIL **except**:

Authorised Version F2026L01327 registered 30/09/2026

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of thyme oil.

TIGOLANER in preparations containing 10% or less of tigolaner.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TOPRAMEZONE

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25% or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

1,1,1-TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs; or

(b) in preparations containing 25% or less of designated solvents; or

(c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or

(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and

(ii) the expression:

WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

Authorised Version F2026L01327 registered 30/09/2026

TRIDIPHANE.

TRIETAZINE.

TRIFLOXYSTROBIN.

TRIFLUDIMOXAZIN **except** in preparations containing 12.5% or less.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

(a) Avoid contact with eyes and skin; and

(b) Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

(a) when packed in a sealed water-soluble measure pack; or

(b) in solid preparations containing 25% or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5% or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TROLAMINE (excluding its salts and derivatives) **except**:

(a) when in Schedule 4; or

(b) in preparations containing 5% or less of trolamine.

TURPENTINE OIL **except** in preparations containing 25% or less of turpentine oil.

VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1% or less of warfarin.

ZINEB.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 6—Poisons

Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.

ABAMECTIN:

(a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or

(b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1% or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH_3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20% or less of acinitrazole.

ACLONIFEN.

ALBENDAZOLE for the treatment of animals **except**:

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 20% or less of allethrin; or

(c) in other preparations containing 1% or less of allethrin.

Authorised Version F2026L01327 registered 30/09/2026

ALLYL ESTERS (excluding derivatives) being:

(a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9); or

(b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5); or

(c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8); or

(d) ALLYL HEXANOATE (CAS No. 123-68-2); or

(e) ALLYL ISOVALERATE (CAS No. 2835-39-4); or

(f) ALLYL NONANOATE (CAS No. 7493-72-3); or

(g) ALLYL OCTANOATE (CAS No. 4230-97-1); or

(h) ALLYL PHENYLACETATE (CAS No. 1797-74-6); or

(i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9); or

(j) ALLYL PHENOXYACETATE (CAS No. 7493-74-5); or

(k) ALLYL (CYCLOHEXYLOXY)ACETATE (CAS No. 68901-15-5);

in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester **except** in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 30% or less of alpha-cypermethrin; or

(b) in other preparations containing 10% or less of alpha-cypermethrin;

except when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMIDOPROPYL BETAINES **except**:

(a) in cosmetic wash-off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(b) in cosmetic leave-on preparations containing 1.5% or less of amidopropyl betaines; or

(c) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

2-AMINO-6-CHLORO-4-NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, **except**:

Authorised Version F2026L01327 registered 30/09/2026

(a) in preparations containing 2% or less of 2-amino-6-chloro-4-nitrophenol when applied directly to the hair, or containing 2% or less of 2-amino-6-chloro-4-nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 2-amino-6-chloro-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

4-AMINO-*m*-CRESOL in hair dyes and eyebrow/eyelash colouring preparations **except**:

(a) in hair dye preparations containing 1.5% or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5mm in height; or

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-*m*-cresol after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

2-AMINO-5-ETHYLPHENOL in hair dye preparations **except** in preparations containing 1% or less of 2-amino-5-ethylphenol when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions

Authorised Version F2026L01327 registered 30/09/2026

should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

4-AMINO-2-HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products **except**:

(a) in hair dye preparations containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5mm in height; or

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

AMINOCARB in preparations containing 25% or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15% or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

4-AMINO-3-NITROPHENOL **except**:

(a) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

Authorised Version F2026L01327 registered 30/09/2026

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL (including its salts) **except**:

(a) in non-oxidative hair dye preparations containing 2.5% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.25% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

m-AMINOPHENOL **except** when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of *m*-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

p- AMINOPHENOL **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of *p*-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

Authorised Version F2026L01327 registered 30/09/2026

AMINOPYRALID **except** when included in Schedule 5.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:

(a) when included in Schedule 5; or

(b) in preparations for human internal therapeutic use; or

(c) in preparations for inhalation when absorbed in an inert solid material; or

(d) in preparations containing 0.5% or less of ammonia.

AMMONIUM COCOYL ISETHIONATE, **except** in cosmetic rinse-off preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of ammonium cocoyl isethionate, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1% or less of aniline.

ANTIMONY COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) antimony chloride in polishes; or

(c) antimony titanate pigments in paint; or

(d) in paints or tinters containing 5% or less of antimony calculated on the non-volatile content of the paint or tinter.

ARBUTIN (ALPHA) **except**:

(a) in preparations for application to the face containing 2% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less; or

(b) in preparations for application to the body containing 0.5% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (BETA) **except**:

(a) when included in Schedule 4; or

(b) oral herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose; or

(c) in preparations for application to the face containing 7% or less beta-arbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (DEOXY OR OTHER DERIVATIVES).

ARSENIC:

(a) in ant poisons containing 0.4% or less of arsenic; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in animal feed premixes containing 4% or less of arsenic; or

(c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

except when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1% or less of azaconazole.

AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

(a) when included in Schedule 5; or

(b) in preparations for human internal use; or

(c) debitterised neem seed oil; or

(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

BARIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) barium sulfate; or

(c) in paints or tinters containing 5% or less of barium calculated on the non-volatile content of the paint or tinter.

BASIC BLUE 26 (CAS No. 2580-56-5) **except** when used as a colourant in cosmetics not intended to be in contact with mucous membranes.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except**:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

(b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN;

(ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not

Authorised Version F2026L01327 registered 30/09/2026

be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

BASIC RED 76 (CAS No. 68391-30-0) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free *o*-anisidine.

BAY OIL except:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

(a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or

(b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or

(c) in insoluble granular preparations containing 5% or less of bendiocarb; or

(d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb;

except when included in Schedule 5.

BENQUINOX.

Authorised Version F2026L01327 registered 30/09/2026

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of benzalkonium chloride.

1,2-BENZENEDIOL.

BENZOVINDIFLUPYR.

6-BENZYLADENINE **except** in preparations containing 10% or less of 6-benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BICYCLOPYRONE **except** when included in Schedule 5.

BIFENTHRIN in preparations containing 25% or less of bifenthrin **except** in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of bioallethrin.

1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE (including its salts) **except** when in hair dye preparations containing 1.2% or less of 1,3-bis(2,4-diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER **except** in rinse-off cosmetic products containing 1% or less of bis-isobutyl PEG/PPG-20/35/amodimeticone copolymer when labelled with a warning to the following effect:

Authorised Version F2026L01327 registered 30/09/2026

IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.

N,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1% or less of *N*,*N*-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine, or a combination of *N*,*N*-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

(a) IRRITANT; and

(b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

(c) Avoid contact with eyes; and

(d) Avoid contact with skin; and

(e) Wear protective gloves when mixing or using; and

(f) Ensure adequate ventilation when using.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1% or less of *N*,*N*-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of *N*,*N*-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and *N*,*N*-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

(a) IRRITANT; and

(b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

(c) Avoid contact with eyes; and

(d) Avoid contact with skin; and

(e) Wear protective gloves when mixing or using; and

(f) Ensure adequate ventilation when using.

BITHIONOL for the treatment of animals.

BORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF_3) **except** when included in Schedule 5.

BPA GLYCIDYL DIACRYLATE in preparations for cosmetic use.

BPA GLYCIDYL DIMETHACRYLATE in preparations for cosmetic use.

BRODIFACOUM in preparations containing 0.25% or less of brodifacoum.

BROFLANILIDE **except** when included in Schedule 5.

BROMADIOLONE in preparations containing 0.25% or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01% or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

Authorised Version F2026L01327 registered 30/09/2026

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL in preparations containing 1.5% or less of bromoxynil.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its acetates **except**:

(a) in plant growth regulator preparations containing 20% or less of such substances; or

(b) in other preparations containing 10% or less of such substances.

2-BUTOXY-2'-THIOCYANODIETHYL ETHER.

n-BUTYL ALCOHOL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of n-butyl alcohol; or

(c) in preparations for cosmetic or therapeutic use other than in spray form.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

(a) in animal feed premixes containing 4% or less of arsenic; or

(b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) in paints or tinters containing 0.1% or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos.

CAFFEINE **except**:

(a) when included in Schedule 4; or

(b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

Authorised Version F2026L01327 registered 30/09/2026

(c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

(d) in preparations for external use; or

(e) in other preparations with a concentration of less than 5% of caffeine.

CAJUPUT OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cajuput oil; or

(f) in oils containing 25% or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1% or less of calciferol.

CAMBENDAZOLE.

CAMPHOR **except**:

(a) when included in Schedule 4 or 5; or

(b) when enclosed in an inhaler device which prevents ingestion of its contents; or

(c) in solid or semi-solid preparations containing 12.5% or less of camphor; or

(d) in liquid preparations containing 2.5% or less of camphor; or

(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

Authorised Version F2026L01327 registered 30/09/2026

(ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(A) KEEP OUT OF REACH OF CHILDREN; and

(B) NOT TO BE TAKEN; or

(iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(A) KEEP OUT OF REACH OF CHILDREN; and

(B) NOT TO BE TAKEN; or

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE **except**:

(a) when included in Schedule 5; or

(b) in other preparations containing 9% or less of carbamide peroxide.

CARBETAMIDE.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1% or less of castor oil, monomaleate.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36% or less of chlorfenapyr **except** when included in Schedule 5.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7% or less of chlorhexidine **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of chlorhexidine; or

(c) when in solid preparations.

Authorised Version F2026L01327 registered 30/09/2026

CHLORINATING COMPOUNDS **except**:

(a) when included in Schedule 5; or

(b) when separately specified in these Schedules; or

(c) sodium hypochlorite preparations with a pH of less than 11.5; or

(d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(e) in liquid preparations containing less than 2% of available chlorine; or

(f) in other preparations containing 4% or less of available chlorine.

CHLORMEQUAT.

CHLOROACETAMIDE

(a) in preparations for cosmetic use; or

(b) in preparations for topical therapeutic use; or

(c) in other preparations containing more than 0.3% of chloroacetamide.

2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL **except**:

(a) in non-oxidative hair dye preparations containing 3% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.5% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

CHLOROFORM **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10% or less of chloroform.

ALPHA-CHLOROHYDRIN.

Authorised Version F2026L01327 registered 30/09/2026

CHLOROPHACINONE.

(*E*)-(*S*)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) **except** in preparations containing 5% or less of (*E*)-(*S*)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1*H*-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5% or less of chloropicrin.

CHLOROTHALONIL **except** in water-based paint containing 0.5% or less of chlorothalonil.

2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.

CHLORPYRIFOS **except**:

(a) when included in Schedule 5; or

(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) **except** in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRICHLORIDE HEXAHYDRATE **except** in preparations containing 0.5% or less chromium.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CHRYSOIDINE BASE **except** when in Schedule 10.

CINEOLE **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

Authorised Version F2026L01327 registered 30/09/2026

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cineole; or

(f) in oils containing 25% or less of cineole; or

(g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cinnamon leaf oil.

CLIMBAZOLE **except**:

(a) when included in Schedule 5; or

(b) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

(c) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except**

(a) when included in Schedule 5; or

(b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

Authorised Version F2026L01327 registered 30/09/2026

CLOTRIMAZOLE for the external treatment of animals.

CLOVE OIL **except**:

(a) when included in Schedule 5; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(f) in preparations containing 25% or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.

COCOYL GLYCINATE in cosmetic preparations **except**:

(a) in leave-on preparations containing 5% or less of cocoyl glycinate; or

(b) in wash-off preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

COPPER ACETATE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS **except**:

(a) when separately specified in these Schedules; or

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or

Authorised Version F2026L01327 registered 30/09/2026

(d) in feed additives containing 1% or less of copper; or

(e) in other preparations containing 5% or less of copper compounds.

COPPER HYDROXIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5% or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations for internal use; or

(c) in marine paints; or

(d) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5% of less of copper oxychloride.

COPPER SULFATE **except**:

(a) when included in Schedule 5; or

(b) in preparations for internal use; or

(c) in other preparations containing 5% or less of copper sulfate.

COUMAPHOS:

(a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

(b) in other preparations containing 5% or less of coumaphos.

COUMATETRALYL in rodenticides containing 1% or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

(a) when included in Schedule 2; or

(b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or

(c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

Authorised Version F2026L01327 registered 30/09/2026

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.

CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) when presented in a wipe and when packaged in a container with a child-resistant closure, with chemical resistant gloves and labelled with the following effect:

(a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and

(b) KEEP OUT OF EYES.

CYFLUTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1% or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

(a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or

(b) in wettable granular preparations containing 25% or less of deltamethrin; or

(c) in water-dispersible tablets each containing 500 mg or less of deltamethrin; or

(d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbons; or

(e) in other preparations containing 3% or less of deltamethrin;

except:

(f) when included in Schedule 5; or

(g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

(h) in preparations containing 0.1% or less of deltamethrin.

Authorised Version F2026L01327 registered 30/09/2026

DERQUANTEL.

1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL *N*-COCO ACYL DERIVATIVES **except**:

(a) in cosmetic rinse-off preparations containing 8% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or

(b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

2,4-DIAMINOPHENOXYETHANOL **except** when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4-diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

o-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5; or

(b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(c) in liquid preparations containing less than 2% of available chlorine; or

(d) in other preparations containing 4% or less of available chlorine.

4,5-DICHLORO-2-N-OCTYL-3(2*H*)-ISOTHIAZOLONE.

Authorised Version F2026L01327 registered 30/09/2026

DICHLOROPHEN **except**:

(a) when included in Schedule 4 or 5; or

(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50% or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 6.5% or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or 10; or

(b) in paints or paint tinters; or

(c) in other preparations containing 2.5% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER.

DIFENACOUM in preparations containing 0.25% or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025% or less of difethialone.

5,6-DIHYDROXYINDOLINE.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

Authorised Version F2026L01327 registered 30/09/2026

2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6-dimethoxy-3,5-pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

N,*N*-DIMETHYLDECANAMIDE.

DIMETHYLFORMAMIDE **except**:

(a) when included in Schedule 5; or

(b) in silicone rubber mastic containing 2% or less of dimethylformamide.

4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL **except**:

(a) in leave-on cosmetic preparations containing 0.1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or

(b) in rinse-off cosmetic preparations containing 0.5% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or

(c) in other preparations containing 1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal.

DIMETHYL DISULFIDE for agricultural use as a soil fumigant.

3,7-DIMETHYL-2,6-OCTADIEN-1-OL and its isomers **except** in products containing 5% or less 3,7-dimethyl-2,6-octadien-1-ol and its isomers.

N,*N*-DIMETHYLOCTANAMIDE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone):

(a) when not for therapeutic use; or

(b) in cosmetic preparations; or

(c) for the treatment of animals:

(i) when combined with no other therapeutic substance(s); or

(ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or

(iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or

(d) in other preparations **except** when containing 10% or less of dimethyl sulfoxide.

DIMPROPYRIDAZ **except** when included in Schedule 5.

Authorised Version F2026L01327 registered 30/09/2026

DINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE **except**:

(a) in preparations for cosmetic or human internal therapeutic use containing 0.001% or less of dioxane; or

(b) in other preparations containing 0.01% or less of dioxane.

DIPHACINONE.

DIQUAT in preparations containing 20% or less of diquat.

DIRECT RED 254 **except** when included in Schedule 5.

DISPERSE YELLOW 3 **except** when in Schedule 10.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5% or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

(Z,E)-7,9,11-DODECATRIENYL FORMATE for agricultural use as an insect pheromone, **except** when enclosed in a device which, in normal use, prevents access to its contents.

N-(*N*-DODECYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin.

Authorised Version F2026L01327 registered 30/09/2026

DSMA in herbicide or defoliant preparations containing 10% or less of DSMA.

ECONAZOLE for the external treatment of animals.

EMAMECTIN in preparations containing 5% or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20% or less of endothal.

EPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin **except** when included in Schedule 5.

EPTC.

ESBIOTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

(a) when included in Schedule 2, 4 or 5; or

(b) in preparations containing 10% or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.

ETHYL BROMIDE.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or 10; or

(b) in paints or paint tinters; or

Authorised Version F2026L01327 registered 30/09/2026

(c) in other preparations containing 2.5% or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 10% or less of such substances.

ETHYL FORMATE when packed and labelled for use as a fumigant.

ETHYLHEXANEDIOL **except** in preparations containing 5% or less of ethylhexanediol.

2-ETHYLHEXANOIC ACID and its alkyl esters **except** in preparations containing 5% or less calculated as 2-ethylhexanoic acid.

ETRIMFOS.

EUCALYPTUS OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of eucalyptus oil.

EUGENOL **except**:

(a) when included in Schedule 5; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

Authorised Version F2026L01327 registered 30/09/2026

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(f) in preparations containing 25% or less of eugenol.

FAMOXADONE.

FAMPHUR in preparations containing 20% or less of famphur.

FEBANTEL **except**:

(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

(b) in undivided preparations containing 10% or less of febantel.

FENAMIPHOS in granular preparations containing 5% or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENMEZODITIAZ.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPROPIDIN.

FENPYROXIMATE.

FENTHION in preparations containing 60% or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.05% or less of fipronil.

Authorised Version F2026L01327 registered 30/09/2026

FLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen.

FLONICAMID.

FLUAZAINDOLIZINE **except** when included in Schedule 5.

FLUAZIFOP-BUTYL.

FLUAZIFOP-p-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUENSULFONE.

FLUMETHRIN **except** when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations for human use; or

(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUPYRADIFURONE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5% or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

FOLPET.

FOMESAFEN SODIUM.

FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde **except**:

(a) for human therapeutic use; or

(b) in oral hygiene preparations; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

Authorised Version F2026L01327 registered 30/09/2026

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

FURFURAL **except** in preparations containing 0.1% or less of furfural.

GLUTARAL **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

(a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time; or

(b) in preparations containing 5% or less of glycolic acid; or

(c) in preparations containing 20% or less of glycolic acid with a pH of 3.5 or greater.

GLYOXYLIC ACID (including its salts and esters) in cosmetic products.

GUANIDINE **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 1% or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HC VIOLET 1 **except**:

Authorised Version F2026L01327 registered 30/09/2026

(a) in non-oxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

HEPTACHLOR.

HEXACHLOROPHENE:

(a) in preparations for the treatment of animals; or

(b) for cosmetic use.

HEXAZINONE **except** when included in Schedule 5.

HEXYLOXYETHANOL **except** in preparations containing 10% or less of hexyloxyethanol.

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations for therapeutic use; or

(c) in preparations containing 0.5% or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluoride **except** when included in Schedule 5.

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or

(c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10% or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H_2SiF_6) **except** when included in Schedule 5.

HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE (including its salts) **except** in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl-3,4-methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

IMIDACLOPRID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of imidacloprid.

IMIDOCARB.

IMINOCTADINE TRIALBESILATE.

IMIPROTHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10% or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) **except** when included in Schedule 5.

INPYRFLUXAM.

IODINE (excluding its salts, derivatives and iodophors) **except**:

(a) when included in Schedule 2; or

(b) in solid or semi-solid preparations containing 2.5% or less of available iodine.

IODOPHORS **except** in preparations containing 1.5% or less of available iodine.

Authorised Version F2026L01327 registered 30/09/2026

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except**:

(a) when included in Schedule 5; or

(b) in aqueous preparations not for cosmetic use containing 10% or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or

(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE **except** when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals **except**:

(a) when included in Schedule 5; or

(b) in liquid or gel preparations containing 0.1% or less of iron; or

(c) in animal feeds or feed premixes.

ISOCONAZOLE for the external treatment of animals.

ISOCYANATES, free organic, boiling below 300° C, **except** in:

(a) viscous polyurethane adhesives; or

(b) viscous polyurethane sealants;

containing not more than 0.7% of free organic isocyanates boiling below 300°C.

ISOCYCLOSERAM.

ISOEUGENOL **except**:

(a) when included in Schedule 5; or

(b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or

(c) in preparations intended for skin contact containing 0.02% or less of isoeugenol.

ISOPYRAZAM.

ISOTIANIL.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 25% or less of microencapsulated lambda-cyhalothrin; or

(b) in emulsifiable granule formulations containing 25% or less lambda-cyhalothrin; or

(c) in other preparations containing 1.6% or less of lambda-cyhalothrin;

except when included in Schedule 5.

Authorised Version F2026L01327 registered 30/09/2026

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) **except**:

(a) in leave-on preparations containing 1.5% or less of laureth carboxylic acids; or

(b) in wash-off preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

LAURYL SULFATE SALTS (excluding their derivatives) **except**:

(a) in wash-off preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(b) in leave-on preparations containing 1.5% or less of lauryl sulfates; or

(c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or

(d) in other preparations for animal use containing 2% or less of lauryl sulfates; or

(e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LEAD COMPOUNDS **except**:

(a) when included in, or expressly excluded from, Schedule 10; or

(b) in preparations for cosmetic use containing 10 mg/kg or less of lead; or

(c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 25 mg/kg or less of lead; or

(d) in ceramic glazes when labelled with the warning statement:

CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink;

written in letters not less than 1.5 mm in height.

Authorised Version F2026L01327 registered 30/09/2026

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of Leptospermum scoparium oil.

LEVAMISOLE for the treatment of animals **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION **except**:

(a) when included in Schedule 5; or

(b) for human therapeutic use; or

(c) in dust preparations containing 2% or less of malathion.

MCPA **except** when included in Schedule 5.

MCPB.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-*P*.

MEFLUIDIDE.

Authorised Version F2026L01327 registered 30/09/2026

MELALEUCA OIL (tea tree oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MELOXICAM in:

(a) oral transmucosal preparations containing 1% or less of meloxicam for pre-surgical treatment and pain management in livestock during routine husbandry procedures; or

(b) injectable vaccines containing bacterial antigens and 1% or less of meloxicam for single use in lambs undergoing husbandry procedures at marking.

MENAZON.

MERCAPTAMINE for cosmetic use **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid).

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

Authorised Version F2026L01327 registered 30/09/2026

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60% or less of methacrifos.

METHAM.

METAMITRON.

METHANOL (excluding its derivatives) **except**:

(a) when included in Schedule 5; or

(b) when included in Schedule 10; or

(c) in preparations containing 2% or less of methanol.

METHIOCARB in preparations containing 20% or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent.

6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE **except** when used in oxidative or non- oxidative hair dyes at a concentration of 1% or less when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

2-METHOXY-5-NITROPHENOL.

METHYLCHLOROISOTHIAZOLINONE **except**:

(a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylchloroisothiazolinone and methylisothiazolinone in total; or

(b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolinone in total.

Authorised Version F2026L01327 registered 30/09/2026

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

METHYLDIBROMO GLUTARONITRILE **except** when in Schedule 10.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1% or less of methylene bisthiocyanate.

METHYLEUGENOL **except** in preparations containing 1% or less of methyleugenol.

METHYL ETHYL KETONE OXIME **except**:

(a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or

(b) in other preparations containing 1% or less of methyl ethyl ketone oxime.

p-METHYLAMINOPHENOL **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of *p*-methylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

METHYL ISOTHIOCYANATE.

METHYL METHACRYLATE (excluding its derivatives) **except**:

(a) for cosmetic use; or

(b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2% or less of methyl neodecanamide.

METHYLISOTHIAZOLINONE **except**:

(a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylisothiazolinone; or

(b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone

METHYLNORBORNYLPYRIDINE.

N-METHYL-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

Authorised Version F2026L01327 registered 30/09/2026

2-METHYLRESORCINOL **except**:

(a) in non-oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letter not less than 1.5 mm in height.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9) and the following TRIARYLMETHANE DYES:

(a) Acid Violet 49 (CAS No. 1694-09-3);

(b) Ethyl Violet (CAS No. 2390-59-2);

(c) Basic Blue 7 (CAS No. 2390-60-5);

(d) Methylium, 4-(dimethylamino)phenylbis4-(ethylamino)-3-methylphenyl-, acetate (CAS No. 72102-55-7);

except when included in Schedule 4 or Schedule 10.

METHYL SALICYLATE **except**:

(a) when included in Schedule 5; or

(b) in preparations for therapeutic use; or

(c) in preparations containing 5% or less of methyl salicylate.

METOFLUTHRIN **except** when included in Schedule 5.

METOSULAM.

METRAFENONE **except** when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MOMFLUOROTHRIN **except** in preparations containing 0.2% or less of momfluorothrin.

Authorised Version F2026L01327 registered 30/09/2026

MONENSIN:

(a) in animal feed premixes containing 12.5% or less of antibiotic substances; or

(b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances.

MONOETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations containing 5% or less of monoethanolamine.

MORANTEL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10% or less of morantel.

MOXIDECTIN:

(a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

(b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or

(c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle;

except when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10% or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) **except** in liquid hydrocarbons.

1,5-NAPHTHALENEDIOL **except**:

(a) in non-oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

Authorised Version F2026L01327 registered 30/09/2026

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

2,7-NAPHTHALENEDIOL **except**:

(a) in non-oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

1-NAPHTHOL **except** in hair dye preparations containing 1% or less of 1-naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

NAPHTHALOPHOS in preparations containing 80% or less of naphthalophos.

NARASIN in animal feed premixes containing 12% or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

Authorised Version F2026L01327 registered 30/09/2026

NICKEL SULFATE.

NICLOSAMIDE **except** when included in Schedule 2 or Schedule 5.

NIMIDANE in preparations containing 25% or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5% or less of nitric acid (HNO_3).

NITROBENZENE **except**:

(a) in solid or semi-solid polishes; or

(b) in soaps containing 1% or less of nitrobenzene; or

(c) in other preparations containing 0.1% or less of nitrobenzene.

3-NITRO-*p*-HYDROXYETHYLAMINOPHENOL **except**

(a) in non-oxidative hair dye preparations containing 1.85% or less of 3-nitro-*p*-hydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 3% or less of 3-nitro-*p*-hydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides **except** when included in Schedule 4.

Authorised Version F2026L01327 registered 30/09/2026

NITROUS OXIDE **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements:

(i) IRRITANT; and

(ii) Avoid contact with eyes; or

(c) in preparations containing 12.5% or less of nonoxinol 9; or

(d) in preparations for human use.

1-OCTEN-3-OL **except** in preparations containing 5% or less of 1-octen-3-ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the non-volatile content.

N-(*N*-OCTYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10% or less of olaquindox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30% or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except**

(a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or

(b) its insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS STRAIN 251.

PALMITOYLETHANOLAMIDE (excluding derivatives) **except**:

(a) in preparations for therapeutic use; or

(b) in preparations for dermal cosmetic use containing 1% or less of palmitoylethanolamide.

Authorised Version F2026L01327 registered 30/09/2026

PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde **except**:

(a) for human therapeutic use; or

(b) in oral hygiene preparations; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL; or

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION-METHYL in aqueous preparations containing 45% or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(c) in preparations containing 4% or less of **D**-pulegone.

PENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate.

PERMETHRIN **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for human therapeutic use containing 5% or less of permethrin; or

Authorised Version F2026L01327 registered 30/09/2026

(c) in preparations containing 2% or less of permethrin.

2-PHENOXYETHANOL **except**:

(a) in cosmetic preparations containing 1% or less of 2-phenoxyethanol; or

(b) in other preparations containing 15% or less of 2-phenoxyethanol.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10% or less of phenothiazine.

PHENOXYMETHYL OXIRANE.

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules:

(a) in preparations packed and labelled for photographic purposes; or

(b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, "Do not discard testing solutions into the pool"; or

(c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

PHENYL METHYL PYRAZOLONE **except** when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immediate container and primary pack are labelled with warning statements to the following effect:

Authorised Version F2026L01327 registered 30/09/2026

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15% or less of phosphoric acid (H_3PO_4); or

(c) in solid or semi-solid preparations; or

(d) in professional dental kits.

PHOXIM.

o-PHTHALALDEHYDE **except** when included in Schedule 5.

PICRAMIC ACID including its salts (excluding other derivatives) **except** when used in hair dye products at a concentration of 0.6% or less of picramic acid after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIHEXANIDE **except**:

(a) in cosmetic preparations containing 0.3% or less of polihexanide; or

Authorised Version F2026L01327 registered 30/09/2026

(b) when packed and labelled for therapeutic use; or

(c) in other preparations containing 5% or less of polihexanide.

POLIXETONIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5% or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or Schedule 10; or

(b) in preparations containing 5% or less of potassium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.

POTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5% or less of potassium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

(a) when included in Schedule 5; or

(b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or

(c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or

(ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 1% or less of prallethrin.

Authorised Version F2026L01327 registered 30/09/2026

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 30% or less of propionic acid; or

(c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

n-PROPYL ALCOHOL **except:**

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of *n*-propyl alcohol; or

(c) in preparations for cosmetic or therapeutic use other than in spray form.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

D-PULEGONE **except** in preparations containing 4% or less of d-pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

PYRIDALYL.

PYRIDATE.

PYRIPROLE.

Authorised Version F2026L01327 registered 30/09/2026

PYRITHIONE COPPER.

PYRITHIONE ZINC **except**:

(a) when included in Schedule 2 or 5; or

(b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels; or

(c) in semi-solid hair preparations for animal use; or

(d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”; or

(e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or

(f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the non-volatile content.

PYRIOFENONE **except** when included in Schedule 5.

PYROXASULFONE.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

(a) when separately specified in these Schedules; or

(b) when included in Schedule 5; or

(c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(d) in preparations containing 5% or less of such quaternary ammonium compounds.

QUININE in cosmetic preparations **except**:

(a) in rinse-off hair preparations containing 0.5% or less of quinine calculated as free base; or

(b) in leave-on hair preparations containing 0.2% or less of quinine calculated as free base.

QUINOLINE and its salts (excluding other derivatives).

QUIZALOFOP ETHYL.

QUIZALOFOP-*p*-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-*p*-TEFURYL.

RESCALURE for agricultural use **except** when enclosed in a vapour releasing device which in normal use prevents access to its contents.

Authorised Version F2026L01327 registered 30/09/2026

RESMETHRIN **except** when included in Schedule 5.

RESORCINOL **except**:

(a) in preparations for human therapeutic use; or

(b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals;

written in letters not less than 1.5 mm in height.

ROTENONE **except** in solid or semi-solid preparations containing 2% or less of rotenone.

SAFROLE **except**:

(a) for internal use; or

(b) in other preparations containing 1% or less of safrole.

SAGE OIL (Dalmatian) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

Authorised Version F2026L01327 registered 30/09/2026

(ii) NOT TO BE TAKEN; or

(c) in preparations containing 4% or less of thujone.

SALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances.

SAROLANER **except** when included in Schedule 5.

SASSAFRAS OIL **except**:

(a) for internal use; or

(b) in other preparations containing 1% or less of safrole.

SELENIUM:

(a) in preparations containing 2.5% or less of selenium when packed and labelled:

(i) for the blueing of gun barrels; or

(ii) for photographic purposes; or

(iii) for the colouring of lead or lead alloys; or

b) in coated granules containing 1% or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or

(c) for the treatment of animals:

(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or

(ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or

(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

(iv) as barium selenate in preparations for injection containing 5% or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances.

SILICOFLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE **except**:

(a) when included in or expressly excluded from Schedule 2; or

(b) in preparations containing 1% or less of silver.

SINBIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of sinbioallethrin.

Authorised Version F2026L01327 registered 30/09/2026

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

(a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b) in liquid preparations, the pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5% or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or Schedule 10; or

(b) in preparations containing 5% or less of sodium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.

SODIUM NITRITE:

(a) in preparations containing 15% or less of sodium nitrite **except**:

(i) when included in Schedule 2 or 5; or

(ii) in preparations containing 0.5% or less of sodium nitrite; or

(iii) when present as an excipient in preparations for therapeutic use; or

(iv) in aerosols containing 2% or less of sodium nitrite; or

(b) for use in closed-loop water treatment systems (products).

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15% or less of sodium percarbonate.

SODIUM PERSULFATE:

(a) in hair preparations; or

(b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROPIDION.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFOXAFLOR **except** when included in Schedule 5.

Authorised Version F2026L01327 registered 30/09/2026

SULFURIC ACID (excluding its salts and derivatives) **except**:

(a) in fire extinguishers; or

(b) in preparations containing 0.5% or less of sulfuric acid (H_2SO_4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230-290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5% or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or

(c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

TETRAHYDROFURFURYL ALCOHOL (excluding its derivatives).

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

Authorised Version F2026L01327 registered 30/09/2026

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOPHANATE-METHYL **except** when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS **except**:

(a) when separately specified in these Schedules; or

(b) for therapeutic use.

THIRAM **except** in paint containing 0.5% or less of thiram.

THUJONE **except** in preparations containing 4% or less of thujone.

THYMOL when packed and labelled for use as a pesticide.

TIGOLANER **except** when in Schedule 5.

TOLUENE (excluding its derivatives) **except** in preparations containing 50% or less of toluene or toluene and xylene.

TOLUENEDIAMINES not elsewhere specified in these Schedules:

(a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(c) in nail polish preparations containing 2,5-toluenediamine **except** when labelled “avoid contact with skin”.

TOLYLFLUANID.

Authorised Version F2026L01327 registered 30/09/2026

TRANSFLUTHRIN **except**:

(a) in preparations containing 1% or less of transfluthrin; or

(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

(a) when included in Schedule 5; or

(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

(a) when included in Schedule 4 or 5; or

(b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20% or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 5% or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20% or less of trisodium nitrilotriacetate.

VAMIDOTHION.

VINYL ACETATE MONOMER (excluding its derivatives) **except**:

(a) in preparations for therapeutic use; or

(b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or

(c) in other preparations containing 1% or less of vinyl acetate.

Authorised Version F2026L01327 registered 30/09/2026

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50% or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10% or less of zeta-cypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 5% or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5% or less of zinc para-phenolsulfonate.

ZINC LACTATE in toothpaste **except** in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement:

Not recommended for children under twelve years of age.

ZINC SULFATE **except**:

(a) when included in or expressly excluded from Schedule 4; or

(b) in other preparations containing 5% or less of zinc sulfate.

ZIRAM in granular preparations.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 7—Dangerous poisons

Note: See section 16, subsection 54(4) and sections 55, 56, 62 and 65.

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-*S*-METHYL.

ACRIFLAVINIUM CHLORIDE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL **except**:

(a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or

(b) when separately specified in these Schedules.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINOACRIDINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

2-AMINO-5-METHYLPHENOL **except** when included in Schedule 10.

4-AMINOPROPIOPHENONE.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 4 or 6; or

(c) as selenium arsenide in photocopier drums; or

(d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or

Authorised Version F2026L01327 registered 30/09/2026

(e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:

(i) in contact with foodstuffs, animal feeds or potable water; or

(ii) of clothing and footwear in contact with the skin; or

(iii) used as infant wear; or

(iv) intended for use as packaging materials; or

(f) in animal feeds containing 75 g/tonne or less of arsenic; or

(g) in paints containing 0.1% or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

AZO DYES that are derivatives by diazotisation of any of the following substances:

(a) *p*-aminoazobenzene (CAS No. 60-09-3);

(b) *o*-aminoazotoluene (CAS No. 97-56-3);

(c) *o*-anisidine (CAS No. 90-04-0);

(d) *p*-chloroaniline (CAS No. 106-47-8);

(e) 4-chloro-*o*-toluidine (CAS No. 95-69-2);

(f) 2,4-diaminoanisole (CAS No. 615-05-4);

(g) 6-methoxy-*m*-toluidine (p-cresidine) (CAS No. 120-71-8);

(h) 4,4-methylenedianiline (CAS No. 101-77-9);

(i) 2-naphthylamine (CAS No. 91-59-8);

(j) 5-nitro-*o*-toluidine (CAS No. 99-55-8);

(k) 2,4-toluenediamine (CAS No. 95-80-7);

(l) *o*-toluidine (CAS No. 95-53-4);

(m) 2,4,5-trimethylaniline (CAS No. 137-17-7);

except for BASIC RED 76 (CAS No. 68391-30-0) when included in Schedule 6.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5% or less of benomyl.

BENZENE (excluding its derivatives) **except**:

(a) preparations containing 15 mL/L or less of benzene; or

Authorised Version F2026L01327 registered 30/09/2026

(b) petrol containing 50 mL/L or less of benzene.

BENZIDINE-BASED AZO DYES being:

(a) 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[*N*-(4-chlorophenyl)-3-oxobutanamide] (CAS No. 94249-03-3); or

(b) Acid Red 85 (Acid Fast Red A): 1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, disodium salt (CAS No. 3567-65-5); or

(c) C.I Acid Black 29: (CAS No. 12217-14-0); or

(d) C.I. Direct Orange 1: (CAS No. 54579-28-1); or

(e) Direct Black 38: 2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt (CAS No. 1937-37-7); or

(f) Direct Blue 2: 2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium salt (CAS No. 2429-73-4); or

(g) Direct Blue 6: 2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt (CAS No. 2602-46-2); or

(h) Direct Brown 2: 5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxy- benzoic acid disodium salt (CAS No. 2429-82-5); or

(i) Direct Brown 95: Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt (CAS No. 16071-86-6); or

(j) Direct Green 1: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt (CAS No. 3626-28-6); or

(k) Direct Green 6: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt (CAS No. 4335-09-5); or

(l) Direct Red 28 (Congo Red): 1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt (CAS No. 573-58-0); or

(m) Direct Red 37: 1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt (CAS No. 3530-19-6).

BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

(a) when included in Schedule 6; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BROMOXYNIL **except** when included in Schedule 6.

BRUCINE **except** in alcohol containing 0.02% or less of brucine as a denaturant.

CACODYLIC ACID **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.35% or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1% or less of carbon tetrachloride.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedule 5 or 6.

Authorised Version F2026L01327 registered 30/09/2026

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

(a) when included in Schedule 5 or 6; or

(b) in preparations containing 1% or less of chlorhexidine; or

(c) in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

4-CHLORO-*o*-TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHAL-DIMETHYL.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

(a) ferricyanides; or

(b) ferrocyanides; or

(c) when separately specified in these Schedules.

CYANOGEN.

CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) **except** when included in Schedule 6.

CYHALOTHRIn (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except**:

(a) when included in Schedule 5 or 6; or

Authorised Version F2026L01327 registered 30/09/2026

(b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

(c) in preparations containing 0.1% or less of deltamethrin.

DEMETON.

DEMETON-*O*-METHYL.

DEMETON-*S*-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE **except** in biocidal preparations containing 0.3% or less of 1,3-dichloropropene.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (*N*,*N*-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4, 6 or 10.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

Authorised Version F2026L01327 registered 30/09/2026

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5 or 6.

ETACONAZOLE.

ETHALFLURALIN.

ETHION.

ETHOPROPHOS **except** when included in Schedule 6.

2-ETHOXYETHANOL and its acetates **except** in preparations containing 0.5% or less of 2-ethoxyethanol.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN **except** when included in Schedule 6.

Authorised Version F2026L01327 registered 30/09/2026

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FORMETANATE.

FOSTHIAZATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C **except**:

(a) when in solid polymers; or

(b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or

(c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

(a) when included in Schedule 4; or

(b) its salts and derivatives other than cyanides separately specified in this Schedule; or

(c) in preparations containing 10 mg/kg or less of hydrocyanic acid.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

Authorised Version F2026L01327 registered 30/09/2026

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.

MADURAMICIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

2-METHOXYETHANOL and its acetates **except** in preparations containing 0.5% or less of 2-methoxyethanol.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 2, 4 or 6; or

(c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or

(d) mercury (metallic) in scientific instruments; or

(e) dental amalgams; or

(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

Authorised Version F2026L01327 registered 30/09/2026

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL **except**:

(a) when included in Schedule 6; or

(b) when used in laboratory analysis; or

(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

(a) when included in Schedule 3 or 4; or

(b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or

(c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

2-NITROTOLUENE.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

Authorised Version F2026L01327 registered 30/09/2026

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01% or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

(a) when included in Schedule 5 or 6; or

(b) in preparations containing 0.5% or less of potassium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SAFLUFENACIL **except** when included in Schedule 5.

SCHRADAN.

SELENIUM **except**:

(a) when included in Schedule 6; or

(b) as selenium arsenide in photocopier drums; or

(c) in preparations for therapeutic use other than:

(i) drench concentrates containing 2.5% or less of selenium; or

(ii) pour-on preparations containing 0.5% or less of selenium; or

Authorised Version F2026L01327 registered 30/09/2026

(d) in paints or tinters containing 0.1% or less of selenium calculated on the non-volatile content of the paint or tinter; or

(e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

(a) when included in Schedule 2, 5 or 6; or

(b) in preparations containing 0.5% or less of sodium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule; or

(b) in plastics; or

(c) in semi-solid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or

Authorised Version F2026L01327 registered 30/09/2026

(d) in paint containing 1% or less of such compounds calculated as tin in the non-volatile content of the paint.

o-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (S,S,S-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 8—Controlled drugs

Note 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1).

Note 2: Substances marked # are listed in Appendix D.

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

ALPRAZOLAM.

AMFETAMINE.

AMOBARBITAL **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITAL.

BUTORPHANOL.

CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:

(a) cultivated or produced, or in products manufactured[1], in accordance with the *Narcotic Drugs Act 1967*; and/or

(b) for use in products manufactured in accordance with the *Narcotic Drugs Act 1967*; and/or

(c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

(d) in therapeutic goods supplied in accordance with the Act;

except:

[1] "Cultivation", "production" and "manufacture" have the same meaning as in the *Narcotic Drugs Act 1967*

Authorised Version F2026L01327 registered 30/09/2026

(e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic *Goods Regulations 1990* applies; or

(f) when separately specified in the NABIXIMOLS entry in this Schedule; or

(g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

(h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 4.

CODEINE-*N*-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITAL.

DEXAMFETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 3 or 4.

DIHYDROMORPHINE.

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ESKETAMINE.

ETHYLAMFETAMINE.

Authorised Version F2026L01327 registered 30/09/2026

ETHYLMORPHINE **except** when included in Schedule 4.

FENTANYL.

FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMFETAMINE.

LEVOMETHAMFETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

LISDEXAMFETAMINE.

METHADONE.

METAMFETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

NABIXIMOLS (botanical extract of *Cannabis sativa* which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

Authorised Version F2026L01327 registered 30/09/2026

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITAL **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

PSILOCYBINE in preparations for human therapeutic use for the treatment of treatment-resistant depression.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITAL.

SECOBARBITAL.

SODIUM OXYBATE for human therapeutic use.

SUFENTANIL.

TAPENTADOL.

TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:

(a) included in products manufactured in accordance with the *Narcotic Drugs Act 1967*; and/or

(b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

Authorised Version F2026L01327 registered 30/09/2026

(c) in therapeutic goods supplied in accordance with the Act;

except when:

(d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the *Therapeutic Goods Regulations 1990* applies; or

(e) separately specified in the NABIXIMOLS entry in this Schedule; or

(f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

(g) in hemp seed oil at a concentration of 10 mg/kg or less.

THEBACON.

THEBAINE.

THIAFENTANIL.

TILIDINE.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 9—Prohibited substances

Note 1: See paragraph 7(b) and subsection 57(2).

Note 2: Trivial or unofficial names are marked *.

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMFETAMINES and substituted alkoxyamfetamines **except** when separately specified in these Schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines **except** when separately specified in these Schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these Schedules.

BENZETHIDINE.

BENZOYLINDOLES **except** when separately specified in these Schedules.

BENZYLPIPERAZINE *(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

Authorised Version F2026L01327 registered 30/09/2026

BETAPRODINE.

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly).

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).

BUFOTENINE.

BUTONITAZENE.

CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), **except**:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or

(c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CATHINONES **except** when separately specified in these Schedules.

CLONAZOLAM.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 0.5% or less of cyclohexylphenols.

DESCHLOROETIZOLAM.

DESOMORPHINE.

N,*N*-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES **except** when separately specified in these Schedules.

N,*N*-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.

DIAMPROMIDE.

DIBENZOPYRANS **except** when separately specified in these Schedules.

Authorised Version F2026L01327 registered 30/09/2026

3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-*N*-METHYLBENZAMIDE (U-47700).

3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921).

DICLAZEPAM.

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE *(DET).

2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-1-ONE (SGT-151).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMFETAMINE *(DMA).

2,5-DIMETHOXY-4-BROMOAMFETAMINE *(DOB).

2,5-DIMETHOXY-4-ETHYL-*a*-AMFETAMINE *(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).

2,5-DIMETHOXY-4-(*N*)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) **except** when included in Schedule 8.

N,*N*-DIMETHYLAMFETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,*N*-DIMETHYLTRYPTAMINE *(DMT).

DIOXAPHETYL BUTYRATE.

DIPHENIDINE.

ECGONINE.

EPHENIDINE.

Authorised Version F2026L01327 registered 30/09/2026

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(*N*-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE *(PCE).

ETODESNITAZENE.

ETONITAZENE.

ETONITAZEPIPNE.

ETONITAZEPYNE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4-FLUORO-*N*-METHYLAMFETAMINE.

FLUBROMAZEPAM.

FLUBROMAZOLAM.

FLUNITAZENE.

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

(a) containing 0.1% or less of harmala alkaloids; or

(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).

4-HYDROXYBUTANOIC ACID and its salts **except** for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).

2-[(1*R*,3*S*)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).

2-[(1*R*,3*S*)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497).

Authorised Version F2026L01327 registered 30/09/2026

HYDROXYPETHIDINE.

IBOTENIC ACID.

ISOMETHADONE.

ISOPHENIDINE.

ISOTONITAZENE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLONAZEPAM.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

METHOXPHENIDINE.

5-METHOXY- α –METHYLTRYPTAMINE *(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE *(MMDA).

4-METHOXY- α –METHYLPHENYLETHYLAMINE *(PMA).

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE *(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMFETAMINE *(MDA).

3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).

Authorised Version F2026L01327 registered 30/09/2026

3-METHYLFENTANYL.

4-METHYLMETHCATHINONE *(MEPHEDRONE).

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(*N*-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

6-METHYLNICOTINE.

METHYLONE *(MDMC).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).

4-METHYLTHIOAMFETAMINE.

3-METHYLTHIOFENTANYL.

METODESNITAZENE.

METONITAZENE.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES **except** when separately specified in these Schedules.

NAPHTHOYLPYRROLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES **except** when separately specified in these Schedules.

NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).

NICOCODINE.

Authorised Version F2026L01327 registered 30/09/2026

NICODICODINE.

NICOMORPHINE.

NIFOXIPAM.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122).

1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE *(PCP).

PHENIBUT.

N-PHENETHYL-4-PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES **except** when separately specified in these Schedules.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PROPYLPHENIDINE.

PROTONITAZENE.

PSILOCYBINE **except** when included in Schedule 8.

PYRAZOLAM.

RACEMETHORPHAN.

Authorised Version F2026L01327 registered 30/09/2026

RACEMORPHAN.

ROLICYCLIDINE *(PHP or PCPY).

SALVIA DIVINORUM.

SYNTHETIC CANNABINOMIMETICS **except** when separately specified in these Schedules.

TENOCYCLIDINE *(TCP).

TETRAHYDROCANNABINOLS and their alkyl homologues, **except**:

(a) when included in Schedule 4 or Schedule 8; or

(b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or

(c) in hemp seed oil at a concentration of 10 mg/kg or less.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE *(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine **except**:

(a) methoxyphenamine; or

(b) when separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

Authorised Version F2026L01327 registered 30/09/2026

Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use

Note 1: See subsection 57(2) and section 63.

Note 2: Schedule 10 contains substances previously included in Appendix C.

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5; or

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(c) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKYLAMINES WITH STIMULANT PROPERTIES **except** when separately specified in these schedules.

2-AMINO-5-METHYLPHENOL in preparations for cosmetic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use**.**

AMYGDALIN for therapeutic use **except** in preparations containing 10 mg/kg or less of amygdalin.

ANCHUSA OFFICINALIS for therapeutic use.

o-ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows **except** in preparations containing 0.001% or less of *o*-anisidine.

APRONAL for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** “debitterised neem seed oil”.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

Authorised Version F2026L01327 registered 30/09/2026

1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.

BUTYL BENZYL PHTHALATE for cosmetic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

CARDARINE.

CHRYSOIDINE BASE in preparations for use in hair dyes.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use **except** or when being used solely for experimental purposes in humans and where such use:

(a) is in accordance with:

(i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and

(ii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(1A) of the Act; and

(iii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(4A) of the Act; or

(b) is in accordance with the requirements of item 3 of Schedule 5A to the *Therapeutic Goods* Regulations 1*990*.

COAL TAR for cosmetic use other than in therapeutic goods.

Authorised Version F2026L01327 registered 30/09/2026

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DIBUTYL PHTHALATE for cosmetic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5% or less of diethylphthalate.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6-dihydroxyindoline.

DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.

DIISOBUTYL PHTHALATE for cosmetic use.

1,3-DIMETHYLAMYLAMINE (DMAA).

1,3-DIMETHYLBUTYLAMINE (DMBA) **except** when separately specified in these schedules.

1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette).

1,5-DIMETHYLHEXYLAMINE (DMHA) **except** when separately specified in these schedules.

DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.

1,4-DIMETHYLPENTYLAMINE (DMPA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5% or less of dimethylphthalate.

2,4-DINITROPHENOL for human use.

Authorised Version F2026L01327 registered 30/09/2026

DISPERSE YELLOW 3 for use in hair dyes.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25% or less of ethylene glycol.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde **except** in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in preparations for domestic and cosmetic use.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

ISOPROPYL NITRITE.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

KAMBO.

LEAD COMPOUNDS:

(a) in anti-fouling paints **except** in preparations containing 0.06% or less of lead calculated on the non-volatile content of the paint; or

(b) in paints (other than anti-fouling paints), tinters, inks or ink additives **except** in preparations containing 0.009% or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive; or

(c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead.

LIGULARIA DENTATA for therapeutic use.

Authorised Version F2026L01327 registered 30/09/2026

MELIA AZEDARACH including its extracts and derivatives.

METHANOL in hand sanitiser preparations containing more than 5% methanol.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:

(a) Acid Violet 49; or

(b) Ethyl Violet; or

(c) Basic Blue 7; or

(d) Basic Blue 26 (CI 44045).

NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use **except** when enclosed in a device which, in normal use, prevents removal or ingestion of its contents.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde **except** in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENPROMETHAMINE.

PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

n-PROPYL NITRITE.

PTERIDIUM spp. for therapeutic use.

Authorised Version F2026L01327 registered 30/09/2026

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1% or less of safrole.

SANGUINARIA CANADENSIS (bloodroot) in preparations for human use **except** in preparations containing 0.01% or less of SANGUINARINE.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

SYMPHYTUM spp. (Comfrey) in preparations for human or animal use **except** when in Schedule 5.

2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.

TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

o-TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows **except** in preparations containing 0.001% or less of *o*-toluidine.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

WILD CHERRY BARK for therapeutic use **except** in preparations containing:

(a) 10 mg/kg or less of amygdalin; and

(b) 10 mg/kg or less of hydrocyanic acid.

Authorised Version F2026L01327 registered 30/09/2026

Appendix A—General exemptions

Note: See paragraph 11(a).

1 Exempt preparations and products

The following table specifies preparations and products for the purposes of paragraph 11(a).

Exempt preparations and products	
Item	**Column 1** **Preparation or product**
1	ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products
2	BACTERIAL CULTURE MEDIA containing antibiotics
3	CERAMICS
4	CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4:2020, *Safety of toys,* Part 4: *Experimental sets for chemistry and related activities*
5	COPPER COMPOUNDS in paints
6	DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders
7	ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
8	ELECTRONIC COMPONENTS
9	ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging
10	EXPLOSIVES
11	FOOD **except**: (a) food additives before incorporation into food; or (b) when used as a means of administering a poison for therapeutic use
12	FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules
13	GLASS (including CRYSTAL WARE)
14	GLAZED POTTERY
15	HUMAN BLOOD PRODUCTS including: (a) whole blood; (b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and (c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives: (i) albumin; (ii) anticoagulation complex; (iii) C1 esterase inhibitors; (iv) clotting factors; (v) fibrinogen; (vi) protein C; (vii) prothrombin complex concentrate (PCC);

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Exempt preparations and products	
Item	**Column 1** **Preparation or product**
	(viii) thrombin
16	IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8
17	INTRAOCULAR VISCOELASTIC PRODUCTS
18	LUBRICANTS in preparations that provide a lubricating action between machinery parts, **except** soluble oils and solvent-deposited lubricating agents
19	MATCHES
20	MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
21	MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, **except** the following: (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen; (b) medical devices which include anticoagulants; (c) artificial tears; (d) urinary catheters; (e) intra-articular fluids
22	MOTOR, HEATING or FURNACE FUELS **except** the following: (a) when the contrary intention appears in any Schedule; (b) when containing methanol; (c) toy or hobby fuels; or (d) petrol or kerosene when packed in containers having a capacity of 20 L or less
23	NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION
24	PAPER **except**: (a) when prepared for pesticidal use; or (b) when containing a poison included in Schedule 8 or 9
25	PHOTOGRAPHIC PAPER or FILM
26	PIGMENTS when immobilised in a polymer
27	PORCELAIN
28	PRINTING INKS or INK ADDITIVES **except**: (a) when containing a pesticide; or (b) preparations containing more than 0.009% of lead calculated on the non-volatile content of the ink or ink additive
29	RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use
30	RADIOISOTOPES for therapeutic use
31	SEEDS treated with seed protectants
32	SINGLE-USE TUBES for the estimation of alcohol content of breath
33	TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting
34	TIMBER or WALLBOARD
35	TREATMENT LAYERS OF COATED METAL ARTICLES **except** articles intended for use in the collection of drinking water when not compliant with the health and safety

Authorised Version F2026L01327 registered 30/09/2026

Exempt preparations and products	
Item	**Column 1** **Preparation or product**
	requirements of the Australian Standard AS 4020:2018, *Testing of products for use in contact with drinking water*
36	VITREOUS ENAMELS
37	WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix B—Substances considered not to require control by scheduling

Note: See paragraph 11(b).

1 Reasons for including substances in the table in clause 3

For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item.

Reasons for including substances in the table in clause 3

Item	Column 1 Letter	Column 2 Reason
1	a	Low Toxicity
2	b	Use pattern restricts hazard
3	c	Presentation/packaging restricts hazard
4	d	Industrial use only

2 Areas of use in relation to substances included in the table in clause 3

For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, sub-area or sub-sub-area of use specified in column 2, 3 or 4 (as applicable) of the item.

Areas of use in relation to substances included in the table in clause 3

Item	Column 1 Number	Column 2 Area	Column 3 Sub-area	Column 4 Sub-sub-area
1	1	Agriculture		
2	1.1		Herbicide	
3	1.2		Insecticide	
4	1.2.1			Insecticide for codling moth
5	1.2.2			Termiticide
6	1.3		Fungicide	
7	1.3.1			On seed fungicide
8	1.4		Bird Repellent	
9	1.5		Fertiliser	
10	1.6		Plant Growth Regulator	
11	1.7		Insect Pheromone	
12	1.8		Mushroom Bactericide	
13	1.9		Acaricide	
14	1.10		Biological control agent	
15	1.11		Adjuvant in agricultural products	

Authorised Version F2026L01327 registered 30/09/2026

Areas of use in relation to substances included in the table in clause 3				
Item	**Column 1 Number**	**Column 2 Area**	**Column 3 Sub-area**	**Column 4 Sub-sub-area**
16	2	Veterinary		
17	2.1		For animal use	
18	2.2		Treatment of mastitis in cows	
19	2.3		Coccidiostat	
20	2.4		Feed additive	
21	2.5		Antiseptic	
22	2.6		Scabicide	
23	2.7		Anthelmintic	
24	2.8		Vitamin/Mineral	
25	2.9		Growth Promotant	
26	2.10		Ectoparasiticide	
27	3	Domestic		
28	3.1		Aromatherapy	
29	3.2		Food additive	
30	3.3		Cosmetic	
31	3.4		Human use	
32	3.5		Miticide	
33	4	Industrial		
34	4.1		Water treatment	
35	4.2		Biological control agent	
36	5	Environmental		
37	5.1		Mosquito control	
38	6	Human therapeutic use		
39	6.1		Diagnostic agent	
40	6.2		Medical device	
41	6.3		Antiseptic	
42	6.4		Sunscreen	
43	6.5		External use	
44	6.6		Laxative	
45	6.7		Antiseborrheic	
46	6.8		Cytoprotective	
47	6.9		Vitamin/Mineral	
48	6.10		Eye Drops	
49	7	General		
50	7.1		Any use	
51	7.2		Excipient	
52	7.3		Synergist	
53	7.4		Flux	
54	7.5		Pesticide	

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Areas of use in relation to substances included in the table in clause 3				
Item	**Column 1 Number**	**Column 2 Area**	**Column 3 Sub-area**	**Column 4 Sub-sub-area**
55	7.6		Insect repellent	
56	7.7		Solvent	
57	7.8		Disinfectant	
58	7.9		Preservative	
59	7.10		Antioxidant	
60	7.11		Resin activator/accelerant	
61	7.12		Sweetener artificial	
62	7.13		Food additive	

3 Substances exempt in certain uses

For the purposes of paragraph 11(b), the following table specifies:

(a) substances; and

(b) areas, sub-areas and sub-sub-areas of use in relation to those substances.

Note: Columns 3 and 4 of the table are included for information only.

Substances exempt in certain uses				
Item	**Column 1 Substance**	**Column 2 Area, sub-area or sub-sub-area of use**	**Column 3 Reason for inclusion**	**Column 4 Date of inclusion**
1	4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE	1.7	b	Feb 2005
2	AFIDOPYROPEN	1.2	b	Jun 2018
3	ALCOHOL, DEHYDRATED	6	b	Aug 2000
4	ALUM	7.1	a	May 1997
5	ALUMINIUM AMMONIUM SULFATE	7.1	a	May 1997
6	ALUMINIUM POTASSIUM SULFATE	7.1	a	May 1997
7	ALUMINIUM SILICATE	7.1	a	Nov 1974
8	ALUMINIUM tris (ETHYLPHOSPHONATE)	1	a	Aug 1986
9	AMETOCTRADIN	1.3	a	May 2012
10	AMMONIUM PHOSPHATE	7.1	a	Nov 1974
11	AMMONIUM THIOSULPHATE	7.1	a	Nov 1974
12	AMPROLIUM	2.3	a	Jun 1969
13	AMYL ACETATE	7.1	a	Nov 1974
14	α -AMYLASE derived from *Aspergillus niger*	2.4	a	Feb 2005
15	AMYL CINNAMALDEHYDE	3.3	a, b	Feb 2017
16	ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT	2.1	a	Jun 2004
17	ASPARTIC ACID	6	a	-

Authorised Version F2026L01327 registered 30/09/2026

Substances exempt in certain uses

Item	Column 1 Substance	Column 2 Area, sub-area or sub-sub-area of use	Column 3 Reason for inclusion	Column 4 Date of inclusion
18	ASULAM	1	a	May 1986
19	*AUREOBASIDIUM PULLULANS* (strains DSM14940 and DSM14941)	1.3	a	Oct 2017
20	AZIMSULFURON	1.1	a	Jun 2003
21	*BACILLUS AMYLOLIQUEFACIENS*	1.3	a	Jun 2018
22	*BACILLUS PARALICHENIFORMIS*	1.10	a	Oct 2026
23	*BACILLUS SPHAERICUS*, STRAIN 2362	5.1	a	Feb 2003
24	*BACILLUS THURINGIENSIS*	5.1	a	May 1992
25	*BACILLUS THURINGIENSIS* (excluding endotoxin)	2.10	a	Jun 2003
26	*BACILLUS TOYOI*	2.9	a	Aug 1980
27	*BACULOVIRUS CYDIA POMONELLA*	1.2	a	Jun 2006
28	BENFLURALIN	1.1	a	-
29	BENSULFURON-METHYL	1	a	Aug 1987
30	BENTONITE	7.1	a	Jun 2002
31	BENZYL BENZOATE	1.2	a	Aug 1989
32	BETAINE HYDROCHLORIDE	7.1	a	Nov 1974
33	BIFENAZATE	1.9	a	Oct 2002
34	BISMUTH SUBNITRATE	2.1	b, c	Nov 1999
35	BISTRIFLURON	1.2.2	a	Feb 2014
36	BIURET	2.4	a	Nov 1974
37	BIXLOZONE	1.1	a	Feb 2020
38	BLAD (banda de Lupinus albus doce)	1.3	a	Feb 2016
39	BOSCALID	1.3	a	June 2003
40	BOVINE SOMATOTROPHIN	2	a	May 1992
41	BROMACIL	1	a	Aug 1987
42	BROMOPROPYLATE	1	a	Nov 1994
43	BUPIRIMATE	1	a	Nov 1990
44	BUTAFENACIL	1	a	May 2000
45	BUTOXYPOLYPROPYLENE GLYCOL	7.7	a	Nov 1974
46	n-BUTYL BUTYRATE	7.1	a	-
47	n-BUTYL LACTATE	7.1	a	-
48	CARBOXIN	1	a	Aug 1987
49	CARFENTRAZONE-ETHYL	1	a	Aug 1998
50	CELLULASE derived from *Aspergillus niger*	2.4	a	Feb 2005
51	CETYL ALCOHOL	7.1	a	Nov 1974
52	CHAMOMILE OIL	3.1	a	Feb 2000
53	CHINA CLAY	1.2	a	Sep 2008

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Substances exempt in certain uses				
Item	**Column 1 Substance**	**Column 2 Area, sub-area or sub-sub-area of use**	**Column 3 Reason for inclusion**	**Column 4 Date of inclusion**
54	CHLORANTRANILIPROLE	1.2	a	Sep 2008
55	CHLORFLUAZURON	1.2.2	a	Oct 2005
56	CHLORFLURENOL	1.6	a	Feb 1974
57	CHLORIDAZON	1	a	May 1988
58	CHLOROXYLENOLS	7.8	a	Feb 1975
59	CITRONELLA OIL	7.1	a	Feb 2000
60	CLARY SAGE OIL	7.1	a	Feb 2000
61	CLITORIA TERNATEA EXTRACT	1.2	a	Feb 2016
62	CLOPIDOL	2.3	d	Nov 1974
63	COBALT NAPHTHENATE	7.1	d	-
64	CROSPOVIDONE	2	a	Aug 1996
65	*CULICINOMYCES CLAVOSPORUS*	5.1	a	Nov 1982
66	CYCLAMIC ACID	7.1	a	Nov 1971
67	CYCLANILIPROLE	1.2	a	Oct 2016
68	CYCLOBUTRIFLURAM	1.3, 1.3.1	a	Oct 2022
69	CYCLOHEXANE	7.7	a	Nov 1974
70	CYCLOHEXANOL ACETATE	7.7	a	-
71	*CYPRINID HERPESVIRUS-3*	1.10	a	Oct 2018
72	CYROMAZINE	2	a	Nov 1980
73	DICLAZURIL	2.3	a	Nov 2001
74	DIETHYL CARBONATE	7.1	a	-
75	DIFLUFENICAN	1	a	Feb 1987
76	DIKEGULAC-SODIUM	1.6	a	Mar 1980
77	DIMETHYL ETHER	4	d	Nov 1988
78	DIMETICONE	7.1	a	-
79	DIPHENYLAMINE	1	a	Feb 1988
80	DIPROPYLENE GLYCOL MONOMETHYL ETHER	4	a	Nov 1987
81	DISODIUM MANGANESE EDTA	2.1	a	Feb 2022
82	DIURON	1	a	Nov 1987
83	DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)	7.1	a	Feb 1970
84	2,2-DPA	1	a	Nov 1989
85	DROMETRIZOLE TRISILOXANE	6.4	a	Oct 2003
86	*DUDDINGTONIA FLAGRANS*, STRAIN IAH 1297	2.7	a	Feb 2018
87	EPSIPRANTEL	2	a	Nov 1991
88	ETHAMETSULFURON-METHYL	1.1	a	Nov 2000

Authorised Version F2026L01327 registered 30/09/2026

Substances exempt in certain uses

Item	Column 1 Substance	Column 2 Area, sub-area or sub-sub-area of use	Column 3 Reason for inclusion	Column 4 Date of inclusion
89	ETHOPABATE	2.3	d	Jun 1969
90	ETHYL ACETATE	7.1	a	Nov 1974
91	ETHYL ALCOHOL	7.1	a	Nov 1974
92	ETHYLBUTYLACETYL AMINOPROPRIONATE	3.4	a	Aug 2000
93	ETHYL BUTYRATE	7.1	a	-
94	ETHYL LACTATE	7.1	a	-
95	ETOFENPROX	1.2	a	Jun 2018
96	ETOXAZOLE	1.2	a	Oct 2003
97	*EUBACTERIUM sp. strain DSM11798*	2.4	a	Sep 2013
98	FENFURAM	1.3.1	a	May 1977
99	FENHEXAMID	1	a	Feb 1999
100	FENOXYCARB	1	a	Feb 1988
101	FLORPYRAUXIFEN-BENZYL	1, 1.1	a	Feb 2018
102	FLORYLPICOXAMID	1.3	a	Feb 2021
103	FLUFENOXURON	1	a	Feb 1997
104	FLUMETSULAM	1	a	Feb 1992
105	FLUOMETURON	1	a	Aug 1989
106	FLUOPICOLIDE	1.3	a	Oct 2016
107	FLUOXAPIPROLIN	1.3	a	Feb 2022
108	FLUTOLANIL	1.3	a	Nov 2001
109	FLUROXYPYR	1	a, c	May 1986
110	FORCHLORFENURON	1.6	a	Feb 2005
111	FULLERS EARTH	7.1	a	Nov 1974
112	FUNGAL PROTEASE derived from *Aspergillus niger*	2.4	a	Feb 2005
113	GERANIUM OIL	7.1	a	Feb 2000
114	GIBBERELLIC ACID	1.6	a	Nov 1974
115	α-GLUCANASE derived from *Aspergillus niger*	2.4	a	Feb 2005
116	HALAUXIFEN METHYL	1, 1.1	a	Oct 2014
117	HELIONAL	7	a	Feb 2023
118	HEXAFLURON	1	a	Nov 1988
119	HEXYL ACETATE	7.7	a	-
120	HEXYL CINNAMALDEHYDE	3.3	a, b	Feb 2017
121	HEXYTHIAZOX	1	a	Feb 1988
122	HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	6.2	b	Aug 2001
123	HYDROPRENE	1	a	Feb 1988
124	HYDROXYPROPYL CELLULOSE	7.1	a	Nov 1982

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Substances exempt in certain uses				
Item	**Column 1 Substance**	**Column 2 Area, sub-area or sub-sub-area of use**	**Column 3 Reason for inclusion**	**Column 4 Date of inclusion**
125	ICODEXTRIN	6	b	Nov 2000
126	INDOLE-3-ACETIC ACID	1.6	b	Feb 1985
127	IPFLUFENOQUIN	1.3, 1.3.1	a	Sep 2022
128	ISOPRENE ALCOHOL	7.1	a	-
129	IPRODIONE	1	a	Feb 1997
130	ISETHIONATE, as mixed ammonium and ethanolamine salts of 2-hydroxyethanesulfonic acid	1.11	a, b	Jun 2016
131	ISOFETAMID	1.3	a	Feb 2018
132	ISOSTEARYL ALCOHOL ETHOXYLATE	5.1	a	Nov 1999
133	KAOLIN	7.1	a	Nov 1974
134	KINETIN	1.6	a	Feb 2022
135	KRESOXIM-METHYL	1	a	Aug 1999
136	KUNZEA OIL	7.1	a	Feb 2000
137	LAURIC ACID	7.1	a	Oct 2005
138	LAURYL ALCOHOL (1-DODECANOL)	7.1	a	Nov 1974
139	LAVANDIN OIL	7.1	a	Feb 2000
140	LAVENDER OIL	7.1	a	Feb 2000
141	LEAD METALLIC	7.1	a	-
142	LIMONENE (DIPENTENE)	7.1	a	Jun 2002
143	LINOLEIC ACID	7.1	a	Oct 2005
144	LINSEED FATTY ACIDS	2.1	a	Aug 1990
145	LINURON	1	a	Feb 1990
146	LIQUORICE, DEGLYCYRRHISINISED	7.1	a	May 1999
147	MAGNESIUM HYDROXIDE	7.1	a	Jun 2021
148	MALEIC HYDRAZIDE	1	a	Nov 1992
149	MANGANESE DIOXIDE	1	b	May 1999
150	*MEGASPHAERA ELSDENII strain 41125*	2.4	a	Sep 2013
151	MESOSULFURON-METHYL	1.1	a	Feb 2002
152	*METARHIZIUM ANISOPLIAE*	4.2	b	Feb 2000
153	*METARHIZIUM ANISOPLIAE*	1.10	a	Jun 2003
154	METCAMIFEN	1.1	a	Feb 2020
155	METHOPRENE	1	a	Aug 1987
156	METHOXYFENOZIDE	1	a	Nov 2000
157	METHYL ACETATE	7.7	a	-
158	METHYL BENZOQUATE	2.3	d	Nov 1974
159	1-METHYLCYCLOPROPENE	1.6	a	Jun 2003
160	METHYL *p*-HYDROXYBENZOATE	7.9	a	Nov 1974

Authorised Version F2026L01327 registered 30/09/2026

Substances exempt in certain uses

Item	Column 1 Substance	Column 2 Area, sub-area or sub-sub-area of use	Column 3 Reason for inclusion	Column 4 Date of inclusion
161	METSULFURONMETHYL	1.1	a	Nov 1985
162	MYRISTIC ACID	7.1	a	Oct 2005
163	NAPROPAMIDE	1	a	Aug 1987
164	NAPTHYL ACETAMIDE	1.6	a	Nov 1974
165	NEROLI OIL	7.1	a	Feb 2000
166	NICARBAZIN	2.3	d	Jun 1969
167	NISIN	3.2	a	Jun 2003
168	NORFLURAZON	1.1	a	Nov 1983
169	NOVALURON	1	a	Nov 2000
170	NUCLEAR POLYHEDROSIS VIRUS of *Helicoverpa armigera* occlusion bodies	1.2	a	Feb 2004
171	OCTYL ALCOHOLS	7.1	a	Nov 1974
172	OLEIC ACID	7.1	a	Oct 2005
173	ORANGE OIL, SWEET	7.1	a	Aug 2000
174	OXABETRINIL	1	a	Feb 1987
175	OXATHIAPIPROLIN	1.3	a	Jun 2016
176	OXYFLUORFEN	1	a	May 2001
177	PALMAROSA OIL	7.1	a	Feb 2000
178	PALMITIC ACID	7.1	a	Oct 2005
179	PATCHOULI OIL	7.1	a	Feb 2000
180	PECTINASE derived from *Aspergillus niger*	2.4	a	Feb 2005
181	PEGBOVIGRASTIM	2.1	a	Jun 2017
182	PENCYCURON	1	a	Aug 1994
183	PENTADECANOIC ACID	7.1	a	Oct 2005
184	PEPPERMINT OIL	7.1	a	Feb 2000
185	PHENMEDIPHAM	1.1	a	May 1989
186	**D**-PHENOTHRIN	7.5, 1.2	a	Feb 1982
187	PHYTASE	2.4	a	Feb 1996
188	PICLORAM	1	a	Aug 1987
189	PICOLINAFEN	1	a	May 2000
190	PIMELIC ACID	7.1	a	Oct 2005
191	PIPERONYL BUTOXIDE	7.5	a	Aug 1991
192	POLOXALENE	7.1	a	Nov 1974
193	POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC)	4.1	a	Nov 1997
194	POLYHEDROSIS VIRUS of *Helico zea* occlusion bodies	1	a	Nov 1996
195	POLY (GNRF) OVALBUMIN	2	a	Feb 1990

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Substances exempt in certain uses				
Item	**Column 1 Substance**	**Column 2 Area, sub-area or sub-sub-area of use**	**Column 3 Reason for inclusion**	**Column 4 Date of inclusion**
196	POLYSORBATE 20	1	a	May 2001
197	PORCINE SOMATOTROPHIN	2	c	Nov 1991
198	POTASSIUM SORBATE	1.3	a	Oct 2004
199	POTASSIUM BICARBONATE	1	a	Jun 2004
200	PROPYL ACETATES	7.1	a	-
201	PROPYLENE GLYCOL	7.1	a	Nov 1974
202	2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER	4	a	Nov 1987
203	PROTHIOCONAZOLE	1.3.1	a	Jun 2005
204	*PSEUDOMONAS FLUORESCENS*	1.8	a	May 1985
205	PYDIFLUMETOFEN	1.3	a	Feb 2018
206	PYRIMETHANIL	1	a	Feb 1996
207	PYRIPROXYFEN	1	a	Aug 1994
208	QUASSIA	6, 2.1	d	Nov 1974
209	QUINOXYFEN	1.3	a	Nov 2001
210	*RHIZOBIUM RHIZOGENES*	1	b	Nov 1989
211	ROSEMARY OIL	7.1	a	Feb 2000
212	SAGE OIL (Spanish)	7.1	a	Feb 2000
213	SANDALWOOD OIL	7.1	a	Feb 2000
214	SEAWEED & UNFRACTIONED SEAWEED EXTRACTS	1.5	d	Feb 1985
215	SILVER OXIDE	7.14	b	Jun 2018
216	SIMAZINE	1.1	a	Nov 1987
217	SODIUM BICARBONATE	1	a	Jun 2004
218	SODIUM PROPIONATE	1.3	a	Oct 2004
219	STERIC ACID	7.1	a	Oct 2005
220	STREPTOMYCES LYDICUS WYEC 108	1.3	a	Oct 2016
221	SUCRALFATE	6.8	a	Aug 1982
222	SULESOMAB	6.1	b	Jun 2002
223	SULFOSULFURON	1	a	Feb 1998
224	SULPHATED POLYSACCHARIDES	7.1	a	-
225	TANNIC ACID	7.1	a	Dec 1965
226	TANNIC ACID/BENZYL ALCOHOL PRODUCT	7.1	a	Nov 1993
227	TERBACIL	1	a	Aug 1987
228	THAUMATIN	3.2	a	Nov 1990
229	THIDIAZURON	1	a	Nov 1989
230	TIAFENACIL	1	a	June 2019

Authorised Version F2026L01327 registered 30/09/2026

Substances exempt in certain uses

Item	Column 1 Substance	Column 2 Area, sub-area or sub-sub-area of use	Column 3 Reason for inclusion	Column 4 Date of inclusion
231	TRIASULFURON	1	a	Feb 1988
232	TRICHODERMA HARZIANUM	1	a	May 1996
233	(*Z*)-9-TRICOSENE	1	a	Aug 1991
234	TRIETHYLENE GLYCOL	7.1	a	Nov 1974
235	TRIFLOXYSULFURON	1.1	a	Feb 2002
236	TRIFLURALIN	1	a	Aug 1990
237	TRIFORINE	1	a	Aug 1987
238	ULOCLADIUM OUDEMANSII	1.10	a	Oct 2003
239	UREA	7.1	a	Nov 1974
240	^{13}C-UREA	6.1	a	May 2001
241	VETIVER OIL	7.1	a	Feb 2000
242	VINYL ETHER	6	b	Nov 1987
243	VITAMIN K	6.9, 2.8	a	Jul 1963
244	XANTHOPHYLL (lutein)	7.1	a	Nov 1974
245	XYLANASE derived from *Aspergillus niger*	2.4	a	Feb 2005
246	YLANG YLANG OIL	7.1	a	Feb 2000
247	ZINC NAPHTHENATE	1.3	a	-

Authorised Version F2026L01327 registered 30/09/2026

Appendix C—Blank

Note 1: Appendix C is intentionally blank.

Note 2: Appendix C previously included poisons now included in Schedule 10.

Authorised Version F2026L01327 registered 30/09/2026

Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8

Note: See section 64.

1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner

A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner.

Item	Poison
1	CANNABIS for human use
2	CLOMIFENE for human use
3	CLOZAPINE for human use
4	CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use
5	CYCLOFENIL for human use
6	DINOPROST for human use
7	DINOPROSTONE for human use
8	FOLLITROPIN ALFA (recombinant human follicle-stimulating hormone) for human use
9	FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use
10	FOLLITROPIN DELTA (recombinant human follicle-stimulating hormone) for human use
11	LUTEINISING HORMONE for human use
12	NABIXIMOLS for human use
13	SODIUM OXYBATE for human use
14	TETRAHYDROCANNABINOLS for human use
15	TERIPARATIDE for human use
16	UROFOLLITROPIN (human follicle-stimulating hormone) for human use

2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist

A poison specified in the following table may be supplied for human use:

(a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and

(b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician or dermatologist has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and

(iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Item	Poison
1	ACITRETIN for human use
2	BEXAROTENE for human use
3	ETRETINATE for human use
4	ISOTRETINOIN for human oral use
5	THALIDOMIDE for human use

3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act

A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force.

Item	Poison
1	DRONABINOL (delta-9-tetrahydrocannabinol)

4 Poisons available only from or on the order of a specialist physician

A poison specified in the following table may be supplied:

(a) only by, or on the prescription or order of, a specialist physician; and

(b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

Item	Poison
1	LENALIDOMIDE
2	POMALIDOMIDE
3	RIOCIGUAT for human use
4	TRETINOIN for human oral use

5 Poisons for which possession without authority is illegal

The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).

Item	Poison
1	ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4
2	ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4
3	AOD-9604 (CAS No. 221231-10-3)

Authorised Version F2026L01327 registered 30/09/2026

Item	Poison
4	BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8
5	BPC-157
6	CAPROMORELIN
7	CJC-1295 (CAS No. 863288-34-0)
8	DARBEPOETIN
9	DEXTROPROPOXYPHENE
10	*N, α* -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA)
11	EPHEDRINE
12	EPOETINS
13	ERYTHROPOIETIN
14	ERYTHROPOIETINS **except** when separately specified in this Appendix
15	FIBROBLAST GROWTH FACTORS
16	FOLLISTATIN
17	GLUTETHIMIDE
18	GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4
19	GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4
20	GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6)
21	GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4
22	HEXARELIN
23	IBUTAMOREN
24	INSULIN-LIKE GROWTH FACTORS
25	IPAMORELIN
26	LONAPEGSOMATROPIN
27	MOLIDUSTAT
28	NICOTINE
29	PERAMPANEL for human use
30	PHENTERMINE
31	PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2))
32	PSILOCYBINE
33	SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4
34	SOMAPACITAN
35	SOMATROGON
36	SOMATROPIN (human growth hormone)
37	STENABOLIC (SR9009) and other synthetic REV-ERB agonists
38	TB-500
39	THYMOSIN BETA 4 (THYMOSIN β4)
40	TIANEPTINE

Authorised Version F2026L01327 registered 30/09/2026

Clause 6

Item	Poison
41	VADADUSTAT

6 Poisons available for human use only from or on the prescription or order of a specialist physician

A poison specified in the following table may be supplied for human use:

(a) only by, or on the prescription or order of, a specialist physician; and

(b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

Item	Poison
1	AMBRISENTAN for human use
2	BOSENTAN for human use
3	ENZALUTAMIDE for human use
4	MACITENTAN for human use
5	SITAXENTAN for human use

7 Poisons available for human use only from or on the prescription or order of a dermatologist

A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist.

Item	Poison
1	ALEFACEPT for human use

8 Poisons which must be stored in a locked container to prevent unauthorised access

The following table specifies poisons that must be stored in a locked container to prevent unauthorised access.

Item	Poison
1	PENTOBARBITAL in injectable preparations

9 Poisons available only when prescribed or authorised in certain circumstances

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder:

Authorised Version F2026L01327 registered 30/09/2026

(a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner:
  (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and
  (ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or
(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression:

(a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner:
  (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and
  (ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or
(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix E—First aid instructions for poisons

Note: See section 31.

1 Standard statements for first aid instructions

For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents:

(a) the statement specified in column 3 of the item; or

(b) a different statement that has the same intent as the statement specified in column 3 of the item.

Standard statements for first aid instructions

Item	Column 1 Category	Column 2 Statement code	Column 3 Statement
1	Basic	A	For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).
2	Basic	Z	First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
3	General	G1	Urgent hospital treatment is likely to be needed. (Note - the words “at once” to be added to instruction A).
4	General	G2	If swallowed, give activated charcoal if instructed. (Note - the words “at once” to be added to instruction A).
5	General	G3	If swallowed, do NOT induce vomiting.
6	General	G4	Immediately give a glass of water.
7	General	G5	Avoid giving milk or oils.
8	General	G6	If sprayed in mouth, rinse mouth with water.
9	Eyes	E1	If in eyes wash out immediately with water.
10	Eyes	E2	If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.
11	Respiratory system	R1	If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
12	Respiratory system	R2	If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.
13	Skin	S1	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
14	Skin	S2	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g.

Authorised Version F2026L01327 registered 30/09/2026

Standard statements for first aid instructions			
Item	**Column 1 Category**	**Column 2 Statement code**	**Column 3 Statement**
			phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
15	Skin	S3	If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
16	Skin	S4	If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
17	Skin	S5	If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).
18	Special Purpose	SP1	If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

2 Poisons information centre contact information in statements

A statement required for a poison that includes a reference to a Poisons Information Centre must include:

(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

(b) immediately following the reference to a Poisons Information Centre:

(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

(ii) the telephone number for another poisons information centre:

(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

3 First aid instructions for poisons

(1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

(2) A statement required for a poison must:

Authorised Version F2026L01327 registered 30/09/2026

(a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or non-toxic) or is in a particular physical form or presentation); and

(b) if the statement refers to a Poisons Information Centre—comply with clause 2.

Poisons that must be labelled with first aid instructions

Item	Column 1 Poison	Column 2 Statement code
1	ACETIC ACID	A, G3, E2, S1
2	ACETIC ANHYDRIDE	A, G3, E2, S1
3	ACETONE	A, G3
4	ACROLEIN	A, G1, G2, G3, E2, R2, S2
5	ALKALINE SALTS	A, G3, E2, S1
6	ALKYL NITRITES	A
7	AMIDOPROPYL BETAINES—in cosmetic wash-off preparations when included in Schedule 6	E1
8	AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6	E1, S1
9	AMINES for use as curing agents	A, G3, E1, S1
10	2-AMINO-6-CHLORO-4-NITROPHENOL	A, E1
11	4-AMINO-*m*-CRESOL	A, E1
12	2-AMINO-5-ETHYLPHENOL	A
13	4-AMINO-2-HYDROXYTOLUENE	A, E1
14	4-AMINO-3-NITROPHENOL	A
15	2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL	E1
16	*m*-AMINOPHENOL	A, S1
17	*p*-AMINOPHENOL	A, S1
18	4-AMINOPYRIDINE	A, G1, G2, E1, S1
19	AMMONIA—5% or less	A
20	AMMONIA—above 5%	A, G3, E1, R1, S1
21	AMMONIUM COCOYL ISETHIONATE	E1
22	AMMONIUM PERSULFATE	A, G3, E2
23	AMMONIUM THIOCYANATE	A
24	AMYL NITRITE	A
25	ANHYDRIDES, organic acid, for use as curing agents for epoxy resins	A, G3, E1, S1
26	ANILINE	A, E2, R1, S1
27	ANISE OIL	A, G3
28	ANITMONY CHLORIDE	A, E2, S2
29	ANTIMONY COMPOUNDS, **except** antimony chloride	A
30	ARBUTIN when included in Schedule 6	A, G2, G3, E2, R2, S1

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
31	AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6	A, E1
32	AZELAIC ACID	A, E1
33	AZO DYES (derivatives by diazotisation)	A
34	BARIUM SALTS, **except** barium sulfate	A
35	BASIC RED 76	A
36	BASIL OIL	A, G3
37	BAY OIL	A, G3
38	BENZALKONIUM CHLORIDE—when included in Schedule 5	A, G3, E2
39	BENZALKONIUM CHLORIDE—when included in Schedule 6	A, G3, E2, S1
40	BENZENE	A, G3, E1, R1, S1
41	1,2-BENZENEDIOL (Catechol)	A, E1, S1
42	BENZOYL PEROXIDE—above 20%	A, E2, S1
43	BENZOYL PEROXIDE—above 10% up to 20%	A, E1
44	BENZOYL PEROXIDE—10% or less	A
45	BERGAMOT OIL	A, G3
46	BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5	A
47	BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7	A, G3, E2, S5
48	1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE	E1, S1
49	BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER	A, E1
50	BORAX	A
51	BORIC ACID	A
52	BORON TRIFLUORIDE—when included in Schedule 5	A
53	BORON TRIFLUORIDE—when included in Schedule 6 or 7	A, G3, E2, S5
54	BPA GLYCIDYL DIACRYLATE	A
55	BPA GLYCIDYL DIMETHACRYLATE	A
56	BROMOFORM	A, G3, E2, R1, S2
57	BRUCINE	A, G1, G2, G3, R2
58	2-BUTOXYETHANOL and its acetates	A, E2, S1
59	n-BUTYL ALCOHOL	A, E1, S1
60	BUTYL NITRITE	A
61	CADMIUM COMPOUNDS	A
62	CAJUPUT OIL	A, G3
63	CAMPHOR	A, G1, G3, G5
64	CARBAMIDE PEROXIDE—more than 9% up to 60%	A, G3, E2, S1
65	CARBAMIDE PEROXIDE—more than 60%	A, G1, G3, G4, E2, S1

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
66	CARBON DISULFIDE	A, G3, E2, R1, S2
67	CARBON TETRACHLORIDE	A, G3, E1, R1, S1
68	CASSIA OIL	A, G3
69	CHLORINATING COMPOUNDS, **except** when separately specified—containing above 4% and below 10% of available chlorine	A, G3, E1, S1
70	CHLORINATING COMPOUNDS, **except** when separately specified—containing 10% or more of available chlorine	A, G3, E2, S1
71	CHLORIDE (gas)	A, E1, R1
72	CHLOROACETAMIDE	A
73	CHLOROCRESOL	A, G3, E2, S2
74	2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL	A, S1
75	CHLOROFORM	A, G3, E1, R1, S1
76	CHROMATES	A, G3, E2, S1
77	CHROMIUM TRIOXIDE	A, G3, E2, S1
78	CHRYSOIDINE BASE	A, S1, E1
79	CINEOLE	A, G1, G3
80	CINNAMON BARK OIL	A, G3
81	CINNAMON LEAF OIL	A, G3
82	CLIMBAZOLE	A
83	CLOVE OIL	A, G1, G3, E2
84	COCOYL GLYCINATE	E1
85	COPPER SULFATE	A, G3, E2, S1
86	CREOSOTE	A, G3, E2, S1
87	CRESOLS	A, G3, E2, S3
88	CRESOLS in pressurised spray packs	A, G6, E1, S1
89	CYANIDES	A, G1, E1, R2
90	CYANOACRYLIC ACID ESTERS	A
91	CYANURIC ACID	A
92	CYCLOHEXANONE PEROXIDE	A, G3, E2, S1
93	CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2)	A, E2, S1
94	CYCTEAMINE	E1
95	1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES	E1
96	2,4-DIAMINOPHENOXYETHANOL	A, E2, S1
97	*o*-DICHLOROBENZENE	A, G3, E1, S1
98	para-DICHLOROBENZENE (PDB)	A

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
99	DICHLOROETHYL ETHER	A, G3, E1, R1, S1
100	DICHLOROISOCYANURATES	A, G3, E1, S1
101	DICHLOROMETHANE (methylene chloride)	A, G3, G5, E1, R1, S1
102	DICHLOROMETHANE (methylene chloride)—in pressurised spray packs	A, G6, S1
103	DICHROMATES	A, G1, G3, E2, S1
104	DIDECYLDIMETHYLAMMONIUM SALTS	A, G3
105	DIESEL (distillate)	A, G3
106	DIETHANOLAMINE—when included in Schedule 5	A, G3
107	DIETHANOLAMINE—when included in Schedule 6	A, G3, E2, S1
108	DIETHYLENE GLYCOL MONOBUTYL ETHER	A, E1, S1
109	5,6-DIHYDROXYINDOLINE	E1
110	DIMETHYLFORMAMIDE—less than 75%	A
111	DIMETHYLFORMAMIDE—75% or more	A, E1, R1, S1
112	4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL	A, E2
113	3,7-DIMETHYL-2,6-OCTADIEN-1-OL	A, E1, S1
114	DIMETHYL SULFOXIDE	A, G3, E1, S1
115	DINITROCRESOLS	A, G1, E1, S1
116	DINITROPHENOLS	A, G1, E1, S1
117	DIOXANE	A, G3, E1, R1, S1
118	DISPERSE YELLOW 3	A, S1
119	DISTILLATE	A, G3
120	*N*-(*N*-DODECYL)-2-PYRROLIDONE—when included in Schedule 5	A, G3, E1
121	*N*-(*N*-DODECYL)-2-PYRROLIDONE—when included in Schedule 6	A, G3, E2, S1
122	EPOXY RESINS liquid	A, G3, E2, S1
123	Essential oils containing CAMPHOR as natural component unless otherwise specified	A, G3
124	ETHER	A, G3, E1, R1
125	ETHYL BROMIDE	A, E2, S1, R1
126	ETHYLENE GLYCOL	A
127	ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, **except** when separately specified	A, G3, E2, S1
128	ETHYLENE OXIDE	A, E2, R1
129	ETHYLHEXANEDIOL	A, E2
130	2-ETHYLHEXANOIC ACID	A
131	EUCALYPTUS OIL	A, G1, G3
132	EUGENOL	A, G1, G3, E2
133	FENNEL OIL	A, G3

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
134	FLUORIDES **except** when separately specified—when included in Schedule 5	A
135	FLUORIDES **except** when separately specified—when included in Schedule 6	A, G1, G3, E2, S1
136	FORMALDEHYDE (see also paraformaldehyde)	A, G3, E2, R1, S1
137	FORMIC ACID	A, G3, E2, S1
138	FURFURAL	A, E1, S1
139	GLUTARAL—below 5%	A, G3, E1
140	GLUTARAL—5% or more	A, G3, E2, S1
141	GLYCOLIC ACID	A, G3, E2
142	GLYOXLIC ACID	A, G3, E2
143	GUANIDINE when included in Schedule 6	A, G3, E2, S1
144	HC VIOLET 1	E1
145	HEXACHLOROPHENE when included in Schedule 6	A
146	HEXYLOXYETHANOL	A, G3, E2, S1
147	HYDRAZINE	A, G1, G3, E2, R1, S1
148	HYDROCARBONS, liquid	A, G3
149	HYDROCHLORIC ACID	A, G3, E2, S1
150	HYDROCHLORIC ACID—when included in Schedule 5	A, G3
151	HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 5	A
152	HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 6 or 7	A, G3, E2, S5
153	HYDROGEN PEROXIDE—more than 3% up to 20%	A, G3, E2, S1
154	HYDROGEN PEROXIDE—more than 20%	A, G1, G3, G4, E2, S1
155	HYDROQUINONE—when included in Schedule 2	A
156	HYDROQUINONE—when included in Schedule 4 or 6	A, G2, G3, E2, R2, S1
157	HYDROSILICOFLUORIC ACID—when included in Schedule 5	A
158	HYDROSILICOFLUORIC ACID—when included in Schedule 6 or 7	A, G3, E2, S5
159	2-HYDROXYETHYL METHACRYLATE	A, E1, S1
160	HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE	E1, S1
161	IODINE (excluding salts, derivatives and iodophors)—2.5% or more for human external use	A, E2
162	IODINE (excluding salts, derivatives and iodophors)—2.5% or more for other uses	A, E2, S1
163	IODINE (excluding salts, derivatives and iodophors)—below 2.5%	A
164	IODOPHORS	A
165	ISOAMYL NITRITE	A
166	ISOBUTYL NITRITE	A

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
167	ISOCYANATES, free organic	A, E2, S1
168	ISOEUGENOL	A, E1, S1
169	ISOPHORONE	A, G3, E2, S1
170	KEROSENE	A, G3
171	LAURETH CARBOXYLIC ACIDS—leave-on or wash-off preparations above 5%	E1
172	LAURETH CARBOXYLIC ACIDS—other preparations above 5%	E1, S1
173	LAURYL ISOQUINOLINIUM BROMIDE	A, E1
174	LEAD COMPOUNDS—in hair cosmetics	A
175	LEAD COMPOUNDS—in other preparations	A, S1
176	LEMON OIL	A, G3
177	LEPTOSPERMUM SCOPARIUM OIL (manuka oil)	A, G1, G3
178	LIME OIL	A, G3
179	MAGNESIUM CHLORATE	A
180	MALATHION at 20% or less	A
181	MARJORAM OIL	A, G3
182	MELALEUCA OIL	A, G1, G3
183	MERCAPTOACETIC ACID	A, E1
184	MERCURIC CHLORIDE—for external therapeutic use	A
185	MERCURIC CHLORIDE—for other uses	A, G1, G3, E2, R2, S1
186	MERCURIC IODIDE	A, G1, G3, E2, R2, S1
187	MERCURIC NITRATE	A, G1, G3, E2, R2, S1
188	MERCURIC OXIDE	A, G1, G3
189	MERCURIC POTASSIUM IODIDE	A, G1, G3, E2, R2, S1
190	MERCURIC THIOCYANATE	A, G1, G3, E2, R2, S1
191	MERCUROCHROME	A
192	MERCUROUS CHLORIDE	A
193	MERCURY—metallic	A
194	MERCURY—organic compounds	A, S1
195	MERCURY—organic compounds in preparations for human external use	A
196	METALDEHYDE	A, E1, S1
197	METHANOL—above 10%	A, G3
198	METHANOL—10% or less	A
199	METHYLATED SPIRIT(S)	A, G3
200	METHYLATED SPIRIT(S)—when packed and labelled as a “biofuel” suitable for use in “spirit burners”	A, G3
201	METHYL ETHYL KETONE	A, G3
202	METHYL ETHYL KETONE OXIME	A, E1, S1

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
203	METHYL ETHYL KETONE PEROXIDE	A, G3, E2, S1
204	METHYLEUGENOL	A
205	METHYL ISOAMYL KETONE	A, G3
206	METHYL ISOBUTYL KETONE	A, G3
207	N-METHYL-2-PYRROLIDONE—when included in Schedule 5	A, G3, E1
208	N-METHYL-2-PYRROLIDONE—when included in Schedule 6	A, G3, E2
209	2-METHYLRESORCINOL	A, E1
210	METHYL SALICYLATE LIQUID when included in Schedule 5 or 6	A, G3, E1
211	MONOETHANOLAMINE—when included in Schedule 5	A, G3, E1
212	MONOETHANOLAMINE—when included in Schedule 6	A, G3, E2, S1
213	1,5-NAPHTHALENEDIOL	A, E1, S1
214	2,7-NAPHTHALENEDIOL	A, E1, S1
215	NAPHTHALENE	A, G1, G3
216	1-NAPHTHOL	A, E1, S1
217	NITRIC ACID	A, G3, E2, S1
218	NITROBENZENE	A, G3, E1, S1
219	3-NITRO-*p*-HYDROXYETHYLAMINOPHENOL	E1
220	NITROPHENOL	A, G3, E2, S1
221	NITROPRUSSIDES—in aerosols	A, G6, R1
222	NITROPRUSSIDES—in other preparations	A, G3
223	NITROUS OXIDE	A
224	NONOXINOL 9	A, E2
225	NUTMEG OIL	A, G3
226	OCTHILINONE	A, G3, E2, S1
227	OCTYL NITRITE	A
228	*N*-(*N*-OCTYL)-2-PYRROLIDONE—when included in Schedule 5	A, G3, E1
229	*N*-(*N*-OCTYL)-2-PYRROLIDONE—when included in Schedule 6	A, G3, E2
230	ORANGE OIL (bitter)	A, G3
231	OXALIC ACID	A, G3, E2, S1
232	PARAFORMALDEHYDE	A, G3, E2, R1, S1
233	PENNYROYAL OIL	A, G3
234	PERACETIC ACID—when included in Schedule 5	A, G3, E1, S1
235	PERACETIC ACID—when included in Schedule 6	A, G3, E2, S1
236	PETROL	A, G3, R1
237	2-PHENOXYETHANOL	A, E1
238	PHENOL when included in Schedule 6	A, E1
239	PHENOLS—25% and less	A, G3, E2, S3

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
240	PHENOLS—above 25%	A, G3, E2, S4
241	PHENOLS—in pressurised spray packs	A, E1
242	PHENOXYMETHYL OXIRANE	A, E1
243	PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes	A, E1
244	PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes	A, G1, G3, E1, S1
245	PHENYL METHYL KETONE as such, or in preparations of similar viscosity	A, G3, E1
246	PHENYL METHYL PYRAZOLONE	A, S1
247	*N*,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE -2,5-DIMETHANAMINE	A, E2, S1
248	*N*,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE -2,6-DIMETHANAMINE	A, E2, S1
249	*o*-PHENYLPHENOL	A, G3, E2, S1
250	*o*-PHENYLPHENOL—in pressurised spray packs	A, G6, E2, S1
251	PHOSPHONIC ACID	A, G3, E2, S1
252	PHOSPHONIC ACID—neutralised to pH 6 (approx)	A
253	PHOSPHONIC ACID—in spray packs	A, E2, S1
254	PHOSPHORIC ACID	A, G3, E2, S1
255	PHOSPHORUS, YELLOW	A, G1, G3, E2, R2, S2
256	*o*-PHTHALALDEHYDE—when included in Schedule 5	A, E1
257	*o*-PHTHALALDEHYDE—when included in Schedule 6	A, G3, E2, S1
258	PICRAMIC ACID including its salts (excluding other derivatives)	A, E1
259	PICRIC ACID	A, G1, G3, E2, R1, S1
260	POLIHEXANIDE	E1
261	POLYETHANOXY (15) TALLOW AMINE	A, E2, S1
262	POLY(OXY-1,2-ETHANEDIYL), A -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- A -HYDROXY-,MONO-C13-15-ALKYL ETHERS	A, E1
263	POTASSIUM BROMATE	A
264	POTASSIUM CHLORATE	A
265	POTASSIUM CYANATE	A, E1, S1
266	POTASSIUM HYDROXIDE	A, G3, E2, S1
267	POTASSIUM METABISULPHITE	A
268	POTASSIUM NITRITE—when included in Schedule 7	A, G1, G3
269	POTASSIUM NITRITE—when included in Schedule 5 or 6	A, G3
270	POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 5	A, G3, E1

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
271	POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 6	A, G3, E2, S1
272	POTASSIUM PERSULFATE	A, G3, E2
273	POTASSIUM SULFIDE	A, G3, E2, S1
274	PROPIONIC ACID	A, G3, E1, S1
275	n-PROPYL ALCOHOL	A, E1
276	**D**-PULEGONE	A, G3
277	PYRITHIONE ZINC	A, E1
278	QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—above 20%	A, G3, E2
279	QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—20% and below	A, E2
280	QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—in pressurised spray packs	A, E2, G6
281	QUINOLINE	A, E1, S1
282	RESORCINOL	A, E2, S1
283	SAFROLE	A, G1, G3
284	SAGE OIL (Dalmatian)	A, G3
285	SASSAFRAS OIL	A, G1, G3
286	SELENIUM COMPOUNDS	A, G1, E1, S1
287	SILICOFLUORIDES—when included in Schedule 5	A
288	SILICOFLUORIDES—when included in Schedule 6	A, G1, G3, E2, S1
289	SILVER SALTS	A, E2
290	SODIUM ALUMINATE	A, G3, E2, S1
291	SODIUM BROMATE	A, G1
292	SODIUM CHLORATE	A
293	SODIUM DIACETATE	A, G3, E2, S1
294	SODIUM DICHLOROISOCYANURATE	A, G3, E1, S1
295	SODIUM DODECYLBENZENE SULFONATE	A, G3, E2, S1
296	SODIUM HYDROGEN SULFATE	A, G3, E1, S1
297	SODIUMHYDROSULFITE	A, G3, E2, S1
298	SODIUM HYDROXIDE	A, G3, E2, S1
299	SODIUM LAURETH-6 CARBOXYLATE	A
300	LAURYL SULFATE SALTS—leave-on or wash-off preparations above 5%	E1
301	LAURYL SULFATE SALTS—other preparations above 5%	E1, S1
302	SODIUM METABISULPHITE	A, G3
303	SODIUM NITRITE—when included in Schedule 7	A, G1, G3
304	SODIUM NITRITE—when included in Schedule 5 or 6	A, G3
305	SODIUM PERCARBONATE—when included in Schedule 5	A, G3, S1
306	SODIUM PERCARBONATE—when included in Schedule 6	A, G3, E2, S1

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
307	SODIUM PERSULFATE	A, G3, E2
308	SODIUM STANNATE	A, E1
309	SODIUM SULFIDE	A, G3, E2, S1
310	SODIUM TRICHLOROACETATE	A
311	STRYCHNINE	A, G1, G2, G3, R2
312	STYRENE	A, G3, S1, E1
313	SULCOFURON	A
314	SULFAMIC ACID	A, G3, E2, S1
315	SULFURIC ACID	A, G3, E2, S1
316	TERPENES, chlorinated	A, G3
317	TETRACHLOROETHANE	A, G3, E1, R1, S1
318	TETRACHLOROETHYLENE	A, G3, E2, R1, S1
319	THIOUREA	A
320	THUJONE	A, G3
321	THYME OIL	A, G3
322	*o*-TOLIDINE	A
323	TOLUENE—above 75%	A, G3, E1, R1, S1
324	TOLUENE—75% and below	A, G3
325	TOLUENE—in pressurised spray packs	A
326	TOLUENEDIAMINES—in hair dyes	A, E1
327	TOLUENEDIAMINES—in other preparations	A, G1, G3, E1, S1
328	TRICHLOROACETIC ACID	A, G3, E2, S1
329	TRICHLOROACETIC ACID ALKALI SALTS	A
330	1,1,1-TRICHLOROETHANE	A, G3, E1, R1, S1
331	TRICHLOROETHYLENE	A, G3, E1, R1, S1
332	TRICHLOROISOCYANURIC ACID	A, G3, E1, S1
333	TRIETHYL PHOSPHATE	A, E1
334	TRIFLUOROMETHANESULFONIC ACID	A, G3, E2
335	TRIISOPROPANOLAMINE LAURYL ETHER SULFATE	A, E1, S1
336	TROLAMINE	A, G3, E1, S1
337	TURPENTINE (mineral)	A, G3
338	TURPENTINE OIL (vegetable)	A, G3, E2
339	VINYL ACETATE MONOMER	A, R1
340	WHITE SPIRIT	A, G3
341	XYLENE—above 75%	A, G3, E1, R1, S1
342	XYLENE—75% and below	A, G3
343	XYLENE—in pressurised spray packs	A, G6, E1, S1
344	XYLENOLS in pressurised spray packs	A, E1
345	ZINC CHLORIDE	A, G3, E2, S1

Authorised Version F2026L01327 registered 30/09/2026

Clause 3

Poisons that must be labelled with first aid instructions		
Item	**Column 1** **Poison**	**Column 2** **Statement code**
346	ZINC SULFATE	A, G3, E2, S1

Authorised Version F2026L01327 registered 30/09/2026

Appendix F—Warning statements and general safety directions for poisons

Note: See sections 29 and 30, subsection 33(2) and section 42.

1 Warning statements

For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item.

Note: See section 30.

Warning statements

Item	Column 1 Warning statement
1	Highly corrosive.
2	Corrosive.
3	Corrosive liquid.
4	Strongly alkaline.
5	Irritant.
6	May cause cancer.
7	WARNING – Causes birth defects.
8	WARNING – May be fatal to children.
9	Can be fatal to children if sucked or swallowed.
10	May produce severe burns.
11	WARNING – Vapour may be harmful.
12	Vapour is harmful to health on prolonged exposure.
13	May be fatal if inhaled, swallowed or absorbed through skin.
14	Dust will irritate and burn eyes, nose and skin.
15	Liquid will cause burns.
16	Forms dangerous gas near radiators or naked flames.
17	Contact with eyes even for short periods can cause blindness.
18	Product will irritate the eyes, nose, throat and skin.
19	WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use.
20	May give off dangerous gas if mixed with other products.
21	WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
22	Highly reactive oxidising chlorine compound.
23	May cause fire or explosion.
24	For external washing only. Rinse skin thoroughly after use.

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Warning statements	
Item	**Column 1** **Warning statement**
25	Do not use on broken skin. Wash hands thoroughly after use.
26	(Powder) (and) (concentrated solutions) are dangerous if swallowed.
27	Not for therapeutic use.
28	(Over) (Repeated) exposure may cause sensitisation.
29	If congestion persists, consult your doctor or pharmacist.
30	WARNING – Do not use on face or on anal or genital areas.
31	WARNING – Do not use on face or on anal or genital areas except on doctor's advice.
32	This preparation should be part of an overall treatment plan regularly assessed with your doctor.
33	Do not take for periods longer than four weeks except on medical advice.
34	WARNING – This medication may be dangerous when used in large amounts or for a long time (period).
35	CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful. or CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
36	For use under medical supervision only.
37	Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
38	CAUTION – Do not use for children under 2 years unless a doctor has told you to.
39	This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
40	This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
41	Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor's advice.
42	WARNING – Overuse may stain the skin or mouth.
43	Use of this product is not necessary in areas supplied with fluoridated water.
44	WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
45	WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor's advice.
46	WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
47	WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

Authorised Version F2026L01327 registered 30/09/2026

Warning statements	
Item	**Column 1** **Warning statement**
48	WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
49	WARNING – Do not mix with other medication except on veterinarian's advice.
50	Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.
51	Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52	Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
53	CAUTION – (Name of substance) should not be used by pregnant women.
54	Seek medical advice before first course of treatment.
55	Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
56	WARNING – Can cause elevated blood pressure and interact adversely with other medication.
57	Not to be applied to infants under 12 months of age unless on doctor's advice.
58	Highly reactive oxidising bromine and chlorine compound.
59	May cause allergy.
60	Do not mix with detergents or other chemicals.
61	WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking.
62	Do not use if pregnant.
63	See a doctor if you are pregnant or diabetic.
64	See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.
65	If getting better, keep using for (Insert number of days as per approved Product Information) days.
66	See a doctor if problem returns.
67	Do not use if pregnant or likely to become pregnant.
68	If symptoms persist beyond 5 days consult a doctor (or) (dentist).
69	If symptoms recur within two weeks of completing the course, consult a doctor.
70	Use only under medical supervision if you are taking other medicines.
71	Do not use during the last three months of pregnancy.
72	Do not use in the eyes.
73	Do not use for acne.
74	Do not use under waterproof bandages unless a doctor has told you to.
75	Do not use for more than 7 days unless a doctor has told you to.
76	Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.
77	WARNING - May cause birth defects.
78	Attacks skin and eyes.
79	Will irritate eyes.

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Warning statements	
Item	**Column 1** **Warning statement**
80	WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury.
81	(Intentionally blank)
82	(Intentionally blank)
83	This paint is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use on, in or around the home.
84	Breathing the vapour is dangerous. Provide adequate ventilation during application. Do not use in the presence of a naked flame. Do not smoke.
85	This paint contains lead and is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use for painting any building or fixed structure. Do not use where contact with food or drinking water is possible.
86	This tinter contains lead. Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
87	(Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.
88	This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
89	Application to skin may increase sensitivity to sunlight.
90	This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
91	CAUTION – Total iodine intake may exceed recommended level when taking this preparation.
92	WARNING – Contains iodine - do not take when pregnant except on physician’s advice.
93	Causes severe burns, which are not likely to be immediately painful or visible.
94	WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
95	CAUTION – Do not use for children under 12 years unless a doctor has told you to.
96	CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
97	Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.
98	Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

Authorised Version F2026L01327 registered 30/09/2026

Warning statements	
Item	**Column 1** **Warning statement**
99	If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
100	Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
101	Don't use [this product/name of the product]: If you have a stomach ulcer. In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] If you are allergic to (name of substance) or anti-inflammatory medicines.
102	Unless a doctor has told you to, don't use [this product/name of the product]: For more than a few days at a time. With other medicines containing aspirin or other anti-inflammatory medicines. If you have asthma. In children under 12 years of age. In children 12-16 years of age with or recovering from chicken pox, influenza or fever. If you are pregnant.
103	See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]
104	Unless a doctor has told you to, don't use [this product/name of the product]: For more than a few days at a time. With other medicines containing (name of substance) or other anti-inflammatory medicines. If you have asthma. If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]
105	Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.
106	Contains formaldehyde.
107	Not recommended for children under twelve years of age.
108	Breathing of solder fumes is harmful and may cause asthma or sensitisation.
109	See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI).
110	See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed.
111	Do not use if breastfeeding or planning to breastfeed.
112	WARNING – May cause irreversible nerve damage if inhaled.
113	Stop use and see a doctor if you have yellowing skin or eyes, unusual fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching.
114	To be taken with food.

Authorised Version F2026L01327 registered 30/09/2026

Clause 2

2 Safety directions—general

For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item.

Note: See section 29.

Safety directions	
Item	**Column 1** **Safety direction**
1	Avoid contact with eyes.
2	Attacks eyes - protect eyes when using.
3	Wear eye protection when mixing or using.
4	Avoid contact with skin.
5	Wear protective gloves when mixing or using.
6	Wash hands after use.
7	Wash hands thoroughly after use.
8	Avoid breathing dust (or) vapour (or) spray mist.
9	Use only in well ventilated area.
10	Ensure adequate ventilation when using.
11	No smoking.
12	Do not allow product to come into contact with other chemicals, especially acids.
13	Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
14	Do not allow to get damp.
15	Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16	Store and transport in an upright container.
17	Do not mix with other chemicals.
18	Do not mix with different types of chlorinating chemicals.
19	Use clean containers for dispensing.
20	Mix with water only.
21	Do not add water to product - add product to water, but in case of fire drench with water.
22	In case of spillage flush with large quantities of water.
23	Keep away from heat, sparks and naked flames.
24	Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
25	Avoid contact with food.
26	Avoid contact with clothing.
27	Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.
28	Do not mix with hot water.
29	Obtain a supply of calcium gluconate gel.
30	(Intentionally blank)
31	Do not use on broken skin.
32	Do not use under occlusive dressing.

Authorised Version F2026L01327 registered 30/09/2026

Safety directions	
Item	**Column 1** **Safety direction**
33	Mix strictly according to instructions.
34	May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
35	Wash gloves thoroughly, immediately after use.
36	Protect cuticles with grease or oil.
37	Avoid breathing solder fumes.
38	Do not intentionally inhale contents.
39	Do not use during pregnancy and do not use for at least 30 days prior to planned pregnancy.
40	Do not breastfeed during treatment and for at least 30 days after the last dose.

3 Poisons information centre contact information in statements

A statement required for a poison that includes a reference to a Poisons Information Centre must include:

(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

(b) immediately following the reference to a Poisons Information Centre:

(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

(ii) the telephone number for another poisons information centre:

(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

4 Poisons that must be labelled with warning statements and safety directions

(1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table:

(a) the warning statement represented by each item number specified in column 2 of the item;

(b) the safety direction represented by each item number specified in column 3 of the item.

(2) A warning statement or safety direction required for a poison must:

(a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and

(b) if the statement includes a reference to a Poisons Information Centre—comply with clause 3.

Note: For paragraph (a), for example:

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

(a) a statement or direction may require completion by including the name of the poison; and

(b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances.

(3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

Poisons that must be labelled with warning statements and safety directions

Item	Column 1 Poison	Column 2 Warning statement item number	Column 3 Safety direction item number
1	ACETIC ACID in concentrations of 80% or more **except** when included in Schedule 2	2	1, 4, 8
2	ACETIC ANHYDRIDE	2	1, 4, 8
3	ACETONE in concentrations greater than 75%		1, 4, 8
4	ACITRETIN—for oral use	7, 62, 76	
5	ACITRETIN—for topical use	62, 77	
6	ADAPALENE for topical use	62, 77	
7	ALCLOMETASONE when included in Schedule 3	38, 72, 73, 74, 75	
8	ALKALINE SALTS	4	1, 4
9	AMBRISENTAN	7, 62, 76	
10	AMINES used as curing agents for epoxy resins		1, 3, 4, 5, 8
11	2-AMINO-6-CHLORO-4-NITROPHENOL	28	
12	4-AMINO-*m*-CRESOL	28	
13	2-AMINO-5-ETHYLPHENOL	21	
14	4-AMINO-2-HYDROXYTOLUENE	28	
15	4-AMINO-3-NITROPHENOL	28	
16	2,2'-[(4-AMINO-3-NITROPHENYL)IMINO] BISETHANOL	28	
17	*m*-AMINOPHENOL	28	4, 8
18	*p*-AMINOPHENOL	28	
19	AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia **except** in smelling salts	4	1, 4, 8
20	AMMONIUM PERSULFATE	5, 21, 25	1, 5, 23, 33, 34
21	ANHYDRIDES, organic acid, for use as curing agents for epoxy resins		1, 3, 4, 5, 8
22	ANILINE	13	1, 4, 8
23	ANTIHISTAMINES not separately specified in this Appendix **except** the following: (a) dermal, ocular, parenteral and paediatric preparations; (b) oral preparations of astemizole, azelastine, bilastine, cetirizine, desloratadine, fexofenadine, loratadine, or terfenadine;	39 or 40	

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
	(c) nasal preparations of azelastine or olopatadine; (d) preparations for the treatment of animals		
24	ARBUTIN when included in Schedule 6	45	1, 4
25	AROMATIC EXTRACT OILS		1, 3, 4, 5, 6
26	ASPIRIN—for inhibition of platelet aggregation	36	
27	ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin	36	
28	ASPIRIN—in other preparations	101, 102, 103	
29	ASTEMIZOLE	61	
30	ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis	63, 64, 69, 75, 109, 110	
31	ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis	63, 75, 109, 110	
32	AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6	67	
33	AZELAIC ACID		1, 4
34	AZOCYCLOTIN	48	
35	AZO DYES (derivatives by diazotisation)	6	5
36	BASIC RED 76		5
37	BENOMYL	46	
38	BENZENE	12	1, 4, 9
39	1,2-BENZENEDIOL (Catechol)	51, 59	1, 4, 8
40	BENZOYL PEROXIDE—when included in Schedule 2	55	
41	BENZOYL PEROXIDE—when included in Schedule 5		1, 4, 8
42	BERGAMOT OIL	89	
43	BERYLLIUM		1, 4, 8
44	BEXAROTENE—for human use	7, 62, 76	
45	BEXAROTENE—for topical use	62, 77	
46	BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5	1, 4	
47	BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7	1, 17, 93	1, 3, 4, 5, 8, 29, 35
48	1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE	28, 79	1
49	BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER		1
50	BITHIONOL for the treatment of animals		1, 4, 8
51	BORIC ACID when used in Schedule 5	25, 26	
52	BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5	2	1, 4

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
53	BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7	1, 17, 93	1, 3, 4, 5, 8, 29, 35
54	BOSENTAN	7, 62, 76	
55	BPA GLYCIDYL DIACRYLATE	28	4
56	BPA GLYCIDYL DIMETHACRYLATE	28	4
57	BROMOFORM	1, 4, 8	
58	2-BUTOXY-2'-THIOCYANODIETHYL ETHER		1, 4, 8
59	2-BUTOXYETHANOL and its acetates		1, 4, 8
60	n-BUTYL ALCOHOL	5	2, 4, 8
61	CAMELLIA SINENSIS EXTRACT (GREEN TEA EXTRACT)	113, 114	
62	CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents	9	
63	CAMPHOR—in other forms	9	1
64	CANNABIDIOL when included in Schedule 3	67, 111	
65	CARBAMIDE PEROXIDE—more than 9% up to 30%	5	1
66	CARBAMIDE PEROXIDE—more than 30% up to 60%	5	2
67	CARBAMIDE PEROXIDE—more than 60%	2	2, 4
68	CARBON DISULFIDE	12	1, 4, 8, 9, 23
69	CARBON TETRACHLORIDE	12	1, 4, 8, 9
70	CASSIA OIL		4
71	CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations	20	
72	CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine	11	1, 4, 10
73	CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine	3, 18	1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26
74	CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine	10, 18, 22, 23	1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
75	CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code	10, 18, 22	1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
76	CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine	10, 22, 23	12, 13, 14, 15, 17, 18, 19, 21

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
	except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid		
77	CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code **except** in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid	10, 22	12, 13, 14, 15, 17, 18, 19, 21
78	CHLOROACETAMIDE	28	4
79	2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL	28	4
80	CHLOROFORM when included in Schedule 6		1, 4, 8
81	alpha-CHLOROHYDRIN	13, 51	1, 4, 8, 9
82	CHROMATES (including dichromates) of alkali metals or ammonia		1, 4, 8
83	CHROMIUM TRIOXIDE	2, 14, 15, 23	1, 4, 8, 13
84	CIMETIDINE when included in Schedule 3	70, 96	
85	CINNAMON BARK OIL		4
86	CLOBETASONE when included in Schedule 3	72, 73, 74, 75, 95	
87	CLOTRIMAZOLE in vaginal preparations when included in Schedule 3	54, 63, 64, 66	
88	CLOVE OIL		1
89	CYANIDES when included in Schedule 7	13	4, 8
90	CYANURIC ACID		1, 4, 8
91	CYCLOHEXANONE PEROXIDE		1, 4, 8
92	CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2)	2, 10, 78	1, 4, 5, 35
93	CYCTEAMINE		1
94	1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL *N*-COCO ACYL DERIVATIVES	79	1
95	4,4-DIAMINODIPHENYLMETHANE (methylene dianiline)		1, 4, 8
96	2,4-DIAMINOPHENOXYETHANOL	28, 79	1, 4
97	*o*-DICHLOROBENZENE		1, 4, 8
98	para-DICHLOROBENZENE		1, 4
99	DICHLOROETHYLENE		1, 4, 8
100	DICHLOEOETHYL ETHER		1, 4, 8

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
101	DICHLOROISOCYANURATES—in household cleaning or bleaching preparations	20	
102	DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine	11	1, 4, 10
103	DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine	3, 18	1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26
104	DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine	10, 18, 22, 23	1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
105	DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code	10, 18, 22	1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
106	DICHLOROISOCYANURATES—in anti-bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate	60	
107	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine **except** in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only	10, 22, 23	12, 13, 14, 15, 17, 18, 19, 21
108	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code **except** in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only	10, 22	12, 13, 14, 15, 17, 18, 19, 21
109	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage	10, 22, 23	12, 13, 14, 15, 17, 18, 21
110	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use	5	1, 4, 7, 12
111	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1:	10, 22	12, 13, 14, 15, 17, 18, 21

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
	Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage		
112	DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use	5	1, 4, 7, 12
113	DICHLOROMETHANE (methylene chloride)—in paint or lacquer removers	12, 16	1, 4, 8, 11
114	DICHLOROMETHANE (methylene chloride)—other than in paint or lacquer removers		1, 4, 8, 25
115	DICLOFENAC	101, 104	
116	DIENESTROL	67	
117	DIETHANOLAMINE—when included in Schedule 5	5	1, 4
118	DIETHANOLAMINE—when included in Schedule 6	2, 11, 18	1, 4, 8
119	DIETHYLTOLUAMIDE for human use	44	
120	DIETHYLENE GLYCOL MONOBUTYL ETHER	5	1, 4, 8, 9
121	5,6-DIHYDROXYINDOLINE	21, 28	
122	2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE	28	
123	DIMETHYLFORMAMIDE		1, 4, 8
124	4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL	5, 28	1, 2
125	3,7-DIMETHYL-2,6-OCTADIEN-1-OL	5	1, 4
126	DIMETHYL SULFATE	2	1, 4, 8
127	DIMETHYL SULFOXIDE—when not packed and labelled for therapeutic use	27	1, 4, 5, 8
128	DIMETHYL SULFOXIDE—when packed and labelled for the treatment of animals	49	1, 4, 5, 8
129	DINITROCRESOLS (and their homologues) **except** when for therapeutic use		1, 4, 8
130	DINITROPHENOLS (and their homologues) **except** when for therapeutic use		1, 4, 8
131	DINOCAP	47	
132	DIOXANE		1, 4, 8
133	DIPHENOXYLATE when included in Schedule 3	39 or 40, 41	
134	DISPERSE YELLOW 3	28	4
135	ECONAZOLE in vaginal preparations when included in Schedule 3	54, 63, 64, 66	

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
136	ENZALUTAMIDE	7, 67, 87	
137	EPHEDRINE in nasal preparations for topical use	29	
138	EPICHLOROHYDRIN	2	1, 4, 8
139	EPOXY RESINS, liquid		1, 3, 4, 5, 8
140	ETHER when included in Schedule 5 or 6		1, 4, 8
141	2-ETHOXYETHANOL	77	1, 4, 8
142	ETHOXYETHYLMERCURIC CHLORIDE		1, 4
143	ETHYL BROMIDE		1, 4, 8
144	ETHYLENE CHLOROHYDRIN		1, 4, 8
145	ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates **except** when separately specified		1, 4, 8
146	ETHYLENE OXIDE		1, 4, 8
147	ETHYLHEXANEDIOL	79	1
148	2-ETHYLHEXANOIC ACID	53	
149	ETHYLMERCURIC CHLORIDE		1, 4
150	ETHYL METHACRYLATE	28	4, 9, 23
151	ETRETINATE	7, 62, 76	
152	EUGENOL		1
153	FAMOTIDINE when included in Schedule 2	96	
154	FENTEROL in metered aerosols	32	
155	FLUCONAZOLE in oral preparations when included in Schedule 3	64	
156	FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 **except** when separately specified		1, 4
157	FORMALDEHYDE—in nail hardener cosmetics	106	1, 4, 8, 36
158	FORMALDEHYDE—in other preparations	106	1, 4, 8
159	FORMIC ACID		1, 4, 8
160	FURFURAL	5	1, 4
161	Glazing preparations containing LEAD COMPOUNDS	50	
162	GLUTARAL **except** when included in Schedule 2—25% or less	5, 59	1, 4, 5
163	GLUTARAL **except** when included in Schedule 2—more than 25%	3, 59	1, 4, 5, 8
164	GLYCOLIC ACID	79	1, 5, 6, 31
165	GLYOXYLIC ACID	79	1, 5, 6, 10, 31
166	HC VIOLET 1	28	
167	HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3% or less of hexachlorophene	24	
168	HEXYLOXYETHANOL	2	1, 4, 8

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
169	HYDRAZINE		1, 4, 8
170	HYDROCHLORIC ACID—30% or less of HCl		1, 4
171	HYDROCHLORIC ACID—more than 30% of HCl		1, 4, 8
172	HYDROCORTISONE—for dermal use when included in Schedule 2 or 3	38, 72, 73, 74, 75	
173	HYDROCORTISONE—for topical rectal use when included in Schedule 2 or 3	38, 75	
174	HYDROCYANIC ACID when included in Schedule 7	13	4, 8
175	HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 5	2	1, 4
176	HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 6 or 7	1, 17, 93	1, 3, 4, 5, 8, 29, 35
177	HYDROGEN PEROXIDE—more than 3% up to 10%	5	1
178	HYDROGEN PEROXIDE—more than 10% up to 20%	5	2
179	HYDROGEN PEROXIDE—more than 20%	2	2, 4
180	HYDROQUINONE—when included in Schedule 2	45	
181	HYDROQUINONE—**except** when included in Schedule 2 or 4		1, 4
182	HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 5	2	1, 4
183	HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 6 or 7	1, 17, 93	1, 3, 4, 5, 8, 29, 35
184	2-HYDROXYETHYL METHACRYLATE	28	4
185	HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE	28	
186	IBUPROFEN	101, 104	
187	IODINE—more than 20%		1, 4, 8
188	IODINE—in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose	91, 92	
189	IPRATROPIUM BROMIDE in metered aerosols	32	
190	ISOCYANATES (free organic)—when in paint	28, 52	1, 5, 8, 10, 27
191	ISOCYANATES (free organic)—other than in paint	28, 52	1, 4, 8
192	ISOEUGENOL	19, 28, 79	1, 4
193	ISOPRENALINE in metered aerosols	32	
194	ISOTRETINOIN—for human oral use	7, 62, 76	
195	ISOTRETINOIN—for topical use	62, 77	
196	LEAD COMPOUNDS—in hair cosmetics	25	

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
197	LEAD COMPOUNDS—when included in Schedule 6 preparations that are not hair cosmetics		1, 4, 8
198	LEFLUNOMIDE	7, 62, 87	
199	LEMON OIL	89	
200	LENALIDOMIDE	7, 62, 76	
201	LEVOCABASTINE—in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine	62	
202	LEVOCABASTINE—in other preparations	62 and either 39 or 40	
203	LIME OIL	89	
204	LOPERAMIDE when included in Schedule 2	41	
205	MAGNESIUM CHLORATE		1, 4
206	MEFENAMIC ACID	101, 104	
207	MERCAPTOACETIC ACID	5, 28	1, 31
208	MERCURIC THIOCYANATE		1, 4
209	METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals		1, 4
210	METHANOL **except** in methylated spirit		1, 4, 8
211	METHOXAMINE in nasal preparations for topical use	29	
212	2-METHOXYETHANOL	77	1, 4, 8
213	METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”	80	
214	*p*-METHYLAMINOPHENOL	28	
215	METHYL CHLORIDE		1, 4, 8
216	METHYL ETHYL KETONE	5	1, 4, 8
217	METHYL ETHYL KETONE OXIME	5, 28	1, 4
218	METHYL ETHYL KETONE PEROXIDE	2	2, 3, 4, 6
219	METHYL ISOAMYL KETONE		1, 4, 8
220	METHYL ISOBUTYL KETONE		1, 4, 8
221	METHYL ISOTHIOCYANATE	5, 12	1, 4, 8
222	METHYL METHACRYLATE	28	4, 9, 23
223	METHYLCHLOROISOTHIAZOLINONE	28	
224	METHYLDIBROMO GLUTARONITRILE	28	1, 4, 7
225	METHYLENE BISTHIOCYANATE		1, 4
226	METHYLEUGENOL		1, 6
227	METHYLISOTHIAZOLINONE	28	
228	METHYLNORBORNYLPYRIDINE	59	
229	2-METHYLRESORCINOL		1

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
230	1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHY LAMINOBENZENE		1, 4, 8
231	MICONAZOLE in vaginal preparations when included in Schedule 3	54, 63, 64, 66	
232	MISOPROSTOL	53	
233	MONOETHANOLAMINE when included in Schedule 5	5	1, 4
234	MONOETHANOLAMINE when included in Schedule 6	2, 11, 18	1, 4, 8
235	NAPHAZOLINE in nasal preparations for topical use	29	
236	NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents	9, 105	
237	NAPHTHALENE—in other forms	9, 105	1
238	1,5-NAPHTHALENEDIOL	28	1
239	2,7-NAPHTHALENEDIOL	28	1, 3
240	1-NAPHTHOL	28	1
241	NAPROXEN	101, 104	
242	NICOTINE **except** when in tobacco		1, 4
243	NITRIC ACID—75% or less HNO_3	2	1, 4
244	NITRIC ACID—more than 75% HNO_3	2	1, 4, 8
245	NITROBENZENE		1, 4, 8
246	3-NITRO-*p*-HYDROXYETHYLAMINOPHENOL	28	
247	NITROPHENOLS		1, 4
248	NITROPRUSSIDES in aerosols	84	8
249	NITROUS OXIDE	112	38
250	NIZATIDINE when included in Schedule 2	96	
251	NORADRENALINE in metered aerosols	32	
252	NYSTATIN in vaginal preparations when included in Schedule 3	54, 63, 64, 65, 66	
253	ORANGE OIL (bitter)	89	
254	ORCIPRENALINE in metered aerosols	32	
255	OXALATES, metallic		4, 8
256	OXALIC ACID	2	4, 8
257	OXYMETAZOLINE in nasal preparations for topical use	29	
258	OXYQUINOLINE (including salts and derivatives) when prepared for internal use	33	
259	PAINT—first group paints	83	
260	PAINT—second group paints	84	
261	PALOVAROTENE	7, 62, 76, 111	

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
262	PARACETAMOL	97 and/or 98, 99, 100	
263	PENTACHLOROPHENOL		1, 4, 8
264	PERACETIC ACID	2	1, 4, 8
265	PERMANGANATES	2	24
266	2-PHENOXYETHANOL	5	1
267	PHENOL and any other homologue of phenol		1, 4
268	PHENOL when included in Schedule 6	3, 51	2, 4, 8
269	PHENOLS		5
270	PHENOXYMETHYL OXIRANE	12, 28, 51	1, 3, 4, 5, 7, 8, 9
271	PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes	21	
272	PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes	28	1, 4, 8
273	PHENYL METHYL PYRAZOLONE	28	4
274	PHENYLEPHRINE in nasal preparations for topical use	29	
275	POMALIDOMIDE	7, 62, 76	
276	*N*,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE	5, 28	1, 4, 5, 10
277	*o*-PHENYLPHENOL **except** when in antiseptics		1, 4
278	PHENYLPROPANOLAMINE	56	
279	PHENYTOIN in pastes for the treatment of horses	9	
280	PHOSPHONIC ACID		1, 4
281	PHOSPHORIC ACID		1, 4
282	PHOSPHORUS (yellow)	2	1, 4
283	*o*-PHTHALALDEHYDE—when included in Schedule 5	51, 52, 59	1, 4, 5, 8, 10
284	*o*-PHTHALALDEHYDE—when included in Schedule 6	51, 52, 59	2, 4, 5, 8, 10
285	PICRAMIC ACID including its salts (excluding other derivatives)	28	5
286	PICRIC ACID (more than 20%)		1, 4
287	PODOPHYLLIN—in preparations specifically for use on anal or genital area	36	
288	PODOPHYLLIN—in other liquid preparations when included in Schedule 2 or 3	31	
289	PODOPHYLLIN—in other solid or semi-solid preparations when included in Schedule 2	30	
290	PODOPHYLLOTOXIN—in preparations specifically for use on anal or genital area	36	

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
291	PODOPHYLLOTOXIN—in other liquid preparations when included in Schedule 2 or 3	31	
292	PODOPHYLLOTOXIN—in other solid or semi-solid preparations when included in Schedule 2	30	
293	POLIHEXANIDE	28	1, 4, 8
294	POLYETHANOXY (15) TALLOW AMINE		1, 4
295	POLY(OXY-1,2-ETHANEDIYL), *A* -[2-[(2-HYDROXYETHYL)AMINO] -2-OXOETHYL]- A -HYDROXY-,MONO-C_{13-15} -ALKYL ETHERS	5, 88	1, 5
296	POTASSIUM HYDROXIDE—in preparations containing 0.5% or less of potassium hydroxide	5	1, 4, 6
297	POTASSIUM HYDROXIDE—in solid preparations containing more than 0.5% of potassium hydroxide	2, 10, 78	3, 5, 28
298	POTASSIUM HYDROXIDE—in liquid preparations containing more than 0.5% of potassium hydroxide	2, 10, 78	3, 5
299	POTASSIUM PERSULFATE	5, 21, 25	1, 5, 23, 33, 34
300	POTASSIUM SULFIDE	2	1, 4
301	PROPIONIC ACID when included in Schedule 6	2	1, 4
302	n-PROPYL ALCOHOL	5	1, 9
303	QUININE	28	
304	QUINOLINE	79	1, 4
305	RANITIDINE when included in Schedule 2	96	
306	RESORCINOL	19, 28, 79	1, 3, 4
307	ROSIN	108	37
308	SAFROLE—in preparations for therapeutic use		1
309	SAFROLE—other than for therapeutic use		1, 4
310	SALBUTAMOL in metered aerosols or in dry powder formulations	32	
311	SALICYLAMIDE	34 or 35	
312	SASSAFRAS OIL—in preparations for therapeutic use		1
313	SASSAFRAS OIL—other than for therapeutic use		1, 4
314	SELENIUM COMPOUNDS **except** when for therapeutic use (human or animal)		1, 4, 8
315	SILVER in smoking deterrents	42	
316	SITAXENTAN	7, 62, 76	
317	SODIUM ALUMINATE	2	1, 4
318	SODIUM CHLORATE		1, 4
319	SODIUM DODECYLBENZENE SULFONATE	79	1
320	SODIUM FLUORIDE in preparations for human ingestion when included in Schedule 2	43	

Authorised Version F2026L01327 registered 30/09/2026

Clause 4

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
321	SODIUM HYDROGEN SULFATE		1, 4, 8
322	SODIUM HYDROSULFITE (more than 50%)	5, 26	1, 4, 8
323	SODIUM HYDROXIDE—in preparations containing 0.5% or less of sodium hydroxide	5	1, 4, 6
324	SODIUM HYDROXIDE—in solid preparations containing more than 0.5% of sodium hydroxide	2, 10, 78	3, 5, 28
325	SODIUM HYDROXIDE—in liquid preparations containing more than 0.5% of sodium hydroxide	2, 10, 78	3, 5
326	SODIUM LAURETH-6 CARBOXYLATE	79	1
327	SODIUM METABISULPHITE (more than 50%)	5, 26	1, 4
328	SODIUM NITRITE in pickling or curing salts	94	
329	SODIUM PERSULFATE	5, 21, 25	1, 5, 23, 33, 34
330	SODIUM SULFIDE	2	1, 4
331	STYRENE		1, 4, 8
332	SULFAMIC ACID	2	1, 4
333	SULFURIC ACID	2	1, 4
334	SYMPHYTUM SPP. (Comfrey) when included in Schedule 5		31, 32
335	TAZAROTENE for topical use	77, 62	
336	TEPROTUMUMAB	7, 62, 76, 110	
337	TERBUTALINE in metered aerosols or in dry powder formulations	32	
338	TERFENADINE		61
339	TERIFLUNOMIDE	7, 62, 87	
340	TERPENES, chlorinated		1, 4, 8
341	TETRACHLOROETHANE	12	8
342	TETRACHLOROETHYLENE when included in Schedule 5 or 6	12, 16	1, 4, 8, 11
343	TETRYZOLINE in nasal preparations for topical use	29	
344	THALIDOMIDE	7, 62, 76	
345	THIOUREA		1, 4
346	TOLUENE		1, 4, 8
347	TOLUENEDIAMINES—in hair dyes	21	
348	TOLUENEDIAMINES—in preparations other than hair dyes		1, 4, 8
349	TRAMAZOLINE in nasal preparations for topical use	29	
350	TRETINOIN—for human oral use	7, 62, 76	
351	TRETINOIN—for topical use	62, 77	
352	TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers	64 or 68	

Authorised Version F2026L01327 registered 30/09/2026

Poisons that must be labelled with warning statements and safety directions			
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**	**Column 3** **Safety direction item number**
353	TRICHLOROACETIC ACID **except** when for therapeutic use	2	1, 4
354	1,1,1-TRICHLOROETHANE		8, 9
355	TRICHLOROETHYLENE **except** when for therapeutic use	12	1, 4, 5, 8, 9
356	TRICHLOROPHENOL		1, 4, 8
357	TRIETHYL PHOSPHATE		1, 4, 8
358	TRIFLUOROMETHANESULFONIC ACID—more than 10%	1, 17	1, 4, 8
359	TRIFLUOROMETHANESULFONIC ACID—10% or less		1, 4, 8
360	TRIISOPROPANOLAMINE LAURYL ETHER SULFATE		1, 4, 6
361	3,6,9-TRIOXAUNDECANEDIOIC ACID	5	1
362	TROLAMINE	5	1, 4
363	TYMAZOLINE in nasal preparations for topical use	29	
364	VINCLOZOLIN	46	
365	VINYL ACETATE MONOMER	11	8, 9
366	XYLENE		1, 4, 8
367	XYLOMETAZOLINE in nasal preparations for topical use	29	
368	ZINC CHLORIDE		1, 4
369	ZINC LACTATE	107	
370	ZINC SULFATE when included in Schedule 6		1, 4

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix G—Dilute preparations

Note: See paragraph 11(c).

1 Substances exempt at or below certain concentrations

For the purposes of paragraph 11(c), the following table specifies:
(a) substances; and
(b) concentrations in relation to those substances.

Substances and concentrations

Item	Column 1 Substance	Column 2 Concentration (quantity per litre or kilogram)
1	ACETYLCHOLINE	1 mg
2	ALDOSTERONE	10 micrograms
3	ANTIMONY COMPOUNDS	1 mg
4	APOMORPHINE	1 mg
5	ARSENIC	1 mg
6	ATROPA BELLADONNA (belladonna)	300 micrograms
7	ATROPINE	300 micrograms
8	CANTHARIDIN	10 micrograms
9	CHLORINE	5 mg
10	CROTON TIGLIUM (croton oil)	1 mg
11	EPIDERMAL GROWTH FACTOR	2 mg
12	ERYSIMUM spp.	1 mg
13	ESTRADIOL	10 micrograms
14	ESTRONE	100 micrograms
15	FOLLICLE-STIMULATING HORMONE	100 micrograms
16	GELSEMIUM SEMPERVIRENS	1 mg
17	GLUCAGON	100 micrograms
18	GLYCERYL TRINITRATE	100 micrograms
19	GROWTH HORMONE	10 micrograms
20	HALOPERIDOL	1 mg
21	HYDROCYANIC ACID	1 microgram
22	HYOSCINE	300 micrograms
23	HYOSCYAMINE	300 micrograms
24	HYOSCYAMUS NIGER	300 micrograms
25	HYPOTHALAMIC RELEASING FACTORS	10 micrograms
26	INDOMETACIN	1 mg
27	MERCURY	1 mg
28	METHYLMERCURY	300 micrograms
29	NAPHTHALENE	1 mg

Authorised Version F2026L01327 registered 30/09/2026

Substances and concentrations		
Item	**Column 1** **Substance**	**Column 2** **Concentration (quantity per litre or kilogram)**
30	NERIUM OLEANDER	1 mg
31	OXYTOCIN	1 microgram
32	PHOSPHORUS	1 mg
33	PODOPHYLLUM RESIN (podophyllin)	1 mg
34	PROGESTERONE	1 mg
35	PROPRANOLOL	1 mg
36	SELENIUM	100 micrograms
37	STROPHANTHUS spp.	1 mg
38	STRYCHNINE	1 mg
39	TESTOSTERONE	1 mg
40	THYROXINE	10 micrograms

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix H—Schedule 3 medicines permitted to be advertised

Note: See paragraph 57(1)(a).

1 Schedule 3 medicines permitted to be advertised

The following table specifies poisons for the purposes of paragraph 57(1)(a).

Schedule 3 medicines permitted to be advertised	
Item	**Column 1** **Poison**
1	ADAPALENE
2	ADRENALINE
3	ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis and for the prevention of recurrent bacterial vaginosis
4	BILASTINE
5	BUTOCONAZOLE
6	CELECOXIB
7	CICLOPIROX
8	CLOBETASONE
9	CLOTRIMAZOLE
10	CYTISINE
11	DICLOFENAC
12	DIMENHYDRINATE—for the prevention and relief of motion sickness
13	DIPHENOXYLATE
14	ECONAZOLE
15	ELETRIPTAN
16	FAMCICLOVIR
17	FLUCONAZOLE
18	FLUORIDES
19	GLUCAGON
20	GLYCERYL TRINITRATE
21	HYDROCORTISONE
22	HYOSCINE BUTYLBROMIDE
23	IBUPROFEN
24	ISOCONAZOLE
25	KETOPROFEN
26	LANSOPRAZOLE
27	LEVONORGESTREL
28	MELATONIN
29	METHENAMINE
30	MICONAZOLE

Authorised Version F2026L01327 registered 30/09/2026

Schedule 3 medicines permitted to be advertised	
Item	**Column 1** **Poison**
31	NALOXONE
32	NAPROXEN
33	NARATRIPTAN
34	NYSTATIN
35	OMEPRAZOLE
36	OXICONAZOLE
37	PANTOPRAZOLE
38	PARACETAMOL
39	PODOPHYLLOTOXIN
40	PODOPHYLLUM EMODI (podophyllin)
41	PODOPHYLLUM PELTATUM (podophyllin)
42	RABEPRAZOLE
43	RIZATRIPTAN
44	SALICYLIC ACID
45	SUMATRIPTAN
46	TIOCONAZOLE
47	TRIAMCINOLONE
48	ULIPRISTAL—for emergency post-coital contraception
49	VITAMIN D
50	ZOLMITRIPTAN

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix I—Blank

Note 1: Appendix I is intentionally blank.

Note 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2.

Authorised Version F2026L01327 registered 30/09/2026

Appendix J—Conditions for availability and use of certain poisons included in Schedule 7

Note: See subsection 62(6).

1 Conditions for supply of certain poisons included in Schedule 7

For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied:

(a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and

(b) if "a" appears in column 2 of the item—only for analytical or research purposes; and

(c) if "p" appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison.

Conditions for supply of certain poisons included in Schedule 7

Item	Column 1 Poison	Column 2 Condition
1	ABAMECTIN	
2	ACIBENZOLAR-S-METHYL	
3	ACROLEIN	
4	ACRYLONITRILE	
5	ALACHLOR	a
6	ALLYL ALCOHOL	
7	4-AMINOPROPIOPHENONE	p
8	4-AMINOPYRIDINE	
9	ARPRINOCID	a
10	ARSENIC	p
11	AZOCYCLOTIN	a
12	BENZENE	
13	BIFLUORIDE	
14	BORON TRIFLUORIDE	
15	BRODIFACOUM	
16	BROMADIOLONE	
17	BROMINE	
18	BRUCINE	
19	CALCIFEROL	
20	CARBADOX	
21	CARBON TETRACHLORIDE	
22	CARBONYL SULFIDE	
23	CHLORDECONE	a

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Conditions for supply of certain poisons included in Schedule 7		
Item	**Column 1** **Poison**	**Column 2** **Condition**
24	CHLORDIMEFORM	a
25	CHLORINE	
26	CHLOROMETHIURON	a
27	CHLOROPICRIN	
28	4-CHLORO-*o*-TOLUIDINE	a
29	COLECALCIFEROL	
30	COUMATETRALYL	
31	CYANOGEN	
32	CYHEXATIN	a
33	4,4-DIAMINODIPHENYLMETHANE	
34	1,2-DIBROMO-3-CHLOROPROPANE	a
35	1,3-DICHLOROPROPENE	
36	DIFENACOUM	
37	4-DIMETHYLAMINOAZOBENZENE	a
38	DINITROCRESOLS	a
39	DINITROPHENOLS	a
40	DINOSEB	a
41	EPICHLOROHYDRIN	
42	EPIDERMAL GROWTH FACTOR	
43	ETACONAZOLE	a
44	ETHYLENE DIBROMIDE	a
45	ETHYLENE OXIDE	
46	FLUOROACETAMIDE	p
47	FLUOROACETIC ACID	p
48	HALOFUGINONE	
49	HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS	a
50	HCB	a
51	HYDROCYANIC ACID AND CYANIDES	p
52	HYDROFLUORIC ACID	
53	HYDROSILICOFLUORIC ACID	
54	IODOMETHANE	
55	MADURAMICIN	
56	MERCURY	
57	METHACRIFOS	
58	METHOXYETHYLMERCURIC ACETATE	a
59	METHOXYETHYLMERCURIC CHLORIDE	
60	METHYL BROMIDE	
61	4,4'-METHYLENEBIS[2-CHLOROANILINE]	
62	MIREX	a
64	MOLINATE	

Authorised Version F2026L01327 registered 30/09/2026

Conditions for supply of certain poisons included in Schedule 7		
Item	**Column 1** **Poison**	**Column 2** **Condition**
65	NICOTINE **except** when in tobacco	
66	NITROFEN	a
67	PHENYLMERCURIC ACETATE	
68	PHOSPHIDE, metallic	
69	PHOSPHINE	
70	PROPYLENE OXIDE	
71	PYRINURON	a
72	STRYCHNINE	p
73	SULCOFURON	a
74	TETRACHLOROETHANE	
75	2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE	
76	THALLIUM	p
77	*o*-TOLIDINE	
78	VINYL CHLORIDE	

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Appendix K—Human medicines required to be labelled with a sedation warning

Note: See subsection 33(2).

1 Human medicines required to be labelled with a sedation warning

The following table specifies poisons for the purposes of subsection 33(2).

Human medicines required to be labelled with a sedation warning	
Item	**Column 1** **Poison**
1	ALIMEMAZINE
2	ALPRAZOLAM
3	AMISULPRIDE
4	AMITRIPTYLINE
5	AMOBARBITAL
6	ARIPIPRAZOLE
7	ASENAPINE
8	AZATADINE
9	BACLOFEN
10	BENZATROPINE
11	BREXPIPRAZOLE
12	BRIVARACETAM
13	BROMAZEPAM
14	BROMPHENIRAMINE
15	BUCLIZINE
16	BUPRENORPHINE
17	BUTOBARBITAL
18	CANNABIS **except** cannabidiol when included in Schedule 3 or 4
19	CETIRIZINE
20	CHLORAL HYDRATE
21	CHLORDIAZEPOXIDE
22	CHLORMETHIAZOLE
23	CHLORPHENAMINE
24	CHLORPROMAZINE
25	CLEMASTINE
26	CLOMIPRAMINE
27	CLONAZEPAM
28	CLONIDINE
29	CLORAZEPATE
30	CLOZAPINE

Authorised Version F2026L01327 registered 30/09/2026

Human medicines required to be labelled with a sedation warning	
Item	**Column 1** **Poison**
31	CODEINE.
32	CYCLIZINE
33	CYCLOBARBITAL
34	CYCLOSERINE
35	CYPROHEPTADINE
36	DANTROLENE
37	DESIPRAMINE
38	DEUTETRABENAZINE.
39	DEXCHLORPHENAMINE
40	DEXTROMORAMIDE
41	DEXTROPROPOXYPHENE
42	DIAZEPAM
43	DIFELIKEFALIN
44	DIFENOXIN
45	DIHYDROCODEINE
46	DIMENHYDRINATE
47	DIMETHINDENE
48	DIPHENHYDRAMINE
49	DIPHENOXYLATE
50	DIPHENYLPYRALINE
51	DOSULEPIN
52	DOXEPIN
53	DOXYLAMINE
54	DRONABINOL (delta-9-TETRAHYDROCANNABINOL)
55	DROPERIDOL
56	DULOXETINE
57	ESKETAMINE
58	ETHYLMORPHINE
59	FENFLURAMINE
60	FENTANYL
61	FLUNITRAZEPAM
62	FLUPENTIXOL
63	FLUPHENAZINE
64	FLURAZEPAM
65	GABAPENTIN
66	GEMCITABINE
67	GLUTETHIMIDE
68	GUANFACINE
69	HALOPERIDOL
70	HYDROCODONE

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Human medicines required to be labelled with a sedation warning	
Item	**Column 1** **Poison**
71	HYDROMORPHONE
72	HYDROXYZINE
73	IMIPRAMINE
74	LAMOTRIGINE
75	LEMBOREXANT.
76	LEVETIRACETAM
77	LEVOCABASTINE
78	LEVOCETIRIZINE
79	LORAZEPAM
80	LURASIDONE.
81	MAZINDOL
82	MEBHYDROLIN
83	MECLOZINE
84	MEDAZEPAM
85	MEPROBAMATE
86	MEPYRAMINE
87	MERCAPTAMINE
88	METHADONE
89	METHDILAZINE
90	METHOCARBAMOL
91	METHYLPHENOBARBITAL
92	MIANSERIN
93	MIDAZOLAM
94	MIRTAZAPINE
95	MORPHINE
96	NABIXIMOLS.
97	NALBUPHINE
98	NITRAZEPAM
99	NORMETHADONE
100	NORTRIPTYLINE
101	OLANZAPINE
102	OPIUM in any form **except** the alkaloids noscapine and papaverine
103	OXAZEPAM
104	OXYCODONE
105	PALIPERIDONE
106	PAPAVERETUM
107	PENTAZOCINE
108	PENTOBARBITAL
109	PERAMPANEL
110	PERICIAZINE

Authorised Version F2026L01327 registered 30/09/2026

Human medicines required to be labelled with a sedation warning	
Item	**Column 1** **Poison**
111	PERPHENAZINE
112	PETHIDINE
113	PHENELZINE
114	PHENIRAMINE
115	PHENOBARBITAL
116	PHENOPERIDINE
117	PHENYLTOLOXAMINE
118	PHOLCODINE
119	PIMOZIDE
120	PIZOTIFEN
121	PRAZEPAM
122	PREGABALIN
123	PROCHLORPERAZINE
124	PROMAZINE
125	PROMETHAZINE
126	PROTRIPTYLINE
127	QUETIAPINE
128	RETIGABINE
129	RISPERIDONE
130	ROTIGOTINE
131	RUFINAMIDE
132	RUPATADINE
133	SAFINAMIDE
134	SECBUTOBARBITAL
135	SECOBARBITAL
136	SELETRACETAM
137	SODIUM OXYBATE
138	STIRIPENTOL
139	SUVOREXANT
140	TAPENTADOL
141	TEMAZEPAM
142	TETRAHYDROCANNABINOLS **except** cannabidiol when included in Schedule 3 or 4
143	THENYLDIAMINE
144	THIETHYLPERAZINE
145	THIOPROPAZATE
146	THIORIDAZINE
147	THIOTHIXENE
148	TRABECTEDIN
149	TRAMADOL
150	TRANYLCYPROMINE

Authorised Version F2026L01327 registered 30/09/2026

Clause 1

Human medicines required to be labelled with a sedation warning	
Item	**Column 1** **Poison**
151	TRIFLUOPERAZINE
152	TRIMIPRAMINE
153	TRIPROLIDINE
154	ZIPRASIDONE
155	ZOLPIDEM
156	ZONISAMIDE
157	ZOPICLONE

Authorised Version F2026L01327 registered 30/09/2026

Appendix L—Requirements for dispensing labels for medicines

Note: See subsection 33(1) and paragraph 40(b).

1 General

(1) This clause sets out requirements for the purposes of paragraph 40(b).

(2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height.

(3) All symbols, numbers and words on a label must be in durable characters.

(4) The label on a container of a substance for therapeutic use must contain the following details:

(a) the name, address and telephone number of the dispenser supplying the substance;

(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser's own formula);

(c) adequate directions for use;

(d) the strength and form of the substance;

(e) the total quantity of the goods in the container;

(f) the words "KEEP OUT OF REACH OF CHILDREN" in red on a white background;

(g) if the substance is intended for external use only, the word "POISON", or the words "FOR EXTERNAL USE ONLY", in red on a white background;

(h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and

(i) if the substance is a veterinary chemical, the species of animal, the name of the animal's owner and the words "FOR ANIMAL TREATMENT ONLY".

(5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include:

(a) the prescription reference number; and

(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

(c) the directions for use set out in the prescription.

2 Additional warning statements for certain human medicines

(1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

Note: For the warning statements represented by the item numbers, see clause 1 of Appendix F.

Authorised Version F2026L01327 registered 30/09/2026

Clause 2

(2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

Additional warning statements for certain human medicines

Item	Column 1 Poison	Column 2 Warning statement item number
1	ACITRETIN—for oral use	7, 62, 76
2	ACITRETIN—for topical use	62, 77
3	ADAPALENE—for oral use	7, 62, 76
4	ADAPALENE—for topical use	62, 77
5	AMBRISENTAN	7, 62, 76
6	BELUMOSUDIL	62, 77
7	BEXAROTENE—for oral use	7, 62, 76
8	BEXAROTENE—for topical use	62, 77
9	BOSENTAN	7, 62, 76
10	DIENESTROL	67
11	ETRETINATE—for oral use	7, 62, 76
12	ETRETINATE—for topical use	62, 77
13	ENZALUTAMIDE	7, 67, 87
14	FARICIMAB	76
15	FINERENONE	67, 111
16	FINGOLIMOD	76
17	ISAVUCONAZOLE	53
18	ISOTRETINOIN—for oral use	7, 62, 76
19	ISOTRETINOIN—for topical use	62, 77
20	LEFLUNOMIDE	7, 62, 87
21	LENALIDOMIDE—for oral use	7, 62, 76
22	LENALIDOMIDE—for topical use	62, 77
23	LEVOCABASTINE	62
24	MACITENTAN	7, 62, 76
25	MISOPROSTOL	53
26	PALOVAROTENE	7, 62, 76, 111
27	PLITIDEPSIN	7, 62, 63, 76, 87
28	POMALIDOMIDE	7, 62, 76
29	PONESIMOD	76
30	RIOCIGUAT	7, 62, 76
31	RUFINAMIDE	62, 76, 77
32	SAFINAMIDE	62, 76, 77
33	SELINEXOR	62, 77
34	SELUMETINIB.	76
35	SITAXENTAN	7, 62, 76
36	TEPLIZUMAB	39, 40
37	TEPROTUMUMAB	7, 62, 76, 110

Authorised Version F2026L01327 registered 30/09/2026

Additional warning statements for certain human medicines		
Item	**Column 1** **Poison**	**Column 2** **Warning statement item number**
38	TERIFLUOMIDE	7, 62, 87
39	THALIDOMIDE—for oral use	7, 62, 76
40	THALIDOMIDE—for topical use	62, 77
41	TIRZEPATIDE	67
42	TRASTUZUMAB DERUXTECAN	62, 77
43	TRETINOIN—for oral use	7, 62, 76
44	TRETINOIN—for topical use	62, 77

Authorised Version F2026L01327 registered 30/09/2026

Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist

Note: Appendix M is intentionally blank. It is reserved for future use.

Authorised Version F2026L01327 registered 30/09/2026

Index

A

ABACAVIR
Schedule 4

ABALOPARATIDE
Schedule 4

ABAMECTIN
Schedule 7
Schedule 6
Schedule 5
Appendix J, clause 1

ABATACEPT
Schedule 4

ABCIXIMAB
Schedule 4

ABEMACICLIB
Schedule 4

ABIRATERONE ACETATE
Schedule 4

ABROCITINIB
Schedule 4

ABRUS PRECATORIUS
cross reference: JEQUIRITY
Schedule 10

ABSCISIC ACID
Schedule 5

ACALABRUTINIB
Schedule 4

ACAMPROSATE CALCIUM
Schedule 4

ACARBOSE
Schedule 4

ACEBUTOLOL
Schedule 4

ACEPHATE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ACEPROMAZINE
Schedule 4

ACEQUINOCYL
Schedule 5

ACETAMIPRID
Schedule 6

ACETANILIDE
cross reference: ALKYL ACETANILIDES
Schedule 4

ACETARSOL
Schedule 4

ACETAZOLAMIDE
Schedule 4

ACETIC ACID
Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

ACETIC ANHYDRIDE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ACETOHEXAMIDE
Schedule 4

ACETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ACETORPHINE
cross reference: CAS No. 25333-77-1
Schedule 9

ACETYL-ALPHA-METHYLFENTANYL
cross reference: CAS No. 101860-00-8
Schedule 9

ACETYLCARBROMAL
Schedule 4

ACETYLCHOLINE
Schedule 4
Appendix G, clause 1

Authorised Version F2026L01327 registered 30/09/2026

ACETYLCYSTEINE
Schedule 4
Schedule 2

ACETYLDIGITOXIN
Schedule 4

ACETYLDIHYDROCODEINE
Schedule 8

ACETYL ISOVALERYLTYLOSIN
Schedule 4

ACETYLMETHADOL
Schedule 8

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
Schedule 4

ACETYLMORPHINES
Schedule 8

4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE
Appendix B, clause 3

ACETYLSTROPHANTHIDIN
Schedule 4

ACIBENZOLAR-S-METHYL
Schedule 7
Appendix J, clause 1

ACICLOVIR
Schedule 4

ACIFLUORFEN
Schedule 6

ACINITRAZOLE
Schedule 6

ACIPIMOX
Schedule 4

ACITRETIN
Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

ACLIDINIUM BROMIDE
Schedule 4

ACLONIFEN
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ACOKANTHERA OUABAIO
Schedule 4

ACOKANTHERA SCHIMPERI
Schedule 4

ACONITUM spp.
Schedule 4
Schedule 2

ACORUS CALAMUS
cross reference: CALAMUS
Schedule 10

ACRIFLAVINE
cross reference: ACRIFLAVINIUM CHLORIDE

ACRIFLAVINUM CHLORIDE
Schedule 7
Schedule 5

ACRIVASTINE
Schedule 4

ACROLEIN
Schedule 7
Appendix E, clause 3
Appendix F, clause 4

ACRYLONITRILE
Schedule 7
Appendix J, clause 1

ADALIMUMAB
Schedule 4

ADAPALENE
Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1
Appendix L, clause 2

ADEFOVIR
Schedule 4

ADENOSINE
Schedule 4

ADIPHENINE
Schedule 4

ADONIS VERNALIS
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ADRAFINIL
Schedule 4

ADRENALINE
Schedule 4
Schedule 3
Appendix H, clause 1

ADRENOCORTICAL HORMONES
Schedule 4

AFAMELANOTIDE
cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I
Schedule 4

AFATINIB DIMALEATE
Schedule 4

AFIDOPYROPEN
Appendix B, clause 3

AFLIBERCEPT
Schedule 4

AFOXOLANER
Schedule 5

AGALSIDASE
Schedule 4

AGLEPRISTONE
Schedule 4

AGOMELATINE
Schedule 4

AKLOMIDE
Schedule 5

ALACHLOR
Schedule 7
Appendix J, clause 1

ALANYLGLUTAMINE
Schedule 4

ALATROFLOXACIN MESILATE
cross reference: ALATROFLOXACIN MESYLATE
Schedule 4

ALBENDAZOLE
Schedule 6
Schedule 5
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ALCLOFENAC
Schedule 4

ALCLOMETASONE
Schedule 4
Schedule 3
Appendix F, clause 4

ALCOHOL, DEHYDRATED
Appendix B, clause 3

ALCURONIUM
Schedule 4

ALDESLEUKIN
Schedule 4

ALDICARB
Schedule 7

ALDOSTERONE
Schedule 4
Appendix G, clause 1

ALDOXYCARB
Schedule 7

ALDRIN
Schedule 6

ALECTINIB
Schedule 4

ALEFACEPT
Schedule 4
Appendix D, clause 7

ALEMTUZUMAB
Schedule 4

ALENDRONIC ACID
Schedule 4

ALFACALCIDOL
Schedule 4

ALFENTANIL
Schedule 8

ALFUZOSIN
Schedule 4

ALGICIDES
Appendix A, clause 1

Authorised Version F2026L01327 registered 30/09/2026

ALGLUCERASE
Schedule 4

ALGLUCOSIDASE
Schedule 4

ALIMEMAZINE
cross reference: TRIMEPRAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

ALIROCUMAB
Schedule 4

ALISKIREN
Schedule 4

ALKALINE SALTS
cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S)
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ALKOXYAMFETAMINES
cross reference: ALKOXYAMPHETAMINES
Schedule 9

ALKOXYLATED FATTY ALKYLAMINE POLYMER
Schedule 6
Schedule 5

ALKOXYPHENYLETHYLAMINES
Schedule 9

ALKYLAMINES WITH STIMULANT PROPERTIES
cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), 1,4-DIMETHYLPENTYLAMINE, DMPA, 1,4-DIMETHYLAMYLAMINE, DMAA.
Schedule 10

ALKYL NITRITES
Schedule 4
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

ALKYLTHIOAMFETAMINES
cross reference: ALKYLTHIOAMPHETAMINES
Schedule 9

ALLERGENS
Schedule 4

ALLETHRIN
Schedule 6
Schedule 5

ALLOPURINOL
Schedule 4

ALLOXYDIM
Schedule 5

ALLYL ALCOHOL
Schedule 7
Appendix J, clause 1

ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
Schedule 6

ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
Schedule 6

ALLYL ESTERS (excluding derivatives)
Schedule 6

ALLYLESTRENOL
cross reference: ALLYLOESTRENOL
Schedule 4

ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
Schedule 6

ALLYL HEXANOATE (CAS No. 123-68-2)
Schedule 6

ALLYL ISOVALERATE (CAS No. 2835-39-4)
Schedule 6

ALLYL NONANOATE (CAS No. 7493-72-3)
Schedule 6

ALLYL OCTANOATE (CAS No. 4230-97-1)
Schedule 6

ALLYLOESTRENOL
cross reference: ALLYLESTRENOL

ALLYL PHENYLACETATE (CAS No. 1797-74-6)
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ALLYLPRODINE
cross reference: CAS No. 25384-17-2
Schedule 9

ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
Schedule 6

ALOGLIPTIN
Schedule 4

ALOSETRON
Schedule 4

ALOXIPRIN
Schedule 2

ALPELISIB
Schedule 4

ALPHACETYLMETHADOL
Schedule 8

ALPHA-CHLOROHYDRIN
Schedule 6
Appendix F, clause 4

ALPHA-CYPERMETHRIN
Schedule 7
Schedule 6
Schedule 5

ALPHADOLONE
Schedule 4

ALPHAMEPRODINE
cross reference: CAS No. 468-51-9
Schedule 9

ALPHAMETHADOL
cross reference: CAS No. 17199-54-1
Schedule 9

ALPHA-METHYLFENTANYL
cross reference: CAS No. 79704-88-4
Schedule 9

ALPHA-METHYLTHIOFENTANYL
cross reference: CAS No. 103963-66-2
Schedule 9

ALPHAPRODINE
Schedule 8

Authorised Version F2026L01327 registered 30/09/2026

ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
cross reference: CAS No. 14530-33-7
Schedule 9

ALPHA1-PROTEINASE INHIBITOR (HUMAN)
Schedule 4

ALFAXALONE
Schedule 4

ALPRAZOLAM
Schedule 8
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

ALPRENOLOL
Schedule 4

ALPROSTADIL
Schedule 4

ALSEROXYLON
Schedule 4

ALTEPLASE
Schedule 4

ALTRENOGEST
Schedule 4

ALTRETAMINE
cross reference: HEXAMETHYLMELAMINE
Schedule 4

ALUM
Appendix B, clause 3

ALUMINIUM AMMONIUM SULFATE
Appendix B, clause 3

ALUMINIUM POTASSIUM SULFATE
Appendix B, clause 3

ALUMINIUM SILICATE
Appendix B, clause 3

ALUMINIUM tris (ETHYLPHOSPHONATE)
Appendix B, clause 3

AMANTADINE
Schedule 4

AMBENONIUM CHLORIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

AMBRISENTAN
Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

AMBUCETAMIDE
Schedule 4

AMBUTONIUM BROMIDE
Schedule 4

AMCINONIDE
Schedule 4

AMETOCTRADIN
Appendix B, clause 3

AMETRYN
Schedule 5

AMICARBAZONE
Schedule 6

AMIDITHION
Schedule 6

AMIDOPROPYL BETAINES
Schedule 6
Appendix E, clause 3

AMIFAMPRIDINE
Schedule 4

AMIFOSTINE
Schedule 4

AMIKACIN
Schedule 4

AMILORIDE
Schedule 4

AMINACRINE
cross reference: AMINOACRIDINE

AMINES
cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

AMINOACRIDINE
cross reference: AMINACRINE
Schedule 7
Schedule 5

AMINOCAPROIC ACID
Schedule 4

AMINOCARB
Schedule 7
Schedule 6

2-AMINO-6-CHLORO-4-NITROPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

4-AMINO-m-CRESOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

5-AMINO-o-CRESOL
cross reference: 4-AMINO-2-HYDROXYTOLUENE

1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID
Schedule 5

AMINOCYCLOPYRACHLOR
Schedule 5

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE
cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1)
Schedule 9

AMINOETHOXYVINYLGLYCINE
Schedule 6

2-AMINO-5-ETHYLPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOGLUTETHIMIDE
Schedule 4

4-AMINO-2-HYDROXYTOLUENE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

5-AMINOLEVULINIC ACID
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE
Schedule 6

2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
cross reference: HC VIOLET 1

2-AMINO-5-METHYLPHENOL
cross reference: CAS No. 2835-98-5
Schedule 10
Schedule 7

AMINOMETRADINE
Schedule 4

4-AMINO-3-NITROPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
cross reference: HC RED 13
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOPHENAZONE
cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2)
Schedule 10
Schedule 4

m-AMINOPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

p-AMINOPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOPHYLLINE
Schedule 4
Schedule 3

4-AMINOPROPIOPHENONE
cross reference: PARA-AMINOPROPIOPHENONE (PAPP)
Schedule 7
Appendix J, clause 1

5-(2-AMINOPROPYL)INDAN
cross reference: CAS No. 13396-94-6
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

AMINOPTERIN
Schedule 4

AMINOPYRALID
Schedule 6
Schedule 5

4-AMINOPYRIDINE
cross reference: FAMPRIDINE
Schedule 7
Schedule 4
Appendix E, clause 3
Appendix J, clause 1

AMINOREX
Schedule 4

AMINOSALICYLIC ACID
Schedule 4

AMIODARONE
Schedule 4

AMIPHENAZOLE
Schedule 4

AMISOMETRADINE
Schedule 4

AMISULBROM
Schedule 5

AMISULPRIDE
Schedule 4
Appendix K, clause 1

AMITON
Schedule 7

AMITRAZ
Schedule 6

AMITRIPTYLINE
Schedule 4
Appendix K, clause 1

AMITROLE
Schedule 5

AMLODIPINE
Schedule 4

AMMI VISNAGA
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

AMMONIA
cross reference: AMMONIUM HYDROXIDE, CHROMATES
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

AMMONIUM BROMIDE
Schedule 4

AMMONIUM COCOYL ISETHIONATE
Schedule 6
Appendix E, clause 3

AMMONIUM PERSULFATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMMONIUM PHOSPHATE
Appendix B, clause 3

AMMONIUM THIOCYANATE
Schedule 5
Appendix E, clause 3

AMMONIUM THIOSULPHATE
Appendix B, clause 3

AMOBARBITAL
Schedule 8
Schedule 4
Appendix K, clause 1

AMODIAQUINE
Schedule 4

AMOROLFINE
Schedule 4
Schedule 2

AMOXAPINE
Schedule 4

AMOXICILLIN
Schedule 4

AMOXYCILLIN
cross reference: AMOXICILLIN

AMFETAMINE
cross reference: AMPHETAMINE
Schedule 8

Authorised Version F2026L01327 registered 30/09/2026

AMPHOMYCIN
Schedule 4

AMPHOTERICIN
cross reference: AMPHOTERICIN B

AMPHOTERICIN B
Schedule 4

AMPICILLIN
Schedule 4

AMPRENAVIR
Schedule 4

AMPROLIUM
Appendix B, clause 3

AMRINONE
Schedule 4

AMSACRINE
Schedule 4

AMYGDALIN
cross reference: CAS No. 29883-15-6, APRICOT KERNELS
Schedule 10

AMYL ACETATE
Appendix B, clause 3

AMYL NITRITE
Schedule 4
Schedule 3
Appendix E, clause 3

α-AMYLASE derived from Aspergillus niger
Appendix B, clause 3

AMYL CINNAMALDEHYDE
Appendix B, clause 3

AMYLOBARBITAL
cross reference: AMOBARBITAL

AMYLOBARBITONE
cross reference: AMOBARBITAL

AMYLOCAINE
Schedule 4

ANABOLIC STEROIDAL AGENTS
cross reference: ANDROSTERONE, STEROIDAL AGENTS
Schedule 4
Appendix D, clause 5

Authorised Version F2026L01327 registered 30/09/2026

ANACAULASE-BCDB
Schedule 4

ANAGRELIDE
Schedule 4

ANAKINRA
Schedule 4

ANASTROZOLE
Schedule 4

ANCESTIM
Schedule 4

ANCHUSA OFFICINALIS
Schedule 10

ANCROD
Schedule 4

ANDEXANET ALFA
Schedule 4

ANDROGENIC STEROIDAL AGENTS
cross reference: STEROIDAL AGENTS
Schedule 4
Appendix D, clause 5

ANDROISOXAZOLE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTANOLONE
Schedule 4

ANDROSTENEDIOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTENEDIONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTENEDIONE ALBUMEN
Appendix B, clause 3

ANECORTAVE
Schedule 4

ANGIOTENSIN AMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ANHYDRIDES, ORGANIC ACID
cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ANIDULAFUNGIN
Schedule 4

ANILERIDINE
Schedule 8

ANILINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ANIMAL BLOOD PRODUCTS
Schedule 4

ANIRACETAM
cross reference: RACETAMS
Schedule 4

ANISE OIL
Schedule 5
Appendix E, clause 3, Part 4

***o*-ANISIDINE**
cross reference: CAS No. 90-04-0, *o*-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2)
Schedule 10

ANISTREPLASE
Schedule 4

ANTAZOLINE
Schedule 4
Schedule 2

ANTIBIOTIC SUBSTANCES
cross reference: NISIN
Schedule 4

ANTIGENS
Schedule 4

ANTIHISTAMINES
cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, CETIRIZINE, DESLORATADINE, FEXOFENADINE, LORATADINE, OLOPATADINE, TERFENADINE
Schedule 4
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

ANTIMONY
cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix G, clause 1

ANTISERA
cross reference: IMMUNOSERA
Schedule 4

AOD-9604 (CAS No. 221231-10-3)
Schedule 4
Appendix D, clause 5

APADAMTASE ALFA
Schedule 4

APALUTAMIDE
Schedule 4

APIXABAN
Schedule 4

APOCYNUM spp.
Schedule 4

APOMORPHINE
Schedule 4
Appendix G, clause 1

APRACLONIDINE
Schedule 4

APRAMYCIN
Schedule 4

APREMILAST
Schedule 4

APREPITANT
Schedule 4

APRICOT KERNELS
cross reference: AMYGDALIN, HYDROCYANIC ACID

APRONAL
cross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7)
Schedule 10

APROTININ
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ARBUTIN (ALPHA)
cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ARBUTIN (BETA)
cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

ARBUTIN (DEOXY OR OTHER DERIVATIVES)
cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ARECOLINE
Schedule 4

ARIPIPRAZOLE
Schedule 4
Appendix K, clause 1

ARISTOLOCHIA spp.
Schedule 10

ARISTOLOCHIC ACID(S)
cross reference: ASARUM spp, BRAGANTIA (CAS No. 313-67-7)
Schedule 10

ARPRINOCID
Schedule 7
Appendix J, clause 1

ARMODAFINIL
Schedule 4

ARSENIC
cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER-CHROME-ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE
Schedule 7
Schedule 6
Schedule 4
Appendix G, clause 1
Appendix J, clause 1

ARTEMETHER
Schedule 4

ARTESUNATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ARTICAINE
Schedule 4

ASARUM spp
Schedule 10

ASCIMINIB
Schedule 4

ASENAPINE
Schedule 4
Appendix K, clause 1

ASFOTASE ALFA
Schedule 4

ASPARAGINASE
cross reference: CRISANTASPASE
Schedule 4

ASPARTIC ACID
Appendix B, clause 3

ASPIRIN
cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix F, clause 4

ASTEMIZOLE
Schedule 4
Appendix F, clause 4

ASTODRIMER SODIUM
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

ASULAM
Appendix B, clause 3

ASUNAPREVIR
Schedule 4

ATAMESTANE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ATAZANAVIR
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ATENOLOL
Schedule 4

ATEZOLIZUMAB
Schedule 4

ATINVICITINIB
Schedule 4

ATIPAMEZOLE
Schedule 4

ATOMOXETINE
Schedule 4

ATORVASTATIN
Schedule 4

ATOSIBAN
Schedule 4

ATOVAQUONE
Schedule 4

ATRACURIUM BESILATE
cross reference: ATRACURIUM BESYLATE
Schedule 4

ATRAZINE
Schedule 5

ATROPA BELLADONNA
cross reference: BELLADONNA
Schedule 4
Schedule 2
Appendix G, clause 1

ATROPINE
Schedule 4
Schedule 2
Appendix G, clause 1

ATROPINE METHONITRATE
Schedule 4

AURANOFIN
Schedule 4

AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)
Appendix B

AUROTHIOMALATE SODIUM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

AVACINCAPTAD PEGOL
Schedule 4

AVACOPAN
Schedule 4

AVATROMBOPAG
Schedule 4

AVELUMAB
Schedule 4

AVILAMYCIN
Schedule 4

AVIPTADIL
Schedule 4

AVOPARCIN
Schedule 4

AXITINIB
Schedule 4

AZACITIDINE
Schedule 4

AZACONAZOLE
Schedule 6

AZACYCLONOL
Schedule 4

AZADIRACHTA INDICA
cross reference: DEBITTERISED NEEM SEED OIL, NEEM
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

AZADIRACHTA INDICA EXTRACTS
Schedule 5

AZAFENIDIN
Schedule 7

AZAMETHIPHOS
Schedule 6

AZAPERONE
Schedule 4

AZAPROPAZONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

AZARIBINE
Schedule 4

AZATADINE
Appendix K, clause 1

AZATADINE
Schedule 4
Schedule 3

AZATHIOPRINE
Schedule 4

AZELAIC ACID
cross reference: NONANEDIOIC ACID
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

AZELASTINE
Schedule 4
Schedule 2

AZIMSULFURON
Appendix B, clause 3

AZINPHOS-ETHYL
Schedule 7

AZINPHOS-METHYL
Schedule 7

AZITHROMYCIN
Schedule 4

AZLOCILLIN
Schedule 4

AZOBENZENE
Schedule 6

AZOCYCLOTIN
Schedule 7
Appendix F, clause 4
Appendix J, clause 1

AZO DYES (derivatives by diazotisation)
Schedule 7
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

AZOXYSTROBIN
Schedule 5

AZTREONAM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

B

BACAMPICILLIN
Schedule 4

BACILLUS AMYLOLIQUEFACIENS
cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, BACILLUS VELEZENSIS STRAIN MBI 600
Appendix B, clause 3

BACILLUS PARALICHENIFORMIS
Appendix B, clause 3

BACILLUS SPHAERICUS, STRAIN 2362
Appendix B, clause 3

BACILLUS SUBTILIS, STRAIN QST 713
cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713

BACILLUS THURINGIENSIS
cross reference: ENDOTOXIN
Appendix B, clause 3

BACILLUS THURINGIENSIS DELTA ENDOTOXIN
Schedule 5

BACILLUS TOYOI
Appendix B, clause 3

BACITRACIN
Schedule 4

BACLOFEN
Schedule 4
Appendix K, clause 1

BACTERIAL CULTURE MEDIA
cross reference: ANTIBIOTIC SUBSTANCES
Appendix A, clause 1

BACTERICIDES
Appendix A, clause 1

BACULOVIRUS CYDIA POMONELLA
Appendix B, clause 3

BALOXAVIR MARBOXIL
Schedule 4

BALSALAZIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

BAMBERMYCIN
cross reference: FLAVOPHOSPHOLIPOL
Schedule 6
Schedule 4

BAMBUTEROL
Schedule 4

BAMETHAN
Schedule 4

BAMIPINE
Schedule 4

BPA GLYCIDYL DIACRYLATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BPA GLYCIDYL DIMETHACRYLATE
Schedule 6
Appendix E, clause 3

Appendix F, clause 4**BARBITURATES**
Schedule 4

BARICITINIB
Schedule 4

BARIUM SALTS
cross reference: BARIUM METABORATE, BARIUM SULFATE
Schedule 6
Appendix E, clause 3

BARIUM SILICOFLUORIDE
Schedule 5

BASIC BLUE 26
Schedule 10
Schedule 6

BASIC ORANGE 31
cross reference: 2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9)
Schedule 10
Schedule 6

BASIC RED 76 (CAS No. 68391-30-0)
cross reference: [7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
Schedule 7
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

Appendix E, clause 3
Appendix F, clause 4

BASIL OIL
cross reference: METHYL CHAVICOL
Schedule 5
Appendix E, clause 3

BASILIXIMAB
Schedule 4

BATTERIES
Appendix A, clause 1

BAY OIL
Schedule 6
Appendix E, clause 3

BAZEDOXIFENE
Schedule 4

BEAUVERIA BASSIANA
Schedule 6
Schedule 5

BECAPLERMIN
Schedule 4

BECLAMIDE
Schedule 4

BECLOMETASONE
cross reference: BECLOMETHASONE
Schedule 4
Schedule 2

BECLOMETHASONE
cross reference: BECLOMETASONE

BELANTAMAB MAFODOTIN
Schedule 4

BELATACEPT
Schedule 4

BELIMUMAB
Schedule 4

BELUMOSUDIL
Schedule 4
Appendix L, clause 2

BELZUTIFAN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

BEMEGRIDE
Schedule 4

BEMPEDOIC ACID
Schedule 4

BENACTYZINE
Schedule 4

BENALAXYL
Schedule 5

BENAZEPRIL
Schedule 4

BENDAMUSTINE
Schedule 4

BENDIOCARB
cross reference: DENATONIUM BENZOATE
Schedule 7
Schedule 6
Schedule 5

BENDROFLUAZIDE
Schedule 4

BENETHAMINE PENICILLIN
Schedule 4

BENFLURALIN
Appendix B, clause 3

BENOMYL
Schedule 7
Appendix F, clause 4

BENORYLATE
Schedule 4

BENOXAPROFEN
Schedule 4

BENPERIDOL
Schedule 4

BENQUINOX
Schedule 6

BENRALIZUMAB
Schedule 4

BENSERAZIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

BENSULFURON-METHYL
Appendix B, clause 3

BENSULIDE
Schedule 6

BENTAZONE
Schedule 5

BENTONITE
Appendix B, clause 3

BENZALKONIUM CHLORIDE
Schedule 6
Schedule 5
Appendix E, clause 3

BENZATHINE PENICILLIN
Schedule 4

BENZENE
cross reference: LIQUID HYDROCARBONS
Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

1,2-BENZENEDIAMINE
cross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1)
Schedule 10

1,3-BENZENEDIAMINE
cross reference: CAS No. 108-45-2
Schedule 10

1,2-BENZENEDIOL
cross reference: CATECHOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BENZETHIDINE
cross reference: CAS No. 3691-78-9
Schedule 9

BENZHEXOL
cross reference: TRIHEXYPHENIDYL

BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES
Schedule 7

BENZIDINE-BASED AZO DYES
Schedule 7

Authorised Version F2026L01327 registered 30/09/2026

BENZILONIUM
Schedule 4

BENZOCAINE
Schedule 4
Schedule 2

BENZODIAZEPINE DERIVATIVES
Schedule 4
Appendix D, clause 5

BENZOFENAP
Schedule 5

BENZOIC ACID
Schedule 5

BENZOVINDIFLUPYR
Schedule 6

BENZOYL PEROXIDE
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

BENZOYLINDOLES
Schedule 9

BENZPHETAMINE
Schedule 4

BENZTHIAZIDE
Schedule 4

BENZATROPINE
cross reference: BENZITROPINE
Schedule 4
Appendix K, clause 1

BENZYDAMINE
Schedule 4
Schedule 2

6-BENZYLADENINE
Schedule 6

BENZYL BENZOATE
Appendix B, clause 3

BENZYLMORPHINE
Schedule 8

Authorised Version F2026L01327 registered 30/09/2026

BENZYLPENICILLIN
Schedule 4

BENZYLPIPERAZINE
cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1)
Schedule 9

BEPHENIUM SALTS
Schedule 2

BEPRIDIL
Schedule 4

BERACTANT
Schedule 4

BERGAMOT OIL
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

BERYLLIUM
Schedule 6
Appendix F, clause 4

BESIFLOXACIN
Schedule 4

BETACETYLMETHADOL
cross reference: CAS No. 17199-59-6
Schedule 9

BETACYFLUTHRIN
Schedule 7
Schedule 6
Schedule 5

BETA-CYPERMETHRIN
Schedule 6

BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID
cross reference: PHENIBUT

BETAHISTINE
Schedule 4

BETA-HYDROXY-3-METHYLFENTANYL
cross reference: CAS No. 78995-14-9
Schedule 9

BETA-HYDROXYFENTANYL
cross reference: CAS No. 78995-10-5
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

BETAINE HYDROCHLORIDE
Appendix B, clause 3

BETAMEPRODINE
cross reference: CAS No. 468-50-8
Schedule 9

BETAMETHADOL
cross reference: CAS No. 17199-55-2
Schedule 9

BETAMETHASONE
Schedule 4

1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3
Appendix F, clause 4

BETAPRODINE
cross reference: CAS No. 468-59-7
Schedule 9

BETAXOLOL
Schedule 4

BETHANECHOL CHLORIDE
Schedule 4

BETHANIDINE
Schedule 4

BEVACIZUMAB
Schedule 4

BEVANTOLOL
Schedule 4

BEXAROTENE
Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

BEZAFIBRATE
Schedule 4

BEZITRAMIDE
Schedule 8

BEZLOTOXUMAB
Schedule 4

BHC
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

BIBROCATHOL
Schedule 4

BICALUTAMIDE
Schedule 4

BICTEGRAVIR
Schedule 4

BICYCLOPYRONE
Schedule 6
Schedule 5

BIFENAZATE
Appendix B, clause 3

BIFENTHRIN
Schedule 7
Schedule 6

BIFLUORIDES
cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS
Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

BIFONAZOLE
Schedule 4
Schedule 2

BILASTINE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

BIMATOPROST
Schedule 4

BINIMETINIB
Schedule 4

BIOALLETHRIN
Schedule 6
Schedule 5

BIORESMETHRIN
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

BIPERIDEN
Schedule 4

BISACODYL
Schedule 2

1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BISMUTH COMPOUNDS
cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE
Schedule 4

BISMUTH SUBNITRATE
Appendix B, clause 3

BISOPROLOL
Schedule 4

***N*,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE**
cross reference: *N,N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

***N*,*N*-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE**
cross reference: *N,N*-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BISPYRIBAC
Schedule 5

BISTRIFLURON
Appendix B, clause 3

BITHIONOL
cross reference: CAS No. 97-18-7
Schedule 10
Schedule 6
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

BIURET
Appendix B, clause 3

BIVALIRUDIN
Schedule 4

BIXAFEN
Schedule 5

BIXLOZONE
Appendix B, clause 3

BLAD (banda de Lupinus albus doce)
Appendix B, clause 3

BLEOMYCIN
Schedule 4

BLINATUMOMAB
Schedule 4

BOCEPREVIR
Schedule 4

BOLANDIOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLASTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLAZINE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLDENONE
cross reference: DEHYDROTESTOSTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLENOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLMANTALATE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BORAGO OFFICINALIS
cross reference: BORAGE
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

BORIC ACID
cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA-BORATE, MIPA-BORATE
Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

BORON
cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS
Schedule 4

BORON TRIFLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

BORTEZOMIB
Schedule 4

BOSCALID
Appendix B, clause 3

BOSENTAN
Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

BOSUTINIB
Schedule 4

BOTULINUM TOXINS
Schedule 4

BOVINE SOMATOTROPHIN
Appendix B, clause 3

BPC-157
Schedule 4
Appendix D, clause 5

BRAGANTIA spp
Schedule 10

BRENTUXIMAB VEDOTIN
Schedule 4

BRETYLIUM TOSILATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

BRETYLIUM TOSYLATE
cross reference: BRETYLIUM TOSILATE

BREXPIPRAZOLE
Schedule 4
Appendix K, clause 1

BRIGATINIB
Schedule 4

BRIMONIDINE
Schedule 4
Schedule 2

BRINZOLAMIDE
Schedule 4

BRIVARACETAM
cross reference: RACETAMS
Schedule 4
Appendix K, clause 1

BRODIFACOUM
Schedule 7
Schedule 6
Appendix J, clause 1

BROFLANILIDE
Schedule 6
Schedule 5

BROMACIL
Appendix B, clause 3

BROMADIOLONE
Schedule 7
Schedule 6
Appendix J, clause 1

BROMAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

BROMETHALIN
Schedule 7
Schedule 6

BROMHEXINE
Schedule 2

BROMIDES
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

BROMINE
Schedule 7
Appendix J, clause 1

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE
cross reference: BROMO-DRAGONFLY (CAS No. 502759-67-3)
Schedule 9

BROMOCRIPTINE
Schedule 4

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE
cross reference: BDMPEA (CAS No. 66142-81-2)
Schedule 9

BROMOFORM
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

BROMOPHOS
Schedule 6

BROMOPHOS-ETHYL
Schedule 6

BROMOPROPYLATE
Appendix B, clause 3

BROMOXYNIL
Schedule 7
Schedule 6

BROMPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

BROMUCONAZOLE
Schedule 6
Schedule 5

BROMVALETONE
Schedule 4

BROTIANIDE
Schedule 6

BRUCINE
Schedule 7
Appendix E, clause 3
Appendix J, clause 1

Authorised Version F2026L01327 registered 30/09/2026

BRUGMANSIA spp.
Schedule 4

BUCLIZINE
Schedule 4
Schedule 3
Appendix K, clause 1

BUCLOSAMIDE
cross reference: CAS No. 575-74-6
Schedule 10

BUDESONIDE
Schedule 4
Schedule 2

BUFEXAMAC
Schedule 4

BUFOTENINE
cross reference: CAS No. 487-93-4
Schedule 9

BULEVIRTIDE
Schedule 4

BUMETANIDE
Schedule 4

BUNAMIDINE
Schedule 6

BUNIODYL SODIUM
cross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0)
Schedule 10

BUPHENINE
Schedule 4

BUPIRIMATE
Appendix B, clause 3

BUPIVACAINE
Schedule 5
Schedule 4

BUPRENORPHINE
Schedule 8
Appendix K, clause 1

BUPROFEZIN
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

BUPROPION
cross reference: AMFEBUTAMONE
Schedule 4

BUSERELIN
Schedule 4

BUSPIRONE
Schedule 4

BUSULPHAN
Schedule 4

BUTACAINE
Schedule 4

BUTACARB
Schedule 6

BUTAFENACIL
Appendix B, clause 3

BUTAMBEN
cross reference: BUTYL AMINOBENZOATE
Schedule 4

1,4-BUTANEDIOL
cross reference: CAS No. 110-63-4
Schedule 10

BUTHIDAZOLE
Schedule 5

BUTOBARBITAL
Schedule 8
Appendix K, clause 1

BUTOBARBITONE
cross reference: BUTOBARBITAL

BUTOCONAZOLE
Schedule 4
Schedule 3
Appendix H, clause 1

BUTONITAZENE
cross reference: CAS No. 95810-54-1
Schedule 9

BUTORPHANOL
Schedule 8

BUTOXYCARBOXIM
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

2-BUTOXYETHANOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BUTOXYPOLYPROPYLENE GLYCOL
Appendix B, clause 3

2-BUTOXY-2'-THIOCYANODIETHYL ETHER
Schedule 6
Appendix F, clause 4

BUTRACONAZOLE
Schedule 4

BUTRALIN
Schedule 5

BUTROXYDIM
Schedule 5

***n*-BUTYL ALCOHOL**
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

BUTYL AMINOBENZOATE
cross reference BUTAMBEN

BUTYL BENZYL PHTHALATE
cross reference: CAS No. 85-68-7
Schedule 10

***n*-BUTYL BUTYRATE**
Appendix B, clause 3

***n*-BUTYL LACTATE**
Appendix B, clause 3

BUTYL NITRITE
Schedule 4
Appendix E, clause 3

BUTYLCHLORAL HYDRATE
Schedule 4

BUTYRIC ACID
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

C

CABAZITAXEL
Schedule 4

CABERGOLINE
Schedule 4

CABOTEGRAVIR
Schedule 4

CABOZANTINIB
Schedule 4

CACALIA spp.
Schedule 10

CACODYLIC ACID
Schedule 7
Schedule 6

CADMIUM COMPOUNDS
cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE
Schedule 6
Schedule 4
Appendix E, clause 3

CADUSAFOS
Schedule 7
Schedule 6

CAFFEINE
cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE
Schedule 6
Schedule 4

CAJUPUT OIL
Schedule 6
Appendix E, clause 3

CALCIFEDIOL
Schedule 4

CALCIFEROL
Schedule 7
Schedule 6
Appendix J, clause 1

CALCIPOTRIOL
Schedule 4

CALCITONIN SALMON
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CALCITRIOL
Schedule 4

CALCIUM CARBIMIDE
Schedule 4

CALCIUM HYDROXYLAPATITE
Schedule 4

CALCIUM POLYSTYRENE SULPHONATE
Schedule 4

CALOTROPIS GIGANTEA
Schedule 4

CALOTROPIS PROCERA
Schedule 4

CALUSTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CAMBENDAZOLE
Schedule 6

CAMELLIA SINENSIS EXTRACT
cross reference: GREEN TEA EXTRACT
Schedule 5
Appendix F, clause 4

CAMPHOR
cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CAMPHORATED OIL
Schedule 4

CAMPHOTAMIDE
Schedule 4

CANAGLIFLOZIN
Schedule 4

CANAKINUMAB
Schedule 4

CANDESARTAN CILEXETIL
Schedule 4

CANDICIDIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CANINE TICK ANTI-SERUM
Schedule 4

CANNABICHROMENE
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
Schedule 4
Schedule 3
Appendix F, clause 4

CANNABIDIOLIC ACID
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIVAROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIGEROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOIDS
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIS
cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS
Schedule 9
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

CANTHARIDIN
Schedule 4
Appendix G, clause 1

CAPECITABINE
Schedule 4

CAPIVASERTIB
Schedule 4

CAPMATINIB
Schedule 4

CAPREOMYCIN
Schedule 4

CAPROMORELIN
Schedule 4
Appendix D, clause 5

Authorised Version F2026L01327 registered 30/09/2026

CAPTAFOL
Schedule 7

CAPTAN
Schedule 6

CAPTODIAME
Schedule 4

CAPTOPRIL
Schedule 4

CAPURIDE
Schedule 4

CARAMIPHEN
Schedule 4

CARBACHOL
Schedule 4

CARBADOX
Schedule 7
Appendix J, clause 1

CARBAMAZEPINE
Schedule 4

CARBAMIDE PEROXIDE
cross reference: CAS No. 124-43-6
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CARBARYL
Schedule 6
Schedule 5
Schedule 4

CARBAZOCHROME
Schedule 4

CARBENDAZIM
Schedule 7

CARBENICILLIN
Schedule 4

CARBENOXOLONE
Schedule 4

CARBETAMIDE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

CARBETAPENTANE
Schedule 2

CARBETOCIN
Schedule 4

CARBIDOPA
Schedule 4

CARBIMAZOLE
Schedule 4

CARBOCISTEINE
Schedule 2

CARBOCROMEN
Schedule 4

CARBOFURAN
Schedule 7

CARBON DISULFIDE
Schedule 6
Appendix E, clause 3

CARBON TETRACHLORIDE
Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

CARBONYL SULFIDE
Schedule 7
Appendix J, clause 1

CARBOPHENOTHION
Schedule 7

CARBOPLATIN
Schedule 4

CARBOPROST
Schedule 4

CARBOSULFAN
Schedule 7

CARBOXIN
Appendix B, clause 3

CARBROMAL
Schedule 4

CARBUTAMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CARBUTEROL
Schedule 4

CARDARINE
cross reference: CAS No. 317318-70-0
Schedule 10

CARFENTANYL
Schedule 8

CARFENTRAZONE-ETHYL
Appendix B, clause 3

CARFILZOMIB.
Schedule 4

CARGLUMIC ACID
Schedule 4

CARINDACILLIN
Schedule 4

CARIPRAZINE
Schedule 4

CARISOPRODOL
Schedule 4

CARMUSTINE
Schedule 4

CARNIDAZOLE
Schedule 4

CARPROFEN
Schedule 4

CARVEDILOL
Schedule 4

CASIRIVIMAB
Schedule 4

CASPOFUNGIN
Schedule 4

CASSIA OIL
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CASTOR OIL, MONOMALEATE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

CATHINE
Schedule 4

CATHINONES
cross reference: SYNTHETIC CATHINONES
Schedule 9

CATUMAXOMAB
Schedule 4

CEDAZURIDINE
Schedule 4

CEFACETRILE
cross reference: CEPHACETRILE
Schedule 4

CEFACLOR
Schedule 4

CEFADROXIL
Schedule 4

CEFALEXIN
cross reference: CEPHALEXIN
Schedule 4

CEFALORIDINE
cross reference: CEPHALORIDINE
Schedule 4

CEFALOTIN
cross reference: CEPHALOTHIN, CEFALOTHIN
Schedule 4

CEFAMANDOLE
cross reference: CEPHAMANDOLE
Schedule 4

CEFAPIRIN
cross reference: CEPHAPIRIN
Schedule 4

CEFAZOLIN
cross reference: CEPHAZOLIN
Schedule 4

CEFEPIME
Schedule 4

CEFETAMET
Schedule 4

CEFIDEROCOL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CEFIXIME
Schedule 4

CEFODIZIME
Schedule 4

CEFONICID
Schedule 4

CEFOPERAZONE
Schedule 4

CEFOTAXIME
Schedule 4

CEFOTETAN
Schedule 4

CEFOTIAM
Schedule 4

CEFOVECIN
Schedule 4

CEFOXITIN
Schedule 4

CEFPIROME
Schedule 4

CEFPODOXIME
Schedule 4

CEFQUINOME
Schedule 4

CEFSULODIN
Schedule 4

CEFTAROLINE FOSAMIL
Schedule 4

CEFTAZIDIME
Schedule 4

CEFTIBUTEN
Schedule 4

CEFTIOFUR
Schedule 4

CEFTRIAXONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CEFUROXIME
Schedule 4

CELECOXIB
Schedule 4
Schedule 3
Appendix H, clause 1

CELIPROLOL
Schedule 4

CELLULASE derived from Aspergillus niger
Appendix B, clause 3

CENEGERMIN
Schedule 4

CEPHAELIS ACUMINATA
cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA
Schedule 4

CEPHAELIS IPECACUANHA
cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA
Schedule 4

CEPHALEXIN
cross reference: CEFALEXIN

CEPHALONIUM
Schedule 4

CEPHALOTHIN
cross reference: CEFALOTIN

CEPHRADINE
Schedule 4

CERAMICS
Appendix A, clause 1

CERITINIB
Schedule 4

CERIVASTATIN
Schedule 4

CERLIPONASE ALFA
Schedule 4

CERTOLIZUMAB PEGOL
Schedule 4

CERULETIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CETIRIZINE
Schedule 4
Schedule 2
Appendix K, clause 1

CETRORELIX
Schedule 4

CETUXIMAB
Schedule 4

CETYL ALCOHOL
Appendix B, clause 3

CHAMOMILE OIL
Appendix B, clause 3

CHEMISTRY SETS
Appendix A, clause 1

CHENODEOXYCHOLIC ACID
Schedule 4

CHINA CLAY
Appendix B, clause 3

CHLOPHEDIANOL
Schedule 2

CHLORAL FORMAMIDE
Schedule 4

CHLORAL HYDRATE
Schedule 4
Appendix K, clause 1

CHLORALOSE
cross reference: ALPHA-CHLORALOSE
Schedule 6
Schedule 4

CHLORAMBUCIL
Schedule 4

CHLORAMPHENICOL
Schedule 4
Schedule 3

CHLORANDROSTENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CHLORANTRANILIPROLE
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

CHLORAZANIL
Schedule 4

CHLORBUTANOL
Schedule 3
Schedule 2

CHLORBUTOL
cross reference: CHLOROBUTANOL

CHLORCYCLIZINE
Schedule 4

CHLORDANE
Schedule 6

CHLORDECONE
Schedule 7
Appendix J, clause 1

CHLORDIAZEPOXIDE
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

CHLORDIMEFORM
Schedule 7
Appendix J, clause 1

CHLORFENAC
Schedule 5

CHLORFENAPYR
Schedule 7
Schedule 6
Schedule 5

CHLORFENETHOL
Schedule 6

CHLORFENSON
Schedule 5

CHLORFENVINPHOS
Schedule 7

CHLORFLUAZURON
Appendix B, clause 3

CHLORFLURENOL
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

CHLORHEXIDINE
Schedule 7
Schedule 6
Schedule 5

CHLORIDAZON
Appendix B, clause 3

CHLORIDE
Appendix E, clause 3

CHLORINATING COMPOUNDS
cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

CHLORINE
cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID
Schedule 7
Appendix G, clause 1
Appendix J, clause 1

CHLORMEQUAT
Schedule 6

CHLORMERODRIN
Schedule 4

CHLORMETHIAZOLE
Schedule 4
Appendix K, clause 1

CHLORMEZANONE
Schedule 4

CHLORNIDINE
Schedule 5

CHLOROACETAMIDE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHLOROCRESOL
Schedule 5
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHLOROFORM
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

4-CHLOROMETHANDIENONE
Schedule 4
Appendix D, clause D (Anabolic and/or androgenic steroidal agents)

CHLOROMETHIURON
Schedule 7
Appendix J, clause 1

5-CHLORO-3-METHYL-4-NITROPYRAZOLE
Schedule 7

2-CHLORO-5-NITRO-N-HYDROXYETHYL-*p*-PHENYLENEDIAMINE
cross reference: PHENYLENEDIAMINES

CHLOROPHACINONE
Schedule 6

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE
Schedule 4

CHLOROPICRIN
Schedule 7
Schedule 6

CHLOROPICRIN
Appendix J, clause 1

CHLOROQUINE
Schedule 4

CHLOROTHALONIL
Schedule 6

CHLOROTHIAZIDE
Schedule 4

4-CHLORO-*o*-TOLUIDINE
Schedule 7
Appendix J, clause 1

CHLOROTRIANISENE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE
Schedule 6

CHLOROXYDIENONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CHLOROXYLENOLS
Appendix B, clause 3

CHLORPHENAMINE
cross reference: CHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

CHLORPHENIRAMINE
cross reference: CHLORPHENAMINE

CHLORPHENTERMINE
Schedule 4

CHLORPROMAZINE
Schedule 4
Appendix K, clause 1

CHLORPROPAMIDE
Schedule 4

CHLORPROPHAM
Schedule 5

CHLORPROTHIXENE
Schedule 4

CHLORPYRIFOS
Schedule 6
Schedule 5

CHLORPYRIFOS-METHYL
Schedule 6

CHLORQUINALDOL
Schedule 4

CHLORSULFURON
Schedule 5

CHLORTALIDONE
Schedule 4

CHLORTETRACYCLINE
Schedule 5
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CHLORTHAL-DIMETHYL
Schedule 7

CHLORTHALIDONE
cross reference: CHLORTALIDONE

CHLORTHIAMID
Schedule 6

CHLORTHIOPHOS
Schedule 7

CHLORZOXAZONE
Schedule 4

CHOLECALCIFEROL
cross reference: COLECALCIFEROL
Schedule 7
Appendix J, clause 1

CHOLERA VACCINE
Schedule 4

CHOLESTYRAMINE
cross reference: COLESTYRAMINE

CHOLIC ACID
Schedule 4

CHOLINE SALICYLATE
Schedule 2

CHROMATES
cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER-CHROME-ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHROMIUM TRICHLORIDE HEXAHYDRATE
Schedule 6

CHROMIUM TRIOXIDE
cross reference: CHROMIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHRYSOIDINE BASE
cross reference: CAS No. 495-54-5
Schedule 10
Schedule 6
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

CHYMOPAPAIN
Schedule 4

CICLACILLIN
Schedule 4

CICLESONIDE
Schedule 4

CICLOPIROX
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

CICLOSPORIN
Schedule 4

CIDOFOVIR
Schedule 4

CILASTATIN
Schedule 4

CILAZAPRIL
Schedule 4

CILGAVIMAB
Schedule 4

CILOSTAZOL
Schedule 4

CIMETIDINE
Schedule 4
Schedule 3
Appendix F, clause 4

CIMICOXIB
Schedule 4

CINACALCET
Schedule 4

CINCHOCAINE
Schedule 4
Schedule 2

CINCHOPHEN
cross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58-1), CINCHOPHEN SODIUM (CAS No. 5949-18-8)
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

CINEOLE
cross reference: CAMPHOR OIL (white), ROSEMARY OIL
Schedule 6
Appendix E, clause 3

CINMETHYLIN
Schedule 5

CINNAMEDRINE
Schedule 2

CINNAMON BARK OIL
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CINNAMON LEAF OIL
Schedule 6
Appendix E, clause 3

CINNARIZINE
Schedule 4

CINOXACIN
Schedule 4

CIPAGLUCOSIDASE ALFA
Schedule 4

CIPROFLOXACIN
Schedule 4

CISAPRIDE
Schedule 4

CISATRACURIUM BESILATE
cross reference: CISATRACURIUM BESYLATE
Schedule 4

CIS-JASMONE
cross reference: (Z)-JASMONE
Schedule 5

CISPLATIN
Schedule 4

CITALOPRAM
Schedule 4

CITRONELLA OIL
Appendix B, clause 3

CJC-1295 (CAS No. 863288-34-0)
Schedule 4
Appendix D, clause 5

Authorised Version F2026L01327 registered 30/09/2026

CLADRIBINE
Schedule 4

CLANOBUTIN
Schedule 4

CLARITHROMYCIN
Schedule 4

CLARY SAGE OIL
Appendix B, clause 3

CLASCOTERONE
Schedule 4

CLAVULANIC ACID
Schedule 4

CLEMASTINE
Schedule 4
Schedule 3
Appendix K, clause 1

CLEMIZOLE
Schedule 4

CLENBUTEROL
Schedule 4

CLETHODIM
Schedule 5

CLEVIDIPINE
Schedule 4

CLIDINIUM BROMIDE
Schedule 4

CLIMBAZOLE
Schedule 6
Schedule 5
Appendix E, clause 3

CLINDAMYCIN
Schedule 4

CLIOQUINOL
cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130-26-7)
Schedule 10
Schedule 4

CLITORIA TERNATEA EXTRACT
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

CLOBAZAM
Schedule 4

CLOBETASOL
Schedule 4

CLOBETASONE
Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1

CLOCORTOLONE
Schedule 4

CLODINAFOP-PROPARGYL
Schedule 6

CLODRONIC ACID
cross reference: SODIUM CLODRONATE
Schedule 4

CLOFARABINE
Schedule 4

CLOFAZIMINE
Schedule 4

CLOFENAMIDE
Schedule 4

CLOFENTEZINE
Schedule 5

CLOFIBRATE
Schedule 4

CLOMAZONE
Schedule 6

CLOMIFENE
cross reference: CLOMIPHENE
Schedule 4
Appendix D, clause 1

CLOMIPHENE
cross reference: CLOMIFENE

CLOMIPRAMINE
Schedule 4
Appendix K, clause 1

CLOMOCYCLINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

CLONAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

CLONAZOLAM
cross reference: CAS No. 33887-02-4
Schedule 9

CLONIDINE
Schedule 4
Appendix K, clause 1

CLONITAZENE
cross reference: CAS No. 3861-76-5
Schedule 9

CLOPAMIDE
Schedule 4

CLOPIDOGREL
Schedule 4

CLOPIDOL
Appendix B, clause 3

CLOPROSTENOL
Schedule 4

CLOPYRALID
Schedule 5

CLOQUINTOCET
Schedule 5

CLORAZEPATE
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

CLOREXOLONE
Schedule 4

CLORPRENALINE
Schedule 4

CLORSULON
Schedule 5

CLOSANTEL
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

CLOSTEBOL
cross reference: 4-CHLOROTESTOSTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CLOTHIANIDIN
Schedule 6
Schedule 5

CLOTRIMAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

CLOVE OIL
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CLOXACILLIN
Schedule 4

CLOZAPINE
Schedule 4
Appendix D, clause 1
Appendix K, clause 1

COAL TAR
Schedule 10

COBALT
cross reference: DICOBALT EDETATE
Schedule 4

COBALT NAPHTHENATE
Appendix B, clause 3

COBICISTAT
Schedule 4

COBIMETINIB
Schedule 4

COCA LEAF
Schedule 9

COCAINE
Schedule 8

Authorised Version F2026L01327 registered 30/09/2026

_N_-COCO-1,3-DIAMINOPROPANE
Schedule 6

COCOYL GLYCINATE
Schedule 6
Appendix E, clause 3

COCOYL METHYL GLUCAMAIDE
cross reference: 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL *N*-COCO ACYL DERIVATIVES

CODEINE
Schedule 8
Schedule 4
Appendix K, clause 1

CODEINE-*N*-OXIDE
Schedule 8

CO-DERGOCRINE
Schedule 4

CODOXIME
cross reference: CAS No. 7125-76-0
Schedule 9

COLASPASE
cross reference: ASPARAGINASE

COLCHICINE
Schedule 4

COLCHICUM AUTUMNALE
Schedule 4

COLECALCIFEROL
cross reference: CHOLECALCIFEROL
Schedule 7
Appendix J, clause 1

COLESTIPOL
Schedule 4

COLESTYRAMINE
Schedule 4

COLFOSCERIL PALMITATE
Schedule 4

COLISTIN
Schedule 4

COLLAGEN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Schedule 4

COLURACETAM
cross reference: RACETAMS
Schedule 4

CONCENTRATE OF POPPY STRAW
Schedule 8

CONCIZUMAB
Schedule 4

CONIUM MACULATUM
cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99-9), CONIINE S-ISOMER (CAS No. 458-88-8)
Schedule 10

CONVALLARIA KEISKI
Schedule 4

CONVALLARIA MAJALIS
Schedule 4

COPPER ACETATE
Schedule 6
Schedule 5

COPPER COMPOUNDS
cross reference: COPPER
Schedule 6
Schedule 5
Schedule 4
Appendix A, clause 1

COPPER HYDROXIDE
Schedule 6
Schedule 5

COPPER NITRATE
cross reference: COPPER CHLORIDE
Schedule 6

COPPER OXIDES
Schedule 6
Schedule 5

COPPER OXYCHLORIDE
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

COPPER SULFATE
Schedule 6
Schedule 5
Appendix E, clause 3

CORIFOLLITROPIN ALFA
cross reference: FOLLICLE STIMULANT, RECOMBINANT
Schedule 4
Appendix D, clause 1

CORONILLA spp.
Schedule 4

CORTICOSTERONE
Schedule 4

CORTICOTROPHIN
Schedule 4

CORTISONE
Schedule 4

COTARNINE
cross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02-6), COTARNINE CHLORIDE (CAS No. 10018-19-6)
Schedule 10

CO-TRIMOXAZOLE
Schedule 4

COUMAPHOS
Schedule 7
Schedule 6

COUMARIN
Schedule 4

COUMATETRALYL
Schedule 7
Schedule 6
Schedule 5
Appendix J, clause 1

4-CPA
Schedule 5

CREOSOTE
cross reference: BEECHWOOD, PHENOL, WOOD
Schedule 7
Schedule 6
Schedule 2
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

CRESOLS
Appendix E, clause 3

CRISABOROLE
Schedule 4

CRIZOTINIB
Schedule 4

CROFELEMER
Schedule 4

CROSPOVIDONE
Appendix B, clause 3

CROTALARIA spp.
Schedule 10

CROTON TIGLIUM
cross reference: CROTON OIL
Schedule 10
Appendix G, clause 1

CROTOXYPHOS
Schedule 6

CRUFOMATE
Schedule 6

CRYSTAL VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET

CULICINOMYCES CLAVOSPORUS
Appendix B, clause 3

CUPRIMYXIN
Schedule 4

CURARE
Schedule 4

^{13}C-UREA
Appendix B, clause 3

CYANAMIDE
Schedule 6

CYANATRYN
Schedule 5

CYANAZINE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

CYANIDES
cross reference: FERRICYANIDES, FERROCYANIDES
Schedule 7
Appendix E, clause 3
Appendix F, clause 4

CYANOACRYLATE ESTERS
Schedule 5

CYANOACRYLIC ACID ESTERS
Appendix E, clause 3

4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE
cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1)
Schedule 9

CYANOGEN
cross reference: ETHANEDINITRILE, OXALONITRILE
Schedule 7
Appendix J, clause 1

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE
cross reference: PETHIDINE INTERMEDIATE A
Schedule 8

CYANTRANILIPROLE
Schedule 5

CYANURIC ACID
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CYAZOFAMID
Schedule 5

CYCLAMIC ACID
Appendix B, clause 3

CYCLANDELATE
Schedule 4

CYCLANILIDE
Schedule 6

CYCLANILIPROLE
Appendix B

CYCLIZINE
Schedule 4
Schedule 3
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

CYCLOBARBITAL
Schedule 8
Appendix K, clause 1

CYCLOBARBITONE
cross reference: CYCLOBARBITAL

CYCLOBENZAPRINE
Schedule 4

CYCLOBUTRIFLURAM
Appendix B, clause 3

CYCLOFENIL
Schedule 4
Appendix D, clause 1

CYCLOHEXANE
Appendix B, clause 3

CYCLOHEXANOL ACETATE
Appendix B, clause 3

CYCLOHEXANONE PEROXIDE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CYCLOHEXIMIDE
Schedule 4

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM
cross reference: K-HDO
Schedule 6

CYCLOHEXYLPHENOLS
Schedule 9

CYCLOPENTHIAZIDE
Schedule 4

CYCLOPENTOLATE
Schedule 4

CYCLOPHOSPHAMIDE
Schedule 4

CYCLOPROPANE
Schedule 4

CYCLOPROTHRIN
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

CYCLOSERINE
Schedule 4
Appendix J, clause 1

CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2)
Schedule 7
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CYCLOSPORIN
cross reference: CICLOSPORIN

CYCLOTHIAZIDE
Schedule 4

CYCLOXYDIM
Schedule 5

CYCRIMINE
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

CYFLUFENAMID
Schedule 5

CYFLUMETOFEN
Schedule 5

CYFLUTHRIN
Schedule 6
Schedule 5

CYHALOFOP-BUTYL
Schedule 5

CYHALOTHRIN
Schedule 7

CYHEXATIN
Schedule 7

CYMARIN
Schedule 4

CYMIAZOLE
Schedule 5

CYNOGLOSSUM spp.
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

CYOMETRINIL
Schedule 6

CYPERMETHRIN
cross reference: ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN, ZETA-CYPERMETHRIN
Schedule 6
Schedule 5

CYPHENOTHRIN
Schedule 6
Schedule 5

CYPRINID HERPESVIRUS-3
Appendix B, clause 3

CYPROCONAZOLE
Schedule 5

CYPRODINIL
Schedule 5

CYPROHEPTADINE
Schedule 4
Schedule 3
Appendix K, clause 1

CYPROTERONE
Schedule 4

CYROMAZINE
Appendix B, clause 3

CYSTEAMINE
cross reference: MERCAPTAMINE

CYTARABINE
Schedule 4

CYTHIOATE
Schedule 6
Schedule 5

CYTISINE
Schedule 4
Schedule 3
Appendix H, clause 1

Authorised Version F2026L01327 registered 30/09/2026

D

2,4-D
Schedule 6
Schedule 5

DABIGATRAN
Schedule 4

DABRAFENIB MESILATE
Schedule 4

DACARBAZINE
Schedule 4

DACLATASVIR
Schedule 4

DACLIZUMAB
Schedule 4

DACTINOMYCIN
Schedule 4

DALFOPRISTIN
Schedule 4

DALTEPARIN
Schedule 4

DAMINOZIDE
Schedule 5

DANAPAROID
Schedule 4

DANAZOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DANICOPAN
Schedule 4

DANTHRON
Schedule 4

DANTROLENE
Schedule 4
Appendix K, clause 1

DAPAGLIFLOZIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DAPOXETINE
Schedule 4

DAPSONE
Schedule 4

DAPTOMYCIN
Schedule 4

DARATUMUMAB
Schedule 4

DARBEPOETIN
Schedule 4
Appendix D, clause 5

DARIFENACIN
Schedule 4

DAROLUTAMIDE
Schedule 4

DARUNAVIR
Schedule 4

DASABUVIR
Schedule 4

DASATINIB
Schedule 4

DATOPOTAMAB DERUXTECAN
Schedule 4

DATURA spp.
Schedule 4
Schedule 2

DATURA STRAMONIUM
cross reference: STRAMONIUM
Schedule 4
Schedule 2

DATURA TATULA
cross reference: STRAMONIUM
Schedule 4
Schedule 2

DAUNORUBICIN
Schedule 4

DAZOMET
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

2,4-DB
Schedule 5

DEANOL
cross reference: 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA
Schedule 4

DEBRISOQUINE
Schedule 4

DECAMETHONIUM
Schedule 4

DECITABINE
Schedule 4

DECOQUINATE
Schedule 5

DEFERASIROX
Schedule 4

DEFERIPRONE
Schedule 4

DEFIBROTIDE
Schedule 4

DEFLAZACORT
Schedule 4

DEGARELIX
Schedule 4

DEHYDROCHLOROMETHYLTESTOSTERONE
cross reference: CHLOROMESTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DEHYDROCORTICOSTERONE
Schedule 4

DELAVIRDINE
cross reference: DELAVIRDINE MESILATE

DELAVIRDINE MESILATE
Schedule 4

DELGOCITINIB
Schedule 4

DELPHINIUM STAPHISAGRIA
cross reference: STAPHISAGRIA
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

DELTAMETHRIN
Schedule 7
Schedule 6
Schedule 5

DEMBREXINE
Schedule 5
Schedule 4

DEMECARIUM
Schedule 4

DEMECLOCYCLINE
Schedule 4

DEMETON
Schedule 7

DEMETON-O-METHYL
Schedule 7

DEMETON-S-METHYL
Schedule 7

DENGUE VACCINE
cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4)
Schedule 4

DENOSUMAB
Schedule 4

DEOXYCHOLIC ACID
Schedule 4

DEOXYCORTONE
Schedule 4

1-DEOXY-1-(METHYLAMINO)-*D*-GLUCITOL *N*-COCO ACYL DERIVATIVES
cross reference: COCOYL METHYL GLUCAMAIDE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DEOXYRIBONUCLEASE
Schedule 4

DEPEMOKIMAB
Schedule 4

DERACOXIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT
Schedule 4

DERQUANTEL
Schedule 6

2,4-DES
Schedule 5

DESCHLOROETIZOLAM
cross reference: CAS No. 40054-73-7
Schedule 9

DESFERRIOXAMINE
Schedule 4

DESFLURANE
Schedule 4

DESIPRAMINE
Schedule 4
Appendix K, clause 1

DESIRUDIN
Schedule 4

DESLANOSIDE
Schedule 4

DESLORATADINE
Schedule 4
Schedule 2

DESLORELIN
Schedule 4

DESMOPRESSIN
cross reference: D.D.A.V.P.
Schedule 4

DESOGESTREL
Schedule 4

DESOMORPHINE
cross reference: CAS No. 427-00-9
Schedule 9

DESONIDE
Schedule 4

DESOXYMETHASONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DESVENLAFAXINE
Schedule 4

DETOMIDINE
Schedule 4

DEUCRAVACITINIB
Schedule 4

DEUTETRABENAZINE
Schedule 4
Appendix K, clause 1

DEUTIVACAFTOR
Schedule 4

DEXAMETHASONE
Schedule 4

DEXAMFETAMINE
cross reference: DEXAMPHETAMINE
Schedule 8

DEXCHLORPHENAMINE
cross reference: DEXCHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

DEXCHLORPHENIRAMINE
cross reference: DEXCHLORPHENAMINE

DEXFENFLURAMINE
Schedule 4

DEXMEDETOMIDINE
Schedule 4

DEXRAZOXANE
Schedule 4

DEXTRANS
Appendix A

DEXTROMETHORPHAN
Schedule 4
Schedule 2

DEXTROMORAMIDE
cross reference: MORAMIDE
Schedule 8
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

DEXTROPROPOXYPHENE
Schedule 8
Schedule 4
Appendix D, clause 5
Appendix K, clause 1

DEXTRORPHAN
Schedule 4

***N*,*N*-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES**
cross
reference:3,4-DICHLORO-N-[(1*R*,2*R*)-2-(DIMETHYLAMINO)CYCLOHEXYL]-*N*-METH
YLBENZAMIDE *(U-47700) (CAS No. 82657-23-6)
Schedule 9

***N*,*N*-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES**
Cross
reference:3,4-DICHLORO-*N*-{[1-(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZ
AMIDE *(AH-7921) (CAS No. 55154-30-8)
Schedule 9

4,4-DIAMINODIPHENYLMETHANE
cross reference: METHYLENE DIANILINE
Schedule 7
Appendix F, clause 4
Appendix J, clause 1

2,4-DIAMINO-5-METHYLPHENETOLE
cross reference: PHENYLENEDIAMINES

2,4-DIAMINOPHENOXYETHANOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DIAFENTHIURON
Schedule 5

DIALIFOS
Schedule 7

***N*,*N*-DIALLYLDICHLOROACETAMIDE**
Schedule 5

DIAMPROMIDE
cross reference: CAS No. 552-25-0
Schedule 9

DIAMTHAZOLE
Schedule 4

DIAVERIDINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DIAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

DIAZINON
Schedule 6
Schedule 5

DIAZOXIDE
Schedule 4

DIBENZEPIN
Schedule 4

DIBENZOPYRANS
Schedule 9

DIBOTERMIN
Schedule 4

1,2-DIBROMO-3-CHLOROPROPANE
Schedule 7
Appendix J, clause 1

DIBROMOPROPAMIDINE
Schedule 4
Schedule 2

DIBUTYL PHTHALATE
cross reference: CAS No. 84-74-2
Schedule 10

DICAMBA
Schedule 6
Schedule 5

DICLAZEPAM
cross reference: CAS No. 2894-68-0
Schedule 9

DICHLOBENIL
Schedule 6

***o*-DICHLOROBENZENE**
Appendix F, clause 4

DICHLOEOETHYL ETHER
Appendix F, clause 4

DICHLOFENTHION
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

DICHLOFLUANID
Schedule 6

DICHLONE
Schedule 5

DICHLORALPHENAZONE
Schedule 4

DICHLOROBENZENE
Schedule 6
Schedule 5
Appendix E, clause 3

3,4-DICHLORO-N-[(1*R*,2*R*)-2-(DIMETHYLAMINO)CYCLOHEXYL]-*N*-METHYLBENZAMIDE (U-47700)
cross reference: *N,N*-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-6)
Schedule 9

DICHLOROETHYL ETHER
Schedule 6
Appendix E, clause 3

DICHLOROETHYLENE
Appendix F, clause 4

DICHLOROISOCYANURIC ACID
cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DICHLOROMETHANE
cross reference: METHYLENE CHLORIDE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

3,4-DICHLORO-*N*-{[1-DIMETHYLAMINO)CYCLOHEXYL]METHYL} BENZAMIDE
cross reference: AH-7921 (CAS No. 55154-30-8)
Schedule 9

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE
Schedule 6

DICHLOROPHEN
Schedule 6
Schedule 5
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

2,4-DICHLORPROP
Schedule 6

1,2-DICHLOROPROPANE
Schedule 6

1,3-DICHLOROPROPENE
Schedule 7
Appendix J, clause 1

DICHLORPHENAMIDE
Schedule 4

DICHLORVOS
Schedule 7
Schedule 6
Schedule 5

DICHROMATES
Appendix E, clause 3

DICLAZURIL
Appendix B, clause 3

DICLOBUTRAZOL
Schedule 5

DICLOFENAC
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

DICLOFOP-METHYL
Schedule 6

DICLORAN
Schedule 5

DICLOXACILLIN
Schedule 4

DICOFOL
Schedule 5

DICOPHANE
cross reference: DDT (CAS No. 50-29-3)
Schedule 10

DICROTOPHOS
Schedule 7

DICYCLANIL
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

DICYCLOMINE
Schedule 4

DIDANOSINE
Schedule 4

DIDECYLDIMETHYLAMMONIUM SALTS
Schedule 6

DIELDRIN
Schedule 6

DIENESTROL
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

DIENOGEST
Schedule 4

DIESEL
Appendix E, clause 3

DIETHANOLAMINE
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIETHAZINE
Schedule 4

DIETHYL CARBONATE
Appendix B, clause 3

DIETHYLCARBAMAZINE
Schedule 4

DIETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6)
Schedule 10
Schedule 6
Schedule 5

DIETHYLENE GLYCOL MONOBUTYL ETHER
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIETHYLENE GLYCOL MONOMETHYL ETHER
cross reference: CAS No. 111-77-3
Schedule 10
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

DIETHYLHEXYL PHTHALATE
cross reference: DEHP (CAS No. 117-81-7)
Schedule 10

DIETHYLPHTHALATE
cross reference: CAS No. 84-66-2
Schedule 10

DIETHYLPROPION
Schedule 4

DIETHYLTHIAMBUTENE
cross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4)
Schedule 9

DIETHYLTOLUAMIDE (DEET)
Schedule 5
Appendix F, clause 4

***N,N*-DIETHYLTRYPTAMINE**
cross reference: DET (CAS No. 61-51-8)
Schedule 9

DIFELIKEFALIN
Schedule 4
Appendix K, clause 1

DIFENACOUM
Schedule 7
Schedule 6
Appendix J, clause 1

DIFENOCONAZOLE
Schedule 5

DIFENOXIN
Schedule 8
Schedule 4
Appendix K, clause 1

DIFENZOQUAT
Schedule 6

DIFETHIALONE
Schedule 7
Schedule 6

DIFLORASONE
Schedule 4

DIFLOXACIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DIFLUBENZURON
Schedule 5

DIFLUCORTOLONE
Schedule 4

DIFLUFENICAN
Appendix B, clause 3

DIFLUNISAL
Schedule 4

DIGITALIS LANATA
Schedule 4

DIGITALIS PURPUREA
Schedule 4

DIGITOXIN
Schedule 4

DIGOXIN
Schedule 4

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab)
Schedule 4

DIHYDRALAZINE
Schedule 4

DIHYDROCODEINE
Schedule 8
Schedule 4
Schedule 3
Appendix K, clause 1

DIHYDROERGOTOXINE
Schedule 4

DIHYDROLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-1-ONE (SGT-151)
cross reference: SGT-151, CUMYL-PEGACLONE (CAS No. 2160555-55-3)
Schedule 9

DIHYDROMORPHINE
Schedule 8

DIHYDROSTREPTOMYCIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DIHYDROTACHYSTEROL
Schedule 4

5,6-DIHYDROXYINDOLINE
cross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7)
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DIIODOHYDROXYQUINOLINE
cross reference: IODOQUINOL (CAS No. 83-73-8)
Schedule 10
Schedule 4
Schedule 3

DI-IODOHYDROXYQUINOLINE
cross reference: DIIODOHYDROXYQUINOLINE

DIISOBUTYL PHTHALATE
cross reference: CAS No. 84-69-5
Schedule 10

DIISOPROPYLAMINE DICHLOROACETATE
Schedule 4

DIKEGULAC-SODIUM
Appendix B, clause 3

DILTIAZEM
Schedule 4

DIMEFOX
Schedule 7

DIMENHYDRINATE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1
Appendix K, clause 1

DIMENOXADOL
cross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1)
Schedule 9

DIMEPHEPTANOL
cross reference: CAS No. 545-90-4
Schedule 9

DIMERCAPROL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DIMETHANDROSTANOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DIMETHAZINE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DIMETHENAMID-P
Schedule 6

DIMETHICODIETHYLBENZALMALONATE
cross reference: POLYSILICONE-15
Schedule 5

DIMETHICONE
cross reference: DIMETICONE

DIMETHINDENE
Schedule 4
Appendix K, clause 1

DIMETHIPIN
Schedule 6

DIMETHIRIMOL
Schedule 5

DIMETHOATE
Schedule 6

DIMETHOMORPH
Schedule 5

DIMETHOTHIAZINE
Schedule 4

DIMETHOXANATE
Schedule 4

2,5-DIMETHOXYAMFETAMINE
cross reference: 2,5-DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9)
Schedule 9

2,5-DIMETHOXY-4-BROMOAMFETAMINE
cross reference: 2,5-DIMETHOXY-4-BROMOAMPHETAMINE, DOB (CAS No. 64638-07-9)
Schedule 9

2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE
cross reference: 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE, DOET (CAS No. 22004-32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE
cross reference: 2C-T-2 (CAS No. 207740-24-7)
Schedule 9

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE
cross reference: 2C-I (CAS No. 69587-11-7)
Schedule 9

2,5-DIMETHOXY-4-(*N*)-PROPYLTHIOPHENETHYLAMINE
cross reference: 2C-T-7 (CAS No. 207740-26-9)
Schedule 9

2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE
Schedule 6
Appendix F, clause 4

DIMETHYLACETAMIDE
Schedule 6
Schedule 5

***N,N*-DIMETHYLAMFETAMINE**
cross reference: *N,N*-DIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9)
Schedule 9

4-DIMETHYLAMINOAZOBENZENE
cross reference: MOCA, *N,N*-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE
Schedule 7
Appendix J, clause 1

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE
cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6)
Schedule 9

1,3-DIMETHYLAMYLAMINE
cross reference: 4-METHYLHEXANE-2-AMINE, DMAA (CAS No. 105-41-9)
Schedule 10

1,3-DIMETHYLBUTYLAMINE (DMBA)
cross reference: OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 108-09-8)
Schedule 10

4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

N,N-DIMETHYLDECANAMIDE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

DIMETHYL DISULFIDE
Schedule 6

DIMETHYL ETHER
Appendix B, clause 3

1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette)
cross reference: AMBER MUSK (CAS No. 83-66-9)
Schedule 10

DIMETHYLFORMAMIDE
cross reference: DESIGNATED SOLVENT
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIMETHYL FUMARATE
Schedule 4

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6*H*-DIBENZO (b,d) PYRAN
cross reference: DMHP (CAS No. 32904-22-6)
Schedule 9

1,5-DIMETHYLHEXYLAMINE (DMHA)
cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 543-82-8), 1,5-DIMETHYLHEXYLAMINE HYDROCHLORIDE (CAS No. 5984-59-8), 1,5-DIMETHYLHEXYLAMINE S-ISOMER (CAS No. 70419-10-2), 1,5-DIMETHYLHEXYLAMINE R-ISOMER (CAS No. 70419-11-3)
Schedule 10

***N, α* -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA)**
cross reference: 3,4-METHYLENEDIOXY-*N*-*α*-DIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 42542-10-9), MDMA HYDROCHLORIDE (CAS No. 64057-70-1)
Schedule 9
Schedule 8
Appendix D, clause 5
Appendix D, clause 9

1,4-DIMETHYLNAPHTHALENE
Schedule 5

3,7-DIMETHYL-2,6-OCTADIENAL
cross reference: CITRAL, NERAL, GERANIAL
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

3,7-DIMETHYL-2,6-OCTADIEN-1-OL
cross reference: GERANIOL, NEROL, CITROL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

***N,N*-DIMETHYLOCTANAMIDE**
Schedule 6

DI(METHYLOXYETHYL) PHTHALATE
cross reference: CAS No. 117-82-8
Schedule 10

1,4-DIMETHYLPENTYLAMINE (DMPA)
cross reference: 1,4-DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5)
Schedule 10

DIMETHYLPHTHALATE
cross reference: CAS No. 131-11-3
Schedule 10

DIMETHYL SULFATE
Schedule 7
Appendix F, clause 4

DIMETHYL SULFOXIDE
cross reference: COPPER SALICYLATE, METHYL SALICYLATE
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

DIMETHYLTHIAMBUTENE
cross reference: CAS No. 524-84-5
Schedule 9

***N,N*-DIMETHYLTRYPTAMINE**
cross reference: DMT (CAS No. 61-50-7)
Schedule 9

DIMETICONE
cross reference: DIMETHICONE
Appendix B, clause 3

DIMETILAN
Schedule 7

DIMETRIDAZOLE
Schedule 4

DIMIRACETAM
cross reference: RACETAMS
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

DIMPROPYRIDAZ
Schedule 6
Schedule 5

DINICONAZOLE
Schedule 5

2,4-DINITROCHLOROBENZENE
Schedule 4

DINITROCRESOLS
Schedule 7
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix J, clause 1

DINITRONAPHTHOLS
Schedule 4

2,4-DINITROPHENOL
cross reference: CAS No. 51-28-5
Schedule 10

DINITROPHENOLS
Schedule 10
Schedule 7
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

DINITROTHYMOLS
Schedule 4

DINOCAP
Schedule 7
Appendix F, clause 4

DINOPROST
Schedule 4
Appendix D, clause 1

DINOPROSTONE
Schedule 4
Appendix D, clause 1

DINOSEB
Schedule 7
Appendix J, clause 1

DINOTEFURAN
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

DI-*n*-PROPYL ISOCINCHOMERONATE (previously di-*N* propyl isocinchomeronate)
Schedule 5

DIOXACARB
Schedule 6

DIOXANE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DIOXAPHETYL BUTYRATE
cross reference: CAS No. 467-86-7
Schedule 9

DIPERODON
Schedule 4

DIPHACINONE
Schedule 6

DIPHEMANIL
Schedule 4

DIPHENAMID
Schedule 5

DIPHENHYDRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

DIPHENIDINE
cross reference: CAS No. 28383-15-5
Schedule 9

DIPHENIDOL
Schedule 4

DIPHENOXYLATE
Schedule 8
Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1
Appendix K, clause 1

DIPHENYLAMINE
Appendix B, clause 3

DIPHENYLPYRALINE
Schedule 4
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

DIPHTHERIA TOXOID
cross reference: TRIPLE ANTIGEN VACCINE
Schedule 4

DIPIPANONE
Schedule 8

DIPIVEFRIN
Schedule 4

DIPROPYLENE GLYCOL
Appendix B, clause 3

DIPYRIDAMOLE
Schedule 4

DIQUAT
Schedule 7
Schedule 6

DIRECT RED 254
cross reference: 2-NAPHTHALENESULFONIC ACID, 7-AMINO-4-HYDROXY-3-[[*p*-[(*p*-SULFOPHENYL)AZO]PHENYL]AZO]-, (3*Z*)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID, (3*Z*)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3*Z*)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID DISODIUM SALT
Schedule 6
Schedule 5

DIRITHROMYCIN
Schedule 4

DIRLOTAPIDE
Schedule 4

DIROXIMEL FUMARATE
Schedule 4

DISODIUM MANGANESE EDTA
Appendix B, clause 3

DISOPHENOL
Schedule 4

DISOPYRAMIDE
Schedule 4

DISPERSE YELLOW 3
cross reference: CAS No. 2832-40-8
Schedule 10
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

Appendix E, clause 3
Appendix F, clause 4

DISTIGMINE
Schedule 4

DISTILLATE
Appendix E, clause 3

DISULFIRAM
Schedule 6
Schedule 4

DISULFOTON
Schedule 7
Schedule 6

DISULPHAMIDE
Schedule 4

DITHIANON
Schedule 6

DITHIAZANINE
Schedule 6
Schedule 4

DITHIOPYR
Schedule 5

DITHRANOL
Schedule 3

DITIOCARB
Schedule 4

DIUREDOSAN
Schedule 6

DIURON
Appendix B, clause 3

DOBUTAMINE
Schedule 4

DOCETAXEL
Schedule 4

DOCUSATE SODIUM
cross reference: DIOCTYL SODIUM SULFOSUCCINATE
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

(Z,E)-7,9,11-DODECATRIENYL FORMATE
Schedule 6

***N*-(*N*-DODECYL)-2-PYRROLIDONE**
cross reference: DESIGNATED SOLVENT, *N*-(*N*-OCTYL)-2-PYRROLIDONE, *N*-METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, clause 3

DODINE
Schedule 6

DOFETILIDE
Schedule 4

DOLASETRON
Schedule 4

DOLUTEGRAVIR
Schedule 4

DOMPERIDONE
Schedule 4

DONEPEZIL
Schedule 4

DOPAMINE
Schedule 4

DOPEXAMINE
Schedule 4

DORAMECTIN
Schedule 7
Schedule 6
Schedule 5

DORAVIRINE
Schedule 4

DORIPENEM
Schedule 4

DORNASE
Schedule 4

DORZOLAMIDE
Schedule 4

DOSULEPIN
cross reference: DOTHIEPIN.
Schedule 4
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

DOTHIEPIN
cross reference: DOSULEPIN

DOXANTRAZOLE
Schedule 4

DOXAPRAM
Schedule 4

DOXAZOSIN
Schedule 4

DOXEPIN
Schedule 4
Appendix K, clause 1

DOXORUBICIN
Schedule 4

DOXYCYCLINE
Schedule 4

DOXYLAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

2,2-DPA
cross reference: SODIUM 2,2-DICHLOROPROPIONATE
Appendix B, clause 3

DROMETRIZOLE TRISILOXANE
Appendix B, clause 3

DRONABINOL
cross reference: DELTA-9-TETRAHYDROCANNABINOL, NABIXIMOLS
Schedule 8
Appendix D, clause 3
Appendix K, clause 1

DRONEDARONE
Schedule 4

DROPERIDOL
Schedule 4
Appendix K, clause 1

DROSPIRENONE
Schedule 4

DROSTANOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

Authorised Version F2026L01327 registered 30/09/2026

DROTEBANOL
Schedule 8

DROTRECOGIN
Schedule 4

DSMA
Schedule 7
Schedule 6

DUBOISIA LEICHHARDTII
Schedule 4
Schedule 2

DUBOISIA MYOPOROIDES
Schedule 4
Schedule 2

DUDDINGTONIA FLAGRANS, STRAIN IAH 1297
Appendix B, clause 3

DULAGLUTIDE
Schedule 4

DULCIN
cross reference: CAS No. 150-69-6
Schedule 10

DULOXETINE
Schedule 4
Appendix K, clause 1

DUPILUMAB
Schedule 4

DURVALUMAB
Schedule 4

DUTASTERIDE
Schedule 4

DYDROGESTERONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

E

(*E*)-(*S*)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL
cross reference: UNICONAZOLE-P
Schedule 6

ECGONINE
cross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31-6), ECGONINE RACEMATE (CAS No. 876657-17-9)
Schedule 9

ECONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

ECOTHIOPATE
cross reference: ECOTHIOPATE IODIDE
Schedule 4

ECTYLUREA
Schedule 4

ECULIZUMAB
Schedule 4

EDARAVONE
Schedule 4

EDETIC ACID
cross reference: DICOBALT EDETATE
Schedule 4

EDOXUDINE
Schedule 4

EDROPHONIUM
Schedule 4

EFALIZUMAB
Schedule 4

EFANESOCTOCOG ALFA
Schedule 4

EFAVIRENZ
Schedule 4

EFGARTIGIMOD ALFA
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

EFLORNITHINE
Schedule 4

EFORMOTEROL
cross reference: FORMOTEROL

ELACESTRANT DIHYDROCHLORIDE
Schedule 4

ELAFIBRANOR
Schedule 4

ELBASVIR
Schedule 4

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
Appendix A, clause 1

ELECTRONIC COMPONENTS
Appendix A, clause 1

ELETRIPTAN
Schedule 4
Schedule 3
Appendix H, clause 1

ELEXACAFTOR
Schedule 4

ELINZANETANT
Schedule 4

ELOSULFASE ALFA
Schedule 4

ELOTUZUMAB
Schedule 4

ELRANATAMAB
Schedule 4

ELTENAC
Schedule 4

ELTROMBOPAG
Schedule 4

ELUXADOLINE
Schedule 4

ELVITEGRAVIR
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

EMAMECTIN
Schedule 7
Schedule 6
Schedule 5

EMEPRONIUM
Schedule 4

EMETINE
cross reference: CEPHAELIS ACUMINATA
Schedule 4

EMODEPSIDE
Schedule 6
Schedule 5

EMPAGLIFLOZIN
Schedule 4

EMTRICITABINE
Schedule 4

ENALAPRIL
Schedule 4

ENASIDENIB
Schedule 4

ENCORAFENIB
Schedule 4

ENDOSULFAN
Schedule 7
Schedule 6

ENDOTHAL
Schedule 7
Schedule 6

ENDRIN
Schedule 7

ENESTEBOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ENFLICOXIB
Schedule 4

ENFLURANE
Schedule 4

ENFORTUMAB VEDOTIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ENFUVIRTIDE
Schedule 4

ENHANCING AGENTS
cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING
Appendix A, clause 1

ENOBOSARM
Schedule 4
Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)

ENOXACIN
Schedule 4

ENOXAPARIN
Schedule 4

ENOXIMONE
Schedule 4

ENPROSTIL
Schedule 4

ENROFLOXACIN
Schedule 4

ENTACAPONE
Schedule 4

ENTECAVIR
Schedule 4

ENTRECTINIB
Schedule 4

ENZALUTAMIDE
Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

EPHEDRA spp.
Schedule 4

EPHEDRINE
cross reference: EPHEDRA
Schedule 4
Appendix D, clause 5
Appendix F, clause 4

EPHENIDINE
cross reference: CAS No. 60951-19-1, EPHENIDINE HYDROCHLORIDE (CAS No. 6272-

Authorised Version F2026L01327 registered 30/09/2026

97-5)
Schedule 9

EPICHLOROHYDRIN
Schedule 7
Appendix F, clause 4
Appendix J, clause 1

EPICILLIN
Schedule 4

EPIDERMAL GROWTH FACTOR
cross reference: SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
Schedule 7
Appendix G, clause 1
Appendix J, clause 1

EPINASTINE
Schedule 4

EPINEPHRINE
cross reference: ADRENALINE

EPIRUBICIN
Schedule 4

EPITIOSTANOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

EPLERENONE
Schedule 4

EPLONTERSEN
cross reference: EPLONTERSEN SODIUM
Schedule 4

EPOETINS
cross reference: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Schedule 4
Appendix D, clause 5

EPOPROSTENOL
Schedule 4

EPOXICONAZOLE
Schedule 5

EPOXY RESINS, LIQUID
cross reference: RESINS
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

EPRINOMECTIN
Schedule 7
Schedule 6
Schedule 5

EPROSARTAN
Schedule 4

EPSIPRANTEL
Appendix B, clause 3

EPTC
Schedule 6

EPTIFIBATIDE
Schedule 4

EPYRIFENACIL
Schedule 5

EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
cross reference: IMMUNOGLOBULINSERGOMETRINE
Schedule 4

ERENUMAB
Schedule 4

ERGOT
Schedule 4

ERGOTAMINE
Schedule 4

ERGOTOXINE
Schedule 4

ERIBULIN MESILATE
cross reference: ERIBULIN MESYLATE
Schedule 4

ERLOTINIB
Schedule 4

ERTAPENEM
Schedule 4

ERTUGLIFLOZIN
Schedule 4

ERYSIMUM spp.
Schedule 4
Appendix G, clause 1

ERYTHRITYL TETRANITRATE
Schedule 3

Authorised Version F2026L01327 registered 30/09/2026

ERYTHROMYCIN
Schedule 4

ERYTHROPOIETIN
Schedule 4
Appendix D, clause 5

ERYTHROPOIETINS
Schedule 4
Appendix D, clause 5

ESBIOTHRIN
Schedule 6
Schedule 5

ESCITALOPRAM
Schedule 4

ESFENVALERATE
Schedule 6
Schedule 5

ESKETAMINE
Schedule 8
Appendix K, clause 1

ESLICARBAZEPINE ACETATE
Schedule 4

ESMOLOL
Schedule 4

ESOMEPRAZOLE
Schedule 4
Schedule 2

ESTETROL MONOHYDRATE
Schedule 4

ESTRADIOL
Schedule 5
Schedule 4
Appendix G, clause 1

ESTRAMUSTINE
Schedule 4

ESTRIOL
Schedule 4

ESTROGENS
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ESTRONE
Schedule 4
Appendix G, clause 1

ESTROPIPATE
cross reference: PIPERAZINE ESTRONE SULFATE
Schedule 4

ETACONAZOLE
Schedule 7
Appendix J, clause 1

ETACRYNIC ACID
Schedule 4

ETAFEDRINE
Schedule 2

ETANERCEPT
Schedule 4

ETHACRYNIC ACID
cross reference: ETACRYNIC ACID

ETHALFLURALIN
Schedule 7

ETHAMBUTOL
Schedule 4

ETHAMETSULFURON-METHYL
Appendix B, clause 3

ETHAMIVAN
Schedule 4

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND *N*-METHYLMETHANAMINE
cross reference: *N*-METHYLMETHANAMINE
Schedule 5

ETHANOL
cross reference: ETHYL ALCOHOL

ETHANOLAMINE
cross reference: MONOETHANOLAMINE

ETHCHLORVYNOL
Schedule 4

ETHEPHON
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ETHER
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

ETHERIFIED STARCHES
Appendix A

ETHINAMATE
Schedule 4

ETHINYLESTRADIOL
Schedule 4

ETHINYLOESTRADIOL
cross reference: ETHINYLESTRADIOL

ETHIOFENCARB
Schedule 6

ETHION
Schedule 7

ETHIONAMIDE
Schedule 4

ETHISTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHOATE-METHYL
Schedule 6

ETHOFUMESATE
Schedule 5

ETHOGLUCID
Schedule 4

ETHOHEPTAZINE
Schedule 4

ETHOPABATE
Appendix B, clause 3

ETHOPROPAZINE
Schedule 4

ETHOPROPHOS
cross reference: LINSEED OIL
Schedule 7
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ETHOSUXIMIDE
Schedule 4

ETHOTOIN
Schedule 4

2-ETHOXYETHANOL
Schedule 7
Appendix F, clause 4

ETHOXYETHYLMERCURIC CHLORIDE
Appendix F, clause 4

ETHOXYQUIN
Schedule 5

ETHOXYSULFURON
Schedule 5

ETHOXZOLAMIDE
Schedule 4

ETHYL ACETATE
Appendix B, clause 3

ETHYL ALCOHOL
Appendix B, clause 3

ETHYL BROMIDE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYL BUTYRATE
Appendix B, clause 3

ETHYL CHLORIDE
Schedule 4

ETHYL FORMATE
Schedule 6

ETHYL LACTATE
Appendix B, clause 3

ETHYL METHACRYLATE
Schedule 5
Appendix F, clause 4

ETHYLAMFETAMINE
cross reference: ETHYLAMPHETAMINE
Schedule 8

ETHYLBUTYLACETYL-
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

ETHYLDIENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHYLENE CHLOROHYDRIN
Schedule 6
Appendix F, clause 4

ETHYLENE DIBROMIDE
Schedule 7
Appendix J, clause 1

ETHYLENE DICHLORIDE
Schedule 6

ETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1)
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3

ETHYLENE GLYCOL MONOALKYL ETHERS
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYLENE OXIDE
Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

ETHYLESTRENOL
cross reference: ETHYLOESTRENOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHYLHEXANEDIOL
cross reference: ETHOHEXADIOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2-ETHYLHEXANOIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYLMERCURIC CHLORIDE
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

_N_-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE
cross reference: _N_-ETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9)
Schedule 9

ETHYLMETHYLTHIAMBUTENE
cross reference: CAS No: 441-61-2
Schedule 9

ETHYLMORPHINE
Schedule 8
Schedule 4
Appendix K, clause 1

ETHYLOESTRENOL
cross reference: ETHYLESTRENOL

ETHYNODIOL
cross reference: ETYNODIOL

ETICYCLIDINE
cross reference: PCE (CAS No. 2201-15-2)
Schedule 9

ETIDOCAINE
Schedule 4

ETIDRONIC ACID
cross reference: ETIDRONATE DISODIUM
Schedule 4

ETILEFRIN
Schedule 4

ETIPROSTON
Schedule 4

ETODESNITAZENE
cross reference: CAS No. 14030-76-3, ETAZENE
Schedule 9

ETODOLAC
Schedule 4

ETOFENAMATE
Schedule 4
Schedule 2

ETOFENPROX
Appendix B, clause 3

ETOMIDATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ETONITAZENE
cross reference: CAS No. 911-65-9
Schedule 9

ETONITAZEPIPNE
cross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE
Schedule 9

ETONITAZEPYNE
cross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE
Schedule 9

ETONOGESTREL
Schedule 4

ETOPOSIDE
Schedule 4

ETORICOXIB
Schedule 4

ETORPHINE
cross reference: CAS No. 14521-96-1
Schedule 9

ETOXAZOLE
Appendix B, clause 3

ETOXERIDINE
cross reference: CAS No. 469-82-9
Schedule 9

ETRANACOGENE DEZAPARVOVEC
Schedule 4

ETRASIMOD
Schedule 4

ETRAVIRINE
Schedule 4

ETRETINATE
Schedule 4
Appendix D, clause 5
Appendix F, clause 4
Appendix L, clause 2

ETRIDIAZOLE
Schedule 5

ETRIMFOS
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

ETYNODIOL
cross reference: ETHYNODIOL
Schedule 4

EUBACTERIUM sp. strain DSM11798
Appendix B, clause 3

EUCALYPTUS OIL
Schedule 6
Appendix E, clause 3

EUGENOL
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

EUPATORIUM CANNABINUM
cross reference: HEMP AGRIMONY
Schedule 10

EVEROLIMUS
Schedule 4

EXEMESTANE
Schedule 4

EXENATIDE
Schedule 4

EXPLOSIVES
Appendix A, clause 1

EXTRACT OF LEMON EUCALYPTUS
cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS
Schedule 5

EZETIMIBE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

F

FAMCICLOVIR
Schedule 4
Schedule 3
Appendix H, clause 1

FAMOTIDINE
Schedule 4
Schedule 2
Appendix F, clause 4

FAMOXADONE
Schedule 6

FAMPHUR
Schedule 7
Schedule 6

FARFUGIUM JAPONICUM
Schedule 10

FARICIMAB
Schedule 4
Appendix L, clause 2

FASORACETAM
cross reference: RACETAMS
Schedule 4

FEBANTEL
Schedule 6

FEBUXOSTAT
Schedule 4

FEDRATINIB
Schedule 4

FELBINAC
Schedule 4
Schedule 2

FELODIPINE
Schedule 4

FELYPRESSIN
Schedule 4

FENAMIPHOS
Schedule 7
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

FENARIMOL
Schedule 5

FENAZAFLOR
Schedule 6

FENBENDAZOLE
Schedule 5
Schedule 4

FENBUCONAZOLE
Schedule 5

FENBUFEN
Schedule 4

FENBUTATIN OXIDE
Schedule 6

FENCAMFAMIN
Schedule 4

FENCHLORAZOLE-ETHYL
Schedule 5

FENCHLORPHOS
Schedule 6

FENCLOFENAC
Schedule 4

FENETYLLINE
cross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892-80-4)
Schedule 9

FENFLURAMINE
Schedule 4
Appendix K, clause 1

FENFURAM
Appendix B, clause 3

FENHEXAMID
Appendix B, clause 3

FENITROTHION

FENMEZODITIAZ
Schedule 6

FENNEL OIL
Schedule 5
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

FENOFIBRATE
Schedule 4

FENOLDOPAM
Schedule 4

FENOPROFEN
Schedule 4

FENOPROP
Schedule 5

FENOTEROL
Schedule 4

FENOXACRIM
Schedule 7
Schedule 6

FENOXAPROP-ETHYL
Schedule 5

FENOXAPROP-*p*-ETHYL
Schedule 5

FENOXYCARB
Appendix B, clause 3

FENPIPRAMIDE
Schedule 4

FENPIPRANE
Schedule 4

FENPROPIDIN
Schedule 6

FENPROPOREX
Schedule 4

FENPROSTALENE
Schedule 4

FENPYRAZAMINE
Schedule 5

FENPYROXIMATE
Schedule 6

FENSON
Schedule 5

FENSULFOTHION
Schedule 7

Authorised Version F2026L01327 registered 30/09/2026

FENTANYL
Schedule 8
Appendix K, clause 1

FENTEROL
Appendix F, clause 4

FENTHION
Schedule 7
Schedule 6
Schedule 5

FENTHION-ETHYL
Schedule 7

FENVALERATE
Schedule 6

FERRIC DERISOMALTOSE
Schedule 4

FEXOFENADINE
Schedule 4
Schedule 2

FEZOLINETANT
Schedule 4

FIBRINOLYSIN
Schedule 4

FIBROBLAST GROWTH FACTORS
Schedule 4
Appendix D, clause 5

FIDAXOMICIN
Schedule 4

FILGOTINIB
Schedule 4

FILGRASTIM
Schedule 4

FINASTERIDE
Schedule 4

FINERENONE
Schedule 4
Appendix L, clause 2

FINGOLIMOD
Schedule 4
Appendix L, clause 2

Authorised Version F2026L01327 registered 30/09/2026

FIPRONIL
Schedule 6
Schedule 5

FIROCOXIB
Schedule 4

FLAMPROP-METHYL
Schedule 5

FLAMPROP-M-METHYL
Schedule 5

FLAVOXATE
Schedule 3

FLAZASULFURON
Schedule 5

FLECAINIDE
Schedule 4

FLEROXACIN
Schedule 4

FLOCOUMAFEN
Schedule 7
Schedule 6

FLOCTAFENINE
Schedule 4

FLONICAMID
Schedule 6

FLORASULAM
Schedule 5

FLORFENICOL
Schedule 4

FLORPYRAUXIFEN-BENZYL
Appendix B, clause 3

FLORYLPICOXAMID
Appendix B, clause 3

FLUANISONE
Schedule 4

FLUAZAINDOLIZINE
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

FLUAZIFOP-BUTYL
Schedule 6

FLUAZIFOP-*p*-BUTYL
Schedule 6

FLUAZINAM
Schedule 6

FLUAZURON
Schedule 5

FLUBENDAZOLE
Schedule 5

FLUBENDIAMIDE
Schedule 5

FLUBROMAZEPAM
cross reference: CAS No. 2647-50-9
Schedule 9

FLUBROMAZOLAM
cross reference: CAS No. 612526-40-6
Schedule 9

FLUCHLORALIN
Schedule 5

FLUCLOROLONE
Schedule 4

FLUCLOXACILLIN
Schedule 4

FLUCOFURON
Schedule 7
Schedule 6

FLUCONAZOLE
Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1

FLUCYTHRINATE
Schedule 7

FLUCYTOSINE
Schedule 4

FLUDARABINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

FLUDIOXONIL
Schedule 5

FLUDROCORTISONE
Schedule 4

FLUENSULFONE
Schedule 6

FLUFENAMIC ACID
Schedule 4

FLUFENOXURON
Appendix B, clause 3

FLUMAZENIL
Schedule 4

FLUMETASONE
cross reference: FLUMETHASONE
Schedule 4

FLUMETHASONE
cross reference: FLUMETASONE

FLUMETHIAZIDE
Schedule 4

FLUMETHRIN
Schedule 6
Schedule 5

FLUMETSULAM
Appendix B, clause 3

FLUMICLORAC PENTYL
Schedule 5

FLUMIOXAZIN
Schedule 7
Schedule 6

FLUNISOLIDE
Schedule 4

FLUNITAZENE
cross reference: CAS No. 2249-36-7, FLUNITAZENE HYDROCHLORIDE (CAS No. 2728-91-8)
Schedule 9

FLUNITRAZEPAM
Schedule 8
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

FLUNIXIN MEGLUMINE
Schedule 4

FLUOCINOLONE
Schedule 4

FLUOCINONIDE
Schedule 4

FLUOCORTIN
Schedule 4

FLUOCORTOLONE
Schedule 4

FLUOMETURON
Appendix B, clause 3

FLUOPICOLIDE
Appendix B, clause 3

FLUOPYRAM
Schedule 5

FLUORESCEIN
Schedule 4

FLUORIDES
cross reference: SILICOFLUORIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 3
Schedule 2
Appendix E, clause 3
Appendix F, clause 4
Appendix H, clause 1

FLUOROACETAMIDE
Schedule 7

FLUOROACETIC ACID
Schedule 7
Appendix J, clause 1

FLUOROMETHOLONE
Schedule 4

4-FLUORO-*N*-METHYLAMFETAMINE
cross reference: 4-FLUORO-*N*-METHYLAMPHETAMINE, 4-FLUORO-*N*-METHAMFETAMINE (CAS No. 351-03-1)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE
cross reference: AM-694 (CAS No. 335161-03-0)
Schedule 9

FLUOROURACIL
Schedule 4

FLUOXETINE
Schedule 4

FLUOXYMESTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

FLUPENTIXOL
cross reference: FLUPENTHIXOL
Schedule 4
Appendix K, clause 1

FLUPHENAZINE
Schedule 4
Appendix K, clause 1

FLUPROPANATE
cross reference: TETRAPION
Schedule 6

FLUPROSTENOL
Schedule 4

FLUPYRADIFURONE
Schedule 6

FLUQUINCONAZOLE
Schedule 6

FLURALANER
cross-reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE
Schedule 5
Schedule 4

FLURANDRENOLONE
Schedule 4

FLURAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

FLURBIPROFEN
Schedule 4
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

FLUOROACETAMIDE
Appendix J, clause 1

FLUOXAPIPROLIN
Appendix B, clause 3

FLUROXENE
Schedule 4

FLUROXYPYR
Appendix B, clause 3

FLUSILAZOL
Schedule 6

FLUSPIRILENE
Schedule 4

FLUTAMIDE
Schedule 4

FLUTICASONE
cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE
Schedule 4

FLUTICASONE FUROATE
cross reference FLUTICASONE

FLUTICASONE PROPIONATE
cross reference: FLUTICASONE
Schedule 4
Schedule 2

FLUTOLANIL
Appendix B, clause 3

FLUTRIAFOL
Schedule 6

FLUVALINATE
Schedule 6
Schedule 5

FLUVASTATIN
Schedule 4

FLUVOXAMINE
Schedule 4

FLUXAPYROXAD
Schedule 5

FOLIC ACID
Schedule 4
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

FOLINIC ACID
cross reference: CALCIUM FOLINATE
Schedule 4
Schedule 2

FOLLICLE-STIMULATING HORMONE
Schedule 4
Appendix D, clause 1

FOLLISTATIN
Schedule 4
Appendix D, clause 5

FOLLITROPIN ALFA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, clause 1

FOLLITROPIN BETA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, clause 1

FOLLITROPIN DELTA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, clause 1

FOLPET
Schedule 6

FOMEPIZOLE
Schedule 4

FOMESAFEN SODIUM
Schedule 6

FOMIVIRSEN
Schedule 4

FONDAPARINUX
Schedule 4

FOOD
Appendix A, clause 1

FORAMSULFURON
Schedule 5

FORCHLORFENURON
Appendix B, clause 3

FORMALDEHYDE
cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE

Authorised Version F2026L01327 registered 30/09/2026

FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0)
Schedule 10
Schedule 6
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

FORMALDEHYDE CONDENSATION PRODUCT
Schedule 6

FORMEBOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

FORMESTANE
Schedule 4

FORMETANATE
Schedule 7

FORMIC ACID
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

FORMOTEROL
Schedule 4

FORMOTHION
Schedule 6

FOSAMPRENAVIR
Schedule 4

FOSAPREPITANT
Schedule 4

FOSCARNET
Schedule 4

FOSFESTROL
cross reference: DIETHYLSTILBESTROL DIPHOSPHATE
Schedule 4

FOSFOMYCIN
Schedule 4

FOSINOPRIL
Schedule 4

FOSNETUPITANT
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

FOSPHENYTOIN
Schedule 4

FOSPIRATE
Schedule 6
Schedule 5

FOSTEMSAVIR
Schedule 4

FOSTHIAZATE
Schedule 7

FOTEMUSTINE
Schedule 4

FRAMYCETIN
Schedule 4

FRITTED GLAZING OR ENAMELLING PREPARATIONS
Appendix A, clause 1

FRUQUINTINIB
Schedule 4

FULLERS EARTH
Appendix B, clause 3

FULVESTRANT
Schedule 4

FUMAGILLIN
Schedule 6

FUNGAL PROTEASE derived from Aspergillus niger
Appendix B, clause 3

FURALAXYL
Schedule 5

FURALTADONE
Schedule 4

FURATHIOCARB
Schedule 7
Schedule 5

FURAZABOL
Schedule 4

FURAZOLIDONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

Authorised Version F2026L01327 registered 30/09/2026

FURETHIDINE
cross reference: CAS No. 2385-81-1
Schedule 9

FURFURAL
cross reference: 2-FURANCARBOXALDEHYDE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

FUROSEMIDE
cross reference: FRUSEMIDE
Schedule 4

FUSIDIC ACID
Schedule 4

FUTIBATINIB
Schedule 4

FUZAPLADIB SODIUM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

G

GABAPENTIN
Schedule 4
Appendix K, clause 1

GADOQUATRANE
Schedule 4

GALANTAMINE
Schedule 4

GALANTHUS spp.
Schedule 4

GALCANEZUMAB
Schedule 4

GALLAMINE
Schedule 4

GALSULFASE
Schedule 4

GAMMA BUTYROLACTONE
cross reference: CAS No. 96-48-0
Schedule 10

GAMMA HYDROXYBUTYRATE
cross reference: 4-HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE
Schedule 9

GAMMA-CYHALOTHRIN
Schedule 7
Schedule 5

GANCICLOVIR
Schedule 4

GANIRELIX
Schedule 4

GARADACIMAB
Schedule 4

GATIFLOXACIN
Schedule 4

GEFITINIB
Schedule 4

GELATIN – SUCCINYLATED
Appendix A

Authorised Version F2026L01327 registered 30/09/2026

GELSEMIUM SEMPERVIRENS
Schedule 2
Appendix G, clause 1

GEMCITABINE
Schedule 4
Appendix K, clause 1

GEMEPROST
Schedule 4

GEMFIBROZIL
Schedule 4

GEMIFLOXACIN
Schedule 4

GEMTUZUMAB OZOGAMICIN
Schedule 4

GENTAMICIN
Schedule 4

GENTIAN VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET

GEPOTIDACIN
cross reference: GEPOTIDACIN MESILATE
Schedule 4

GERANIUM OIL
Appendix B, clause 3

GESTODENE
Schedule 4

GESTONORONE
Schedule 4

GESTRINONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

GHRH INJECTABLE PLASMID
Schedule 4

GIBBERELLIC ACID
Appendix B, clause 3

GILTERITINIB
Schedule 4

GITALIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

GIVOSIRAN
Schedule 4

GLASS
cross reference: CRYSTAL WARE
Appendix A, clause 1

GLATIRAMER ACETATE
Schedule 4

GLAZED POTTERY
Appendix A, clause 1

GLECAPREVIR
Schedule 4

GLIBENCLAMIDE
Schedule 4

GLIBORNURIDE
Schedule 4

GLICLAZIDE
Schedule 4

GLIMEPIRIDE
Schedule 4

GLIPIZIDE
Schedule 4

GLIPTINS
cross reference: DIPEPTIDYL PEPTIDASE-4 (DDP-4) INHIBITORS
Schedule 4

GLISOXEPIDE
Schedule 4

GLOFITAMAB
Schedule 4

GLUCAGON
Schedule 3
Appendix G, clause 1
Appendix H, clause 1

α-GLUCANASE derived from *Aspergillus niger*
Appendix B, clause 3

GLUFOSINATE-AMMONIUM
Schedule 5

GLUTARAL
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

Schedule 2
Appendix E, clause 3
Appendix F, clause 4

GLUTARALDEHYDE
cross reference: GLUTARAL

GLUTATHIONE
Schedule 4

GLUTETHIMIDE
Schedule 4
Appendix D, clause 5
Appendix K, clause 1

GLYCERYL THIOGLYCOLLATE
Schedule 6

GLYCERYL TRINITRATE
Schedule 4
Schedule 3
Appendix G, clause 1
Appendix H, clause 1

GLYCOLIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

GLYCOPYRRONIUM
Schedule 4

GLYCOSYLATED HYDROQUINONE
cross reference: HYDROQUINONE

GLYMIDINE
Schedule 4

GLYOXYLIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

GLYPHOSATE
Schedule 5

GnRH VACCINE
Schedule 4

GOLIMUMAB
Schedule 4

GONADORELIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

GONADOTROPHIC HORMONES
Schedule 4

GOSERELIN
Schedule 4

GRAMICIDIN
Schedule 4

GRANISETRON
Schedule 4

GRAPIPRANT
Schedule 4

GRAZOPREVIR
Schedule 4

GREPAFLOXACIN
Schedule 4

GRISEOFULVIN
Schedule 4

GROWTH HORMONE RELEASING HORMONES *(GHRHs)
Schedule 4
Appendix D, clause 5

GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6)
Schedule 4
Appendix D, clause 5

GROWTH HORMONE RELEASING PEPTIDE *(GHRPs)
Schedule 4
Appendix D, clause 5

GROWTH HORMONE SECRETAGOGUES *(GHSs)
Schedule 4
Appendix D, clause 5

GUAIFENESIN
cross reference: PARACETAMOL
Schedule 4
Schedule 2

GUAIPHENESIN
cross reference: GUAIFENESIN

GUANABENZ
Schedule 4

GUANACLINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

GUANETHIDINE
Schedule 4

GUANFACINE
Schedule 4
Appendix K, clause 1

GUANIDINE
Schedule 6
Schedule 4
Appendix E, clause 3

GUAZATINE
Schedule 6

GUSELKUMAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

H

HACHIMYCIN
Schedule 4

HAEMATIN
Schedule 4

HAEMOPHILUS INFLUENZAE VACCINE
Schedule 4

HALAUXIFEN METHYL
Appendix B, clause 3

HALCINONIDE
Schedule 4

HALOFANTRINE
Schedule 4

HALOFENATE
Schedule 4

HALOFUGINONE
Schedule 7
Schedule 4
Appendix J, clause 1

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS
cross reference: DIBENZODIOXINS, HALOGENATED - DIBENZOFURANS, HALOGENATED, DIOXINS
Schedule 7
Appendix J, clause 1

HALOPERIDOL
cross reference: BUTYPHENONES
Schedule 4
Appendix G, clause 1
Appendix K, clause 1

HALOSULFURON-METHYL
Schedule 5

HALOTHANE
Schedule 4

HALOXON
Schedule 6

HALOXYFOP
Schedule 6

HARMALA ALKALOIDS
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

HC RED 13
cross reference: 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL

HC VIOLET 1
cross reference: 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HCB
Schedule 7
Appendix J, clause 1

HELIONAL
Appendix B, Part 3

HELIOTROPIUM spp.
Schedule 10

HEMEROCALLIS
Schedule 4

HEMP SEED OIL
cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS

HEPARINS
Schedule 4

HEPATITIS A VACCINE
Schedule 4

HEPATITIS B VACCINE
Schedule 4

HEPTACHLOR
Schedule 6

HEROIN
cross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0)
Schedule 9

HETACILLIN
Schedule 4

HEXACHLOROPHANE
cross reference: HEXACHLOROPHENE

HEXACHLOROPHENE
cross reference: HCB
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

HEXACONAZOLE
Schedule 5

HEXAFLURON
Appendix B, clause 3

HEXAMETHONIUM
Schedule 4

HEXARELIN
Schedule 4
Appendix D, clause 5

HEXAZINONE
Schedule 6
Schedule 5

HEXETIDINE
Schedule 4

HEXLOXYETHANOL
Appendix F, clause 4

HEXOBENDINE
Schedule 4

HEXOCYCLIUM
Schedule 4

HEXOPRENALINE
Schedule 4

HEXYL ACETATE
Appendix B, clause 3

HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)
Schedule 4

HEXYL CINNAMALDEHYDE
Appendix B, clause 3

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN
cross reference: PARAHEXYL (CAS No. 117-51-1)
Schedule 9

HEXYLOXYETHANOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HEXYTHIAZOX
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

HISTAMINE
Schedule 4

HMG-CoA REDUCTASE INHIBITORS
cross reference: STATINS
Schedule 4

HOMATROPINE
Schedule 4

HOMOBRASSINOLIDE
Schedule 5

HUMAN BLOOD PRODUCTS
cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS
Appendix A, clause 1

HUMAN CHORIONIC GONADOTROPHIN
Schedule 4

HUMAN OSTEOGENIC PROTEIN-1 (OP-1)
Appendix B, clause 3

HUMAN PAPILLOMAVIRUS VACCINE
Schedule 4

HYALURONIC ACID
Schedule 4

HYALURONIC ACID AND ITS POLYMERS
Schedule 4

HYDRALAZINE
Schedule 4

HYDRAMETHYLNON
Schedule 6
Schedule 5

HYDRARGAPHEN
Schedule 4

HYDRAZINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HYDROCARBONS LIQUID AROMATIC
cross reference: AROMATIC EXTRACT OILS,
Schedule 7
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

HYDROCARBONS, LIQUID
cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE
Schedule 5
Appendix E, clause 3

HYDROCHLORIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROCHLOROTHIAZIDE
Schedule 4

HYDROCODONE
Schedule 8
Appendix K, clause 1

HYDROCORTISONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

HYDROCORTISONE ACETATE
Schedule 3
Schedule 2

HYDROCYANIC ACID
cross reference: CYANIDES, APRICOT KERNELS
Schedule 7
Schedule 4
Appendix F, clause 4
Appendix G, clause 1
Appendix J, clause 1

HYDROFLUMETHIAZIDE
Schedule 4

HYDROFLUORIC ACID
cross reference: HYDROGEN FLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

Authorised Version F2026L01327 registered 30/09/2026

HYDROGEN PEROXIDE
cross reference: CAS No. 7722-84-1
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROGEN SULFIDE
Schedule 7

HYDROMORPHINOL
Schedule 8

HYDROMORPHONE
Schedule 8
Appendix K, clause 1

HYDROPRENE
Appendix B, clause 3

HYDROQUINONE
cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

HYDROSILICOFLUORIC ACID
cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID
Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

4-HYDROXYBUTANOIC ACID
cross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2)
Schedule 9

HYDROXYCARBAMIDE
Schedule 4

HYDROXYCHLOROQUINE
Schedule 4

2-[(1*R*,3*S*)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL
cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS No. 70434-82-1)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

HYDROXYEPHEDRINE
Schedule 4

4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL
cross reference: 3-NITRO-*p*-HYDROXYETHYLAMINOPHENOL

2-HYDROXYETHYL METHACRYLATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

[7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
cross reference: BASIC RED 76 (CAS No. 68391-30-0)

HYDROXYPETHIDINE
cross reference: CAS No. 468-56-4
Schedule 9

HYDROXYPHENAMATE
Schedule 4

HYDROXYPROGESTERONE
Schedule 4

HYDROXYPROPYL CELLULOSE
Appendix B, clause 3

2-HYDROXYPROPYL METHACRYLATE
Schedule 5

8-HYDROXYQUINOLINE
cross reference: OXYQUINOLINE

HYDROXYSTENOZOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

HYDROXYUREA
cross reference: HYDROXYCARBAMIDE

HYDROXYZINE
Schedule 4
Appendix K, clause 1

HYGROMYCIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

HYOSCINE
cross reference: HYOSCINE BUTYLBROMIDE
Schedule 4
Schedule 2
Appendix G, clause 1

HYOSCINE BUTYLBROMIDE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

HYOSCYAMINE
Schedule 4
Schedule 2
Appendix G, clause 1

HYOSCYAMUS NIGER
Schedule 4
Schedule 2
Appendix G, clause 1

HYPOTHALAMIC RELEASING FACTORS
Schedule 4
Appendix G, clause 1

HYPROMELLOSE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

I

IBAFLOXACIN
Schedule 4

IBANDRONIC ACID
Schedule 4

IBOGAINE
Schedule 4

IBOTENIC ACID
cross reference: MUSCIMOL
Schedule 9

IBRITUMOMAB
Schedule 4

IBRUTINIB
Schedule 4

IBUFENAC
Schedule 4

IBUPROFEN
cross reference: PARACETAMOL
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

IBUTAMOREN
cross reference: MK-677, NUTROBAL
Schedule 4
Appendix D, clause 5

IBUTEROL
Schedule 4

IBUTILIDE
Schedule 4

ICATIBANT
Schedule 4

ICODEXTRIN
Appendix B, clause 3

IDARUBICIN
Schedule 4

IDARUCIZUMAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

IDEBENONE
Schedule 4

IDOXURIDINE
Schedule 4

IDURSULFASE
Schedule 4

IFOSFAMIDE
Schedule 4

ILOPROST
Schedule 4

ILUNOCITINIB
Schedule 4

IMATINIB
Schedule 4

IMAZALIL
cross reference: ENILCONAZOLE
Schedule 5

IMAZAMOX
Schedule 5

IMAZAPIC
Schedule 5

IMAZAPYR
Schedule 5

IMAZETHAPYR
Schedule 5

IMDEVIMAB
Schedule 4

IMEPITOIN
Schedule 4

IMIDACLOPRID
Schedule 6
Schedule 5

IMIDAPRIL
Schedule 4

IMIDOCARB
Schedule 6

IMIGLUCERASE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

IMINOCTADINE TRIALBESILATE
Schedule 6

IMIPENEM
Schedule 4

IMIPRAMINE
Schedule 4
Appendix K, clause 1

IMIPROTHRIN
Schedule 6
Schedule 5

IMIQUIMOD
Schedule 4

IMLIFIDASE

IMLUNESTRANT
Schedule 4

IMMUNOGLOBULINS
cross reference: EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, POLYCLONAL ANTIBODIES
Schedule 4

***IN VITRO* DIAGNOSTIC AND ANALYTICAL PREPARATIONS**
Appendix A, clause 1

INAVOLISIB
Schedule 4

INCLISIRAN
Schedule 4

INDACATEROL
Schedule 4

INDANAZOLINE
Schedule 2

INDAPAMIDE
Schedule 4

INDAZIFLAM
Schedule 6

INDINAVIR
Schedule 4

INDOLE-3-ACETIC ACID
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

INDOMETACIN
Schedule 4
Schedule 2
Appendix G, clause 1

INDOMETHACIN
cross reference: INDOMETACIN

INDOPROFEN
Schedule 4

INDORAMIN
Schedule 4

INDOXACARB
Schedule 6
Schedule 5

INEBILIZUMAB
Schedule 4

INFIGRATINIB
Schedule 4

INFLIXIMAB
Schedule 4

INFLUENZA AND CORYZA VACCINES
cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ
Schedule 4

INGENOL MEBUTATE
Schedule 4

INOTUZUMAB OZOGAMICIN
Schedule 4

INOSITOL NICOTINATE
Schedule 3

INPYRFLUXAM
Schedule 6

INSULIN DEGLUDEC
Schedule 4

INSULIN GLARGINE
Schedule 4

INSULIN-LIKE GROWTH FACTOR I
Schedule 4

INSULIN-LIKE GROWTH FACTORS
Schedule 4
Appendix D, clause 5

Authorised Version F2026L01327 registered 30/09/2026

INSULINS
Schedule 4

INTERFERONS
Schedule 4

INTERLEUKINS
Schedule 4

INTRAOCULAR VISCOELASTIC PRODUCTS
Appendix A, clause 1

IODINE
cross reference: IODOPHORS
Schedule 6
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

IODOMETHANE
Schedule 7
Appendix J, clause 1

IODOPHORS
cross reference: IODINE
Schedule 6
Appendix E, clause 3

3-IODO-2-PROPYNYL BUTYL CARBAMATE
cross reference: IODOCARB
Schedule 6
Schedule 5

IODOSULFURON-METHYL-SODIUM
Schedule 5

IODOTHIOURACIL
Schedule 4

IOXYNIL
Schedule 6

IPAMORELIN
Schedule 4,
Appendix D, clause 5

IPCONAZOLE
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

IPFLUFENOQUIN
Appendix B, Part 3

IPILIMUMAB
Schedule 4

IPRATROPIUM
Schedule 4
Schedule 2

IPRATROPIUM BROMIDE
Appendix F, clause 4

IPRIFLAVONE
Schedule 4

IPRINDOLE
Schedule 4

IPRODIONE
Appendix B, clause 3

IPRONIAZID
Schedule 4

IPTACOPAN
Schedule 4

IRBESARTAN
Schedule 4

IRINOTECAN
Schedule 4

IRON COMPOUNDS
cross reference: IRON OXIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 2

ISAVUCONAZOLE
Schedule 4
Appendix L, clause 2

ISETHIONATE
Appendix B, clause 3

ISOAMINILE
Schedule 4

ISOAMYL NITRITE
Schedule 4
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

ISOBUTYL NITRITE
Schedule 4
Appendix E, clause 3

ISOCARBOPHOS
Schedule 7

ISOCARBOXAZID
Schedule 4

ISOCONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

ISOCYANATES
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ISOCYCLOSERAM
Schedule 6

ISOETARINE
Schedule 4
ISOEUGENOL
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ISOFENPHOS
Schedule 7

ISOFETAMID
Appendix B, clause 3

ISOFLURANE
Schedule 4

ISOMETHADONE
cross reference: CAS No. 466-40-0
Schedule 9

ISOMETHEPTENE
Schedule 4

ISONIAZID
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ISOPHENIDINE
cross reference: CAS No. 774118-46-6, NPDPA, ISOPHENIDINE HYDROCHLORIDE (CAS No. 6267-56-7), ISOPROPYLPHENIDINE
Schedule 9

ISOPHORONE
Schedule 5
Appendix E, clause 3

ISOPRENALINE
Schedule 4
Appendix F, clause 4

ISOPRENE ALCOHOL
Appendix B, clause 3

ISOPRINOSINE
Schedule 4

ISOPROPAMIDE
Schedule 4
Schedule 2

ISOPROPYL NITRITE
cross reference: CAS No. 541-42-4
Schedule 10

ISOPROTURON
Schedule 7

ISOPYRAZAM
Schedule 6

ISOSORBIDE DINITRATE
Schedule 4
Schedule 3

ISOSORBIDE MONONITRATE
Schedule 4

ISOSTEARYL ALCOHOL ETHOXYLATE
Appendix B, clause 3

ISOTIANIL
Schedule 6

ISOTONITAZENE
cross reference: CAS No. 14188-81-9
Schedule 9

ISOTRETINOIN
Schedule 4
Appendix D, clause 2

Authorised Version F2026L01327 registered 30/09/2026

Appendix F, clause 4
Appendix L, clause 2

ISOXABEN
Schedule 5

ISOXAFLUTOLE
Schedule 5

ISOXICAM
Schedule 4

ISOXSUPRINE
Schedule 4

ISRADIPINE
Schedule 4

ITRACONAZOLE
Schedule 4

IVABRADINE
Schedule 4

IVACAFTOR
Schedule 4

IVERMECTIN
Schedule 7
Schedule 5
Schedule 4

IVOSIDENIB
Schedule 4

IXABEPILONE
Schedule 4

IXAZOMIB
Schedule 4

IXEKIZUMAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

J

JAPANESE ENCEPHALITIS VACCINE
Schedule 4

JUNIPERUS SABINE
cross reference: SAVIN(E)
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

K

KAMBO
cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (*Phyllomedusa bicolor*)
Schedule 10

KANAMYCIN
Schedule 4

KAOLIN
Appendix B, clause 3

KEROSENE
Appendix E, clause 3

KETAMINE
Schedule 8

KETANSERIN
Schedule 4

KETAZOLAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

KETOBEMIDONE
cross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1)
Schedule 9

KETOCONAZOLE
Schedule 4
Schedule 2

KETOPROFEN
Schedule 4
Schedule 3
Appendix H, clause 1

KETOROLAC
Schedule 4

KETOTIFEN
Schedule 4
Schedule 2

KHELLIN
Schedule 4

KINETIN
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

KITASAMYCIN
Schedule 5
Schedule 4

KRATOM
cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE

KRESOXIM-METHYL
Appendix B, clause 3

KUNZEA OIL
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

L

LABETALOL
Schedule 4

LACIDIPINE
Schedule 4

LACOSAMIDE
Schedule 4

LAMBDA-CYHALOTHRIN
Schedule 7
Schedule 6
Schedule 5

LAMIVUDINE
Schedule 4

LAMOTRIGINE
Schedule 4
Appendix K, clause 1

LANADELUMAB
Schedule 4

LANATOSIDES
Schedule 4

LANDIOLOL
Schedule 4

LANREOTIDE
Schedule 4

LANSOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

LANTHANUM
Schedule 4

LAPATINIB
Schedule 4

LARONIDASE
Schedule 4

LAROPIPRANT
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LAROTRECTINIB
Schedule 4

LASALOCID
Schedule 6

LASIODIPLODIA PSEUDOTHEOBROMAE
Schedule 5

LATAMOXEF
Schedule 4

LATANOPROST
Schedule 4

LAUDEXIUM
Schedule 4

LAURETH CARBOXYLIC ACIDS
Schedule 6
Appendix E, clause 3

LAURIC ACID
Appendix B, clause 3

LAUROMACROGOLS
cross reference: LAURETH-9
Schedule 4

LAURYL ALCOHOL
cross reference: 1-DODECANOL
Appendix B, clause 3

LAURYL ISOQUINOLINIUM BROMIDE
Schedule 6
Appendix E, clause 3

LAURYL SULFATE SALTS
cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES
Schedule 6
Appendix E, clause 3

LAVANDIN OIL
cross reference: CAMPHOR
Appendix B, clause 3

LAVENDER OIL
Appendix B, clause 3

LAZERTINIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LEAD COMPOUNDS
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4 (in glazing preparations)
Appendix F, clause 4

LEAD METALLIC
Appendix B, clause 3

LEBRIKIZUMAB
Schedule 4

LECANEMAB
Schedule 4

LEDIPASVIR
Schedule 4

LEFETAMINE
Schedule 4

LEFLUNOMIDE
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

LEMBOREXANT
Schedule 4
Appendix K, clause 1

LEMON OIL
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

LEMONGRASS OIL
Schedule 5

LENACAPAVIR
Schedule 4

LENALIDOMIDE
Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

LENIOLISIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LENOGRASTIM
Schedule 4

LENVATINIB
Schedule 4

LEPIRUDIN
Schedule 4

LEPTAZOL
Schedule 4

LEPTOPHOS
Schedule 7

LEPTOSPERMUM SCOPARIUM OIL
cross reference: MANUKA OIL
Schedule 6
Appendix E, clause 3

LERCANIDIPINE
Schedule 4

LESINURAD
Schedule 4

LETERMOVIR
Schedule 4

LETROZOLE
Schedule 4

LEUPRORELIN
Schedule 4

LEVALLORPHAN
Schedule 4

LEVAMISOLE
Schedule 6
Schedule 5
Schedule 4

LEVAMFETAMINE
cross reference: LEVAMPHETAMINE
Schedule 8

LEVETIRACETAM
cross reference: RACETAMS
Schedule 4
Appendix K, clause 1

LEVOBUNOLOL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LEVOBUPIVACAINE
Schedule 4

LEVOCABASTINE
Schedule 4
Schedule 2
Appendix F, clause 4
Appendix L, clause 2

LEVOCETIRIZINE
Schedule 4
Schedule 2
Appendix K, clause 1

LEVODOPA
Schedule 4

LEVOMEPROMAZINE
cross reference: METHOTRIMEPRAZINE
Schedule 4

LEVOMETHAMFETAMINE
cross reference: LEVOMETHAMPHETAMINE
Schedule 8

LEVOMETHORPHAN
cross reference: CAS No. 125-70-2
Schedule 9

LEVOMILNACIPRAN
Schedule 4

LEVOMORAMIDE
Schedule 8

LEVONORGESTREL
Schedule 4
Schedule 3
Appendix H, clause 1

LEVOPHENACYLMORPHAN
cross reference: CAS No. 10061-32-2
Schedule 9

LEVORPHANOL
Schedule 8

LEVOSIMENDAN
Schedule 4

LIDOCAINE
Schedule 5
Schedule 4
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

LIDOFLAZINE
Schedule 4

LIFITEGRAST
Schedule 4

LIGNOCAINE
cross reference: LIDOCAINE

LIGULARIA DENTATA
Schedule 10

LIME OIL
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

LIMONENE
cross reference: DIPENTENE
Appendix B, clause 3

LINACLOTIDE
Schedule 4

LINAGLIPTIN
Schedule 4

LINCOMYCIN
Schedule 4

LINDANE
cross reference: BHC
Schedule 6
Schedule 5
Schedule 4
Schedule 2

LINEZOLID
Schedule 4

LINOLEIC ACID
Appendix B, clause 3

LINSEED FATTY ACIDS
Appendix B, clause 3

LINURON
Appendix B, clause 3

LIOTHYRONINE
cross reference: TRIIODOTHYRONINE
Schedule 4

LIPEGFILGRASTIM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LIQUORICE, DEGLYCYRRHISINISED
Appendix B, clause 3

LIRAGLUTIDE
Schedule 4

LISDEXAMFETAMINE
Schedule 8

LISINOPRIL
Schedule 4

LISURIDE
Schedule 4

LITHIUM
Schedule 4
Schedule 2

LITHIUM PERFLUOROOCTANE SULFONATE
Schedule 7

LIXISENATIDE
Schedule 4

LOBELIA INFLATA
Schedule 2

LOBELINE
Schedule 2

LODOXAMIDE
Schedule 4
Schedule 2

LOFEXIDINE
Schedule 4

LOGIPARIN
Schedule 4

LOMEFLOXACIN
Schedule 4

LOMUSTINE
Schedule 4

LONAPEGSOMATROPIN
Schedule 4
Appendix D, clause 5

LONCASTUXIMAB TESIRINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LOPERAMIDE
Schedule 4
Schedule 2
Appendix F, clause 4

LOPINAVIR
Schedule 4

LOPRAZOLAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

LORACARBEF
Schedule 4

LORATADINE
Schedule 4
Schedule 2

LORAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

LORLATINIB
Schedule 4

LORMETAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

LOSARTAN
Schedule 4

LOTEPREDNOL
Schedule 4

LOTILANER
Schedule 5

LOXAPINE
Schedule 4

LUBRICANTS
Appendix A, clause 1

LUFENURON
Schedule 5

LUMACAFTOR
Schedule 4

LUMASIRAN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

LUMEFANTRINE
Schedule 4

LUMIRACOXIB
Schedule 4

LURASIDONE
Schedule 4
Appendix K, clause 1

LURBINECTEDIN
Schedule 4

LUSPATERCEPT
Schedule 4

LUTEINISING HORMONE
Schedule 4
Appendix D, clause 1

LYMECYCLINE
Schedule 4

LYSERGIC ACID
cross reference: CAS No. 82-58-6
Schedule 9

LYSERGIDE
cross reference: CAS No. 50-37-3
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

M

MACITENTAN
Schedule 4
Appendix D, clause 6
Appendix L, clause 2

MACROGOLS
Schedule 3
Schedule 2

MACROPHOMINA PHASEOLINA
Schedule 5

MADURAMICIN
Schedule 7
Schedule 5
Appendix J, clause 1

MAFENIDE
Schedule 6
Schedule 4

MAGNESIUM CHLORATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

MAGNESIUM HYDROXIDE
Appendix B, clause 3

MAGNESIUM SULFATE
Schedule 3

MALACHITE GREEN
Schedule 7
Schedule 5

MALATHION
cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS
Schedule 6
Schedule 5
Schedule 3
Appendix E, clause 3

MALEIC HYDRAZIDE
Appendix B, clause 3

MANCOZEB
Schedule 5

MANDESTROBIN
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

MANDIPROPAMID
Schedule 5

MANDRAGORA OFFICINARUM
Schedule 4

MANGANESE DIOXIDE
Appendix B, clause 3

MANNITYL HEXANITRATE
Schedule 3

MANNOMUSTINE
Schedule 4

MAPROTILINE
Schedule 4

MARAVIROC
Schedule 4

MARBOFLOXACIN
Schedule 4

MARIBAVIR
Schedule 4

MARJORAM OIL
Schedule 5
Appendix E, clause 3

MAROPITANT
Schedule 4

MARSTACIMAB
Schedule 4

MATCHES
Appendix A, clause 1

MAVACAMTEN
Schedule 4

MAVACOXIB
Schedule 4

MAZIDOX
Schedule 7

MAZINDOL
Schedule 4
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

MCPA
Schedule 6
Schedule 5

MCPB
cross reference: (4-(4-CHLORO-2-METHYLPHENOXY)BUTANOIC ACID
Schedule 6

MEASLES VACCINE
Schedule 4

MEBANAZINE
Schedule 4

MEBENDAZOLE
Schedule 6
Schedule 5
Schedule 2

MEBEVERINE
Schedule 4

MEBHYDROLIN
Schedule 4
Appendix K, clause 1

MEBOLAZINE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MEBUTAMATE
Schedule 4

MECAMYLAMINE
Schedule 4

MECARBAM
Schedule 7

MECASERMIN
Schedule 4

MECILLINAM
Schedule 4

MECLOCYCLINE
Schedule 4

MECLOFENAMATE
Schedule 4

MECLOFENAMIC ACID
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

MECLOFENOXATE
Schedule 4

MECLONAZEPAM
cross reference: CAS No. 58662-84-3
Schedule 9

MECLOQUALONE
cross reference: CAS No. 340-57-8
Schedule 9

MECLOZINE
cross reference: MECLIZINE
Schedule 4
Schedule 2
Appendix K, clause 1

MECOPROP
Schedule 6
Schedule 5

MECOPROP-P
Schedule 6

MEDAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

MEDETOMIDINE
Schedule 4

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
Appendix A, clause 1

MEDICAL DEVICES
cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA-ARTICULAR FLUIDS, URINARY CATHETERS
Appendix A, clause 1

MEDIGOXIN
cross reference: METHYLDIGOXIN
Schedule 4

MEDROXYPROGESTERONE
Schedule 4

MEDRYSONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

MEFENAMIC ACID
Schedule 4
Schedule 2
Appendix F, clause 4

MEFENOREX
Schedule 4

MEFENPYR-DIETHYL
Schedule 5

MEFENTRIFLUCONAZOLE
Schedule 5

MEFLOQUINE
Schedule 4

MEFLUIDIDE
Schedule 6

MEFRUSIDE
Schedule 4

MEGASPHAERA ELSDENII strain 41125
Appendix B, clause 3

MEGESTROL
Schedule 4

MELAGATRAN
Schedule 4

MELALEUCA OIL
cross reference: TEA TREE OIL
Schedule 6
Appendix E, clause 3

MELANOTAN II
cross reference: α–MELANOCYTE STIMULATING HORMONE
Schedule 4

MELATONIN
Schedule 4
Schedule 3
Appendix H, clause 1

MELENGESTROL
Schedule 4

MELENGESTROL ACETATE
Schedule 6

MELIA AZEDARACH
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

MELOXICAM
Schedule 6
Schedule 4

MELPHALAN
Schedule 4

MEMANTINE
Schedule 4

MENAZON
Schedule 6

MENINGOCOCCAL VACCINE
Schedule 4

MENINGOCOCCAL GROUP B VACCINE
cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein
Schedule 4

MENOTROPHIN
cross reference: HUMAN MENOPAUSAL GONADOTROPHIN
Schedule 4

MEPACRINE
Schedule 4

MEPENZOLATE
Schedule 4

MEPHENESIN
Schedule 4

MEPHENTERMINE
Schedule 4

MEPINDOLOL
Schedule 4

MEPIQUAT
Schedule 5

MEPITIOSTANE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MEPIVACAINE
Schedule 4

MEPROBAMATE
Schedule 4
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

MEPTAZINOL
Schedule 4

MEPYRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

MEQUITAZINE
Schedule 4

MERCAPTAMINE
cross reference: CYSTEAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix K, clause 1

MERCAPTOACETIC ACID
cross reference: THIOGLYCOLIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

2-MERCAPTOETHANOL
Schedule 6

MERCAPTOMERIN
Schedule 4

MERCAPTOPURINE
Schedule 4

MERCURIC CHLORIDE
cross reference: CALOMEL
Schedule 7
Appendix E, clause 3

MERCURIC IODIDE
Appendix E, clause 3

MERCURIC NITRATE
Appendix E, clause 3

MERCURIC OXIDE
Schedule 6
Appendix E, clause 3

MERCURIC POTASSIUM IODIDE
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

MERCURIC THIOCYANATE
Appendix E, clause 3
Appendix F, clause 4

MERCUROCHROME
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3

MERCUROUS CHLORIDE
cross reference: CORROSIVE SUBLIMATE
Appendix E, clause 3

MERCURY
cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE
Schedule 7
Schedule 4
Schedule 2
Appendix G, clause 1
Appendix J, clause 1

MERCURY metallic
Appendix E, clause 3

MERCURY, organic compounds
Appendix E, clause 3

MEROPENEM
Schedule 4

MERSALYL
Schedule 4

MESABOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESALAZINE
Schedule 4

MESNA
Schedule 4

MESOSULFURON-METHYL
Appendix B, clause 3

MESOTRIONE
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

MESTANOLONE
cross reference: ANDROSTALONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESTEROLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESTRANOL
Schedule 4

METACRESOLSULPHONIC ACID
Schedule 6
Appendix F, clause 4

METAFLUMIZONE
Schedule 5

METALAXYL
Schedule 6
Schedule 5

METALDEHYDE
Schedule 6
Schedule 5
Appendix E, clause 3

METAMFETAMINE
cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE**,** METHYLAMPHETAMINE
Schedule 8

METAMITRON
Schedule 6

METANDIENONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METARAMINOL
Schedule 4

METARHIZIUM ANISOPLIAE
Appendix B, clause 3

METARYLPICOXAMID
Schedule 5

METAZACHLOR
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

METAZOCINE
cross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0)
Schedule 9

METCAMIFEN
Appendix B, clause 3

METENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METERGOLINE
Schedule 4

METFORMIN
Schedule 4

METHABENZTHIAZURON
Schedule 5

METHACHOLINE
Schedule 4

METHACRIFOS
Schedule 7
Schedule 6
Appendix J, clause 1

METHACYCLINE
Schedule 4

METHADONE
Schedule 8
Appendix K, clause 1

METHALLENESTRIL
cross reference: METHALLENOESTRIL
Schedule 4

METHAM
cross reference: METHAM SODIUM
Schedule 6

METHAMIDOPHOS
Schedule 7

METHANDRIOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHANOL
cross reference: CAS No. 67-56-1
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHANTHELINIUM
Schedule 4

METHAPYRILENE
Schedule 7

METHAQUALONE
cross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340-56-7)
Schedule 9

METHAZOLAMIDE
Schedule 4

METHAZOLE
Schedule 7

METHCATHINONE
cross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2)
Schedule 9

METHDILAZINE
Schedule 4
Schedule 3
Appendix K, clause 1

METHENAMINE
cross reference: 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE
Schedule 5
Schedule 3
Appendix H, clause 1

METHENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHICILLIN
Schedule 4

METHIDATHION
Schedule 7

METHIMAZOLE
cross reference: THIAMAZOLE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

METHIOCARB
Schedule 7
Schedule 6
Schedule 5

METHISAZONE
Schedule 4

METHIOZOLIN
Schedule 5

METHIXENE
Schedule 4

METHOCARBAMOL
Schedule 4
Appendix K, clause 1

METHOFLUTHRIN
Schedule 5

METHOHEXITONE
Schedule 4

METHOIN
Schedule 4

METHOMYL
cross reference: DENATONIUM BENZOATE
Schedule 7
Schedule 6

METHOPRENE
Appendix B, clause 3

METHOTREXATE
Schedule 4

METHOXAMINE
Schedule 4
Schedule 2
Appendix F, clause 4

METHOXPHENIDINE
cross reference: CAS No. 127529-46-8, METHOXPHENIDINE HYDROCHLORIDE (CAS No. 2055777-48-3), MXP
Schedule 9

METHOXSALEN
Schedule 4

METHOXYCHLOR
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

2-METHOXYETHANOL
Schedule 7
Appendix F, clause 4

METHOXYETHYLMERCURIC ACETATE
Schedule 7
Appendix J, clause 1

METHOXYETHYLMERCURIC CHLORIDE
Schedule 7
Appendix J, clause 1

METHOXYFENOZIDE
Appendix B, clause 3

METHOXYFLURANE
Schedule 4

5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84-8)
Schedule 9

4-METHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1)
Schedule 9

5-METHOXY- α –METHYLTRYPTAMINE
cross reference: 5-MeO-AMT (CAS No. 1137-04-8)
Schedule 9

6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE
Schedule 6

2-METHOXY-5-NITROPHENOL
Schedule 6

METHOXYPHENAMINE
Schedule 2

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE
cross reference: JWH-250 (CAS No. 864445-43-2)
Schedule 9

METHSUXIMIDE
Schedule 4

METHYCLOTHIAZIDE
Schedule 4

METHYL ACETATE
Appendix B, clause 3

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL

Authorised Version F2026L01327 registered 30/09/2026

)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE
cross reference: SALVINORIN A (CAS No. 83729-01-5)
Schedule 9

METHYL AMINOLEVULINATE
Schedule 4

***p*-METHYLAMINOPHENOL**
Schedule 6
Appendix F, clause 4

4-METHYLAMINOREX
cross reference: CAS No. 3568-94-3
Schedule 9

METHYLANDROSTANOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYLATED SPIRIT(S)
cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYL BENZOQUATE
Appendix B, clause 3

METHYL BROMIDE
Schedule 7
Appendix J, clause 1

METHYL CHLORIDE
Appendix F, clause 4

METHYLCHLOROISOTHIAZOLINONE
cross reference: METHYLISOTHIAZOLINONE
Schedule 6
Appendix F, clause 4

METHYLCLOSTEBOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL
Schedule 7
Schedule 6

1-METHYLCYCLOPROPENE
Appendix B, clause 3

METHYLDESORPHINE
cross reference: CAS No. 16008-36-9
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

METHYLDIBROMO GLUTARONITRILE
cross reference: CAS No. 35691-65-7
Schedule 10
Schedule 6
Appendix F, clause 4

METHYLDIHYDROMORPHINE
Schedule 8

METHYLDOPA
Schedule 4

4,4'-METHYLENEBIS[2-CHLOROANILINE]
Schedule 7
Appendix J, clause 1

METHYLENE BISTHIOCYANATE
Schedule 6
Appendix F, clause 4

METHYLENE BLUE
Schedule 7
Schedule 5
Schedule 4

3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 3,4-METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4)
Schedule 9

3,4-METHYLENEDIOXYPYROVALERONE
cross reference: MDPV (CAS No. 687603-66-3)
Schedule 9

METHYLEPHEDRINE
Schedule 2

METHYLERGOMETRINE
Schedule 4

METHYL ETHYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYL ETHYL KETONE OXIME
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

METHYL ETHYL KETONE PEROXIDE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYLEUGENOL
Schedule 6
Appendix E, clause 3,
Appendix F, clause 4

3-METHYLFENTANYL
cross reference: CAS No. 42045-86-3
Schedule 9

METHYLPHENYLPIRACETAM
cross reference: RACETAMS
Schedule 4

METHYL *p*-HYDROXYBENZOATE
Appendix B, clause 3

METHYL ISOAMYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, clause 3

METHYL ISOBUTYL KETONE
cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)
Schedule 5
Appendix E, clause 3

METHYL ISOTHIOCYANATE
Schedule 6

METHYLISOTHIAZOLINONE
cross reference: METHYLCHLOROISOTHIAZOLINONE
Schedule 6
Appendix F, clause 4

METHYLMERCURY
Schedule 4
Appendix G, clause 1

METHYL METHACRYLATE
cross reference: CAS No. 80-62-6
Schedule 10
Schedule 6
Appendix F, clause 4

4-METHYLMETHCATHINONE
cross reference: MEPHEDRONE (CAS No. 1189805-46-6)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE
cross reference: MBDB (CAS No. 135795-90-3)
Schedule 9

***N*- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE**
cross reference: N-HYDROXY MDA (CAS No. 74698-47-8)
Schedule 9

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID
cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9)
Schedule 9

METHYLNALTREXONE
Schedule 4

METHYL NEODECANAMIDE
Schedule 6

6-METHYLNICOTINE
cross-reference: CAS No. 13270-56-9
Schedule 9

METHYLNORBORNYLPYRIDINE
Schedule 6

METHYLONE *(MDMC)
cross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80-8)
Schedule 9

METHYLPENTYNOL
Schedule 4

METHYLPHENIDATE
Schedule 8

METHYLPHENOBARBITAL
cross reference: BARBITURATE METHYLPREDNISOLONE
Schedule 4
Appendix K, clause 1

METHYLPHENOBARBITONE
cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE
cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3)
Schedule 9

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID
cross reference: PETHIDINE INTERMEDIATE C
Schedule 8

Authorised Version F2026L01327 registered 30/09/2026

METHYLPREDNISOLONE
Schedule 4

***N*-METHYL-2-PYRROLIDONE**
Schedule 6
Schedule 5
Appendix E, clause 3

2-METHYLRESORCINOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

METHYLROSANILINIUM CHLORIDE
cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-59-2), BASIC BLUE 7 (CAS No. 2390-60-5), BASIC BLUE 26 (CAS No. 2580-56-5)
Schedule 10
Schedule 6
Schedule 4

METHYL SALICYLATE
Schedule 6
Schedule 5
Schedule 4

METHYL SALICYLATE LIQUID
Appendix E, clause 3

METHYLTESTOSTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

4-METHYLTHIOAMFETAMINE
cross reference: 4-METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4)
Schedule 9

3-METHYLTHIOFENTANYL
cross reference: CAS No. 86052-04-2
Schedule 9

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE
Schedule 5

METHYLTHIOURACIL
Schedule 4

METHYLTRIENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYPRYLONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

METHYSERGIDE
Schedule 4

METIRAM
Schedule 5

METOBROMURON
Schedule 5

METOCLOPRAMIDE
Schedule 4
Schedule 3

METODESNITAZENE
cross reference: CAS No. 14030-77-4, METAZENE
Schedule 9

METOFLUTHRIN
Schedule 6
Schedule 5

METOLACHLOR
Schedule 5

METOLAZONE
Schedule 4

METONITAZENE
cross reference: CAS No. 14680-51-4
Schedule 9

METOPON
cross reference: CAS No. 143-52-2
Schedule 9

METOPROLOL
Schedule 4

METOSULAM
Schedule 6

METRAFENONE
Schedule 6
Schedule 5

METRIBOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METRIBUZIN
Schedule 6

METRIFONATE
cross reference: TRICHLORFON
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

METRONIDAZOLE
cross reference: BENZOYL METRONIDAZOLE
Schedule 4

METSULFURONMETHYL
Appendix B, clause 3

METYRAPONE
Schedule 4

MEVINPHOS
Schedule 7

MEXILETINE
Schedule 4

MEZLOCILLIN
Schedule 4

MIANSERIN
Schedule 4
Appendix K, clause 1

MIBEFRADIL
Schedule 4

MIBOLERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MICAFUNGIN
Schedule 4

MICONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

MIDAZOLAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

MIDODRINE
Schedule 4

MIDOSTAURIN
Schedule 4

MIFEPRISTONE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

MIGALASTAT
Schedule 4

MIGLITOL
Schedule 4

MIGLUSTAT
Schedule 4

MILBEMECTIN
Schedule 6
Schedule 5

MILNACIPRAN
Schedule 4

MILBEMYCIN OXIME
Schedule 5
Schedule 4

MILRINONE
Schedule 4

MINOCYCLINE
Schedule 4

MINOXIDIL
Schedule 4
Schedule 2

MIPAFOX
Schedule 7

MIRABEGRON
Schedule 4

MIREX
Schedule 7
Appendix J, clause 1

MIRIKIZUMAB
Schedule 4

MIRTAZAPINE
Schedule 4
Appendix K, clause 1

MIRVETUXIMAB SORAVTANSINE
Schedule 4

MISOPROSTOL
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

Authorised Version F2026L01327 registered 30/09/2026

MITOBRONITOL
Schedule 4

MITOMYCIN
Schedule 4

MITOTANE
Schedule 4

MITOXANTRONE
Schedule 4

MITRAGYNA SPECIOSA
cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2)
Schedule 9

MITRAGYNINE
cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA
Schedule 9

MITRATAPIDE
Schedule 4

MIVACURIUM CHLORIDE
Schedule 4

MOBOCERTINIB
Schedule 4

MOCLOBEMIDE
Schedule 4

MODAFINIL
Schedule 4

MOLGRAMOSTIM
Schedule 4

MOLIDUSTAT
Schedule 4
Appendix D, clause 5

MOLINATE
Schedule 7
Appendix J, clause 1

MOLINDONE
Schedule 4

MOLNUPIRAVIR
Schedule 4

MOMELOTINIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

MOMETASONE
Schedule 4
Schedule 3
Schedule 2

MOMFLUOROTHRIN
Schedule 6

MONENSIN
Schedule 6
Schedule 5
Schedule 4

MONEPANTEL
Schedule 5

MONOBENZONE
cross reference: HYDROQUINONE
Schedule 4

MONOCLONAL ANTIBODIES
Schedule 4

MONOCROTOPHOS
Schedule 7

MONOETHANOLAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

MONTELUKAST
Schedule 4

MOPERONE
Schedule 4

MORANTEL
Schedule 6
Schedule 5

MORAZONE
Schedule 4

MORICIZINE
Schedule 4

MORPHERIDINE
cross reference: CAS No. 469-81-8
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

MORPHINE
Schedule 8
Appendix K, clause 1

MORPHINE METHOBROMIDE
Schedule 8

MORPHINE-N-OXIDE
Schedule 8

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1- YLMETHANONE
cross reference: JWH-200 (CAS No. 103610-04-4)
Schedule 9

MOTOR, HEATING or FURNACE FUELS
cross reference: FUELS, FUELS, HOBBY - FUELS, TOY, KEROSENE, METHANOL, PETROL
Appendix A, clause 1

MOTRAZEPAM
Schedule 4

MOTRETINIDE
Schedule 4

MOXIDECTIN
Schedule 7
Schedule 6
Schedule 5
Schedule 4

MOXIFLOXACIN
Schedule 4

MOXONIDINE
Schedule 4

MSMA
Schedule 7
Schedule 6

MUMPS VACCINE
Schedule 4

MUPIROCIN
Schedule 4

MURAGLITAZAR
Schedule 4

MUROMONAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

MUSCIMOL
cross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72-6)
Schedule 9

MUSTINE
cross reference: NITROGEN MUSTARD
Schedule 4

MYCLOBUTANIL
Schedule 5

MYCOPHENOLIC ACID
cross reference: MYCOPHENOLATE MOFETIL
Schedule 4

MYRISTIC ACID
Appendix B, clause 3

MYROPHINE
cross reference: CAS No. 467-18-5
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

N

NAA
cross reference: NAPTHALENEACETIC ACID
Schedule 5

NABILONE
Schedule 8

NABIXIMOLS
cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

NABUMETONE
Schedule 4

NADOLOL
Schedule 4

NADROPARIN
Schedule 4

NAFARELIN
Schedule 4

NAFTIDROFURYL
Schedule 4

NALBUPHINE
Schedule 4
Appendix K, clause 1

NALED
Schedule 6
Schedule 5

NALIDIXIC ACID
Schedule 4

NALMEFENE
Schedule 4

NALORPHINE
Schedule 4

NALOXEGOL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

NALOXONE
Schedule 4
Schedule 3
Appendix H, clause 1

NALTREXONE
Schedule 4

NANDROLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NAPHAZOLINE
Schedule 2
Appendix F, clause 4

NAPHTHALENE
cross reference: CAS No. 91-20-3
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4
Appendix G, clause 1

1,5-NAPHTHALENEDIOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,7-NAPTHALENEDIOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE
cross reference: JWH-073 (CAS No. 208987-48-8)
Schedule 9

NAPHTHALOPHOS
Schedule 7
Schedule 6

1-NAPHTHOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NAPHTHOYLINDOLES
cross reference: WIN 55,212-2 (CAS 137795-17-6)
Schedule 9

NAPHTHOYLPYRROLES
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

NAPHTHYLMETHYLINDENES
Schedule 9

NAPHTHYLMETHYLINDOLES
Schedule 9

NAPROPAMIDE
Appendix B, clause 3

NAPROXEN
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

NAPTALAM
Schedule 5

NAPTHYL ACETAMIDE
Appendix B, clause 3

NARASIN
Schedule 6
Schedule 4

NARATRIPTAN
Schedule 4
Schedule 3
Appendix H, clause 1

NATALIZUMAB
Schedule 4

NATAMYCIN
cross reference: PIMARCIN
Schedule 4

NATEGLINIDE
Schedule 4

NEBACUMAB
Schedule 4

NEBIVOLOL
Schedule 4

NEBRACETAM
cross reference: RACETAMS
Schedule 4

NEDOCROMIL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

NEFAZODONE
Schedule 4

NEFIRACETAM
cross reference: RACETAMS
Schedule 4

NEFOPAM
Schedule 4

NELARABINE
Schedule 4

NELFINAVIR
Schedule 4

NEOMYCIN
Schedule 4

NEOSCYTALIDIUM NOVAEHOLLANDIAE
Schedule 5

NEOSTIGMIN
Schedule 4

NEPAFENAC
Schedule 4

NERATINIB
Schedule 4

NERIUM OLEANDER
Schedule 4
Appendix G, clause 1

NEROLI OIL
Appendix B, clause 3

NESIRITIDE
Schedule 4

NETILMICIN
Schedule 4

NETOBIMIN
Schedule 6
Schedule 5

NETUPITANT
Schedule 4

NEVIRAPINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

NIALAMIDE
Schedule 4

NICARBAZIN
Appendix B, clause 3

NICARDIPINE
Schedule 4

NICERGOLINE
Schedule 4

NICKEL SULFATE
Schedule 6

NICLOSAMIDE
Schedule 6
Schedule 5
Schedule 2

NICOCODINE
cross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263-01-7)
Schedule 9

NICODICODINE
cross reference: CAS No. 808-24-2
Schedule 9

NICOFURANOSE
Schedule 4

NICOMORPHINE
cross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4)
Schedule 9

NICORANDIL
Schedule 4

NICOTINE
Schedule 7
Schedule 4
Schedule 3
Appendix D, clause 5
Appendix F, clause 4
Appendix J, clause 1

NICOTINIC ACID
cross reference: NICOTINAMIDE
Schedule 5
Schedule 4
Schedule 3

Authorised Version F2026L01327 registered 30/09/2026

NICOTINYL ALCOHOL
Schedule 3

NICOUMALONE
Schedule 4

NIFEDIPINE
Schedule 4

NIFENAZONE
Schedule 4

NIFOXIPAM
cross reference: CAS No. 74723-10-7
Schedule 9

NIKETHAMIDE
Schedule 4

NILOTINIB
Schedule 4

NILUTAMIDE
Schedule 4

NIMESULIDE
Schedule 4

NIMIDANE
Schedule 7
Schedule 6

NIMODIPINE
Schedule 4

NIMORAZOLE
Schedule 4

NINTEDANIB
Schedule 4

NIRAPARIB
Schedule 4

NIRIDAZOLE
Schedule 4

NIRMATRELVIR
Schedule 4

NIRSEVIMAB
Schedule 4

NISIN
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

NISOLDIPINE
Schedule 4

NITENPYRAM
Schedule 6

NITISINONE
Schedule 4

NITRAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

NITRENDIPINE
Schedule 4

NITRIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

NITRIC OXIDE
Schedule 4

NITROBENZENE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROFEN
Schedule 7
Appendix J, clause 1

NITROFURANTOIN
Schedule 4

NITROFURAZONE
Schedule 4

3-NITRO-*p*-HYDROXYETHYLAMINOPHENOL
cross reference: 4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROPHENOLS
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

NITROPRUSSIDES
Schedule 7
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROSCANATE
Schedule 5

2-NITROTOLUENE
Schedule 7

NITROUS OXIDE
Schedule 4
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROXOLINE
Schedule 4

NITROXYNIL
Schedule 6

NIVOLUMAB
Schedule 4

NIZATIDINE
Schedule 4
Schedule 2
Appendix F, clause 4

NOMEGESTROL
Schedule 4

NOMIFENSINE
Schedule 4

NONANOIC ACID
Schedule 5

NONOXINOL 9
Schedule 6
Schedule 5
Appendix E, clause 3

NORACYMETHADOL
cross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0)
Schedule 9

NORADRENALINE
Schedule 4
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

19-NORANDROSTENEDIOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

19-NORANDROSTENEDIONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORANDROSTENOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORBOLETHONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORBORMIDE
Schedule 5

NORCLOSTEBOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORCODEINE
Schedule 8

NORELGESTROMIN
Schedule 4

NOREPINEPHRINE
cross reference: NORADRENALINE

NORETHANDROLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORETHISTERONE
Schedule 4

NORFLOXACIN
Schedule 4

NORFLURAZON
Appendix B, clause 3

NORGESTREL
Schedule 4

NORIBOGAINE
Schedule 4

NORLEVORPHANOL
cross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

NORMAL HUMAN IMMUNOGLOBULIN
Schedule 4

NORMETHADONE
Schedule 8
Appendix K, clause 1

NORMETHANDRONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORMORPHINE
cross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372-02-9)
Schedule 9

NORPIPANONE
cross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033-41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7)
Schedule 9

NORTRIPTYLINE
Schedule 4
Appendix K, clause 1

NOSCAPINE
Schedule 2

NOVALURON
Appendix B, clause 3

NOVOBIOCIN
Schedule 4

NOXIPTYLINE
Schedule 4

NUCLEAR POLYHEDROSIS VIRUS OF *Helicoverpa armigera* occlusion bodies
Appendix B, clause 3

NUSINERSEN
Schedule 4

NUTMEG OIL
Schedule 5

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION
Appendix A, clause 1

NYSTATIN
Schedule 4
Schedule 3
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

Appendix F, clause 4
Appendix H, clause 1

Authorised Version F2026L01327 registered 30/09/2026

O

OBETICHOLIC ACID
Schedule 4

OCLACITINIB
Schedule 4

OCRELIZUMAB
Schedule 4

OCRIPLASMIN
Schedule 4

OCTAMYLAMINE
Schedule 4

OCTATROPINE
Schedule 4

1-OCTEN-3-OL
Schedule 6

OCTHILINONE
Schedule 6

OCTREOTIDE
Schedule 4

OCTYL ALCOHOLS
Appendix B, clause 3

***N*-OCTYL BICYCLOHEPTENE DICARBOXIMIDE**
cross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE
Schedule 5

OCTYL NITRITE
Schedule 4
Appendix E, clause 3

***N*-(*N*-OCTYL)-2-PYRROLIDONE**
cross reference: DESIGNATED SOLVENT, *N*-(*N*-DODECYL)-2-PYRROLIDONE, *N*-METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, clause 3

ODEVIXIBAT
Schedule 4

OESTRADIOL
cross reference: ESTRADIOL

Authorised Version F2026L01327 registered 30/09/2026

OESTRIOL
cross reference: ESTRIOL

OESTROGENS
cross reference: ESTROGENS

OESTRONE
cross reference: ESTRONE

OFATUMUMAB
Schedule 4

OFLOXACIN
Schedule 4

OLANZAPINE
Schedule 4
Appendix K, clause 1

OLAPARIB
Schedule 4

OLAQUINDOX
Schedule 6

OLARATUMAB
Schedule 4

OLEANDOMYCIN
Schedule 5
Schedule 4

OLEANDRIN
Schedule 4

OLEIC ACID
Appendix B, clause 3

***N*-OLEYL-1,3-DIAMINOPROPANE**
Schedule 6

OLIPUDASE ALFA
Schedule 4

OLMESARTAN
Schedule 4

OLODATEROL
Schedule 4

OLOPATADINE
Schedule 4
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

OLSALAZINE
Schedule 4

OLUTASIDENIB
Schedule 4

OMBERACETAM
cross reference: RACETAMS, NOOPEPT, N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER
Schedule 4

OMBITASVIR
Schedule 4

OMALIZUMAB
Schedule 4

OMEGA-3-ACID ETHYL ESTERS
Schedule 4

OMEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

OMETHOATE
Schedule 7
Schedule 6
Schedule 5

ONASEMNOGENE ABEPARVOVEC
Schedule 4

ONDANSETRON
Schedule 4

OPICAPONE
Schedule 4

OPIPRAMOL
Schedule 4

OPIUM
cross reference: NOSCAPINE, PAPAVERINE
Schedule 8
Appendix K, clause 1

ORANGE OIL (BITTER)
Schedule 5
Appendix E, clause 3

ORANGE OIL, SWEET
Appendix B, clause 3

Authorised Version F2026L01327 registered 30/09/2026

ORBIFLOXACIN
Schedule 4

ORCIPRENALINE
Schedule 4
Appendix F, clause 4

ORELABRUTINIB
Schedule 4

ORGANOPHOSPHORUS COMPOUNDS
cross reference: MALATHION
Schedule 4

ORLISTAT
Schedule 4
Schedule 3

ORNIDAZOLE
Schedule 4

ORNIPRESSIN
Schedule 4

ORPHENADRINE
Schedule 4

ORTHOPTERIN
Schedule 4

OSELTAMIVIR
Schedule 4

OSILODROSTAT
Schedule 4

OSIMERTINIB
Schedule 4

OUABAIN
Schedule 4

OVANDROTONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXABETRINIL
Appendix B, clause 3

OXABOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXACILLIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

OXADIARGYL
Schedule 5

OXADIAZON
Schedule 6

OXADIXYL
Schedule 5

OXALATES
Appendix F, clause 4

OXALIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

OXALIPLATIN
Schedule 4

OXAMYL
Schedule 7

OXANDROLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXANTEL EMBONATE
Schedule 5

OXAPROZIN
Schedule 4

OXAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

OXCARBAZEPINE
Schedule 4

OXATHIAPIPROLIN
Appendix B, clause 3

OXEDRINE
cross reference: SYNEPHRINE
Schedule 4

OXETACAINE
cross reference: OXETHAZAINE
Schedule 4
Schedule 2

OXFENDAZOLE
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

OXIBENDAZOLE
Schedule 5

OXICONAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

OXIRACETAM
cross reference: RACETAMS
Schedule 4

OXITROPIUM
Schedule 4

OXOLAMINE
Schedule 4

OXOLINIC ACID
Schedule 4

OXPENTIFYLLINE
cross reference: PENTOXIFYLLINE

OXPRENOLOL
Schedule 4

OXYBUPROCAINE
Schedule 4

OXYBUTYNIN
Schedule 4

OXYCARBOXIN
Schedule 5

OXYCLOZANIDE
Schedule 6

OXYCODONE
Schedule 8
Appendix K, clause 1

OXYDEMETON METHYL
Schedule 7

OXYFLUORFEN
Appendix B, clause 3

OXYMESTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

Authorised Version F2026L01327 registered 30/09/2026

OXYMETAZOLINE
Schedule 2
Appendix F, clause 4

OXYMETHOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXYMORPHONE
Schedule 8

OXYPHENBUTAZONE
Schedule 4

OXYPHENCYCLIMINE
Schedule 4

OXYPHENISATIN
cross reference: CAS No. 125-13-3
Schedule 10

OXYPHENONIUM
Schedule 4

OXYQUINOLINE
Schedule 2
Appendix F, clause 4

OXYTETRACYCLINE
Schedule 5
Schedule 4

OXYTHIOQUINOX
Schedule 5

OXYTOCIN
Schedule 4
Appendix G, clause 1

OZANIMOD
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

P

PACLITAXEL
Schedule 4

PACLOBUTRAZOL
Schedule 5

PAECILOMYCES LILACINUS STRAIN 251
Schedule 6

PAINT
Appendix F, clause 4

PALBOCICLIB
Schedule 4

PALIFERMIN
Schedule 4

PALIPERIDONE
Schedule 4
Appendix K, clause 1

PALIVIZUMAB
Schedule 4

PALMAROSA OIL
Appendix B, clause 3

PALMITIC ACID
Appendix B, clause 3

PALMITOYLETHANOLAMIDE
cross reference: PALMIDROL
Schedule 6

PALONOSETRON
Schedule 4

PALOPEGTERIPARATIDE
Schedule 4

PALOVAROTENE
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

PAMAQUIN
Schedule 4

PAMIDRONIC ACID
cross reference: PAMIDRONATE DISODIUM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PANCREATIC ENZYMES
cross reference: LIPASE
Schedule 4

PANCURONIUM
Schedule 4

PANITUMUMAB
Schedule 4

PANOBINOSTAT
Schedule 4

PANTOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

PAPAVERETUM
Appendix K, clause 1

PAPAVERINE
cross reference: OPIUM
Schedule 4
Schedule 2

PAPER
Appendix A, clause 1

PARA-AMINOPROPIOPHENONE (PAPP)
cross reference: 4-AMINOPROPIOPHENONE

PARACETAMOL
cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

para-DICHLOROBENZENE
cross reference: PDB
Appendix F, clause 4

PARA-FLUOROFENTANYL
cross reference: CAS No. 90736-23-5
Schedule 9

PARAFORMALDEHYDE
cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4)
Schedule 10
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

Schedule 2
Appendix E, clause 3

PARALDEHYDE
Schedule 4

PARAMETHADIONE
Schedule 4

PARAMETHASONE
Schedule 4

PARAQUAT
Schedule 7

PARATHION
Schedule 7

PARATHION-METHYL
Schedule 7
Schedule 6

PARBENDAZOLE
Schedule 6

PARECOXIB
Schedule 4

PARICALCITOL
Schedule 4

PARITAPREVIR
Schedule 4

PAROMOMYCIN
Schedule 4

PAROXETINE
Schedule 4

PASIREOTIDE
Schedule 4

PATCHOULI OIL
Appendix B, clause 3

PATIROMER SORBITEX CALCIUM
Schedule 4

PATISIRAN
Schedule 4

PAZOPANIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PEBULATE
Schedule 6

PECAZINE
Schedule 4

PECTINASE derived from Aspergillus niger
Appendix B, clause 3

PEFLOXACIN
Schedule 4

PEGAPTANIB
Schedule 4

PEGASPARGASE
Schedule 4

PEGBOVIGRASTIM
Appendix B, clause 3

PEGCETACOPLAN
Schedule 4

PEGFILGRASTIM
Schedule 4

PEGINTERFERON
Schedule 4

PEGUNIGALSIDASE ALFA
Schedule 4

PEGVALIASE
Schedule 4

PEGVISOMANT
Schedule 4

PEMIGATINIB
Schedule 4

PERAMIVIR
Schedule 4

PHENOLS
Appendix E, clause 3

PEMBROLIZUMAB
Schedule 4

PEMETREXED
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PEMOLINE
Schedule 4

PEMPIDINE
Schedule 4

PENBUTOLOL
Schedule 4

PENCICLOVIR
Schedule 4

PENCONAZOLE
Schedule 5

PENCYCURON
Appendix B, clause 3

PENDIMETHALIN
Schedule 5

PENETHAMATE
Schedule 4

PENFLUFEN
Schedule 5

PENICILLAMINE
Schedule 4

PENNYROYAL OIL
Schedule 6
Appendix E, clause 3

PENTACHLOROPHENOL
Schedule 7
Schedule 6
Appendix F, clause 4

PENTADECANOIC ACID
Appendix B, clause 3

PENTAERYTHRITYL TETRANITRATE
Schedule 4

PENTAGASTRIN
Schedule 4

PENTAMETHONIUM
Schedule 4

PENTAMIDINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PENTAZOCINE
Schedule 8
Appendix K, clause 1

PENTHIENATE
Schedule 4

PENTHIOPYRAD
Schedule 5

PENTOBARBITONE
cross reference: PENTOBARBITAL

PENTOBARBITAL
Schedule 8
Schedule 4
Appendix D, clause 9
Appendix K, clause 1

PENTOLINIUM
Schedule 4

PENTOSAN POLYSULFATE SODIUM
Schedule 4

PENTOXIFYLLINE
Schedule 4

1-PENTYL-3-(1-NAPHTHOYL)INDOLE
cross reference: JWH-018 (CAS No. 209414-07-3)
Schedule 9

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE
cross reference: JWH-122 (CAS No. 619294-47-2)
Schedule 9

PEPPERMINT OIL
Appendix B, clause 3

PERACETIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PERAMPANEL
Schedule 4
Appendix D, clause 5
Appendix K, clause 1

PERFLUIDONE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

PERGOLIDE
Schedule 4

PERHEXILINE
Schedule 4

PERICIAZINE
Schedule 4
Appendix K, clause 1

PERICYAZINE
cross reference: PERICIAZINE

PERINDOPRIL
Schedule 4

PERMANGANATES
cross reference: POTASSIUM PERMANGANATE
Schedule 6
Appendix F, clause 4

PERMETHRIN
Schedule 6
Schedule 5
Schedule 4

PERPHENAZINE
Schedule 4
Appendix K, clause 1

PERTUSSIS ANTIGEN
cross reference: TRIPLE ANTIGEN VACCINE
Schedule 4

PERTUZUMAB
Schedule 4

PETASITES spp.
Schedule 10

PETHIDINE
Schedule 8
Appendix K, clause 1

PETROL
Schedule 5
Appendix E, clause 3

PHEDRAZINE
Schedule 2

PHENACEMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PHENACETIN
Schedule 4

PHENADOXONE
cross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545-91-5)
Schedule 9

PHENAGLYCODOL
Schedule 4

PHENAMPROMIDE
cross reference: CAS No. 129-83-9
Schedule 9

PHENAZOCINE
cross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9)
Schedule 9

PHENAZONE
Schedule 5
Schedule 4
Schedule 2

PHENAZOPYRIDINE
Schedule 4

PHENCYCLIDINE
cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1)
Schedule 9

PHENDIMETRAZINE
Schedule 8

PHENELZINE
Schedule 4
Appendix K, clause 1

N-PHENETHYL-4-PIPERIDONE
cross reference: CAS No. 39742-60-4
Schedule 9

PHENETICILLIN
Schedule 4

PHENFORMIN
Schedule 4

PHENGLUTARIMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PHENIBUT
cross reference: BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 103095-38-1)
Schedule 9

PHENINDIONE
Schedule 4

PHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

PHENISATIN
Schedule 4

PHENISOPHAM
Schedule 5

PHENMEDIPHAM
Appendix B, clause 3

PHENMETRAZINE
Schedule 8

PHENOBARBITAL
Schedule 4
Appendix K, clause 1

PHENOBARBITONE
cross reference: PHENOBARBITAL

PHENOL
cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

PHENOLPHTHALEIN
Schedule 4

PHENOMORPHAN
cross reference: CAS No. 468-07-5
Schedule 9

PHENOPERIDINE
Schedule 8
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

PHENOTHIAZINE
Schedule 6

D-PHENOTHRIN
Appendix B, clause 3

PHENOXYBENZAMINE
Schedule 4

2-PHENOXYETHANOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENOXYMETHYL OXIRANE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENOXYMETHYLPENICILLIN
Schedule 4

PHENPROMETHAMINE
cross reference: CAS No. 93-88-9
Schedule 10

PHENSUXIMIDE
Schedule 4

PHENTERMINE
Schedule 4
Appendix D, clause 5

PHENTHIMENTONIUM
Schedule 4

PHENTOLAMINE
Schedule 4

PHENYLACETYLINDOLES
Schedule 9

PHENYLBUTAZONE
Schedule 4

PHENYLENEDIAMINES
cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO-PHENYLENEDIAMINES, DIETHYL-PARA-PHENYLENEDIAMINE, DIMETHYL-PARA-PHENYLENEDIAMINE
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

PHENYLEPHRINE
cross reference: CODEINE, IBUPROFEN, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, clause 4

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE
cross reference: PEPAP (CAS No. 64-52-8)
Schedule 9

PHENYLMERCURIC ACETATE
cross reference: MERCURY
Schedule 7
Appendix J, clause 1

PHENYL METHYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, clause 3

***o*-PHENYLPHENOL**
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER
cross reference: PETHIDINE INTERMEDIATE B
Schedule 8

PHENYL METHYL PYRAZOLONE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENYLPIRACETAM
cross reference: RACETAMS
Schedule 4

PHENYLPROPANOLAMINE
Schedule 4

PHENYLTOLOXAMINE
Schedule 4
Appendix K, clause 1

PHENYTOIN
Schedule 4
Appendix F, clause 4

PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract)
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PHOLCODINE
Schedule 8
Schedule 4
Schedule 2
Appendix K, clause 1

PHORATE
Schedule 7

PHOSALONE
Schedule 6

PHOSFOLAN
Schedule 7

PHOSMET
Schedule 6

PHOSPHIDES, METALLIC
cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE
Schedule 7
Appendix J, clause 1

PHOSPHINE
Schedule 7
Appendix J, clause 1

PHOSPHODIESTERASE TYPE 5 INHIBITORS
Schedule 4

PHOSPHONIC ACID
cross reference: PHOSPHOROUS ACID
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PHOSPHORIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PHOSPHORUS
Appendix G, clause 1

PHOSPHORUS, YELLOW
Schedule 7
Appendix E, clause 3
Appendix F, clause 4

PHOTOGRAPHIC PAPER or FILM
Appendix A, clause 1

Authorised Version F2026L01327 registered 30/09/2026

PHOXIM
Schedule 6

***o*-PHTHALADEHYDE**
Appendix F, clause 4

***o*-PHTHALALDEHYDE**
Appendix E, clause 3

PHTHALALDEHYDE
Schedule 6
Schedule 5

PHTHALYLSULFATHIAZOLE
Schedule 4

PHYSOSTIGMINE
Schedule 4

PHYTASE
Appendix B, clause 3

PIBRENTASVIR
Schedule 4

PICARIDIN
Schedule 5

PICLORAM
Appendix B, clause 3

PICOLINAFEN
Appendix B, clause 3

PICRAMIC ACID (including its salts)
cross reference: 2-AMINO-4,6-DINITROPHENOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PICRIC ACID
Appendix E, clause 3
Appendix F, clause 4

PICROTOXIN
Schedule 4

PIGMENTS
Appendix A, clause 1

PILOCARPINE
Schedule 4

PIMECROLIMUS
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PIMELIC ACID
Appendix B, clause 3

PIMINODINE
cross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9)
Schedule 9

PIMOBENDAN
Schedule 4

PIMOZIDE
Schedule 4
Appendix K, clause 1

PINACIDIL
Schedule 4

PINAVERIUM BROMIDE
Schedule 4

PINDOLOL
Schedule 4

PINDONE
Schedule 6

PINE OILS
Schedule 6
Schedule 5

PINOXADEN
Schedule 6
Schedule 5

PIOGLITAZONE
Schedule 4

PIPECURONIUM
Schedule 4

PIPEMIDIC ACID
Schedule 4

PIPENZOLATE
Schedule 4

PIPER METHYSTICUM
cross reference: KAVA, KAVALACTONES
Schedule 4

PIPERACILLIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PIPERAZINE
Schedule 5
Schedule 2

PIPERIDINE
Schedule 4

PIPERIDOLATE
Schedule 4

PIPERONYL BUTOXIDE
Appendix B, clause 3

PIPEROPHOS
Schedule 6

PIPOBROMAN
Schedule 4

PIPOTHIAZINE
Schedule 4

PIPRADROL
Schedule 4

PIRACETAM
cross reference: RACETAMS
Schedule 4

PIRBUTEROL
Schedule 4

PIRENOXINE
cross reference: CATALIN
Schedule 4

PIRENZEPINE
Schedule 4

PIRETANIDE
Schedule 4

PIRFENIDONE
Schedule 4

PIRIMICARB
Schedule 6
Schedule 5

PIRIMIPHOS-ETHYL
Schedule 6

PIRIMIPHOS-METHYL
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

PIRITRAMIDE
Schedule 8

PIROXICAM
Schedule 4

PIRPROFEN
Schedule 4

PIRTOBRUTINIB
Schedule 4

PITAVASTATIN
Schedule 4

PITUITARY HORMONES
Schedule 4

PIVAMPICILLIN
Schedule 4

PIZOTIFEN
Schedule 4
Appendix K, clause 1

PLASMID DNA (rE. coli DH5α pINGhT)
cross reference: VACCINES – PLASMID DNA

PLERIXAFOR
Schedule 4

PLICAMYCIN
Schedule 4

PLITIDEPSIN
Schedule 4
Appendix L, clause 2

PLOZASIRAN
Schedule 4

PNEUMOCOCCAL VACCINE
Schedule 4

PODOPHYLLOTOXIN
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

Authorised Version F2026L01327 registered 30/09/2026

PODOPHYLLUM EMODI
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

PODOPHYLLUM PELTATUM
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

PODOPHYLLUM RESIN
cross reference: PODOPHYLLIN
Appendix G, clause 1

POLIHEXANIDE
cross reference: 1-(DIAMINOMETHYLIDENE)-2-HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO-1,6-HEXANEDIYL), POLYHEXAMETHYLENE BIGUANIDE (PHMB)
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

POLIOMYELITIS VACCINE
Schedule 4

POLIXETONIUM SALTS
Schedule 6
Schedule 5

POLOXALENE
Appendix B, clause 3

POLY (GNRF) OVALBUMIN
Appendix B, clause 3

POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE
cross reference: POLYDADMAC
Appendix B, clause 3

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C_{13-15}-ALKYL ETHERS
Schedule 5
Appendix E, clause 3

POLYACRYLAMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

POLYCAPROLACTONE
Schedule 4

POLYESTRADIOL
Schedule 4

POLYETHANOXY (15) TALLOW AMINE
Schedule 5
Appendix E, clause 3

POLYHEDROSIS VIRUS of *Helico zea* occlusion bodies
Appendix B, clause 3

POLYLACTIC ACID
Schedule 4

POLYMYXIN
Schedule 4

POLYOXIN D ZINC SALT
Schedule 5

POLYSORBATE 20
Appendix B, clause 3

POLYSULFATED GLYCOSAMINOGLYCANS
Schedule 4

POLYTHIAZIDE
Schedule 4

POMALIDOMIDE
Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

PONATINIB
Schedule 4

PONESIMOD
Schedule 4
Appendix L, clause 2

PORACTANT
Schedule 4

PORCELAIN
Appendix A, clause 1

PORCINE SOMATOTROPHIN
Appendix B, clause 3

POSACONAZOLE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

POTASSIUM AZELOYL DIGLYCINATE
Schedule 6

POTASSIUM BICARBONATE
Appendix B, clause 3

POTASSIUM BROMATE
Schedule 6
Appendix E, clause 3

POTASSIUM BROMIDE
Schedule 4

POTASSIUM CHLORATE
Schedule 5
Schedule 2
Appendix E, clause 3

POTASSIUM CHLORIDE
Schedule 4

POTASSIUM CYANATE
Schedule 6
Appendix E, clause 3

POTASSIUM HYDROXIDE
cross reference: CAS No. 1310-58-3
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM METABISULPHITE
Schedule 5
Appendix F, clause 4

POTASSIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM PERCHLORATE
Schedule 4

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

POTASSIUM PERSULFATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM SORBATE
Appendix B, clause 3

POTASSIUM SULFIDE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PRACTOLOL
Schedule 4

PRADOFLOXACIN
Schedule 4

PRALATREXATE
Schedule 4

PRALIDOXIME
Schedule 4

PRALLETHRIN
Schedule 6
Schedule 5

PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)
Schedule 4
Appendix D, clause 5

PRALSETINIB
Schedule 4

PRAMIPEXOLE
Schedule 4

PRAMIRACETAM
cross reference: RACETAMS
Schedule 4

PRAMOCAINE
Schedule 4

PRAMPINE
Schedule 4

PRASTERONE
cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

Authorised Version F2026L01327 registered 30/09/2026

PRASUGREL
Schedule 4

PRAVASTATIN
Schedule 4

PRAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

PRAZIQUANTEL
Schedule 4

PRAZOSIN
Schedule 4

PREDNISOLONE
Schedule 4

PREDNISONE
Schedule 4

PREGABALIN
Schedule 4
Appendix K, clause 1

PREGNENOLONE
Schedule 4

PRENALTEROL
Schedule 4

PRENYLAMINE
Schedule 4

PRILOCAINE
Schedule 4
Schedule 2

PRIMAQUINE
Schedule 4

PRIMIDONE
Schedule 4

PRINTING INKS or INK ADDITIVES
Appendix A, clause 1

PROBENECID
Schedule 4

PROBUCOL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PROCAINAMIDE
Schedule 4

PROCAINE
Schedule 4

PROCAINE BENZYLPENICILLIN
Schedule 4

PROCAINE PENICILLIN
cross reference: PROCAINE BENZYLPENICILLIN

PROCARBAZINE
Schedule 4

PROCHLORAZ
Schedule 6

PROCHLORPERAZINE
Schedule 4
Schedule 3
Appendix K, clause 1

PROCYCLIDINE
Schedule 4
Schedule 2

PROCYMIDONE
Schedule 7

PROFENOFOS
Schedule 6

PROFOXYDIM
Schedule 5

PROGESTERONE
Schedule 5
Schedule 4
Appendix G, clause 1

PROGESTOGENS
Schedule 4

PROGLUMIDE
Schedule 4

PROGUANIL
Schedule 4

PROHEPTAZINE
cross reference: CAS No. 77-14-5
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

PROHEXADIONE CALCIUM
Schedule 5

PROLINTANE
Schedule 4

PROMACYL
Schedule 6

PROMAZINE
Schedule 4
Appendix K, clause 1

PROMETHAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

PROMETRYN
Schedule 5

PROMOXOLANE
Schedule 4

PROPACHLOR
Schedule 6

PROPAFENONE
Schedule 4

PROPAMIDINE
Schedule 4
Schedule 2

PROPAMOCARB
Schedule 5

PROPANIDID
Schedule 4

PROPANIL
Schedule 5

PROPANTHELINE
Schedule 4

PROPAQUIZAFOP
Schedule 5

PROPARGITE
Schedule 6

PROPENTOFYLLINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PROPERIDINE
cross reference: CAS No. 561-76-2
Schedule 9

PROPETAMPHOS
Schedule 6

PROPETANDROL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

PROPICONAZOLE
Schedule 6
Schedule 5

PROPINEB
Schedule 6

PROPIONIBACTERIUM ACNES
Schedule 4

PROPIONIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PROPIRAM
Schedule 8

PROPOFOL
Schedule 4

PROPOXUR
Schedule 6
Schedule 5

PROPRANOLOL
Schedule 4
Appendix G, clause 1

PROPYL ACETATES
Appendix B, clause 3

n-PROPYL ALCOHOL
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

***n*-PROPYL NITRITE**
cross reference: CAS No. 543-67-9
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

PROPYLENE GLYCOL
Appendix B, clause 3

2-PROPYLENE GLYCOL 1-MONOMETHYL
Appendix B, clause 3

PROPYLENE OXIDE
Schedule 7
Appendix J, clause 1

PROPYLHEXEDRINE
Schedule 4

PROPYLPHENIDINE
cross reference: CAS No. 6266-42-8
Schedule 9

PROPYLTHIOURACIL
Schedule 4

PROPYPHENAZONE
Schedule 4

PROPYZAMIDE
Schedule 5

PROQUAZONE
Schedule 4

PROQUINAZID
Schedule 6

PROSCILLARIDIN
Schedule 4

PROSTAGLANDINS
Schedule 4

PROSTIANOL
Schedule 4

PROSULFOCARB
Schedule 6

PROSULFURON
Schedule 6

PROTAMINE
Schedule 4

PROTHIOCONAZOLE
Appendix B, clause 3

PROTHIOCONAZOLE-DESCHLORO
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE
Schedule 5

PROTHIOFOS
Schedule 6

PROTHIONAMIDE
Schedule 4

PROTHIPENDYL
Schedule 4

PROTIRELIN
Schedule 4

PROTONITAZENE
cross reference: CAS No. 95958-84-2
Schedule 9

PROTOVERATRINES
Schedule 4

PROTRIPTYLINE
Appendix K, clause 1

PROTRIPTYLINE
Schedule 4

PROXYMETACAINE
Schedule 4

PRUCALOPRIDE
Schedule 4

PSEUDOEPHEDRINE
Schedule 4
Schedule 3

PSEUDOMONAS FLUORESCENS
Appendix B, clause 3

PSILOCYBINE
cross reference: PSILOCYBIN, CAS No. 520-52-5
Schedule 9
Schedule 8
Appendix D, clause 5
Appendix D, clause 9

PTERIDIUM spp.
Schedule 10

D-PULEGONE
Schedule 6
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

PULMONARIA spp.
Schedule 10

PYDIFLUMETOFEN
Appendix B, clause 3

PYMETROZINE
Schedule 5

PYRACLOFOS
Schedule 6

PYRACLOSTROBIN
Schedule 5

PYRAFLUFEN-ETHYL
Schedule 5

PYRANTEL
Schedule 2

PYRASULFOTOLE
Schedule 5

PYRAZINAMIDE
Schedule 4

PYRAZOLAM
cross reference: CAS No. 39243-02-2
Schedule 9

PYRAZOPHOS
Schedule 6

PYRETHRINS
cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE
Schedule 5
Schedule 2

PYRIDABEN
Schedule 6
Schedule 5

PYRIDALYL
Schedule 6

PYRIDATE
Schedule 6

PYRIDINOLCARBAMATE
Schedule 4

PYRIDOSTIGMINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

PYRIDOXAL
Schedule 4

PYRIDOXAMINE
Schedule 4

PYRIDOXINE
Schedule 4

PYRIFENOX
Schedule 5

PYRIMETHAMINE
Schedule 4

PYRIMETHANIL
Appendix B, clause 3

PYRINURON
Schedule 7
Appendix J, clause 1

PYRIOFENONE
Schedule 6
Schedule 5

PYRIPROLE
Schedule 6

PYRIPROXYFEN
Appendix B, clause 3

PYRITHIOBAC SODIUM
Schedule 5

PYRITHIONE COPPER
Schedule 6

PYRITHIONE ZINC
Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3

PYROVALERONE
Schedule 4

PYROXASULFONE
Schedule 6

PYROXSULAM
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

PYRVINIUM
cross reference: VIPRYNIUMA
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

Q

QUASSIA
Appendix B, clause 3

QUATERNARY AMMONIUM COMPOUNDS
cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS
Schedule 6
Schedule 5
Appendix E, clause 3

QUAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

QUETIAPINE
Schedule 4
Appendix K, clause 1

QUINAGOLIDE
Schedule 4

QUINALBARBITONE
cross reference: SECOBARBITAL

QUINAPRIL
Schedule 4

QUINBOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

QUINCLORAC
Schedule 5

QUINETHAZONE
Schedule 4

QUINIDINE
Schedule 4

QUININE
cross reference: QUININE (CAS No. 130-95-0), QUININE SULFATE (1:1) (CAS No. 549-56-4), QUININE SULFATE (2:1) (CAS No. 804-63-7), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119-70-6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183-68-2), QUININE DIHYDROCHLORIDE (CAS No. 60-93-5), QUININE MONOHYDROCHLORIDE (CAS No. 130-89-2), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119-47-7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549-43-1)
Schedule 7
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

Schedule 4
Appendix F, clause 4

QUINISOCAINE
cross reference: DIMETHISOQUINE
Schedule 4

QUINOLINE
cross reference: 2,3-BENZAPYRIDINE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

QUINOXYFEN
Appendix B, clause 3

QUINTOZENE
cross reference: PENTACHLORONITROBENZENE
Schedule 5

QUINUPRISTIN
Schedule 4

QUIZALOFOP ETHYL
cross reference: QUIZALOFOP ETHYL (D + ISOMER)
Schedule 6

QUIZALOFOP-*p*-ETHYL
Schedule 6
Schedule 5

QUIZALOFOP-*p*-TEFURYL
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

R

RABEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

RABIES VACCINE
Schedule 4

RACEMETHORPHAN
cross reference: CAS No. 510-53-2
Schedule 9

RACEMORAMIDE
Schedule 8

RACEMORPHAN
cross reference: CAS No. 297-90-5
Schedule 9

RACETAMS
Schedule 4

RACTOPAMINE
Schedule 5
Schedule 4

RADIOGRAPHIC CONTRAST MEDIA
cross reference: RADIOPAQUES
Appendix A, clause 1

RADIOISOTOPES
Appendix A, clause 1

RALOXIFENE
Schedule 4

RALTEGRAVIR
Schedule 4

RALTITREXED
Schedule 4

RAMIPRIL
Schedule 4

RAMUCIRUMAB
Schedule 4

RANIBIZUMAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

RANITIDINE
Schedule 4
Schedule 2
Appendix F, clause 4

RANOLAZINE
Schedule 4

RAPACURONIUM
Schedule 4

RASAGILINE
Schedule 4

RASBURICASE
Schedule 4

RAUWOLFIA SERPENTINA
Schedule 4

RAUWOLFIA VOMITORIA
Schedule 4

RAZOXANE
Schedule 4

REBOXETINE
Schedule 4

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
Schedule 4

RED YEAST RICE
Schedule 4

REGDANVIMAB
Schedule 4

REGORAFENIB
Schedule 4

RELUGOLIX
Schedule 4

REMDESIVIR
Schedule 4

REMIBRUTINIB
Schedule 4

REMIFENTANIL
Schedule 8

REMOXIPRIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

REPAGLINIDE
Schedule 4

REPOTRECTINIB
Schedule 4

RESCALURE
cross reference: (3S,6R)-(3S,6S)-6-isopropenyl-3-methyldec-9-en-1-yl acetate, insect sex pheromone
Schedule 6

RESERPINE
Schedule 4

RESLIZUMAB
Schedule 4

RESMETHRIN
Schedule 6
Schedule 5

RESORCINOL
cross reference: 1,3-BENZENEDIOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

RETAPAMULIN
Schedule 4

RETEPLASE
Schedule 4

RETIFANLIMAB
Schedule 4

RETIGABINE
Schedule 4
Appendix K, clause 1

RHIZOBIUM RHIZOGENES
Appendix B, clause 3

RIBAVIRIN
Schedule 4

RIBOCICLIB
Schedule 4

RIDAFOROLIMUS
Schedule 4

RIFABUTIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

RIFAMPICIN
Schedule 4

RIFAMYCIN
Schedule 4

RIFAPENTINE
Schedule 4

RIFAXIMIN
Schedule 4

RILPIVIRINE
Schedule 4

RILUZOLE
Schedule 4

RIMEGEPANT
Schedule 4

RIMEXOLONE
Schedule 4

RIMITEROL
Schedule 4

RIMONABANT
Schedule 4

RIMSULFURON
Schedule 5

RIOCIGUAT
Schedule 4
Appendix D, clause 4
Appendix L, clause 2

RIPRETINIB
Schedule 4

RISANKIZUMAB
Schedule 4

RISDIPLAM
Schedule 4

RISEDRONIC ACID
Schedule 4

RISPERIDONE
Schedule 4
Appendix K, clause 1

Authorised Version F2026L01327 registered 30/09/2026

RITLECITINIB
Schedule 4

RITODRINE
Schedule 4

RITONAVIR
Schedule 4

RITUXIMAB
Schedule 4

RIVAROXABAN
Schedule 4

RIVASTIGMINE
Schedule 4

RIZATRIPTAN
Schedule 4
Schedule 3
Appendix H, clause 1

ROBENACOXIB
Schedule 4

ROBENIDINE
Schedule 5

ROFECOXIB
Schedule 4

ROFLUMILAST
Schedule 4

ROLICYCLIDINE
cross reference: PCPY, PHP (CAS No. 2201-39-0)
Schedule 9

ROLITETRACYCLINE
Schedule 4

ROLZIRACETAM
cross reference: RACETAMS
Schedule 4

ROMIDEPSIN
Schedule 4

ROMIFIDINE
Schedule 4

ROMIPLOSTIM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ROMOSOZUMAB
Schedule 4

RONIDAZOLE
Schedule 4

ROPINIROLE
Schedule 4

ROPIVACAINE
Schedule 4

ROSEMARY OIL
Appendix B, clause 3

ROSIGLITAZONE
Schedule 4

ROSIN
cross reference: COLOPHONY
Schedule 5

ROSOXACIN
Schedule 4

ROSUVASTATIN
Schedule 4

ROTENONE
cross reference: CUBE
Schedule 6

ROTIGOTINE
Schedule 4
Appendix K, clause 1

ROXIBOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ROXITHROMYCIN
Schedule 4

ROZANOLIXIZUMAB
Schedule 4

RUBELLA VACCINE
Schedule 4

RUBOXISTAURIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

RUFINAMIDE
Schedule 4
Appendix K, clause 1
Appendix L, clause 2

RUPATADINE
Schedule 4
Appendix K, clause 1

RUXOLITINIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

S

SACITUZUMAB GOVITECAN
Schedule 4

SACUBITRIL
Schedule 4

SAFINAMIDE
Schedule 4

SAFLUFENACIL
Schedule 7
Schedule 5

SAFROLE
cross reference: CAS No. 94-59-7, SASSAFRAS OIL
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SAGE OIL
cross reference: DALMATIAN, THUJONE
Schedule 6
Appendix E, clause 3

SAGE OIL (Spanish)
cross reference: CAMPHOR
Appendix B, clause 3

SALBUTAMOL
Schedule 4
Schedule 3
Appendix F, clause 4

SALCATONIN
cross reference: CALCITONIN SALMON

SALICYLAMIDE
cross reference: ASPIRIN, CAFFEINE, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, clause 4

SALICYLANILIDE
Schedule 5

SALICYLIC ACID
cross reference: CHOLINE SALICYLATE
Schedule 3
Appendix H, clause 1

Authorised Version F2026L01327 registered 30/09/2026

SALINOMYCIN
Schedule 6
Schedule 4

SALMETEROL
Schedule 4

SALVIA DIVINORUM
Schedule 9

SANDALWOOD OIL
Appendix B, clause 3

SANGUINARIA CANADENSIS (bloodroot)
Schedule 10

SANGUINARINE
cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot)

SANTONIN
Schedule 3

SAPROPTERIN
Schedule 4

SAQUINAVIR
Schedule 4

SARILUMAB
Schedule 4

SAROLANER
Schedule 6
Schedule 5

SARS-COV-2 (COVID-19) VACCINE
Schedule 4

SASSAFRAS OIL
cross reference: SAFROLE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SAXAGLIPTIN
Schedule 4

SCHOENOCAULON OFFICINALE
cross reference: SABADILLA
Schedule 4

SCHRADAN
Schedule 7

Authorised Version F2026L01327 registered 30/09/2026

SCOPOLIA CARNIOLICA
Schedule 4

SEAWEED
Appendix B, clause 3

SEBELIPASE ALFA
Schedule 4

SEBETRALSTAT
Schedule 4

SECBUTOBARBITAL
Schedule 8
Appendix K, clause 1

SECBUTOBARBITONE
cross reference: SECBUTOBARBITAL

SECOBARBITAL
Schedule 8
Appendix K, clause 1

SECUKINUMAB
Schedule 4

SEDAXANE
Schedule 5

SEEDS
Appendix A, clause 1

SELADELPAR
Schedule 4

SELAMECTIN
Schedule 5

SELECTIVE ANDROGEN RECEPTOR MODULATORS
cross reference: SARM
Schedule 4
Appendix D, clause 5

SELEGILINE
Schedule 4

SELENIUM
cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE
Schedule 7
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

Appendix F, clause 4
Appendix G, clause 1

SELETRACETAM
Cross reference RACETAMS
Schedule 4
Appendix K, clause 1

SELEXIPAG
Schedule 4

SELINEXOR
Schedule 4
Appendix L, clause 2

SELPERCATINIB
Schedule 4

SELUMETINIB
Schedule 4
Appendix L, clause 2

SEMAGLUTIDE
Schedule 4

SEMDURAMICIN
Schedule 7
Schedule 6

SENECIO spp.
Schedule 10

SEPIAPTERIN
Schedule 4

SERELAXIN
Schedule 4

SERMORELIN
Schedule 4

SERTINDOLE
Schedule 4

SERTRALINE
Schedule 4

SETHOXYDIM
Schedule 5

SEVELAMER
Schedule 4

SEVOFLURANE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

SEX HORMONES
Schedule 4

SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
cross reference: EPIDERMAL GROWTH FACTOR

SIBUTRAMINE
Schedule 4

SIDURON
Schedule 5

SILANDRONE
Schedule 4
Appendix D, clause 5 (Anabolic steroidal agent)

SILDENAFIL
Schedule 4

SILICOFLUORIDES
cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,
Schedule 6
Schedule 5

SILICONES
Schedule 10
Schedule 4
Appendix F, clause 4

SILODOSIN
Schedule 4

SILTUXIMAB
Schedule 4

SILVER
Schedule 2

SILVER NITRATE
cross reference: SILVER SALTS
Schedule 6
Appendix E, clause 3

SILVER OXIDE
Appendix B, clause 3

SILVER SULFADIAZINE
Schedule 4

SIMAZINE
Appendix B, clause 3

SIMEPREVIR
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

SIMVASTATIN
Schedule 4

SINBIOALLETHRIN
Schedule 6
Schedule 5

SINGLE-USE TUBES
Appendix A, clause 1

SIPONIMOD
Schedule 4

SIROLIMUS
Schedule 4

SISOMICIN
Schedule 4

SITAGLIPTIN
Schedule 4

SITAXENTAN
Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

SLIMICIDES
Appendix A, clause 1

SODIUM ALUMINATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SODIUM BICARBONATE
Appendix B, clause 3

SODIUM BROMATE
Schedule 6
Appendix E, clause 3

SODIUM BROMIDE
Schedule 5
Schedule 4

SODIUM CELLULOSE PHOSPHATE
Schedule 4

SODIUM CHLORATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

SODIUM CITRATE DIHYDRATE
Schedule 4

SODIUM CROMOGLYCATE
Schedule 4
Schedule 2

SODIUM DIACETATE
Schedule 5
Appendix E, clause 3

SODIUM DICHLOROISOCYANURATE
Appendix E, clause 3

SODIUM DODECYLBENZENE SULFONATE
Schedule 5
Appendix E, clause 3, Part
Appendix F, clause 4

SODIUM FLUORIDE
Appendix F, clause 4

SODIUM GLYCEROPHOSPHATE HYDRATE
Schedule 4

SODIUM HYDROGEN SULFATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM HYDROSULFITE
Schedule 5
Appendix F, clause 4

SODIUM HYDROXIDE
cross reference: CAS No. 1310-73-2, LYE WATER
Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM LAURETH-6 CARBOXYLATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM METABISULPHITE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM MORRHUATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

SODIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

SODIUM NITROPRUSSIDE
Schedule 4

SODIUM OXYBATE
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

SODIUM PERCARBONATE
Schedule 6
Schedule 5
Appendix E, clause 3

SODIUM PERSULFATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SODIUM PHENYLBUTYRATE
Schedule 4

SODIUM PHOSPHATE
Schedule 4
Schedule 3

SODIUM PICOSULFATE
Schedule 3

SODIUM POLYSTYRENE SULPHONATE
Schedule 5
Schedule 4

SODIUM PROPIONATE
Appendix B, clause 3

SODIUM SALICYLATE
Schedule 4

SODIUM STANNATE
Schedule 5,
Appendix E, clause 3

SODIUM SULFIDE
Schedule 6
Schedule 5
Appendix E, clause 3

Authorised Version F2026L01327 registered 30/09/2026

Appendix F, clause 4

SODIUM TETRADECYLSULFATE
Schedule 4

SODIUM THIOSULFATE ANHYDROUS
Schedule 4

SODIUM TRICHLOROACETATE
Appendix E, clause 3

SODIUM ZIRCONIUM CYCLOSILICATE.
Schedule 4

SODIUMHYDROSULFITE
Appendix E, clause 3

SOFOSBUVIR
Schedule 4

SOLASODINE
Schedule 4

SOLIFENACIN
Schedule 4

SOMAPACITAN
Schedule 4
Appendix D, clause 5

SOMATOSTATIN
Schedule 4

SOMATOTROPIN EQUINE
Schedule 4

SOMATROGON
Schedule 4
Appendix D, clause 5

SOMATROPIN
cross reference: HUMAN GROWTH HORMONE
Schedule 4
Appendix D, clause 5

SONIDEGIB
Schedule 4

SONTOQUINE
Schedule 4

SORAFENIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

SOTALOL
Schedule 4

SOTATERCEPT
Schedule 4

SOTORASIB
Schedule 4

SOTROVIMAB
Schedule 4

SPARFLOXACIN
Schedule 4

SPARTEINE
Schedule 4

SPECTINOMYCIN
Schedule 4

SPESOLIMAB
Schedule 4

SPIDOXAMAT
Schedule 5

SPINETORAM
Schedule 5

SPINOSAD
Schedule 5

SPIRAMYCIN
Schedule 4

SPIRAPRIL
Schedule 4

SPIROMESIFEN
Schedule 5

SPIRONOLACTONE
Schedule 4

SPIROPIDION
Schedule 6

SPIROTETRAMAT
Schedule 6

SPIROXAMINE
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

SQUILL
Schedule 2

STANOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STANOZOLOL
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STAR ANISE OIL
Schedule 5

STAVUDINE
Schedule 4

STENABOLIC (SR9009) and other synthetic REV-ERB agonists
cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667
Schedule 4
Appendix D, clause 5

STENBOLONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STERIC ACID
Appendix B, clause 3

STEROID HORMONES
Schedule 4

STILBESTROL
cross reference: STILBOESTROL, DIETHYLSTILBESTROL
Schedule 4

STIRIPENTOL
Schedule 4
Appendix K, clause 1

STREPTODORNASE
Schedule 4

STREPTOKINASE
Schedule 4

STREPTOMYCES LYDICUS WYEC 108
Appendix B, clause 3

STREPTOMYCIN
Schedule 4

STRONTIUM RANELATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

STROPHANTHINS
Schedule 4

STROPHANTHUS spp.
Schedule 4
Appendix G, clause 1

STRYCHNINE
cross reference: NUX VOMICA
Schedule 7
Schedule 4
Appendix E, clause 3
Appendix G, clause 1
Appendix J, clause 1

STRYCHNOS spp.
Schedule 4

STYRAMATE
Schedule 4

STYRENE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SUCCIMER
Schedule 4

SUCRALFATE
Appendix B, clause 3

SUCROFERRIC OXYHYDROXIDE
Schedule 4

SUFENTANIL
Schedule 8

SUGAMMADEX
Schedule 4

SULBACTAM
Schedule 4

SULCOFURON
Schedule 7
Schedule 6
Appendix E, clause 3
Appendix J, clause 1

SULCONAZOLE
Schedule 4
Schedule 2

Authorised Version F2026L01327 registered 30/09/2026

SULESOMAB
Appendix B, clause 3

SULFACETAMIDE
Schedule 5
Schedule 4
Schedule 3

SULFADIAZINE
Schedule 5
Schedule 4

SULFADIMETHOXINE
Schedule 4

SULFADIMIDINE
Schedule 5
Schedule 4

SULFADOXINE
Schedule 4

SULFAFURAZOLE
Schedule 4

SULFAGUANIDINE
Schedule 4

SULFAMERAZINE
Schedule 5
Schedule 4

SULFAMETHIZOLE
Schedule 4

SULFAMETHOXAZOLE
Schedule 4

SULFAMETHOXYDIAZINE
Schedule 4

SULFAMETHOXYPYRIDAZINE
Schedule 4

SULFAMETROLE
Schedule 4

SULFAMIC ACID
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

SULFAMONOMETHOXINE
Schedule 4

SULFAMOXOLE
Schedule 4

SULFAPHENAZOLE
Schedule 4

SULFAPYRIDINE
Schedule 4

SULFAQUINOXALINE
Schedule 4

SULFASALAZINE
Schedule 4

SULFATHIAZOLE
Schedule 5
Schedule 4

SULFATROXAZOLE
Schedule 4

SULFENTRAZONE
Schedule 7

SULFINPYRAZONE
Schedule 4

SULFLURAMID
Schedule 6

SULFOMETURON-METHYL
Schedule 5

SULFOMYXIN
Schedule 4

SULFONAMIDE ANTIBIOTICS
cross reference: SULFACETAMIDE, SULPHANILAMIDE
Schedule 4

SULFONMETHANE
cross reference: ALKYL SULFONALS, SULFONAL
Schedule 4

SULFOSULFURON
Appendix B, clause 3

SULFOTEP
Schedule 7

Authorised Version F2026L01327 registered 30/09/2026

SULFOXAFLOR
Schedule 6
Schedule 5

SULFURIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SULFURYL FLUORIDE
Schedule 6

SULINDAC
Schedule 4

SULPHATED POLYSACCHARIDES
Appendix B, clause 3

SULPROFOS
Schedule 6

SULTAMICILLIN
Schedule 4

SULTHIAME
Schedule 4

SUMATRIPTAN
Schedule 4
Schedule 3
Appendix H, clause 1

SUNIFIRAM
cross reference: RACETAMS
Schedule 4

SUNITINIB
Schedule 4

SUPROFEN
Schedule 4

SUTILAINS
Schedule 4

SUVOREXANT
Schedule 4
Appendix K, clause 1

SUXAMETHONIUM
Schedule 4

SUXETHONIUM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

SYMPHYTUM spp.
cross reference: COMFREY
Schedule 10
Schedule 5
Appendix F, clause 4

SYNTHETIC CANNABINOMIMETICS
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

T

2,4,5-T
Schedule 6

TACRINE
Schedule 4

TACROLIMUS
Schedule 4

TADALAFIL
Schedule 4

TAFAMIDIS
Schedule 4

TAFASITAMAB
Schedule 4

TAFENOQUINE SUCCINATE
Schedule 4

TAFLUPROST
Schedule 4

TAGRAXOFUSP
Schedule 4

TALAZOPARIB
Schedule 4

TALIGLUCERASE ALFA
Schedule 4

TALIMOGENE LAHERPAREPVEC
Schedule 4

TALLOW ALKYLAMINE ACETATES
Schedule 6

***N*-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE**
Schedule 6

TAMOXIFEN
Schedule 4

TAMSULOSIN
Schedule 4

TANACETUM VULGARE
cross reference: OIL OF TANSY, TANSY OIL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TANNIC ACID
Appendix B, clause 3

TANNIC ACID/BENZYL ALCOHOL PRODUCT
Appendix B, clause 3

TAPENTADOL
Schedule 8
Appendix K, clause 1

TAPINAROF
Schedule 4

TAR ACIDS
Schedule 6

TASIPIMIDINE SULFATE
Schedule 4

TASONERMIN
Schedule 4

TAZAROTENE
Schedule 4
Appendix F, clause 4

TAZOBACTAM
Schedule 4

TB-500
Schedule 4
Appendix D, clause 5

2,3,6-TBA
Schedule 5

T-CELL RECEPTOR ANTIBODY
Schedule 4

TCMTB
cross reference: 2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE
Schedule 6

TDE
cross reference: 1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE
Schedule 6
Schedule 5

TEBENTAFUSP
Schedule 4

TEBUCONAZOLE
cross reference: TERBUCONAZOLE
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

TEBUFENOZIDE
Schedule 5

TEBUFENPYRAD
Schedule 6

TEBUTHIURON
Schedule 6

TECLISTAMAB
Schedule 4

TEDUGLUTIDE
Schedule 4

TEFLUTHRIN
Schedule 7
Schedule 5

TEGAFUR
Schedule 4

TEGASEROD
Schedule 4

TEICOPLANIN
Schedule 4

TELAPREVIR
Schedule 4

TELBIVUDINE
Schedule 4

TELITHROMYCIN
Schedule 4

TELMISARTAN
Schedule 4

TELOTRISTAT ETHYL
Schedule 4

TEMAZEPAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

TEMEPHOS
Schedule 6
Schedule 5

TEMOZOLOMIDE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TEMSIROLIMUS
Schedule 4

TENECTEPLASE
Schedule 4

TENIPOSIDE
Schedule 4

TENOCYCLIDINE
cross reference: TCP (CAS No. 21500-98-1)
Schedule 9

TENOFOVIR
Schedule 4

TENOXICAM
Schedule 4

TEPLIZUMAB
Schedule 4
Appendix L, clause 2

TEPOTINIB
Schedule 4

TEPOXALIN
Schedule 4

TEPP
Schedule 8

TEPRALOXYDIM
Schedule 5

TEPROTUMUMAB
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

TERAZOSIN
Schedule 4

TERBACIL
Appendix B, clause 3, Part 3

TERBINAFINE
Schedule 4
Schedule 2

TERBUFOS
Schedule 7

Authorised Version F2026L01327 registered 30/09/2026

TERBUTALINE
Schedule 4
Schedule 3
Appendix F, clause 4

TERBUTHYLAZINE
Schedule 6

TERBUTRYN
Schedule 5

TERFENADINE
Schedule 4
Appendix F, clause 4

TERIFLUNOMIDE
Schedule 4
Appendix F, clause 4
Appendix L, clause 2

TERIPARATIDE
Schedule 4
Appendix D, clause 1

TERLIPRESSIN
Schedule 4

TERMITE BARRIERS
Appendix A, clause 1

TERODILINE
Schedule 4

TEROPTERIN
Schedule 4

TERPENES, CHLORINATED
cross reference: CHLORINATED TERPENES
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

TESTOLACTONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

TESTOSTERONE
Schedule 6
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
Appendix G, clause 1

TETANUS ANTITOXIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TETANUS TOXOID
cross reference: TRIPLE ANTIGEN VACCINE
Schedule 4

1,3,5,7-TETRAAZATRICYLO[3.3.1.1^{3,7}] DECANE
cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE
Schedule 5

TETRABENAZINE
Schedule 4

TETRACAINE
cross reference: AMETHOCAINE
Schedule 4
Schedule 2

TETRACHLOROETHANE
Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

TETRACHLOROETHYLENE
cross reference: DESIGNATED SOLVENT
Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

TETRACHLORVINPHOS
Schedule 5

TETRACONAZOLE
Schedule 6
Schedule 5

TETRACOSACTIDE
Schedule 4

TETRACOSACTRIN
cross reference: TETRACOSACTIDE

TETRACYCLINE
Schedule 5
Schedule 4

TETRADIFON
Schedule 6

TETRAETHYLAMMONIUM
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TETRAHYDROCANNABINOLIC ACID
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

TETRAHYDROCANNABINOLS
cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS
Schedule 9
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

TETRAHYDROCANNABIDIVAROL
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

TETRAHYDROFURFURYL ALCOHOL
Schedule 6

TETRAHYDROZOLINE
cross reference: TETRYZOLINE

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE
cross reference: STABAXOL
Schedule 7
Schedule 6
Appendix J, clause 1

TETRAMETHRIN
Schedule 5

TETRAMISOLE
Schedule 6

TETRANILIPROLE
Schedule 5

TETROXOPRIM
Schedule 4

TETRYZOLINE
cross reference: TETRAHYDROZOLINE
Schedule 2
Appendix F, clause 4

TEZACAFTOR
Schedule 4

TEZEPELUMAB
Schedule 4

THALIDOMIDE
Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

Authorised Version F2026L01327 registered 30/09/2026

THALLIUM
cross reference: THALLIUM SULFATE
Schedule 7
Appendix J, clause 1

THAUMATIN
Appendix B, clause 3

THEBACON
Schedule 8

THEBAINE
Schedule 8

THENYLDIAMINE
Schedule 4
Appendix K, clause 1

THEOPHYLLINE
Schedule 4
Schedule 3

THEVETIA PERUVIANA
Schedule 4

THEVETIN
Schedule 4

THIABENDAZOLE
Schedule 5
Schedule 2

THIACETARSAMIDE
Schedule 4

THIACLOPRID
Schedule 6

THIAFENTANIL
Schedule 8

THIAMBUTOSINE
Schedule 4

THIAMETHOXAM
Schedule 6
Schedule 5

THIAZAFLURON
Schedule 6

THIAZOPYR
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

THIAZOSULFONE
Schedule 4

THIDIAZURON
Appendix B, clause 3

THIETHYLPERAZINE
Schedule 4
Appendix K, clause 1

THIFENSULFURON
Schedule 5

THIOACETAZONE
Schedule 4

THIOBENCARB
Schedule 5

THIOCARLIDE
Schedule 4

THIODICARB
Schedule 6
Schedule 5

THIOFANOX
Schedule 7

THIOFENTANYL
cross reference: CAS No. 1165-22-6
Schedule 9

THIOGUANINE
cross reference: TIOGUANINE

THIOMESTERONE
cross reference: TIOMESTERONE
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

THIOMETON
Schedule 6

THIOPENTAL
Schedule 4

THIOPENTONE
cross reference: THIOPENTAL

THIOPHANATE-METHYL
Schedule 6
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

THIOPROPAZATE
Schedule 4
Appendix K, clause 1

THIOPROPERAZINE
Schedule 4

THIORIDAZINE
Schedule 4
Appendix K, clause 1

THIOSTREPTON
Schedule 4

THIOTEPA
cross reference: TRIETHYLENE THIOPHOSPHORAMIDE
Schedule 4

THIOTHIXENE
Schedule 4
Appendix K, clause 1

THIOURACIL
Schedule 4

THIOUREA
cross reference: ALKYL THIOUREAS
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

THIRAM
Schedule 6

THUJONE
Schedule 6
Appendix E, clause 3

THYME OIL
Schedule 5
Appendix E, clause 3

THYMOL
Schedule 6

THYMOSIN BETA 4 (THYMOSIN β4)
Schedule 4
Appendix D, clause 5

THYMOXAMINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

THYROID
Schedule 4

THYROTROPHIN
cross reference: TSH
Schedule 4

THYROXINE
Schedule 4
Appendix G, clause 1

TIAFENACIL
Appendix B, clause 3

TIAGABINE
Schedule 4

TIAMULIN
Schedule 4

TIANEPTINE
Schedule 4
Appendix D, clause 5

TIAPROFENIC ACID
Schedule 4

TIARAMIDE
Schedule 4

TIBOLONE
Schedule 4

TICAGRELOR
Schedule 4

TICARCILLIN
Schedule 4

TICLOPIDINE
Schedule 4

TIEMONIUM
Schedule 4

TIENILIC ACID
Schedule 4

TIGECYCLINE
Schedule 4

TIGILANOL TIGLATE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TIGLOIDINE
Schedule 4

TIGOLANER
Schedule 6
Schedule 5

TILDIPIROSIN
Schedule 4

TILETAMINE
Schedule 4

TILIDINE
Schedule 8

TILMANOCEPT
Schedule 4

TILMICOSIN
Schedule 4

TILUDRONIC ACID
cross reference: DISODIUM TILUDRONATE
Schedule 4

TIMBER
cross reference: WALLBOARD
Appendix A, clause 1

TIMOLOL
Schedule 4

TIMOTHY-GRASS POLLEN EXTRACT
cross reference: PHLEUM PRATENSE POLLEN EXTRACT
Schedule 4

TIN ORGANIC COMPOUNDS
cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN-COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS
Schedule 7

TINIDAZOLE
Schedule 4

TINZAPARIN
Schedule 4

TIOCARBAZIL
Schedule 5

Authorised Version F2026L01327 registered 30/09/2026

TIOCONAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

TIOGUANINE
cross reference: THIOGUANINE
Schedule 4

TIOTROPIUM
Schedule 4

TIPEPIDINE
Schedule 4

TIPIRACIL
Schedule 4

TIPRANAVIR
Schedule 4

TIRBANIBULIN
Schedule 4

TIRILAZAD
Schedule 4

TIROFIBAN
Schedule 4

TIRZEPATIDE
Schedule 4
Appendix L, clause 2

TISLELIZUMAB
Schedule 4

TIXAGEVIMAB
Schedule 4

TOBRAMYCIN
Schedule 4

TOCAINIDE
Schedule 4

TOCERANIB
Schedule 4

TOCILIZUMAB
Schedule 4

TOFACITINIB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TOFERSEN
Schedule 4

TOLAZAMIDE
Schedule 4

TOLAZOLINE
Schedule 4

TOLBUTAMIDE
Schedule 4

TOLCAPONE
Schedule 4

TOLCLOFOS-METHYL
Schedule 5

TOLFENAMIC ACID
Schedule 4

***o*-TOLIDINE**
Schedule 7
Appendix E, clause 3
Appendix J, clause 1

TOLMETIN
Schedule 4

TOLONIUM
Schedule 4

TOLPROPAMINE
Schedule 4

TOLRESTAT
Schedule 4

TOLTERODINE
Schedule 4

TOLTRAZURIL
Schedule 5

TOLUENE
cross reference: XYLENE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,4-TOLUENEDIAMINE
cross reference: CAS No. 95-80-7
Schedule 10

Authorised Version F2026L01327 registered 30/09/2026

TOLUENEDIAMINES
Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

***o*-TOLUIDINE**
cross reference: CAS No. 95-53-4
Schedule 10

TOLVAPTAN
Schedule 4

TOLYLFLUANID
Schedule 6

TOPIRAMATE
Schedule 4

TOPOTECAN
Schedule 4

TOPRAMEZONE
Schedule 5

TORASEMIDE
Schedule 4

TOREMIFENE
Schedule 4

TOXOIDS
Schedule 4

TRABECTEDIN
Schedule 4
Appendix K, clause 1

TRALKOXYDIM
Schedule 5

TRAMADOL
Schedule 4
Appendix K, clause 1

TRAMAZOLINE
Schedule 2
Appendix F, clause 4

TRAMETINIB DIMETHYL SULFOXIDE
Schedule 4

TRANDOLAPRIL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TRANEXAMIC ACID
Schedule 4

TRANSFLUTHRIN
Schedule 6

TRANYLCYPROMINE
Schedule 4
Appendix K, clause 1

TRASTUZUMAB
Schedule 4

TRASTUZUMAB DERUXTECAN
Schedule 4
Appendix L, clause 2

TRASTUZUMAB EMTANSINE
Schedule 4

TRAVOPROST
Schedule 4

TRAZODONE
Schedule 4

TRENBOLONE
cross reference: TRIENBOLONE, TRIENOLONE
Schedule 5
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

TREOSULPHAN
Schedule 4

TREPROSTINIL
Schedule 4

TRESTOLONE
Schedule 4
Appendix D, clause 5 (androgenic steroidal agents)

TRETAMINE
Schedule 4

TRETINOIN
Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

TRIACETYLOLEANDOMYCIN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

TRIADIMEFON
Schedule 6
Schedule 5

TRIADIMENOL
Schedule 5

TRI-ALLATE
Schedule 5

TRIAMCINOLONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4, Part 2
Appendix H, clause 1

TRIAMIPHOS
Schedule 7

TRIAMTERENE
Schedule 4

TRIASULFURON
Appendix B, clause 3

TRIAZBUTIL
Schedule 7

TRIAZIQUONE
Schedule 4

TRIAZOLAM
Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

TRIBENURON-METHYL
Schedule 5

TRIBUFOS
cross reference: s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE
Schedule 7

TRICHLORFON
cross reference: METRIFONATE
Schedule 6

TRICHLORMETHIAZIDE
Schedule 4

TRICHLOROACETIC ACID
Schedule 6
Schedule 5
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

Appendix E, clause 3
Appendix F, clause 4

TRICHLOROACETIC ACID ALKALI SALTS
Schedule 5
Appendix E, clause 3

1,1,1-TRICHLOROETHANE
cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT
Schedule 10
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

TRICHLOROETHYLENE
cross reference: TRICHLOROETHENE
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

TRICHLOROISOCYANURIC ACID
cross reference: CHLORINATING COMPOUNDS
Appendix E, clause 3

TRICHLOROPHENOL
Schedule 6
Appendix F, clause 4

TRICHODERMA HARZIANUM
Appendix B, clause 3

TRICHODESMA AFRICANA
Schedule 10

TRICLABENDAZOLE
Schedule 6

TRICLOFOS
Schedule 4

TRICLOPYR
Schedule 6

TRICLOSAN
Schedule 6

TRICYCLAMOL
Schedule 4

TRIDEMORPH
Schedule 6

Authorised Version F2026L01327 registered 30/09/2026

TRIDIHEXETHYL
Schedule 4

TRIDIPHANE
Schedule 5

TRIENTINE
Schedule 4

TRIETAZINE
Schedule 5

TRIETHANOLAMINE
cross reference: TROLAMINE

TRIETHYL PHOSPHATE
Schedule 6
Appendix E, clause 3

TRIETHYLENE GLYCOL
Appendix B, clause 3

TRIFAROTENE
Schedule 4

TRIFLOXYSTROBIN
Schedule 5

TRIFLOXYSULFURON
Appendix B, clause 3

TRIFLUDIMOXAZIN
Schedule 5

TRIFLUMIZOLE
Schedule 5

TRIFLUMURON
Schedule 5

TRIFLUOPERAZINE
Schedule 4
Appendix K, clause 1

TRIFLUOROMETHANESULFONIC ACID
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE
cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3)
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

TRIFLUPERIDOL
Schedule 4

TRIFLUPROMAZINE
Schedule 4

TRIFLURALIN
Appendix B, clause 3

TRIFLURIDINE
Schedule 4

TRIFORINE
Appendix B, clause 3

TRIHEXYPHENIDYL
cross reference: BENZHEXOL
Schedule 4

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

TRILOSTANE
Schedule 4

TRIMEPERIDINE
cross reference: CAS No. 29606-10-8
Schedule 9

TRIMEPRAZINE
cross reference: ALIMEMAZINE

TRIMETAPHAN
Schedule 4

TRIMETHOPRIM
Schedule 4

3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80-2)
Schedule 9

3,4,5-TRIMETHOXYPHENETHYLAMINE
cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY-PHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92-8), MESCALINE HYDROGEN SULFATE (CAS No. 5967-42-0), MESCALINE HEMISULFATE (CAS No. 642-73-9)
Schedule 9

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE
cross reference: CAS No. 17097-73-3
Schedule 9

Authorised Version F2026L01327 registered 30/09/2026

TRIMIPRAMINE
Schedule 4
Appendix K, clause 1

TRIMUSTINE
Schedule 4

TRINEXAPAC-ETHYL
Schedule 5

TRINITROPHENOL
Schedule 6
Schedule 4

3,6,9-TRIOXAUNDECANEDIOIC ACID
Schedule 5
Appendix F, clause 4

TRIOXYSALEN
Schedule 4

TRIPARANOL
cross reference: CAS No. 78-41-1
Schedule 10

TRIPELENNAMINE
Schedule 4

TRIPLE ANTIGEN VACCINE
cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID

TRIPROLIDINE
Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

TRIPTORELIN
Schedule 4

TRISODIUM NITRILOTRIACETATE
Schedule 6

TRITICONAZOLE
Schedule 5

TROGLITAZONE
Schedule 4

TROLAMINE
Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

TROMETAMOL
Schedule 4

TROPICAMIDE
Schedule 4

TROPISETRON
Schedule 4

TROVAFLOXACIN
Schedule 4

TROXIDONE
Schedule 4

TRYPTOPHAN
Schedule 4

TUAMINOHEPTANE
Schedule 2

TUCATINIB
Schedule 4

TUBERCULIN
Schedule 4

TUBOCURARINE
Schedule 4

TULATHROMYCIN
Schedule 4

TULOBUTEROL
Schedule 4

TURPENTINE OIL
cross reference: OIL OF TURPENTINE
Schedule 5
Appendix E, clause 3

TUSSILAGO FARFARA
cross reference: COLTSFOOT
Schedule 10

TYLOSIN
Schedule 4

TYMAZOLINE
Schedule 4
Appendix F, clause 4

TYPHOID VACCINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

U

ULIPRISTAL
Schedule 4
Schedule 3
Appendix H, clause 1

ULOCLADIUM OUDEMANSII
Appendix B, clause 3

UMECLIDINIUM
Schedule 4

UNIFIRAM
cross reference: RACETAMS
Schedule 4

UNOPROSTONE
Schedule 4

UPADACITINIB
Schedule 4

URACIL
Schedule 4

URAPIDIL
Schedule 4

UREA
Appendix B, clause 3

URETHANE
Schedule 4

UROFOLLITROPIN
cross reference: FOLLICLE-STIMULATING HORMONE, HUMAN
Schedule 4
Appendix D, clause 1

UROKINASE
Schedule 4

URSODEOXYCHOLIC ACID
Schedule 4

USTEKINUMAB
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

V

VACCINES
Schedule 4

VACCINES – PLASMID DNA
cross reference: PLASMID DNA (r*E. coli* DH5α pINGhT)
Schedule 4

VACCINIA VIRUS VACCINE
Schedule 4

VADADUSTAT
Schedule 4
Appendix D, clause 5

VALACICLOVIR
Schedule 4

VALDECOXIB
Schedule 4

VALGANCICLOVIR
Schedule 4

VALNOCTAMIDE
Schedule 4

VALPROIC ACID
Schedule 4

VALSARTAN
Schedule 4

VAMIDOTHION
Schedule 6

VANCOMYCIN
Schedule 4

VANDETANIB
Schedule 4

VANZACAFTOR
Schedule 4

VARDENAFIL
Schedule 4

VARENICLINE
Schedule 4

VARICELLA VACCINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)
cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN

VASOPRESSIN
Schedule 4

VATINOXAN HYDROCHLORIDE
Schedule 4

VECURONIUM
Schedule 4

VEDAPROFEN
Schedule 4

VEDOLIZUMAB
Schedule 4

VELAGLIFLOZIN
Schedule 4

VELAGLUCERASE ALFA
Schedule 4

VELMANASE ALFA
Schedule 4

VELPATASVIR
Schedule 4

VEMURAFENIB
Schedule 4

VENETOCLAX
Schedule 4

VENLAFAXINE
Schedule 4

VERAPAMIL
Schedule 4

VERATRUM
Schedule 4

VERDINEXOR
Schedule 4

VERICIGUAT
Schedule 4

VERNAKALANT
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

VERNOLATE
Schedule 5

VERTEPORFIN
Schedule 4

VETIVER OIL
Appendix B, clause 3

VIDARABINE
Schedule 4

VIGABATRIN
Schedule 4

VILANTEROL
Schedule 4

VILDAGLIPTIN
Schedule 4

VILOXAZINE
Schedule 4

VINBLASTINE
Schedule 4

VINCAMINE
Schedule 4

VINCLOZOLIN
Schedule 6
Appendix F, clause 4

VINCRISTINE
Schedule 4

VINDESINE
Schedule 4

VINFLUNINE
Schedule 4

VINORELBINE
Schedule 4

VINYL ACETATE MONOMER
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

VINYL CHLORIDE
Schedule 7
Appendix J, clause 1

Authorised Version F2026L01327 registered 30/09/2026

VINYL ETHER
Schedule 4

VIRGINIAMYCIN
Schedule 5
Schedule 4

VISMODEGIB
Schedule 4

VISNADINE
Schedule 4

VITAMIN A
Schedule 4

VITAMIN D
cross reference: COLECALCIFEROL, ERGOCALCIFEROL
Schedule 4
Schedule 3
Appendix H, clause 1

VITAMIN K
cross reference: PHYTOMENADIONE
Appendix B, clause 3

VITREOUS ENAMELS
Appendix A, clause 1

VORAPAXAR
Schedule 4

VORASIDENIB
Schedule 4

VORETIGENE NEPARVOVEC
Schedule 4

VORICONAZOLE
Schedule 4

VORINOSTAT
Schedule 4

VORTIOXETINE
Schedule 4

VOSORITIDE
Schedule 4

VOXILAPREVIR
Schedule 4

VUTRISIRAN
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

W

WALLBOARD
cross reference: TIMBER
Appendix A, clause 1

WARFARIN
Schedule 6
Schedule 5
Schedule 4

WILD CHERRY BARK
Schedule 10

WRITING CORRECTION PENS
Appendix A, clause 1

Authorised Version F2026L01327 registered 30/09/2026

X

XAMOTEROL
Schedule 4

XANTHINOL NICOTINATE
Schedule 4

XANTHOPHYLL
cross reference: LUTEIN
Appendix B, clause 3

XIMELAGATRAN
Schedule 4

XIPAMIDE
Schedule 4

XYLANASE derived from Aspergillus niger
Appendix B, clause 3

XYLAZINE
Schedule 4

XYLENE
cross reference: TOLUENE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

XYLOMETAZOLINE
Schedule 2
Appendix F, clause 4

Authorised Version F2026L01327 registered 30/09/2026

Y

YLANG YLANG OIL
Appendix B, clause 3

YOHIMBINE
cross reference: ASPIDOSPERMA QUEBRACHO
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

Z

(*Z*)-9-TRICOSENE
cross reference: TRICOSENE
Appendix B, clause 3

ZAFIRLUKAST
Schedule 4

ZALCITABINE
Schedule 4

ZALEPLON
Schedule 4

ZANAMIVIR
Schedule 4

ZANUBRUTINIB
Schedule 4

ZERANOL
Schedule 6
Schedule 4

ZETA-CYPERMETHRIN
Schedule 7
Schedule 6

ZIDOVUDINE
Schedule 4

ZILPATEROL
Schedule 4

ZILUCOPLAN
Schedule 4

ZIMELDINE
Schedule 4

ZINC BORATE
Schedule 6

ZINC CHLORIDE
Schedule 4
Schedule 2
Appendix E, clause 3

ZINC COMPOUNDS
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ZINC LACTATE
Schedule 6
Appendix F, clause 4

ZINC NAPHTHENATE
Appendix B, clause 3

ZINC para-PHENOLSULFONATE
Schedule 6

ZINC SULFATE
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ZINEB
cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM
Schedule 5

ZIPRASIDONE
Schedule 4
Appendix K, clause 1

ZIRAM
Schedule 7
Schedule 6

ZOLAZEPAM
Schedule 4

ZOLBETUXIMAB
Schedule 4

ZOLEDRONIC ACID
Schedule 4

ZOLMITRIPTAN
Schedule 4
Schedule 3
Appendix H, clause 1

ZOLPIDEM
Schedule 4
Appendix K, clause 1

ZONISAMIDE
Schedule 4
Appendix K, clause 1

ZOPICLONE
Schedule 4
Appendix K, clause 1

ZOXAZOLAMINE
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026

ZUCLOPENTHIXOL
Schedule 4

Authorised Version F2026L01327 registered 30/09/2026